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ABSTRACT 
Autoimmune inflammatory reactions occur in a number of disorders to a variety 
of self antigens but the precise cellular and molecular mechanisms resulting in 
pathology are largely unresolved.  In some instances T cell mediated reactions 
are  thought  to  be  the  main  contributors  to  disease  mechanisms  but  it  is 
becoming increasingly evident that B cells, and their cognate antibodies, play a 
significant  and  contributory  role  in  disease  pathogenesis.    Therefore 
establishing  the  occurrence  of  highly-specific  B  cell  antigen-driven  adaptive 
immune  responses  within  autoimmune  disorders  would  provide  a  valuable 
understanding into the roles of B cells within these disorders.   
 
The  work  of  this  study  sought  to  determine  the  incidence  of  these  B  cell 
antigen-driven  adaptive  immune  responses  in  the  target  tissues  of  the 
autoimmune  disorders  myositis  and  vasculitis,  two  autoimmune  disorders 
characterised by a wide range of autoantibodies which have been implicated in 
the pathological mechanisms of these diseases.  This study aimed to test the 
hypothesis  that  infiltrating  B  cells  within  the  target  tissue  of  myositis  and 
vasculitis patients were being stimulated by antigen present within the tissue 
resulting  in  clonal  diversification  and  affinity  maturation  mechanisms  which 
would contribute to the pathological mechanisms of these disorders.   
 
Initially the cellular phenotypes and organisations of the inflammatory infiltrating 
cell  population  were  characterised  by  immunohistochemical  techniques,  with 
particular  interest  on  the  infiltrating  B  cell  and  plasma  cell  populations.    No 
typical ectopic germinal centre structures were observed in the target tissues 
from  either  disorder;  cellular  aggregations  varied  from  loose  aggregations  to 
dense cellular follicles.  Both B cell and plasma cell phenotypes were included 
in  these  infiltrating  populations  in  correlation  with  varying  numbers  of  cells 
positive  for  helper,  cytotoxic  and  regulatory  T  cell,  follicular  dendritic  cell, 
macrophage and proliferating cell markers.  Double fluorescent labelling of B 
cells with the Ki67 proliferation marker indicated the possible expansion and 
clonal diversification of these cells within the target tissues.  To address the 
main objective of this study and the possible antigen-driven mechanisms and 
active participation of these infiltrating B cells within the target tissue of these II 
disorders, Ig gene repertoires, mutational characteristics, clonal diversification 
and affinity maturation were examined from infiltrating cells microdissected from 
areas  of  aggregation  within  the  target  tissues  of  both  disorders.  From  the 
muscle infiltrating cells, Ig gene selections which were both patient and disease 
specific, mutational characteristics and oligoclonal expansion of B cells were 
observed  establishing  the  involvement  of  muscle  infiltrating  B  cells  in  the 
antigen-driven responses within inflamed muscle.  Alternatively in the inflamed 
skin of vasculitis patients very few Ig gene rearrangements could be identified 
and  no  clonally  related  sequences  or  oligoclonal  expansion  of  B  cells  were 
observed  despite  mutational  characteristics  indicating  that  antigen-driven 
diversification had occurred within these cells.  Collectively the results indicate a 
role for B cells in the antigen-driven responses towards autoantigens within both 
disorders,  either  within  an  active  antigen-driven  response  within  the  target 
tissue or at alternative sites resulting in cell migration into the target tissues.     
  
In the final part of this study recombinant antigens were used to identify antigen-
specific B and plasma cells within the inflammatory infiltrating cell population in 
some  cases  of myositis.    Pilot  experiments  were  conducted  to establish  the 
sequence characteristics of Ig genes from these antigen-specific cells.  
 
Results  of  this  study  demonstrate  the  influence  of  B  cell  antigen-driven 
responses, either directly or indirectly, within the target tissues of myositis and 
vasculitis  patients  respectively,  although  the  exact  mechanisms  leading  to 
autoimmune reactions, and additional roles of B cells within these reactions, 
remain unresolved.  The work presented from this study provides a foundation 
for further work to fully ascertain the role of B cells and antibodies within the 
target  tissues  of  autoimmune  disorders  and  in  characterising  the  disease-
associated antibodies, identifying stimulating antigens as well as assessing the 
effects of somatic hypermutation on the affinity and specificity of autoantigen 
specific antibodies.  Increased understanding of B cells in these disorders will 
ultimately assist in the diagnosis and management of these diseases. 
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Chapter 1 – General Introduction 
1.1 The Immune Response in Health and Autoimmunity 
The immune system is the body’s protection from infections and pathological 
agents and the damage they can cause by utilising a variety of cells and soluble 
factors.  After breaching the initial physical and chemical barriers of the body, 
the immune system mediates the body’s protection from invading pathogens 
using  the  innate  and  adaptive  components  of  the  immune  system  (1).    The 
innate immune system is the body’s immediate line of defence which occurs 
rapidly  following  infection  with  no  specificity  and  limited  memory.  This 
component of the immune system is effective in defending against a large array 
of pathogens due to it’s recognition of common pathogenic structural features.  
Invariant  pathogen  recognition  receptors  (PRRs),  which  include  Toll-like 
receptors  (TLRs),  on  effector  cells  such  as  macrophages,  neutrophils, 
eosinophils,  basophils,  mast  cells  and  dendritic  cells  recognise  simple  and 
regular  molecular  structures  and  patterns,  pathogen-associated  molecular 
patterns (PAMPs) on invading pathogens.  The effector mechanisms of these 
cells, like phagocytosis, aim to eliminate and neutralise the invading pathogen.  
If  these  mechanisms  fail,  the  adaptive  immune  responses  are  activated  to 
enhance  the  protection  generated  by  innate  responses.    In  contrast  to  the 
innate immune system, the responses of adaptive immunity are antigen specific 
and exhibit memory, providing enhanced protection against re-infection of the 
pathogen,  but  occur  in  a  time-delayed  manner  in  comparison  to  the  innate 
responses.  Although these responses work by different mechanisms both can 
work in collaboration with each other through direct cell contacts and cytokine 
and  chemokine  interactions,  ultimately  shaping  the  nature  of  the  immune 
response.  The adaptive immune responses are mediated through the effector 
mechanisms of B and T cells; each expresses a receptor of unique antigen 
specificity,  B  cell  Receptor  (BCR)  and  T  cell  Receptor  (TCR)  respectively, 
following the random recombination of receptor gene segments.  Selection and 
activation of these cells in the immune response can result in humoral and/or 
cell mediated immune responses.  Humoral immunity mechanisms respond to 
extracellular  antigens  and  results  in  the  production  of  antigen-specific 
antibodies produced by B cells which can aid the eradication of pathogens by 
neutralisation, opsonisation and complement activation (1).  Antigens bound to 2 
the  BCR  of  B  cells  are  endocytosed,  processed  and  presented  on  Major 
Histocompatibility Complex (MHC) class II molecules at the cell surface.  These 
B  cells  become  activated  following  interactions  with  antigen-specific  CD4
+  T 
helper cells, which have previously been activated by antigen to differentiate 
into effector cells following antigen recognition and co-stimulation from antigen 
presenting  cells  (APCs)  such  as  dendritic  cells  and  macrophages,  and 
recognise the antigens presented on the MHC class II molecules of B cells at 
the edges of lymphoid follicles in the periphery lymphoid organs.  CD4
+ T helper 
cells activate B cells through a number of paired interactions at the cell surface.  
Key interactions include CD40 ligand (CD154) on T cells with CD40 on B cells.  
This  interaction  causes  B  cells  to  increase  expression  of  co-stimulatory 
molecules, particularly of the B7 family (CD80/CD86), which interact with CD28 
expressed on T cells which provides important signals to sustain T cell growth 
and differentiation.  In addition to these interactions, CD4
+ T helper cells also 
secrete cytokines upon activation.  T helper 1 cells secrete cytokine including 
IFN-γ and TNF-α while T helper 2 cells secrete cytokines including IL-4, 5, 10 
and  13.    These  cytokines,  in  addition  to  other  activation  signals,  can  drive 
proliferation and differentiation of the cells as well as induce clonal expansion, 
isotype switching and synthesis and secretion of antibodies from B cells.  In 
some  instances,  with  T  independent  antigens,  antibody  production  can  be 
induced in the absence of T helper cells as these antigens provide sufficient B 
cell stimulation in the absence of T cells.  Cell mediated mechanisms respond 
to  antigens  that  are  generated  intracellularly,  e.g.  by  virus  infection,  and 
presented on MHC molecules expressed on APCs (1).  CD8
+ and CD4
+ cells 
are activated to differentiate into effector cells in the T cell rich zones of the 
peripheral lymphoid organs.  In cell mediated immunity, CD4
+ T helper cells 
recognise antigens presented on MHC class II molecules by APCs and become 
activated  through  similar  cell  surface  interactions  that  have  been  previously 
described  like  the  CD40L-CD40  and  B7-CD28  interactions  and  activate 
phagocytes.  CD4
+ T helper 1 cells participate in macrophage activation, the 
secretion  of  IFN-γ  by  the  T  cell  along  with  the  co-stimulation  via  the  CD40 
ligand  is  sufficient  to  activate  the  macrophage  and  boost  the  antimicrobial 
mechanisms within the macrophages.  In addition to macrophage activation, the 
IFN-γ released by the T helper 1 cells can also be used to activate other cells 3 
involved in cell mediated immunity such as CD8
+ T cells and NK cells.  CD8
+ T 
cells recognise pathogenic peptides presented by MHC class I molecules on 
APCs and are activated to release cytotoxic effector proteins such as perforins 
and  granzymes,  which  induce  cell  death  of  the  virus  infected  cell.    CD4
+  T 
helper cells may also be required in the activation of CD8
+ T cells.  In cases 
where sufficient co-stimulation is not provided by the APC, CD4
+ T cells may be 
required to provide extra help in the activation and stimulation of CD8
+ T cells 
through  stimulation  of  the  APC  to  upregulate  the  surface  expression  of  B7 
molecules  which  can  increase  the  co-stimulation  to  CD8
+  T  cells  driving 
proliferation  and  differentiation  of  these  cells  in  the  cell  mediated  immune 
response.  Regardless of which mechanism is mediating the immune response, 
any  infection  and  the  responding  immune  mechanisms  will  initiate  an 
inflammatory reaction in response to the invading pathogen.     
 
1.1.1 Inflammation 
Inflammation is a major component of the body’s defence mechanism and is a 
complex  process  initiated  by  physical,  chemical,  biological  or  immunological 
injury and the inflammatory response constitutes an important part in both the 
innate and adaptive immune responses (1).  Inflammation involves activation of 
resident  tissue  cells  and  recruitment  of  immune  cells  from  the  circulation  in 
response  to  inflammatory  mediators  such  as  cytokines  and  chemokines 
resulting in tissue disruption, both structurally and functionally.   
 
The recruitment of B and T lymphocytes, and other inflammatory cells, to sites 
of  inflammation  is  a  multi-step  process  which  includes  tethering  and  rolling, 
activation, firm adhesion and transendothelial migration (TEM) of lymphocytes; 
a  process  which  is  mediated  by  chemokines  and  a  number  of  adhesion 
molecules  (Figure  1.1)  (1-4).    Circulating  lymphocytes  tether  and  role  along 
endothelium as a result of low-affinity interactions with the selectin adhesion 
molecules (L-, P- and E-selectin) which effectively slow down the flow of the 
circulating  lymphocytes.    This  brings  lymphocytes  into  contact  with  the 
endothelial  surface  and  allows  them  to  sample  the  local  environment.  
Activation molecules and stimulation of the cells leads to a firm adhesion to the 
endothelium while in the absence of stimuli the lymphocytes detach and remain 4 
in the circulation.  The firm adhesion of stimulated cells is mediated by the up-
regulation  of  integrins  which  brings  the  adherent  cell  to  arrest  and  allows 
progression to TEM.  TEM is a complex process and the exact mechanisms are 
unresolved but it is dependent on the integrin binding to endothelial cells and 
the activation of lymphocytes by chemokines.  TEM generally occurs through 
endothelial cell junctions, formed by the interactions of a number of adhesion 
molecules,  including  junctional  adhesion  molecules  (JAMs)  along  increasing 
chemokine gradients. JAMs have been implicated in vascular inflammation as a 
result  of  redistribution  to  the  apical  surface  to  increase  the  adhesion  of 
lymphocytes (5).  The final obstacle in the recruitment of lymphocytes is the 
basement membrane but the mechanisms of this are incompletely understood.  
Release of endothelial cells into the circulation as a result of necrosis has been 
observed, intensifying the pathology at the endothelial surface and exacerbating 
inflammatory reactions (6-9).  Resolution of inflammation aims to restore the 
injured tissue back to its normal state but in cases where the stimulating factors 
could not be removed, or by loss of regulation, chronic inflammation results in 
severe tissue damage and loss of function with progressing clinical symptoms.  
These chronic inflammatory reactions can occur due to defects in the body’s 
regulatory processes of tolerance which results in immune and inflammatory 
responses  against  self  components  of  the  body  resulting  in  autoimmune 
responses.      
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Figure 1.1 The Multistep Model of Lymphocyte Extravasation 
 
Recruitment  of  lymphocytes  to  areas  of  inflammation  occurs  from  a  multistep  process.    Initially 
interactions  between  lymphocytes  and  adhesion  molecules  (selectins)  slow  the  rate  of  lymphocyte 
movement  along  the  endothelial  surface.    Chemokines  (  )  at  the  epithelial  surface  stimulate  the 
lymphocyte and integrin binding halts the lymphocyte on the cell surface.  Lymphocytes then migrate 
through the epithelial cell layer by transendothelial migration towards a source of chemokine production.  
Unstimulated  cells  detach  from  the  endothelial  surface  and  remain  in  the  circulation.    Chronic 
inflammation  can  result  in  endothelial  cell  necrosis  causing  them  to  detach  from  the  basement 
membrane and enter the circulation.  Adapted from 1-4. 
 5 
1.1.2 Tolerance Mechanisms in Controlling Autoimmunity 
Tolerance  is  the  regulation  of  immune  responses  to  antigens  ensuring  that 
immune  responses  to  self-antigens  are  controlled  and  repressed  while 
maintaining the capacity to exert an effective immune response against foreign 
antigens;  essentially  the  discrimination  between  self-  and  non-self  antigens.  
Tolerance is applied to cells with antigen-specific receptors, T and B cells, and 
is  acquired  following  interaction  of  a  self-antigen  with  an  antigen-specific 
lymphocyte which results in signalling for cell inactivation.  Due to the process 
of the antigen receptor generation by random recombination of receptor gene 
fragments,  the  development  of  autoreactive  cells  is  a  normal  consequence.  
Between 20 and 50% of TCRs and BCRs generated are thought to bind with 
dangerously high affinity to self antigens; the work of one group found that 75% 
of gene rearrangements in immature B cells were autoreactive (10-12).  Despite 
the  generation  of  these  autoreactive  cells,  tolerance  mechanisms  aim  to 
regulate and arrest the development of these cells.   
 
Tolerance is induced at a number of stages along lymphocyte development and 
differentiation pathways.  To prevent immune responses towards self-antigens, 
developing  T  and  B  cells,  with  specificity  towards  self-antigens,  undergo 
negative selection in early stages of development within the primary lymphoid 
organs, the thymus and bone marrow for T and B cells respectively, resulting in 
cell inactivation.  This process of cell inactivation is known as central tolerance 
but  such  reactions  can  also  be  carried  out  in  the  periphery  with  mature 
lymphocytes,  which  have  either  escaped  central  tolerance  mechanisms  or 
became  self-reactive  as  a  result  of  further  receptor-gene  diversification 
processes in the periphery, resulting in peripheral tolerance.  The lymphocyte 
tolerance mechanisms in these reactions can result in cell editing, deletion or 
inactivation  (anergy)  (1;11;12),  but  these  mechanisms  are  not  mutually 
exclusive and cells that were initially anergised may be deleted at a later stage.  
Upon  detection  of  an  autoreactive  high  affinity  self  antigen  by  BCR  or  TCR 
expressed  on  immature  B  cells  or  immature  thymic  T  cells  within  the  bone 
marrow and thymus respectively, the maturation of the cell is halted.  Within the 
bone  marrow  homing  and  activation  receptors  such  as  CD62L  and  B  cell 
activating  factor  (BAFF)  are  poorly  expressed  or  induced.    Conversely 6 
recombination-activating gene 1 (RAG1) and RAG2 are continually expressed 
to  allow  the  BCRs  to  be  edited.    Receptor  editing  involves  the  further 
rearrangement of the antigen specific receptor to alter the antigen specificity of 
the cells allowing the rescue of these cells from inactivation.  For the antibody 
light (L) chains of B cells, upstream VL and downstream JL gene segments of 
the rearranged VLJL can recombine to form a new VLJL rearrangement (1).  In 
heavy  (H)  antibody  chains  of  B  cells,  due  to  the  process  of  V(D)J 
recombination,  discussed  further  in  section  1.4,  all  unused  D  segments  are 
deleted.    For  editing  of  the  rearranged  gene  to  occur,  cleavage  at  cryptic 
recombination signal sequences (cRSS) located near the 3’ end of the VH gene 
results  in  formation  of  a  double-stranded  break.    Following  cleavage, 
recombination with a new VH gene results in a new V(D)J rearrangement (13), 
reviewed (14).  The receptor editing processes of central tolerance can also 
occur  within  the  periphery  as  receptor  revision.    This  peripheral  tolerance 
mechanism, and its importance in tolerance, has been recently substantiated by 
the work of Wang and Diamond (15) reviewed (16).  This study demonstrated 
the  re-expression  of  RAG  proteins,  essential  components  of  recombination 
processes, in peripheral autoreactive B cells in germinal centre (GC) responses 
but also following activation of autoreactive B cells by soluble antigen outside of 
the GC environment.  This work follows previous studies which have identified 
RAG expressing B cells in the peripheral blood of lupus patients (17) and the 
synovial  tissue  of  Rheumatoid  Arthritis  (RA)  patients  (18).    Within  T  cell 
populations TCRs can stimulate an editing process which downregulates TCRs 
and allows RAG expression to continue to allow the offending TCR α-chain to 
be replaced or diluted with a second α-chain that is less self-reactive.  If the 
receptor fails to edit sufficiently in both B and T cells, cell deletion occurs due to 
increased levels of BIM (BCL-2-interacting mediator of cell death) that inhibit the 
BCL-2 family of proteins which are essential for lymphocyte survival or activate 
death  receptors  such  as  Fas  (11;12).    Both  editing  and  deletion  processes 
occur  within  developing  T  cells  but  deletion  appears  to  be  the  dominant 
process.  Anergy is a process which leaves B and T cells in an unresponsive 
state and occurs when B and T cells recognise antigens without sufficient levels 
of co-stimulation, from helper T cells and APCs that are required for full cell 
activation.  Several mechanisms of anergy have been documented and include 7 
the  downregulation  and  decreased  display  of  BCRs  and  TCRs  on  the  cell 
surface, the blocked transfer of new antigen receptors from the endoplasmic 
reticulum as well as increased expression of inhibitory receptors such as CD5 
on both B and T cells and cytotoxic T-lymphocyte antigen 4 (CTLA-4) on T cells 
which are increased on self reactive cells and inhibit cell activation (1;11;12;19-
21).  An additional mechanism is also thought to play a role in tolerance, clonal 
ignorance in which B and T cells that have failed to be edited or trigger deletion 
co-exist with antigen without being affected by it as the self-reactive cells are 
either not in contact with the stimulating antigen or they binds so weakly that 
there is insufficient signalling to activate the cell.  In the periphery, with large 
numbers  of  circulating  B  and  T  cells,  self-reactive  cells  can  fail  to  receive 
sufficient stimulation and activation factors such as BAFF and IL-7 for B cells 
and T cells respectively and are competitively deleted (22;23).  In addition to 
regulating  self-reactive  cells  that  have  escaped  the  central  tolerance 
mechanisms, peripheral tolerance mechanisms also need to regulate a second 
generation of self-reactive cells that are produced within GC reactions, a result 
of  the  additional  receptor  gene  diversification  mechanisms.    These  cells 
potentially have an increased affinity for self antigens and have the potential to 
diversify into memory and long-lived plasma cells which  would produce self-
reactive antibodies indefinitely.  GC reactions also have the potential to be a 
powerful stimulus for self-reactive cells in the production of autoantibodies by 
the  presentation  of  self  antigens  within  immune  complexes.    Little  is  known 
about  the  tolerance  mechanisms  that  normally  deal  with  self-reactive  cells 
participating  in  GC  reactions  but  it  has  been  demonstrated  that  self-reactive 
BCRs  induce  subtle  differences  in  the  cell’s  responsiveness  to  chemokine 
gradients  which  excludes  them  from  follicles  and  minimises  the  self-reactive 
cell’s participation in germinal centre reactions (12;24).  
 
Another  aspect  of  tolerance  is  the  role  of  regulatory  T  and  B  cells  within 
peripheral  tolerance.    In  recent  years  vast  arrays  of  studies  have  been 
conducted on regulatory T cells (Tregs) and their ability to suppress rather than 
activate immune responses.  These CD4
+ differentiated T cells can arise during 
normal T cell development and are thought to make up approximately 5-10% of 
the CD4
+ cell population but are committed to a regulatory fate in the thymus 8 
after high-affinity binding to MHC molecules containing self peptides rather than 
being deleted or inactivated under the tolerance mechanisms described above 
(25).  Once released into the periphery as a mechanism of tolerance, the exact 
mechanisms of suppression by these cells are not fully established.  Studies 
have  demonstrated  that  suppressive  mechanisms  include  the  regulation  of 
responses by the IL-10 and TGF-β cytokines produced by these cells (26) and it 
has  also  been  shown  that  they  can  affect  the  maturation  and  antigen-
presentation capacity of DCs (27).  Regulatory T cells have been classified as 
natural Tregs but adaptive Tregs have also been described which differentiate 
from a heterogeneous group of naïve CD4
+ T cells in the periphery under the 
influence of particular environmental conditions to elicit suppressive effects on 
auto-reactive responses. 
 
Recently  it  has  been  shown  that  B  cells  may  also  have  a  suppressive  and 
regulatory  role  in  immune  responses  in  addition  to  their  role  as  positive 
regulators of immune responses.  Most of the evidence for regulatory B cells 
presently  comes  from  studies  in  autoimmune  mouse  models,  such  as  EAE 
where they prevent the development of disease as well as reduce the severity 
of disease once it has been established, but the existence of a Breg cell subset 
has yet to be confirmed in humans.  It is thought that these cells may suppress 
the  activation  and  differentiation  of  T  cells,  disrupt  the  antigen-presenting 
function in DCs, promote autoantibody mediated clearance of apoptotic cells to 
reduce the autoantigenic load or induce the activity of Tregs (28;29).   Studies 
have  established  that  Bregs  mediate  their  effects  through  IL-10  but  what 
remains unclear is if this regulatory mechanism is a general property of multiple 
B  cells  subsets  or  if  it  is  unique  to a  specific  suppressive  subset  of  B  cells 
(28;30;31).        
 
Although these mechanisms aim to remove and inactivate self-reactive T and B 
cells, and prevent the initiation of immune reactions towards self-antigens, not 
all of these cells are removed during these tolerance mechanisms under normal 
conditions.  Self-reactive responses may also occur as some antigens may be 
ignored by these mechanisms as they are below the critical threshold and are 
present  at  too  low  a  concentration  or  some  antigens  may  be  present  at 9 
immunologically  privileged  sites  that  do  not  elicit  a  destructive  immune 
response under normal conditions.  Disruption to the integrity of these tolerance 
mechanisms leads to the initiation of self-reactive responses within the body, 
resulting  in  specific  B  and  T  cell  adaptive  immune  responses  against  self 
antigens leading to the development of autoimmune diseases.  
 
1.1.3 Breaking of Self-Tolerance and the Autoimmune Response 
A  vast  array  of  autoimmune  disorders  exists  but  the  precise  aetiology  and 
initiating antigens of these responses is unknown in most cases.  Autoimmune 
disorders can be broadly classified , based on the tissue or organ involved, as 
organ-specific  like  Multiple  Sclerosis  (MS),  Myasthenia  Gravis  (MG),  Type  1 
Diabetes (T1D), Hashimoto’s Thyroiditis (HT) with responses to organ specific 
autoantigens and the formation of tissue specific autoantibodies or non-organ-
specific or systemic which includes Rheumatoid Arthritis (RA), Systemic Lupus 
Erythematosus  (SLE),  Inflammatory  myopathies,  such  as  Dermatomyositis 
(DM),  Sjögrens  Syndrome  (SS)  and  various  vasculitic  disorders  which  affect 
multiple  organs  and  generate  autoantibodies  that  are  not  tissue  specific, 
although  not  all  autoimmune  disorders  can  be  classified  according  to  these 
criteria  (1).    The  initiation  of  autoimmune  responses  occurs  when  there  is 
disruption  of  tolerance  mechanisms  and  activation  of  self-reactive  cells  as 
previously  described,  although  self-reactive  cells  are  part  of  the  normal  cell 
repertoire and activation of self-reactive cells, at a low level, is physiological and 
crucial to the normal immune function and does not always necessarily lead to 
the  development  of  a  pathological  response  to  self-antigens.    Under  normal 
conditions self-reactive cells help to shape and form the repertoire of mature 
lymphocytes.  Autoreactive cells are part of the normal cell repertoire but with 
autoimmune  disorders  occurring  in  approximately  5%  of  the  population  a 
number  of  other  susceptibility  factors  must  also  play  a  role  in  autoimmune 
disorders (1).  Pathological autoimmune responses develop when a number of 
safe-guard and tolerance mechanisms are overcome or disrupted resulting in a 
sustained response towards self-antigen generating effector mechanisms that 
result  in  tissue  damage.    A  combination  of  factors  such  as  genetic 
predisposition  and  exposure  to  environmental  triggers  are  thought  to  initiate 
autoimmune responses in addition to alterations in tolerance mechanisms. 10 
Firstly,  age  and  gender  may  play  a  role  in  the  initiation  of  autoimmune 
responses.    Autoantibodies  are  more  prevalent  in  older  people  and  certain 
autoimmune  disorders  have  female  or  male  bias.    DM  and  SLE  are  more 
commonly observed in females, with a 9:1 female:male bias observed in SLE, 
whereas Ankylosing Spondylitis (AS) affects more male than female patients 
(1;32;33).     
 
Genetic susceptibility factors can have various influences on the development 
of  autoimmune  disorders  from  a  genetic  predisposition  from  inherited  MHC 
genes  to  polymorphisms  of  genes  that  are  involved  in  maintenance  of  self-
tolerance  and  immune  regulation  such  as  regulatory  proteins.    Many 
autoimmune disorders are heterogeneous with no one gene sufficient to initiate 
disease mechanisms.  The most common evidence of a genetic predisposition 
is the higher incidence of disease in monozygotic twins, with a lower but still 
increased  incidence  in  dizygotic  twins  and  family  members  in  relation  to  an 
unrelated  population.    Regardless  of  any  other  variables  for  the  initiation  of 
autoimmune reactions, predispositions of autoimmune disorders are associated 
with certain MHC alleles. MS and RA are associated with the DR2 and DR4 
alleles respectively while SLE, SS, MG and Inclusion Body Myositis (IBM) have 
an association with the DR3 allele (1;34).  Most autoimmune disorders have an 
association  with  MHC  class  II  alleles  but  there  are  cases  for  a  strong 
association with type I alleles, like B27 observed in over 90% of AS patients 
(35), reviewed (36).  These particular alleles may contribute to the development 
of autoimmune reactions through the presentation of self antigens, or mimics, 
driving positive selection of autoreactive cells; the presence or absence of the 
appropriate MHC determines whether a potential autoantigen is presented and 
the  occurrence  of  a  response  to  the  antigen.    These  alleles  may  only  be 
expressed at low levels or have low affinity towards the antigen that would not 
drive a negative selection response but are present at a sufficient level and with 
sufficient affinity to drive positive selection.  It may also be the case that the 
antigens  presented  on  these  alleles  may  fail  to  stimulate  the  formation  of 
regulatory T cells or they are inefficiently presented.  
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Polymorphisms in a number of other genes have also been associated with the 
development  of  autoimmune  reactions.    Single-nucleotide  polymorphisms 
(SNPs) have been observed in the CTLA-4 and PTPN22 genes (1;12;37;38).  
As previously mentioned CTLA-4 is an inhibitory receptor expressed on T cells.  
Lack of CTLA-4 has been shown to cause a large accumulation of self-reactive 
T  cells  in  peripheral and nonlymphoid  organs  and  causes  disruption of both 
TCR-induced proliferation but also impairs the suppressive properties of Tregs.  
Defects in this gene caused by SNPs are associated with diseases such as T1D 
and  Grave’s  disease  (19).    Similarly  to  CTLA-4,  PTPN22,  protein  tyrosine 
phosphate nonreceptor type 22, is involved in suppression of T cell activation 
and SNPs within this gene are associated with T1D as well as RA and SLE 
(39;40).    Mutations  within  the  AIRE  (autoimmune  regulator)  gene,  which 
promotes  the  thymic  expression  of  peripheral  tissue-restricted  genes,  have 
been found to be responsible for autoimmune polyendocrinopathy-candidiasis-
ectodermal  dystrophy  (APECED)  which  leads  to  destruction  of  multiple 
endocrine tissues (1;12;37;38).  In addition to subtle mutational changes within 
genes, the deletion or overexpression of genes resulting in defects in cytokine 
production  or  signalling  can  also  contribute  to  the  pathogenesis  of 
autoimmunity;  overexpression  of  TNF-α  is  associated  with  arthritis  and 
vasculitis while underexpression of the same cytokine is associated with SLE.  
Elevated  BAFF  levels  have  also  been  reported  in  a  number  of  autoimmune 
disorders, including the inflammatory myopathies, in particular DM (41;42).         
 
As well as these genetic mechanisms, defects may also occur in other aspects 
of  the  immune  response.    Defects  in  regulatory  T  cell  functions  have  been 
described in SLE (43) and in MS patients where Treg populations are normal 
but their suppressive activity is defective (1;44).  Several autoimmune disorders 
have also been associated with apoptosis.  The process of programmed cell 
death is essential for the prevention of autoimmune reactions as this process is 
responsible  for  the  removal  of  self-reactive  cells  and  the  downregulation  of 
immune  responses  to  self  antigens.    Impaired  generation  or  clearance  of 
apoptotic cells and alterations in apoptosis machinery can reduce resistance to 
normal  processes  of  cell  death  and  expose  cytoplasmic  and  nuclear 
components that are normally sheltered from the immune system.  Mutations 12 
within Fas genes have been associated with autoimmune lymphoproliferative 
syndrome (ALPS), T1D and MS (1;38).  
 
Breakdowns in tolerance and the initiation of autoimmune reactions have also 
been  associated  with  a  number  of  infections  that  can  initiate  autoimmune 
reactions by a number of pathways.  For example, certain subsets of vasculitis 
have been associated with hepatitis B and C viruses as well as Staphylococcus 
aureus and parvovirus B19 infections (45), SLE has been associated with the 
Epstein-Barr  virus  (32;33)  and  Guillain-Barré  syndrome  is  associated  with 
Campylobacter  jejuni  infections  (12;46;47).      Infectious  agents  may  directly 
activate autoreactive cells by presenting antigens that are cross-reactive with 
self  antigens  in  a  process  of  molecular  mimicry.    As  a  result,  the  immune 
response  and  resultant  antibodies  produced  against  the  infectious  agent are 
directed against self antigens.  The structures of the infections agent and the 
self antigen do not need to be identical as long as they are sufficiently similar to 
be recognised by the same antigen receptor or antibody.  Once self-reactive 
cells  have  been  activated  by  these  cross-reactive  mechanisms,  the  effector 
functions of these cells can lead to tissue destruction.  This mechanism has 
been  shown  for  Guillain-Barré  syndrome  where  antibodies  produced  in 
response  to  C.  jejuni  infections  are  directed  towards  components  of  the 
peripheral nerves (12;46;47).  An infectious agent may not necessarily trigger a 
pathogenic autoimmune response directly; this may follow as a result of epitope 
spreading in the reaction.  Epitope spreading is the diversification of the epitope 
specificity and extension of the autoreactive response from the initial focused 
epitope to new epitopes and new autoantigens (37;38;48).  As a result of the 
immune  response  towards  the  initial  infectious  agent,  previously  hidden  or 
cryptic epitopes of the autoantigen may be presented to the immune system, as 
well  as  a  modified  version  of  the  initial  epitope  due  to  altered  processing 
mechanisms, resulting in a cascade of autoreactive cells within the response 
and  an  extension of  the  self-reactive  immune  response to multiple  epitopes.  
Epitope modification can also occur due to exposure to drugs or other chemical 
agents.  These may modify self-components and result in the formation of neo-
antigens which the immune system has never seen and therefore is not tolerant 
towards, eliciting an autoreactive immune response (1;37).  Drug associated 13 
disorders been observed in a number of autoimmune disorders, including SLE 
patients  following  exposure  to  procainamide,  as  well  as  a  number  of  other 
drugs, and in myositis patients as a result of statin therapy (32;33;49).      
 
The  strong  inflammatory  response  to  infections  may  itself  stimulate  an 
autoreactive response as a result of non-specific activation of self reactive cells 
in a process known as bystander inflammation (37;38;48).  The response to 
infections may result in tissue damage or cell death which may cause release, 
and increase the presentation, of potential autoantigens that have previously 
been sequestered from the immune system which stimulate the activation of 
autoreactive cells.  The inflammatory mediators, such as cytokines, generated 
during  the  immune  response  could  lead  to  the  attraction,  activation  and 
expansion of autoreactive cells at sites of infection as well as stimulation of 
anergic cells which have previously been inactive, perpetuating the autoimmune 
response.  It has also been described that stimulatory ligands released by the 
invading infectious agent, such as CpG dinucleotides, may stimulate antibody 
production  from  autoreactive  B  cells,  stimulating  the  autoimmune  response 
(12;50).    These  ligands  are  recognized  by  TLRs  on  B  cells  and  partially 
substitute for T cell help promoting autoantibody production. 
 
The adaptive immune responses involved during autoimmunity are incapable of 
removing the offending antigen therefore the immune responses persists with a 
constant  supply  of  antigen  resulting  in  amplification  of  the  response  which 
manifests  as  tissue  damage  as  a  result  of  the  effector  mechanisms.    The 
effector  mechanisms  associated  with  autoimmune  disorders  are  generally 
classified according to the scheme adopted for hypersensitivity reactions (1).  
Type I, IgE mediated, reactions do not seem to play a major role in autoimmune 
reactions  but  conversely  Type  II,  autoantibody  mediated,  reactions  are 
common.    Autoantibodies  bind  to  the  cell  surface  and  either  alone  via  Fc 
receptor opsonisation or with the help of complement damage cells.  This is 
observed in autoimmune hemolytic anaemia (AIHA) where IgG autoantibodies 
bind  to  red  blood  cells  leading  to  rapid  destruction  of  the  cells.    In 
Goodpasture’s  syndrome  the  IgG  autoantibodies  bind  directly  to  cells  in  the 
tissue resulting in tissue damage.  Within this type of reaction, the antibodies 14 
can bind and either interfere or enhance the functional activity of the cell.  In 
MG,  the  binding  of  autoantibodies  to  the  acetylcholine  receptor  block  the 
neuromuscular transmission from the receptor whereas in Grave’s disease the 
autoantibodies continually stimulate production of thyroid hormone.  Type III, 
immune  complex  (IC)  mediated  disorders  result  from  circulation  of  ICs 
composed  of  soluble  antigen  and  autoantibodies  resulting  in  systemic 
manifestations.  ICs are normally cleared in healthy individuals but clearance 
may  be  defective  or  may  be  overwhelmed  by  the  continuous  supply  of 
autoantigens in self-reactive responses.  ICs can mediate tissue damage by 
activation of complement or phagocytic cells through Fc receptors.  These types 
of effector mechanisms have been observed in autoimmune disorders such as 
various vasculitic disorders and SLE where ICs are deposited in blood vessels 
and kidneys respectively.  Finally Type IV, T cell mediated, mechanisms occur 
in disorders such as Type 1 diabetes and MS.  These autoreactive T cells not 
only  play  a  helper  role  in  autoimmune  development  but  also  have  a  direct, 
cytotoxic,  role  in  tissue  damage  similar  to  the  mechanisms  during  a  normal 
immune response.  
 
As  described  above,  autoimmune  diseases  are  multifactoral  and  involve  an 
extensive  range  of  cells  and  effector  mechanisms  but  B  cells  and  their 
production of autoantibodies are frequently central to these mechanisms and 
autoimmune reactions.  Some disorders are thought to be directly dependent on 
the actions of B cells while in some disorders it is thought that B cells merely 
play an accessory role.  The full extent of B cell involvement and the precise 
role of these cells have not fully been established in a number of autoimmune 
diseases.    Given  the  potential  for  B  cells  in  GC  reactions  to  generate  and 
diversify high-affinity self-reactive B cells, and the resultant autoantibodies, as 
well as the identification of GCs as tertiary lymphoid organ (TLO) formations at 
ectopic  sites  adjacent  to  autoantigen  sources  in  a  number  of  autoimmune 
disorders,  reviewed  (51),  the  production  of  tissue-specific  and/or  disease 
relevant autoantibodies and development of effector mechanisms in situ is an 
important component of the autoimmune response in a number of disorders.  
Previous studies have identified autoreactive B cells generated in ectopic GCs 
in a number of autoimmune disorders including MG (52), SS (53) and HT (54) 15 
and most recently in RA (55), but they have not yet been identified in a number 
of other autoimmune disorders such as myositis and vasculitis.  Myositis, as 
well  as  vasculitis,  discussed  further  in  sections  1.2  and  1.3,  are  a  series  of 
systemic  disorders  with  unknown  aetiology  that  have  been  associated  with 
aspects of the different genetic and environmental features discussed in this 
section  that  may  disrupt  self  tolerance  resulting  in  the  formation  of 
autoantibodies and leading to the initiation of autoimmune disease.  The work 
presented in this thesis examines the loss of B cell tolerance in these disorders 
to determine if B cells are being locally stimulated by self-antigen leading to the 
production of potentially self reactive high affinity autoantibodies. 
 
1.2 Myositis  
Inflammatory myopathies, or myositis, are inflammatory disorders of the muscle 
composed of 3 principal subsets, dermatomyositis (DM), polymyositis (PM) and 
Inclusion body myositis (IBM) (56-68).  Other forms of myositis have also been 
described and include giant cell myositis, eosinophilic myositis, granulomatous 
myositis, necrotizing myositis and drug-associated myositis, induced notably by 
HMG-CoA reductase inhibitors (statins) (49;56;69;70).  A diagram representing 
normal  muscle  architecture,  in  cross-section,  is  shown  in  Figure  1.2  and 
identifies  the  regions  where  inflammation  and  lymphocyte  aggregation  are 
observed within the 3 myositis subsets.  Each of the 3 principal disorders is 
characterised  by  moderate  to  severe  muscle  weakness  and  mononuclear 
inflammatory  cell  infiltrates  (59).  Patients  with  myositis  present  with  varying 
degrees of muscle weakness which may develop over weeks to months as a 
result of muscle inflammation.  Diagnosis of myositis is based on the results of 
an  electromyography,  elevated  muscle  enzymes  in  serum  (creatine  kinase 
(CK))  by  as  much  as  50  fold  and  a  muscle  biopsy  to  define  histological 
changes.  Concentrations of CK usually parallel the disease activity but normal 
levels may be found in some DM and IBM patients; continuous elevated CK 
levels have been reported during active PM (58;71).  Inflammatory myopathies 
are systemic and often multi-organ illnesses, skin, heart, lungs, gastrointestinal 
tract and joints can all be affected in each disorder (56). Classification criteria 
for myositis was originally devised by Bohan and Peter (72;73) but this failed to 
distinguish  between  PM  and  IBM  and  the  criteria  has  recently  been  revised 16 
(58).  Each of the 3 inflammatory myopathies have been seen in connection 
with  various  autoimmune  and  connective  tissue  diseases  as  well  as  being 
associated with malignancies (58); malignancy is thought to be associated with  
up to 45 % of adult DM patients (71).  DM and PM have been reported in 4-16% 
of Systemic Lupus Erythematosus (SLE) cases with DM most commonly found, 
a retrospective study of myositis in SLE found that the muscle disease observed 
in SLE was similar, in a small sample size, to primary myositis disorders (61).  
The  pathogenesis  and  mechanisms  of  cellular  injury  are  still  unresolved  in 
myositis; possible mechanisms are summarized in Figure 1.3.   
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.1 Dermatomyositis (DM) 
DM, found in both children and adults, is observed in women more than men 
and is the most common inflammatory myopathy (58;63).  DM is characterised 
by a heliotrope rash on the upper eyelids, face or upper trunk accompanying or 
more commonly preceding proximal muscle weakness (63;74;75).  Gottron rash 
is also observed in approximately 30% of DM patients; a raised rash or papules 
at the knuckles, prominent in metacarpophalangeal and interphalangeal joints 
(56;58;63;75). Inflammation is predominately perivascular and/or perimysial or 
in the interfascicular septae and around, rather than within, the muscle fascicles 
but can extend into the individual muscle fascicles along the endomysium at 
fascicle edges (Figure 1.2).  Perivascular atrophy is another characteristic within 
DM patients, a result of degeneration and phagocytosis of muscle fibres often in 
 
Muscle  tissue  consists  of  three  dense 
layers of connective tissue.  The outermost 
layer,  encircling  the  whole  muscle  is  the 
epimysium.    The  perimysium  surrounds 
bundles, or fascicles, of individual muscle 
fibres.  Within the fascicle each individual 
muscle  fibre  is  surrounded  by  the 
endomysium.   Muscles are well supplied 
with blood vessels and capillaries which are 
abundant  within  the  endomysium 
surrounding each muscle fibre. 
 
In  inflammatory  myopathies  various 
patterns  of  lymphocytic  infiltration  are 
observed.    In  DM  this  pattern  is  largely 
perimysial/perivascular  surrounding 
fascicles  while  in  PM/IBM  inflammatory 
infiltrates  are  largely  endomysial  and  are 
found surrounding individual muscle fibres 
within fascicles.   
Epimysium 
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Figure 1.2 Transverse-Sectional 
Representation of Skeletal Muscle Tissue. 
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groups at the periphery of the fascicle at perimysial locations (60). Lymphocyte 
infiltrations in DM have a higher than normal percentage of B and CD4
+ cells 
compared to CD8
+ cells (58-60;65).  The proximity of CD4
+ cells to B cells and 
macrophages  and  the  absence  of  lymphocytic  invasion  into  muscle  fibres 
suggest that DM is a humorally mediated immune response, possibly towards 
microvessels.    B  cells  observed  within  inflammatory  myopathies  are  more 
commonly observed in muscle tissue from patients with DM compared to PM or 
IBM  (65).    The  immune  process  in  DM  is  thought  to  be  directed  against 
microvascular  antigens  in  a  process  mediated  by  the  complement  C5b-9 
membrane attack complex (MAC).  Complement deposits result in necrosis of 
the endothelial cells leading to muscle fibre destruction (58-60).  Complement 
activation  occurs  early  in  disease  triggering  the  release  of  proinflammatory 
cytokines  which  upregulate  VCAM-1  and  ICAM-1  on  endothelial  cells  and 
facilitates the transmigration of activated lymphoid cells to the perimysial and 
endomysial spaces (60).  
 
Different subsets of DM have been described in patients (75-77); patients with 
amyopathic  DM  (ADM)  display  the  classical  cutaneous  features  of  DM  for 
prolonged periods of time without clinical evidence of muscle weakness and 
with  normal  muscle  enzymes.    Hypomyopathic  DM  (HDM)  has  also  been 
described which is similar to ADM except that upon testing evidence of muscle 
inflammation is evident.  These distinctive subsets have also been observed 
within juvenile myositis (78).  DM is the most frequent inflammatory myopathy 
observed  in  children,  approximately  85%  of  all  juvenile  inflammatory 
myopathies (78).  The peak onset age of juvenile DM is approximately 7 years 
although a broad distribution is observed throughout childhood. 25% of cases 
have  onset  prior  to  age  5,  and  is  primarily  observed  within  girls  although  a 
similar incidence has been reported between boys and girls (63;78).  Certain 
characteristics are observed in juvenile DM that are not frequent within the adult 
form of the disease; dystrophic calcification with calcium deposits in the skin, 
subcutaneous tissue or muscle are observed in 30% of patients (78).  For both 
the adult form of the disease and juvenile DM the same major immunogenetic 
risk factors haven been identified which include HLA DRB1*0301 and it’s linked 
allele DQA1*0501.  In addition to similar risk factors, similar protective factors 18 
have  been  identified  in  European  Americans,  DQA1*0201,  *0101  and  *0102 
(78).  The similar risk and protective factors observed between juvenile DM and 
the adult form suggest common elements within the disorders.          
 
1.2.2 Polymyositis (PM) 
PM is generally observed after the second decade of life and is best defined as 
a  subacute myopathy  that  evolves  over  weeks  to months  and  presents  with 
symmetrical weakness of the proximal muscles (58).  The actual onset of PM is 
hard to define as there are no early recognition signs such as the rash observed 
in DM.  As a stand-alone disorder PM is uncommon and is more commonly 
observed  in  conjunction  with  other  autoimmune  and  connective  tissue 
disorders.  PM is characterised by scattered necrotic and regenerating muscle 
fibres  and  endomysial  inflammation  with  invasion  and  destruction  of  non-
necrotic  muscle  fibres  (Figure  1.2)  (65;66).    Inflammatory  infiltrates  mostly 
consist of CD8
+ T cells and macrophages which invade MHC class I antigen 
expressing  muscle  fibres  leading  to  fibre  necrosis  via  the  perforin  pathway 
suggesting  the  immune  reactions  target  muscle  fibres  (56;58-60;63;65;66).  
MHC  class  I  expression,  absent  from  normal  muscle  fibres  but  found 
widespread  in  inflammatory  myopathies  (79),  is  thought  to  be  induced  by 
cytokines secreted by activated T cells and macrophages.    The MHC class I 
(muscle) : CD8 complex (T cell) is characteristic of PM.  A proportion of the infiltrating 
cytotoxic CD8
+ T cells have been shown to be clonally expanded and suggest 
an  antigen-driven  T  cell  response.    These  cells  have  conserved  amino  acid 
sequences  within  the  CDR3  region  of  the  T  cell  receptor  (TCR)  while  other 
infiltrating, non-invading cells are clonally diverse (59;65;67;80-84).  Pathology 
within PM is a result of these clonally expanded CD8
+ T cells invading muscle 
fibres that express the MHC class I antigen which results in fibre necrosis via 
the  perforin  pathway  (63).    Cytotoxic  CD8
+  T  cells  can  release  3  cytotoxic 
proteins: perforin, granzyme and granulysin (65).  Perforin may cause a leak in 
the sarcolemmal surface through which granzymes could invade the muscle to 
initiate fibre necrosis (65).  This pathogenesis pathway has also been observed 
in  perforin/granzyme  expressing  CD4
+  lymphocytes,  reviewed  (65),  although 
perforin was found to be randomly distributed in the cytoplasm of CD4
+ cells in 
comparison to CD8
+ cells where perforin is located towards the target muscle 19 
fibre (85) .  The ER stress response pathway has also been proposed to result 
in muscle damage (86).  Nagaraju et al (86) demonstrated that the ER stress 
response  pathway  was  highly  activated  in  human  myositis  and  that 
overexpression  of  MHC  class  I,  observed  in  muscle  fibres,  induces  the  ER 
response.  
 
Immunohistochemical studies have demonstrated that few CD20
+ B cells are 
present within PM muscle biopsies in contrast to T cells which would indicate 
that humoral mediated immune responses do not play a major role within PM 
(87;88).  Greenberg et al (89) examined the infiltration of CD138
+ plasma cells 
in PM muscle biopsies.  In PM samples B cells displayed a mean density of 2.8 
cells / mm
2, while CD138
+ plasma cells displayed a mean density of 11.0 cells / 
mm
2 which were predominately located in the endomysium.  The identification 
of plasma cells within PM biopsies was confirmed by sequence analysis of Ig V-
genes  expressed  by  single  plasma  cells  isolated  by  laser  capture 
microdissection.  Although the occurrence of plasma cells was established the 
functional role of these cells in PM was unclear until a subsequent study (90) 
demonstrated  that  infiltrating  plasma  cells  in  PM  were  clonally  related  and 
undergoing an antigen-driven response. 
 
1.2.3 Inclusion Body Myositis (IBM) 
In  male  patients  over  the  age  of  50  IBM  is  the  most  frequent  inflammatory 
myopathy with distinctive atrophy and weakness of wrist and finger flexors and 
quadriceps and can often be asymmetrical (34;56;59;60;63;71;91).  Although 
similar to PM, less frequent myofibre necrosis and increased invasion of non-
necrotic fibres by lymphocytic infiltrates have been observed in IBM (65;66).  
Other features of IBM include rimmed vacuoles and groups of atrophic fibres 
(68).   A strong association with HLA DR3 has been reported and is present in 
approximately 75% of cases (34).  CD8
+ T cells are the dominant infiltrating cell 
which  surround  and  invade  MHC  class  I  expressing  muscle  fibres,  the 
characteristic  MHC  class  I  :  CD8  complexes  found  within  PM  are  also 
characteristic of IBM (59;60;63). Also the invading CD8
+ T cells within IBM have 
been demonstrated to be clonally expanded while non-invading infiltrating CD8
+ 
T  cells  were  found  to  be  clonally  diverse  (59;80;92-94).  Amemiya  et  al  (92) 20 
demonstrated  the  clonal  restriction  of  T  cells  within  IBM  and  observed  that 
these clonally related T cell sets persist over the course of the disease.  It was 
also noted that identical rearrangements were found at different muscle biopsy 
sites of the same patient as well as in different patients implying a continued 
response  to  the  same  antigens.    In  addition  to  clonally  expanded  muscle 
infiltrating  T  cells  within  the  muscle,  evidence  has  demonstrated  that  these 
clones also recirculate into the blood (65;80;93) but this may also occur as a 
result of the same antigen being present at both sites leading, independently, to 
the expansion of T cells at both sites.  IBM differs in its clinical presentation as 
the hallmarks of IBM are usually atrophy and weakness of the quadriceps and 
the  wrist  and  finger  flexors,  producing  distal  rather  than  proximal  weakness 
(56;68).  In contrast to PM, IBM has a slowly progressing clinical course, over 
months  to  years  and  is  unresponsive  to  treatment  (34;60).    Pathology 
associated with IBM is thought to occur by the same CD8
+ perforin/granzyme 
mechanism that is observed in PM but an additional pathological mechanism is 
thought to occur in IBM patients.  Granular deposits are found to be distributed 
around vacuoles along with amyloid deposits, first identified in 1991, within or 
next  to  vacuoles,  suggesting  that  two  concurrent  pathological  processes  are 
occurring within IBM (34;59;63).      
 
As found within PM, infiltrating plasma cells were identified in biopsies taken 
from IBM patients (89).  CD138
+ plasma cells displayed a mean density of 17.2 
cells / mm
2 while B cells were observed at a mean density of 4.2 cells / mm
2.  
These infiltrating plasma cells were also found to be clonally related within IBM 
samples  (90)  indicating  that  an  antigen–driven  response  was  also  occurring 
within  IBM  and  that  T  cells  may  not  be  the  only  cell  mediating  an  antigen-
specific  response  within  inflammatory  myopathies  and  other  autoimmune 
diseases.  
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1.2.4 Autoantibodies and Autoantigens in Myositis 
As  with  most  autoimmune  disorders  different  autoantibodies  have  been 
described  within  the  myositis  subsets  DM  and  PM  (95;96).    Classically 
autoantibodies  are  absent  from  IBM  although  they  have  been  detected  in  a 
small  number  of  cases  (95;97).    The  presence  and  diversity  of  these 
autoantibodies  demonstrates  the  significance  of  B  cell  tolerance  in  the 
complexity of these disorders.  Myositis autoantibodies can either be classified 
as  myositis-specific  autoantibodies  (MSAs),  specific  for  the  muscle  disorder 
myositis not specific for muscle tissue, or myositis-associated autoantibodies 
(MAAs)  (95;96), Table 1.1.  Generally individual patients comprise of a single 
MSA but may also have one or more MAAs (95).  Most of these autoantibodies 
are  directed  to  protein  or  ribonucleoprotein  complexes  involved  in  protein 
Figure 1.3 Possible Mechanisms of Pathology in Myositis 
 
 
A muscle lesion induces the overexpression of autoantigens, most notably from regenerating muscle fibres.  The 
released  autoantigen  may  undergo  conformational  changes  resulting  in  cleavage  by  granzyme  B  generating 
unique fragments that were still able to generate a high autoantibody titre response.  Alterations in autoantigens 
may promote apoptosis within muscle fibres.  Autoantigen fragments may exert chemotactic effects resulting in the 
influx of several cell types.  B cell and CD4
+ T cells and may be stimulated to produce autoantibodies which could 
contribute to further pathology or CD8
+ T cells may surround and invade muscle fibres via the Granzyme : perforin 
pathway resulting in muscle fibre necrosis and further autoantigen release.  Adapted from 95.   
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synthesis,  translocation  or  elongation.    MAAs  target  antigens  are  primarily 
located in the nucleoplasm or nucleolus. 
 
                Table 1.1 Myositis-Specific Antigen (MSAs) and Myositis-Associated Antigens (MAAs)  
 
Casciola-Rosen et al (98) recently examined autoantigen expression in normal 
and myositis tissues and observed increased levels of autoantigens in myositis 
affected muscle, particularly in regenerating muscle cells, compared to the low 
levels in control muscle. Low autoantigen expression in normal muscle indicates 
that an immune response, directed against myositis antigens, is unlikely to be 
initiated  in  normal,  unperturbed  normal  muscle.    Enhanced  autoantigen 
expression  was  observed  in  muscle  cells  of  an  immature  and  regenerating 
phenotype.  Despite the emergence of autoantigens in diseased muscle, no site 
of  initiation  for  the  immune  response  was  identified  although  it  was 
hypothesised that forms of proinflammatory muscle injury may induce muscle 
regeneration  which  in  turn  induces  autoantigen  expression  resulting  in 
pathology.  The study suggests that damage focused on cells achieving repair 
produces a feed-forward loop mechanism where regenerating cells provide an 
ongoing antigen supply in the disease progression and therefore are targets for 
Myositis-Specific 
Autoantibodies (MSA)  Target Antigen  Myositis-Associated 
Autoantibodies (MAA)  Target Antigen 
       
Anti-tRNA synthetases -  Aminoacyl-tRNA synthetases – 
 
   
Anti-Jo-1  Histidyl-tRNA synthetase  Anti-Ro60  Cellular Antigen Ro60/SSA 
 
Anti-PL7  Threonyl- tRNA synthetase  Anti-Ro52  Cellular Antigen Ro52/SSA 
 
Anti-PL12  Alanyl-tRNA synthetase  Anti-La  Cellular Antigen La/SSB 
 
Anti-EJ  Glycyl-tRNA synthetase  Anti-RNP  Ribonucleoprotein 
 
Anti-OJ  Isoleucyl-tRNA synthetase  Anti-Ku  Heterodimer bound to 
protein kinase 
 
Anti-KS  Asparaginyl-tRNA synthetase  Anti-PM/Scl  Nucleolar macromolecular 
complex 
Anti-JS  Glutaminyl-tRNA synthetase     
       
Anti-tRNA His  tRNA His     
Anti-tRNA Ala  tRNA Ala     
       
Anti-Mi-2  Nuclear Helicase 
 
   
Anti-SRP  Signal-Recognition Particle 
 
   
Anti-FER  Elongation Factor 1α (eEF1α) 
 
   
Anti-KJ  30/34kDa Translocation Factor 
 
   
Anti-Wa  48kDa unknown peptide 
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attack in the autoimmune process.  This may account for the well defined but 
patchy  histological  changes  of  myositis  next  to  apparently  normal  areas  of 
muscle.    Previous  studies  by  Casciola-Rosen  et  al  (99)  in  SLE  have 
demonstrated  that  the  majority  of  autoantigens  were  effectively  cleaved  by 
granzyme B generating unique fragments that were still able to generate a high 
titre  autoantibody  response,  illustrating  the  complexity  of  antigen-driven 
responses.    
 
1.2.4.1 Aminoacyl-tRNA synthetases (ARS) 
The most prevalent MSAs are directed against amino-acyl-tRNA-synthetases 
(ARS) (95;96;100).  These molecules are cytoplasmic enzymes which catalyse 
the ATP-dependent binding of tRNAs to the corresponding amino acid, forming 
an aminoacyl-tRNA, so that the amino acid can be incorporated into a growing 
polypeptide chain.  The presence of anti-ARS and its clinical manifestations has 
been termed antisynthetase syndrome (ASS) which consists of myositis (DM or 
PM),  idiopathic  interstitial  lung  disease  (ILD),  arthritis  and  Raynaud 
phenomenon  (100;101).    ASS  carries  a  severe  prognosis  with  a  threefold 
increase in mortality compared to myositis without these antibodies (95).  Anti-
ARS antibodies are found in 16-26% of patients with inflammatory myopathies 
but the precise roles of these antibodies are still unresolved (100).  The specific 
anti-ARS antibodies found in myositis patients are shown in Table 1.1.  These 
antibodies are not cross-reactive and occur independently of one another (102).  
Anti-Jo-1  antibodies  are  the  most  prevalent  antibodies  found  in  myositis 
patients;  they  are  found  in  20-30%  of  patients  while  the  other  anti-ARS 
antibodies are only present in 1-3% of patients (100;103;104).  The increased 
occurrence of anti-Jo-1 antibodies indicates that synthetases are not randomly 
targeted;  targeting  of  these  antibodies  may  be  the  result  of  increased 
expression  or  improved  presentation  (105).    Anti-ARS  antibodies  are  mainly 
observed in DM and PM patients and are rarely observed in IBM patients and in 
a  pattern  similar  to  other  MSAs;  only  one  type  anti-ARS  antibody  is  ever 
observed in each myositis patients (95;104).  Anti-OJ and anti-KS antibodies 
have been shown to have a stronger association with ILD than with myositis 
and may distinguish a subtype of ASS (106), while anti-Jo-1 and anti-PL-12 has 
a strong association with ILD in patients with myositis (107;108).  Levine et al 24 
(107)  recently  addressed  whether  alterations  in  histidyl-tRNA  synthetase 
expression and/or conformation was observed in the lung of affected patients.  
A unique, granzyme B cleavable form of histidyl-tRNA synthetase was located 
in the lung.  The presence of this form in the lung and not within muscle focuses 
attention on the lung as the potential driving environment for immunity against 
histidyl-tRNA synthetase.  Muscle may become targeted at later stages upon 
injury  to  muscle  when  histidyl-tRNA  synthetase  antigen  levels  are  increased 
(98).  ARSs can be classified into Class I and Class II synthetases based on 
overall  structure,  characteristic  motifs  and  site  of  tRNA  attachment  (96;105).  
Most of the ARSs found in myositis patients, anti-Jo-1, -PL-7, -PL-12, -EJ and –
KS, belong with Class 2 synthetases but anti-OJ is a Class 1 synthetase that 
exists as part of a multi-enzyme synthetase complex (96;105).  Recent studies 
have  identified  two  new  anti-ARS  antibodies,  anti-phenylalanyl  synthetase 
antibodies (anti-Zo) (109) and anti-tyrosyl antibodies (110).   
 
ARS molecules have been shown to possess chemoattractant properties and 
generate  an  ARS-specific  autoimmune  response  in  myositis  and  ILD 
(105;111;112).  Histidyl-tRNA synthetase and a 1-48 amino acid histidyl-tRNA 
synthetase peptide were chemotactic for human CD4
+, CD8
+ and IL-2 activated 
monocytes  that  express  the  CCR5  receptor  but  not  for  neutrophils  or 
unstimulated  monocytes  that  do  not  express  CCR5  (111;112).    Asparaginyl-
tRNA  synthetase  was  chemotactic  for  CCR3-expressing  mononuclear  cells.  
The chemoattractant properties of these proteins were only two to four folds 
higher over background levels and were not as efficacious as chemokines but 
were  potent  enough  to  induce  migration  in  vitro.    Both  proteins  were  also 
chemotactic for immature dendritic cells (iDC) which express both CCR5 and 
CCR3.  These findings suggest that the tRNA synthetases may participate in 
the initiation of an adaptive immune response which leads to the production of 
autoantibodies; by engaging receptors on iDCs the tRNA synthetases may be 
more likely to initiate T and B cell responses (111).  The chemotactic activity of 
the  tRNA  synthetases  for  iDCs  may  initiate  a  cascade  of  immune  events, 
beginning with the antigen presentation to T lymphocytes and production of B 
lymphocyte stimulating cytokines that results in the production of autoantibodies 
in some patients (111).  These chemotactic effects were not observed for the 25 
nonautoimmune  synthetases  aspartyl  and  lysyl-tRNA  synthetases.    Other 
autoantigens, such as La and ssDNA, were also examined but failed to induce 
leukocyte migration (112).  The reasoning of targeting anti-ARSs or why some 
are targeted over others is largely unknown, as previously described it could 
result from differing expression, presentation or generation of unique fragments 
from granzyme B cleavage.  The similarities in structure may suggest that a 
common structural factor is involved but it has been shown that antibodies to 
different synthetases do not crossreact (96;102). 
 
Anti-Jo-1 antibodies are the most prevalent anti-ARS found in myositis patients 
and are a diagnostic marker for autoimmune myositis and a prognostic marker 
for disease severity (104;113;114).  Anti-Jo-1 antibodies were first described in 
1980 from the serum of a patient affected with PM (104).  Formation of these 
antibodies could be attributed to molecular mimicry from infectious agents, Jo-1 
shares structural homology with a protein, EC-RF4, from Epstein Barr virus and 
the RNA of picornavirus (95;115).  It has been suggested that autoantibodies 
result  from  interaction  of  the  synthetase  with  a  virus  during  viral  replication 
which  leads  to  the  presentation  of  the  synthetase  to  the  immune  system  in 
association with the foreign viral protein resulting in a break in tolerance.  The 
major epitope of histidyl-tRNA synthetase, a 60 amino acid portion, is located at 
the  amino  terminus  of  the  protein  and  is  predicted  to  have  a  coiled-coil 
configuration  (WHEP-TRS  domain)  and  autoantibody  binding  affects  the 
conformation of the N terminus (104;107;113).  Studies on mutant histidyl-tRNA 
synthetase,  to  establish  the  effects  on  reactivity  with  anti-Jo-1  antibodies, 
demonstrated  that  anti-Jo-1  antibodies  recognise  multiple  conformation 
dependent and independent epitopes which may have occurred as a result of 
fragmented  histidyl-tRNA  synthetase  released  from  inflamed  muscle  (104).  
Anti-Jo-1 antibodies have been identified in patients before the onset of myositis 
(116),  similar  to  that  observed  in  other  autoimmune  disorders  such  as  SLE 
(117).  A patient’s anti-Jo-1 status may change from positive to negative during 
the  course  of  disease  (104)  and  has  been  found  to  correlate  with  disease 
activity (118).  The presence of anti-Jo-1 antibodies has been associated with 
the  presence  of  anti-Ro52  antibodies  and  was  first  discovered  in  1997 
(119;120) and was later confirmed in a subsequent study (102).  Rutjes et al 26 
(120) found that 21% of the sera from myositis patients were reactive with Jo-1 
while  20%  was  reactive  with  Ro52.    Isolating  anti-Jo-1  positive  sera 
demonstrated  a  higher  frequency  of  anti-Ro52  antibodies,  58%,  a  similar 
percentage to the 70% found in the study conducted by Frank et al (102).  It 
was established this was not due to cross-reactivity since no competition could 
be  detected  for  recombinant  Jo-1  protein  and  affinity-purified  anti-Ro52  and 
anti-Jo-1 antibodies did not cross react with each other.  Anti-Ro52 antibodies 
were also shown to be associated with other antibodies (102;121); other anti-
tRNA-synthetases, anti-SRP and anti-PM-Scl but are rarely detected in patients 
with anti-Scl70 or anti-centromere antibodies (121). The co-existence of these 
antibodies has recently been considered to generate a programmed cytokine 
imbalance in PM and DM patients (122).  Hassan et al (122) demonstrated that 
female patients with anti-Jo-1 and anti-Ro52 antibodies had a higher TNF:IL-10 
ratio. Elevated TNF cytokine levels have been observed in DM and PM and 
have been implicated in associated pathological mechanisms.  IL-10 is also of 
interest  in  autoimmune  diseases  as  it  exerts  anti-inflammatory  properties  in 
addition  to  stimulatory  effects  on  B  cells  and  autoantibody  production.   This 
elevated ratio was not observed within male patients or within patients who had 
anti-ANA  or  anti-RNP  antibodies.    Elevated  ratios  of  these  cytokines  may 
contribute to the development or aggravation of chronic inflammation.  Reasons 
for  the  association  of  anti-Jo-1  antibodies  and  anti-Ro52  antibodies  remains 
unclear as tRNA synthetases charge their nucleic acids in the cytoplasm and 
Ro52 occurs primarily in the nucleus (119;120) but the concordance of these 
two apparently unrelated ribonucleoproteins may provide a greater insight into 
the aetiology or pathogenesis of inflammatory myopathies (119).  
 
Recently Eloranta et al (123) demonstrated that immune complexes containing 
anti-Jo-1  or  anti-Ro52/Ro60  autoantibodies  may  act  as  endogenous  IFN-α 
inducers  that  activate  IFN-α  production  from  plasmacytoid  dendritic  cells 
(PDCs).  This may suggest that the type 1 IFN system may play a role in the 
disease mechanism of myositis although different mechanisms may occur in 
different myositis subsets.   
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1.2.4.2 Mi-2 
Anti-Mi-2 autoantibodies are classified as MSAs and were first identified in 1976 
in a 60 year old female DM patient (124).  These autoantibodies are directed to 
a  nuclear  macromolecule  complex  of  eight  peptides  ranging  from  34  to  240 
kDa.    The  complete  complex  is  involved  in  transcription  (95;124).    Mi-2 
autoantibodies  preferentially  recognise  the  240  kDa  portion  of  this  complex.  
Two different but highly homologous proteins, resembling the 240 kDa portion 
of the complex, were identified and were labelled Mi-2α and Mi-2β.  Both of 
these proteins are recognised by anti-Mi-2 antibodies (96;124).  These Mi-2α 
and  Mi-2β  components  exert  helicase  and  acetylase-deacetylase  activities 
which  regulate  transcription  factor  binding  to  DNA  (95).    Mi-2β  is  part  of  a 
complex  known  as  NURD  (nucleosome  remodelling  deacetylase)  (95;96).  
Immunogenetic studies have shown a strong correlation of anti-Mi-2 antibodies 
with HLA-DR7 and there is evidence that a tryptophan residue at position 9 of 
the HLA-DRβ chain is a common epitope essential for Mi-2 antibody production 
(124).    Anti-Mi-2  antibodies  have  been  identified  in  approximately  4-18%  of 
patients  with  myositis,  and  are  primarily  observed  in  patients  with  DM 
(95;124;125).  Hengstman et al (100) report the autoantibody occurrence within 
DM as 13 – 21% (100) and it had been reported that more than 90% of anti-Mi-
2 positive patients had juvenile or adult-onset DM (95;124) and show a classic 
representation of DM (124).  As previously mentioned in section 1.2.1 subsets 
of  DM  have  been  described,  a  lower  frequency  of  the  Mi-2  antibody  have 
occasionally  been  reported  in  the  DM  subset  amyopathic  DM  (ADM)  (124).   
Hengstman et al (100) report that these antibodies have only been seen in 2 
patients  with  PM  and  never  in  IBM.    Additional  studies  (126;127)  have 
established the presence of anti-Mi-2 antibodies in the sera of PM and IBM 
patients.  Most studies examining anti-Mi-2 antibodies used the NM fragment of 
the Mi-2β autoantigen which is thought to contain the major antigenic epitope.  
A recent study used the four different fragments of the Mi-2β autoantigen, NT, 
NM,  M  and  CT  fragments,  to  characterise  these  autoantibodies  in  myositis 
patients  (126;127).    Using  these  4  fragments  the  presence  of  anti-Mi-2 
autoantibodies were found in a large number of PM and IBM patients and these 
antibodies did not appear to be a marker for a specific subset of myositis.  This 28 
study  was  unable  to  confirm  that  these  antibodies  were  specific  for  DM  in 
contrast to previous investigations. 
 
1.2.4.3 Additional MSAs 
In addition to the presence of autoantibodies towards the cytoplasmic amino-
acyl-tRNA-synthetase enzymes, autoantibodies may also be directed towards 
the cognate tRNA, tRNA 
His and tRNA 
Ala. Anti- tRNA 
Ala is detected in the sera 
of most patients with anti-PL12 autoantibodies whereas tRNA 
His is present in 
approximately a third of patients with anti-Jo-1 (100). 
 
Another MSA found within myositis patients is the anti-SRP autoantibody, which 
is  directed  against  components  of  the  signal  recognition  particle  (SRP) 
(95;100;128).  Antibodies target a cytoplasmic ribonucleoprotein composed of 
six peptides (SRP 9, 14, 19, 54, 68, 72) including a dominant 54 kDa peptide 
and of a small RNA molecule (7 SL RNA).  SRP recognises signal sequences in 
the  N-termini  of  secretary  proteins  or  membrane  proteins  to  regulate  the 
translocation of newly synthesized proteins across the endoplasmic reticulum 
(ER) membrane.   Anti-SRP antibodies are uncommon and are found in only 
5% of myositis patients, predominately PM although the antibodies have been 
observed  in  a  small  proportion  of  DM  and  IBM  patients  (95;100).  
Autoantibodies are most frequently directed against the SRP 54 protein, those 
directed solely towards the 7 SL RNA may be markers for a less severe disease 
(95).    Patients  with  anti-SRP  antibodies  generally  have  proximal  muscle 
involvement  and  have  been  associated  with  cardiac  involvement.    These 
antibodies are characteristic of necrotizing myopathies (128). 
 
As shown in Table 1.1, other MSAs have been identified which are directed to 
cytoplasmic  antigens.    These  antibodies  are  extremely  rare  and  not  readily 
detectable but characteristically resemble antisynthetase syndrome (95).  Anti-
FER autoantibodies are directed towards an elongation factor, while the target 
antigen for anti-KJ antibodies is a translocation factor.  Anti-Wa antibodies are 
directed towards a 48 kDa peptide with an unknown function. 
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1.2.4.4 MAAs 
As shown in Table 1.1 many MAAs have been described in myositis patients.  
Anti-Ro and anti-La antibodies have been detected in approximately 4 to 58% 
and 3 to 6% of myositis patients respectively (95) and have also been observed 
in SLE and SS patients.  These antibodies are generally associated with an 
anti-synthetase like syndrome in comparison to anti-SRP positive myositis.  A 
faint association of anti-Ro antibodies has been observed in myositis patients 
with anti-Mi-2 and anti-PM-Scl antibodies.  As described in section 1.2.4.1 it is 
generally  anti-Ro52  antibodies  that  are  observed  within  myositis  patients,  in 
conjunction with anti-Jo-1 antibodies. 
 
Anti-RNP  proteins  target  the  70  kDa  peptide  of  an  11  peptide  containing 
complex.  This ribonucleoprotein protein also contains five small RNA’s.  These 
antibodies are also found in other disorders, such as SLE, SS and scleroderma 
but are found in 5-60% of myositis patients (95). 
 
Antibodies to the Ku antigen have been reported in 3-19% of myositis patients 
(95).  The Ku antigen is a heterodimer composed of one 70 kDa and one 80 
kDa peptide bound to a 350 kDa DNA-dependent protein kinase.  The overall 
function of this complex is unknown but is thought to be involved in DNA repair 
and VDJ recombination.  This autoantibody has also been observed within other 
conditions,  such  as  scleroderma,  SS  and  undifferentiated  connective  tissue 
disease (95).  
 
Anti-PM-Scl autoantibodies are observed in 5-25% of myositis patients and are 
directed  against  a  nucleolar  macromolecular  complex  composed  of  11-16 
peptides (95).  This complex is an exosome whose exoribonucleases destroy 
RNA’s.  A 100 kDa peptide is the main target for these autoantibodies.  This 
antibody in myositis in conjunction with overlap syndromes such as scleroderma 
contributes to 43-88% of cases of myositis associated with the autoantibody. 
 
1.2.4.5 Novel Autoantigens 
Recently a number of novel autoantibodies have been identified within myositis 
patients.    Anti-56  kDa  antibodies  have  been  found  in  60-86%  of  myositis 30 
patients and are directed against a nuclear ribonuceloprotein complex (95;129).  
These antibodies are fairly specific for myositis but have also been described in 
other forms of connective tissue disease (95;129).   
 
Sato  et al  (130),  reviewed  (129;131),  identified  autoantibodies to  a  140  kDa 
peptide,  CADM-140,  in  Japanese  patients  with  clinically  amyopathic 
dermatomyositis.  CADM-140 antibodies were identified in 19% of DM patients; 
all of these patients were diagnosed with clinically amyopathic DM (C-ADM).  
These antibodies were found to be associated with rapidly progressive ILD. 
 
Another novel antibody was identified within myositis patients (132), reviewed 
(129;131), directed to a 155 kDa protein.  This antibody was identified in sera 
from  children  and  adults  with  inflammatory  myopathies  and  was  found  to 
precipitate with a 155 kDa protein along with a weaker 140 kDa protein on most 
samples.  This anti-p155 antibody was strongly associated with myositis, more 
frequently within DM (29.4%) compared to PM (4.2%); it was also observed in 
75% of cancer-associated DM patients (132).  Within juvenile DM patients this 
anti-p155  antibody  appeared  to  be  more  common  than  other  defined 
autoantibodies.    Although  this  antibody  was  largely  found  within  myositis 
patients, it has been observed in one patient with SLE who demonstrated no 
signs of myositis. 
 
More recently Kraj et al (133) identified an anti-155/140 antibody  which was 
highly specific for DM and reacted simultaneously with two proteins of 155 and 
140  kDa.    In  this  study  anti-155/140  antibodies  were  found  in  13%  of  DM 
patients, a frequency slightly lower than anti-EJ antibodies but were comparable 
or higher than other MSAs that were examined in the study, including anti-Jo-1, 
anti-OJ,  anti-PL-7,  anti-Mi-2,  anti-SRP  and  anti-CADM140  antibodies.    As 
observed for other MSAs (95) the anti-155/140 antibody did not co-exist with 
other known MSAs.  In this study the anti-155/140 antibody was associated with 
internal  malignancy  and  skin  manifestations  typical  of  DM  but  were  not 
associated with ILD, indicating a high expression of 155/140 kDa antigens in 
cancer, skin and muscle but is absent or poorly expressed in the lung.  Kraj et al 
(133) deemed that this antibody was different to that identified by Sato et al 31 
(130) and Targoff et al (132) as a result of immunodepletion studies and the 
ever presence of the 140 kDa precipitated protein which was not observed in 
every patient within the Targoff study (132).  
 
Autoantibodies towards the small ubiquitin-like modifier 1 (SUMO-1) activating 
enzyme A and B subunits, SAE1 and SAE2 respectively, have recently been 
identified  in  DM  patients  (134).    These  proteins  are  involved  in  the 
posttranslational  modification  of  specific  proteins.    Although  these  antibodies 
were only observed in two patients both patients presented with similar clinical 
features, severe skin disease and interstitial pneumonia, suggesting that these 
autoantibodies may identify a further discrete subset of DM patients.   
 
1.2.5 Therapies in Myositis. 
Treatment  of  inflammatory  myopathies  can  be  complex,  partly  because  the 
specific target antigens are unknown, therefore traditionally therapy has been 
based on non-selective immunosuppression or immunomodulation.  Improved 
muscle strength, normalised CK levels and remission or stabilisation are the 
primary goals in treatment of myositis disorders (135).  DM has been found to 
be  the  most  treatable  myopathy  while  responses  in  PM  have  also  been 
favourable but responses have found to vary.  IBM is characteristically the most 
resistant  myopathy  to  treatment  (62;135;136).    Corticosteroids,  mostly 
prednisolone, are the standard initial treatment for these disorders, particularly 
in DM and PM although a recent case has reported clinical improvements in 
IBM  (137),  and  have  been  used  successfully  for  the  last  three  decades.  
However the frequent side effects associated with the treatment results in a 
reduction or termination of the therapy and a switch, or a combined, approach 
with steroid-sparing immunosuppressive agents like methotrexate, azathioprine, 
cyclosporine  A,  cyclophosphamide  and  mycophenolate  mofetil  which  have 
effects on various aspects of the immune response (62;91;135;136).  Long-term 
use of steroid therapy may result in reappearance of muscle weakness without 
changes in CK levels, necrotizing myopathy, without a prominent infiltration of 
immune  cells  (71;91).    No  standard  choice,  combination  or  dose  of  these 
therapies is used and is influenced by a number of factors including disease 
severity and other underlying medical conditions.  Intravenous immunoglobulin 32 
therapy (IVIg) is also used in treatment strategies; the large range of antibodies 
from this therapy has a number of immunomodulatory effects in these disorders 
(135;138;139).  Favourable responses with this treatment are mostly observed 
in  DM  and  PM  patients  with  no  significant  improvements  in  IBM  patients, 
although some studies report limited effects (135;138).  Recent, more selective, 
therapies  include  the  use  of  monoclonal  antibodies  aimed  at  more  selective 
targets  including  TNF-α  blockers  (Etanercept,  Infliximab  and  Adalimumab), 
complement  component  C5  (Eculizumab)  as  well  as  other  cytokines, 
costimulatory and cell adhesion molecules (135).  Another monoclonal antibody 
therapy  being  tested  in  inflammatory  myopathies,  which  is  relevant  to  the 
current study of this thesis, is Rituximab, a chimeric depleting antibody against 
the  CD20  marker  on  B  cells.    Studies  have  shown  favourable  outcomes  in 
myositis, after successful studies in other autoimmune disorders such as RA 
and SLE (140-149), although relapses in some myositis patients did occur after 
the return of B cells and depletion of autoantibody titres have been found to 
vary (150-153).  The exact mechanism of this antibody is unknown but could 
involve  depletion  by  either  activation  of  complement,  inducing  cell-mediated 
lysis,  by  apoptosis,  or  increased  sensitisation  to  cytotoxic  agents  and 
corticosteroids. Despite the mechanism of action the initial rationale for using 
the  antibody  in  autoimmune  disorders  was  to  reduce  the  production  of 
autoantibodies.  It is also postulated that other B cell functions may be affected 
during  therapy,  such  as  antigen  presentation,  costimulatory  and  regulatory 
functions.  Further studies are now underway with additional CD20 therapies, 
Ocrelizumab  and  Ofatumumab,  a  humanized  CD20  monoclonal  antibody  as 
well  as  TRU-015,  a  single-chain  polypeptide  which  binds  to  CD20.    Other 
therapies aimed at B cells in autoimmune disorders include Epratuzumab, an 
anti-CD22  antibody  and  various  therapies  at  the  B  cell  activating  factor 
BAFF/BLyS (154;155).     
 
As well as treating inflammatory myopathies some therapeutic interventions, for 
other  disorders,  are  known  to  cause  or  contribute  to  the  pathogenesis  of 
inflammatory myopathies.  Although the exact mechanisms leading to pathology 
are unresolved the use of statins as well as corticosteroids have been found to 
result in inflammatory myopathies (49;56;69;70;156). 33 
1.3 Vasculitis 
Vasculitis is inflammation of blood vessel walls; this may occur as a primary 
process  (primary  vasculitis)  or  as  a  secondary  feature  of  other  diseases 
(secondary  vasculitis)  such  as  systemic  autoimmune  disease,  inflammatory 
disease  and  connective  tissue  disease,  which  can  include  the  inflammatory 
myopathies (157-162).  A number of classification systems have been proposed 
to  classify  the  varying  forms  of  vasculitis,  from  the  American  College  of 
Rheumatology (159;163) in 1990 and the Chapel Hill Consensus Conference in 
1994  (164;165)  reviewed  (157-160;166).    Additional  classification  schemes 
have  been  proposed  based  on  the  dominant  blood  vessel  involved,  the 
inflammatory cell primarily mediating vascular damage, the distinction between 
primary  and  secondary  vasculitis  and  the  incorporation  of  pathophysiological 
markers  (157;162).    Multiple  pathogenic  pathways  are  generally  thought  to 
mediate  vasculitis  disorders  (33;157;158),  many  of  which  affect  the  skin 
resulting in cutaneous vasculitis due to the large vascular supply to the skin 
(167).    The  trigger  that  initiates  inflammation  or  determines  the  location  of 
vascular  inflammation  is  unknown.    The  annual  incidence  of  cutaneous 
vasculitis ranges from 39.6 to 59.8 per million (157) and can affect all ages.  
Cutaneous vasculitis is observed slightly less in men than women and is often 
seen in adults more often than children (157).  The mean age of onset is 47 
years in adults and 7 years among children (157).  Vasculitis can have a wide 
range of clinical and pathological manifestations due to its capacity to affect 
vessels  of  different  sizes,  although  considerable  overlap  exists  (Figure  1.4) 
(157-162). 
 
1.3.1 Large Vessel Disease (>150  m) 
Two distinct disorders have been identified that primarily affect larger vessels, 
Giant  cell  arteritis  and  Takayasu’s  arteritis.    Both  disorders  involve 
granulomatosus inflammation, containing activated and antigen-driven T cells 
and macrophages, of the aorta and its major branches but Giant cell arteritis is 
generally observed in patients older than 50 years whereas Takayasu’s arteritis 
commonly occurs in patients younger than 50 years old (168;169).   
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1.3.1.1 Kawasaki Disease (KD) 
KD is an arteritis which can affect large, medium and small vessels, as with 
other vasculitic disorders the cause is unknown (168).  It is primarily a childhood 
disorder  and  is  associated  with  mucocutaneous  lymph  node  syndrome.  
Infectious  agents  have  been  proposed  as  possible  triggering  agents  for  the 
disease in immature immune systems leading to the inability to clear certain 
pathogens.  Boys younger than 5 years are most commonly affected (168;170).  
Oligoclonal  IgA  producing  plasma  cells  have  been  recently  identified  in  KD 
which were critical pathological mediators (167;169;171). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.2 Medium Vessel Disease (50-150  m) 
1.3.2.1 Polyarteritis nodosa (PAN) 
PAN is a necrotizing inflammatory disease of medium or small arteries and is 
observed in 2 to 9 cases per million annually (168;170).  This vasculitic disorder 
is typically considered a medium vessel disorder although it is not restricted to 
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Henoch Scholein Purpura (HSP), Cryoglobulinemic 
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granulomatosis (WG), Churg Strauss syndrome (CSS), 
Microscopic polyangitis 
Figure 1.4 Classifications of Primary Vasculitis Disorders 
 
Classification  of  the  vasculitic  disorders  is based  on  the Chapel  Hill  Consensus  Conference  on  the 
Nomenclature of Systemic Vasculitis (164;165).  These disorders are classified, in part, based on the 
predominant vessel affected; however substantial overlap among different vasculitis disorders exists. 
Adapted from 159. 
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medium vessels and can be observed in smaller vessels.  PAN can occur as a 
systemic disorder but cutaneous PAN represents 10% of cases (161).  Patients, 
20-50%,  normally  present  with  cutaneous  manifestations  such  as  livedo 
reticularis, nodules, ulcerations and digital ischemia as well as symptoms like 
fever, fatigue, myalgias, arthralgias and weight loss (168).  GI tract, renal and 
myocardial  involvement  may  occur  within  patients  rendering  the  disease  life 
threatening (168).   This disease affects men more commonly than women and 
can occur at any age, maximum at 40-60 years (172). PAN been associated 
with hepatitis B infections (5 to 10 %) and streptococcal infection in children 
(161;170).       
 
1.3.3 Small Vessel Disease (<50  m)  
Small vessel vasculitis presents with purpura, papules, vesicles and urticarial 
lesions.  Although skin is the primary organ involved, involvement of the renal, 
musculoskeletal  and  gastrointestinal  systems  may  occur  depending  on  the 
disease  (161).    These  vascular  diseases  are  commonly  associated  with 
connective tissue diseases such as SLE, RA and SS (159;167;172-174).  Small 
vessel  vasculitis  restricted  to  the  skin,  without  systemic  involvement,  is 
classified  as  leukocytoclastic  vasculitis.    Histopathologically  leukocytoclastic 
vasculitis manifests as segmental infiltration and disruption of the vessel wall by 
neutrophils, which is usually accompanied by extravasation of erythrocytes and 
endothelial cell swelling (159;167;172).   
 
1.3.3.1 Henoch-Schonlein Purpura (HSP) 
HSP represents approximately 10% of all cutaneous vasculitis cases.  All cases 
demonstrate palpable purpura but is only the presenting sign in 50% of cases 
(168).  Arthritis, gastrointestinal manifestations and nephritis are also observed 
within this subtype of vasculitis but all may not be present in a given patient.  
HSP is more common in childhood, primarily in boys aged 4 to 8 years old and 
is the most common form of systemic vasculitis in children (172).  The incidence 
of  HSP  in  children  is  approximately  14  cases  per  100,000  per  year  (172).  
Diagnosis of HSP is conditional on the presence of IgA deposition within and 
around blood vessels (175), although these IgA deposits are not specific for 
HSP and are commonly found in other vasculitis disorders (175).  Medium sized 36 
vessels are rarely involved in HSP (172) and the pathogenesis associated with 
small vessels may be related to abnormal glycosylation of IgA.  The precise 
mechanisms mediating pathology in HSP is unknown as is the significance of 
antiendothelial IgA antibodies, anticardiolipin antibodies and IgA antineutrophil 
cytoplasmic antibodies (ANCAs) which can all be detected in HSP. 
 
1.3.3.2 Cryoglobulinemic vasculitis 
Cryoglobulinemic  vasculitis  is  associated  with  circulating,  cold-precipitable 
antibodies,  cryoglobulins.    Mixed  cryoglobulins  consist  of  monoclonal  IgM  or 
polyclonal IgM directed against IgG.  Cryoglobulin immune deposits affect small 
vessels, predominately in the skin and glomeruli (161;168).  Patients present 
with erythematosus and papules often triggered by cold exposure or prolonged 
standing (175).  In this type of vasculitis patients may also present with medium-
sized vessel disease. 
 
1.3.3.3 ANCA-associated Small Vessel Vasculitis 
Wegener’s  granulomatosis  (WG),  Churg-Strauss  syndrome  (CSS)  and 
Microscopic polyangitis (MPA) are 3 forms of small to medium vasculitis that are 
associated with ANCAs but lack deposits of immune complexes, therefore these 
syndromes are also described as pauci-immune syndromes (176;177). 
 
1.3.3.3.1 Wegener’s Granulomatosis (WG) 
WG is a multisystem necrotizing granulomatosus vasculitis involving the upper 
and lower respiratory tract and the kidneys.  Rapidly progressive renal disease 
can occur as a result of necrotising and crescentic glomerulonephritis (178).   
WG can occur at any age and affects both males and females.  Generally the 
incidence  of  WG  is  5  to  10  per  million  annually  and  80-97%  of  cases  are 
observed within Caucasian populations (168;172).  Cutaneous manifestations 
like  palpable  purpura,  oral  ulcers,  papulonecrotic  lesions,  subcutaneous 
nodules and ulcers develop in 46 to 66% of cases, parallel disease activity in 
other  organs  and  are  the  presenting  sign  in  approximately  10%  of  patients 
(168;175).    Renal  disease,  a  necrotizing  pauci-immune  glomerulonephritis, 
develops in 80% of cases.  Cutaneous WG vasculitis is associated with active, 
rapidly  progressive  disease  and  higher  frequency  of  renal  and  joint  disease 37 
compared to WG patients without cutaneous vasculitis (175).  Diagnosis of WG 
is  based  on  clinical  features,  biopsy  and  the  presence  of  ANCA,  described 
further in section 1.3.4.  Up to 80% of WG patients are c-ANCA positive, while 
10-15%  of  WG  patients  are  p-ANCA  positive.    A  small  percentage  of  WG 
patients  are  ANCA  negative,  these  patients  tend  to have  a  better  prognosis 
(168;172). 
 
1.3.3.3.2 Churg-Strauss Syndrome (CSS) 
CSS,  also  known  as  allergic  granulomatosus,  is  a  rare  necrotizing  vasculitis 
which is usually associated with asthma and eosinophilia (168;175).  Clinically 
and pathologically this vasculitis disorder resembles PAN, MPA and WG but 
has distinct features, asthma and tissue eosinophilia, making it a separate entity 
(175).    CSS  affects  small  to  medium  vessels  and  is  reported  to  occur  in  3 
people per million (168).  Vasculitis occurs as the final distinct phase during 
disease  progression,  after  allergic  rhinitis  (asthma)  and  eosinophilic  lung 
infiltration,  but  may  occur  up  to  30  years  after  initial  symptoms  (168;172).  
Vasculitis affects the lungs and heart in addition to peripheral nerves and skin.  
Cutaneous manifestations are reported in 60 to 70% of cases and include not 
only erythematosus lesions but also ulcers, livedo reticularis and facial oedema 
(168).  Renal involvement is also observed within CSS but is less severe than 
that observed in WG.  Diagnosis of CSS is based on clinical presentations, skin, 
lung  and  kidney  biopsies  and blood  eosinophilia.    For  CSS  the  presence  of 
ANCA is not a diagnostic property as it is in WG.  50% of CSS patients are 
ANCA negative; the remaining patients are equally positive for both subtypes of 
ANCAs (168), this suggests that CSS may exist as two distinct disease entities.         
 
1.3.3.3.3 Microscopic Polyangitis (MPA) 
MPA  is  a  pauci-immune  nongranulomatosus  small  and  medium  vessel 
vasculitis most often associated with progressive renal disease (168;175).  90% 
of  patients  have  renal  disease  in  the  form  of  pauci-immune  necrotising  and 
crescentic vasculitis (178).  Although disease can occur within medium sized 
vessels in MPA, the disease is often restricted to small vessels (175).  Features 
of MPA are similar to that of WG except that upper respiratory tract involvement 
is  rarely  observed  (168).    Palable  purpura  is  found  in  46%  of  patients  at 38 
presentation, nodular lesions are not found within MPA and presentation of this 
should direct diagnosis towards WG or CSS (168).  Skin disorders are observed 
in 65% or less of patients; in 15% of cases cutaneous disease is the presenting 
clinical  feature  (175).    Skin  biopsies  from  MPA  patients  closely  resemble 
leukocytoclastic  vasculitis  and  HSP.    Distinction  between  disorders  is 
established  by  the  presence  of  p-ANCA  within  MPA  and  the  absence  of 
immunoglobulin and complement localisation to vessel walls (175).  p-ANCA 
levels correlate with disease activity (175). 
 
1.3.4 Anti-Neutrophilic Cytoplasmic Antibodies (ANCA) 
Anti-neutrophilic  cytoplasmic  antibodies  (ANCA)  are  predominately  IgG 
autoantibodies  directed  against  antigenic  targets  of  primary  granules  of 
neutrophils  and  monocyte  lysosomes  (178)  and  are  implicated  in  the 
pathogenesis  of  ANCA-associated  systemic  vasculitides  (AASV),  necrotizing 
small vessel vasculitis with a paucity of immune complexes in conjunction with 
the presence of ANCAs (6;178).  Titres of these antibodies appear to precede 
clinical disease activity and rising levels of these antibodies during remission 
phases  of  the  disease  are  indicative  of  relapses  (179-181).    Indirect 
immunofluorescence established two patterns of staining with ANCAs; a diffuse 
cytoplasmic  staining  of  neutrophils  and  monocytes,  but  not  lymphocytes,  (c-
ANCA) and a perinuclear staining (p-ANCA).  Two main target antigens were 
identified  from  these  two  ANCAs,  c-ANCAs  are  generally  directed  against 
proteinase  3  (PR3),  while  p-ANCAs  are  directed  against  myeloperoxidase 
(MPO) (6;113;178;182).  PR3 is a 29-30 kDa serine protease consisting of 288 
amino  acids  (182).    The  structure  of  PR3  shows  considerable  homology  to 
neutrophil  elastase.    Under  inflammatory  conditions  PR3  is  released 
extracellularly,  together  with  other  granule  constituents  and  oxygen  radicals 
which  can  degrade  collagens,  proteoglycans  and  other  connective  tissue 
constituents. PR3-cANCA recognise restricted epitopes on PR3 involving the 
catalytic  site  and  interfere  with  the  enzyme  inactivation  (182).    MPO  is  a 
covalently  linked  dimer  with  a  molecular  weight  of  140  kDa  localised  in  the 
azurophilic granules of neutrophils and lysosomes, making up almost 5% of the 
total  protein  content  of  the  neutrophil.    MPO  catalyses  the  formation  of 
intracellular  toxic  products,  such  as  hydrogen  peroxide  and  oxygen  radicals, 39 
which  are  effective  in  killing  phagocytosed  bacteria  and  viruses.    ANCA-
associated vasculitic disorders are characterised by neutrophil infiltration.  Falk 
et  al  (183)  demonstrated  that  neutrophils  express  PR3  and  MPO  on  their 
surface  when  primed  with  low  dose  proinflammatory  cytokines.    Neutrophils 
become fully activated when incubated with sera from PR3-ANCA and MPO-
ANCA positive patients and produce reactive oxygen species as well as release 
lytic enzymes including PR3 and elastase.  Ohlsson et al (184) demonstrated a 
strong increase, 10 fold, in mRNA levels for PR3 in monocytes from patients 
with AASV compared to both healthy controls and SLE disease controls.  These 
high  mRNA  levels  do  not  necessarily  indicate  increased  total  PR3  protein 
levels.  Isolation of neutrophils from the bloodstream demonstrated that different 
individuals differ in their expression of membrane PR3 (mPR3) (185).  Most 
individuals contain a heterogeneous population of neutrophils with both positive 
and negative neutrophils for PR3 membrane expression, the proportion of these 
cells are stable and may be genetically determined (185). In WG or in other 
inflammatory conditions patients have an elevated proportion of mPR3-positive 
neutrophils (185;186). 
  
ANCAs have been implicated in the pathology of AASV.  A direct link between 
ANCA  and  the  development  of  glomerulonephritis  and  vasculitis  was 
demonstrated  in  an  MPO  knockout  mouse  model  where  passive  transfer  of 
mouse  MPO  was  sufficient  to  induce  the  disorders  in  knockout  mice  (187), 
reviewed  (6;157;178;185;188).    The  pathogenic  potential  of  these  antibodies 
was confirmed by transfer of purified anti-MPO IgG into RAG2 knockout mice 
which  developed  focal  necrotizing  and  crescentic  glomerulonephritis  with  a 
paucity  of  glomerular  Ig  deposition  in  the  absence  of  functional  T  or  B 
lymphocytes, although renal lesions were not as widespread as positive control 
mice.  This may indicate that additional factors are required to enhance the 
inflammatory response.  A subsequent study demonstrated that mice depleted 
of  neutrophils  were  completely  protected  from  anti-MPO  induced 
glomerulonephritis (185).  Additionally transfer of recombinant murine PR3 into 
PR3  and  neutrophil  knockout  mice  generated  murine  PR3-specifc  polyclonal 
antibodies  although  antibody  transfer  into  wild-type  mice  did  not  induce 
vasculitis  (6;176;185;188).    An  aggravated  local  immune  response  was 40 
observed supporting PR3 mediated tissue damage.  Comparison of these MPO 
and  PR3  mouse  models  may  indicate  that  anti-MPO  and  anti-PR3  have 
different mechanisms of action.  In addition to mouse studies, a human study 
reported  that  a  newborn  child  developed  glomerulonephritis  and  pulmonary 
haemorrhage  48  hours  after  delivery  from  a  mother  with  MPO-ANCA 
microscopic polyangitis (188).  MPO-ANCA IgG was found in the child’s blood 
concluding  that  transplacental  transfer  of  MPO-ANCA  IgG  resulted  in  the 
glomerulonephritis and pulmonary haemorrhage.   
 
The mechanisms generating ANCAs are unresolved; Pendergraft et al (189), 
reviewed  (159;178;185;188;190),  suggested  the  generation  of  ANCAs  may 
result from autoantigen complementarity.  In patients with inflammatory vascular 
disease the patients generated antibodies to the autoantigen, PR3, as well as 
antibodies to a peptide translated from the antisense, or complementary, DNA 
strand of PR3 (cPR3).   The study was based on the hypothesis that the antigen 
that  initiates  the  sequence  of  events  leading  to  autoimmunity  is  not  an 
autoantigen, but rather the complementary, antisense, peptide or a mimic of this 
peptide.    This  complementary  peptide  initiates  the  autoantibody  production.  
Following  this  an  anti-idiotype  response  occurs.    The  resulting  anti-idiotypes 
react with the antigen derived from the sense peptide and whose amino acid 
sequence  is  complementary  to  the  sequence  of  the  initiating,  antisense, 
antigen.  This theory was confirmed in mouse models where mice immunised 
with  a  complementary  human  peptide,  cPR3  whose  structure mirrors  that  of 
PR3, produced antibodies against that peptide, cPR3, as well as to the peptides 
sense counterpart, PR3.  The structure of cPR3 mirrors that of PR3          
 
At  least  two  separate  signalling  pathways  are  thought  to  be  involved  in  the 
activation of neutrophils by ANCA (6;178;179).  The F(abs’)2 portion of ANCA 
IgG activates a G-protein coupled receptor pathway while the Fc portion of the 
antibody binds to the constitutively expressed FcγRIIa and FcγRIIIb receptors of 
the  neutrophil,  activating  Syk  kinase  and  protein  kinase  C-β  and  mediates 
calcium release.   
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1.3.5 Antiendothelial Cell Antibodies (AECA) 
Antibodies directed against endothelial cells (AECA) have been detected in the 
sera of patients with vasculitis (173), they have also been found in myositis with 
vascular injury resulting in myofibre damage (58).  AECAs are a heterogeneous 
group  of  antibodies  directed  against  a  variety  of  endothelial  cell  antigenic 
membrane  proteins.    Endothelial  cell  dysfunction  and  persistent  local 
inflammation is considered to be an early event which subsequently leads to the 
development and progression of vascular wall disorders, such as vasculitis (7), 
but  may  also  play  a  significant  role  in  other  disorders  like  myositis.    The 
endothelium  participates  in  homeostatic  mechanisms  including  regulation  of 
vascular tone and directing biological responses such as leukocyte trafficking to 
inflammatory sites, Figure 1.1, (7).   The mechanisms of AECA are thought to 
include  complement  or  antibody  dependent  cellular  cytotoxicity,  induction  of 
endothelial cell apoptosis and upregulation of adhesion molecules resulting in 
continued recruitment of leukocytes, but the exact role of AECAs in vasculitis is 
largely unresolved (176;191).  Certain forms of endothelial injury are associated 
with  ANCA.    Endothelial  cells  may  express,  process  and  present  ANCA 
antigens  to  cytotoxic  T  cells.    Previous  studies  have  demonstrated  that 
endothelial cells develop an activated phenotype in ANCA-associated vascular 
injury  with enhanced expression of adhesion molecules, ICAM-1 & VCAM-1, 
that promote interaction with circulatory inflammatory cells (7).  An association 
of  ANCA-associated  vasculitis  and  endothelial  cells  had  been  proposed  by 
Woywodt  et  al  (6;8)  who  demonstrated  that  patients  with  ANCA-associated 
vasculitis  have  high  numbers  of  circulating  endothelial  cells  compared  to 
controls.    It  was  also  observed  that  these  endothelial  cells  had  undergone 
necrosis indicating that they detached from the basement membrane as a result 
of  a  direct,  active  and  pathogenic  mechanism  but  the  exact  role  of  this  in 
vasculitis is unresolved.     
 
Stromal  cells  such  as  fibroblasts  and  smooth  muscle  (SM)  cells  can  also 
produce biologically active proteins that act to regulate endothelial cell function 
(192), thus the interactions of stromal cells with endothelial cells at the sites of 
inflammation are likely to be important in the initiation and maintenance of the 
local inflammatory response and determination of site specificity.  Baiu et al 42 
(193)  studied  the  role  and  pathogenicity  of  anti-SM  antibodies  in  vasculitis.  
Vasculitis was induced by adoptive transfer of SM-stimulated lymphocytes and 
the production of autoantibodies targeting blood vessels and the pathogenicity 
of  these  autoantibodies  was  established.    Results  demonstrated  the 
development of small vessel vasculitis in mice accompanied by the presence of 
pathogenic  antibodies  reactive  with  vascular  smooth  muscle  as  well  as  the 
persistence and expansion of activated, potentially pathogenic, B cells.  These 
results were confirmed as a result of serum transfer experiments.  The anti-SM 
antibodies were shown to recognise intracellular antigens which has also been 
observed in human patients (193) suggesting that other mechanisms resulting 
in damage to vascular cells need to occur first in order for B cells to be exposed 
to the intracellular antigen.  Other antibodies found in vasculitis patients, such 
as anti-Ro, La, DNA or RNP, may be associated with underlying disorders in 
these patients.    
 
1.3.6 Pathogenesis of Vasculitis 
The  pathogenesis  of  vasculitis  includes  different  immune  mechanisms  that 
cause leukocytes to adhere to endothelial cells, penetrate into vessel walls and 
release injurious products resulting in vessel wall injury.  Like the classification 
of  vasculitis  disorders,  the  mechanisms  of  pathogenesis  have  also  been 
classified into 4 types (157;158;162).  The first major pathogenic mechanism in 
vasculitic syndromes is termed allergic vasculitis and is strongly associated with 
atopic disorders.  In vasculitic disorders such as urticarial vasculitis and CSS 
activated  Th2  lymphocytes  play  a  central  role  through  their  production  of 
cytokines to mediate the accumulation of mast cells, basophils and eosinophils.  
Bridging of IgE receptors on these cells leads to the secretion of inflammatory 
and toxic mediators.  Antibody-mediated vasculitis is another major pathogenic 
mechanism, especially in ANCA-associated vasculitis as previously described.  
The  third  pathogenic  mechanism  in  vasculitis  is  immune-complex  vasculitis.  
Immune  complexes  are  associated  with  cutaneous  lesions  of  vasculitic 
disorders  and  are  observed  in  HSP,  cryoglobulinemic  vasculitis, 
leukocytoclastic  vasculitis  and  PAN.    80%  of  direct  immunofluorescence 
examinations are positive for IC or complement deposition (157).  Deposition of 
IC results in complement activation and release of anaphylatoxins C3a and C5a 43 
that recruit inflammatory cells, in particular neutrophils and mast cells which are 
necessary for the progression of IC-mediated vascular damage.  This process is 
also highly regulated by adhesion molecules.  T cell hypersensitivity vasculitis is 
the final classification of immunopathogenic mechanisms.  These mechanisms 
are  largely  seen  in  large  vessel  vasculitic  disorders  or  granulomatous 
vasculitides but lack the IC deposition and ANCA association.  Although the 
immune  mechanism  of  pathogenesis  has  been  classified,  more  than  one 
immune mechanism may be involved over the course of a single disease as 
well as the occurrence of overlap syndromes.         
 
1.3.7 Therapies in Vasculitis 
Therapeutic strategies within vasculitis disorders are similar to those described 
for  myositis  disorders  in  section  1.2.5.    Currently  corticosteroid  and 
immunosuppressive therapies, as previously described, are the foundation of 
treatments  strategies  but  the  regime  and  combination  of  treatments  is 
dependent on a number of factors including vasculitis severity and underlying 
medical  conditions  (157;159).    Similarly  to  myopathies  the  exact  pathogenic 
mechanisms and target antigens are still being defined, therefore treatments to 
date are non-selective but new selective therapies are being studied in different 
vasculitic disorders.  TNF-α treatments, Infliximab and Entanercept, have shown 
promise in some treatments while being disappointing in others and have also 
been  related  to  the  development  of  autoimmune  processes  (157;194-201).  
TNF-α  could  mediate  the  endothelial  dysfunction  in  vasculitis  therefore  such 
targeted therapy could improve endothelial functions in these disorders.  B cell 
depletive therapy using Rituximab has also shown promising results in vasculitic 
disorders in a number of studies (148;157;159;177;202-206).  Depletion of B 
cells in the patients included in these studies were accompanied by partial or 
complete  remission  and  decreased  autoantibody  levels  with  few  side  effects 
which further substantiates the role of B cells in such autoimmune disorders.  
Additional B cell therapies targeting CD20, CD22 and BAFF could also impact 
on these disorders (154;155).   
 
The  aetiology  of  most  autoimmune  disorders  is  largely  unknown,  including 
myositis  and  vasculitis.    Many  different  factors  have  been  implicated  in  the 
different  cellular  and  molecular  mechanisms  associated  with  autoimmune 44 
disorders, including the involvement of B cells, the central theme of this study.  
The  participation  and  significance  of  B  cells  in  these  mechanisms  are 
substantiated  by  the  occurrence  of  autoantibodies  and  immune  complexes 
within  autoimmune  disorders  as  well  as  the  recent  clinical  improvements 
observed using B cell depletive therapies.       
 
1.4 B cells 
B cells, along with T cells, were first identified in 1960 (207) and participate in 
adaptive  immune  responses  by  mediating  humoral  immunity  through  the 
release of antigen specific antibodies.  B cells originate in the bone marrow from 
undifferentiated  hematopoietic  stem  cells  (HSC),  which  have  the  capacity  to 
develop  into  all  lymphohematopoietic  lineages,  and  undergo  a  process  of 
maturation  from  early  lymphoid  progenitors  (ELP)  to  common  lymphoid 
progenitors (CLP) by the increased expression of IL-7Rα (208).  CLPs are also 
the  precursor  cells  for  natural  killer  (NK)  cells,  dendritic  cells  (DCs)  and  T 
lymphocytes  (208;209).    In  B  cell  diversification  CLPs then  diversify  through 
pro-B cell and pre-B cell maturation to an immature B cell stage leading to a 
mature  B  cell  (Figure  1.5)  (154;208-213).    Mature  B  cells  them  become 
activated  by  a  relevant  antigen  and  co-stimulatory  factors  and  migrate  to 
germinal centres to differentiate into memory cells and plasma cells which are 
all specific for the original antigen (154;208-213).  Plasma cells are antibody-
secreting cells which are no longer in cell cycle and generally reside within the 
bone marrow.  Within this phenotype of cells there are long-lived and short-lived 
plasma cells (209;213-216).  Prior to plasma cell differentiation activated B cells 
transition  into  activated  cells,  termed  plasmablasts,  which  secrete  antibodies 
but still remain in cell cycle.  Similarly to plasma cells these can be divided into 
short  and  long-lived  categories.    The  exact  relationship  between  these  cell 
types  remains  to  be  defined.    Memory  cells  can  also  be  differentiated  into 
antibody  secreting  cells  by  repeated  antigenic  challenge  resulting  in 
reactivation, rapid proliferation and mutation of memory B cells (209;213).  B 
cell generation depends on signalling through the c-kit, Flt3 and IL-7 receptors 
and development control is exerted by a network of key transcription factors that 
include  PU.1,  Ikaros,  Bcl11a,  E2A,  EBF,  Foxp1  and  Pax5  (217-219);  in  the 
absence of these regulators B cell development is severely affected.  During the 45 
life  span  of  B  cells  they  circulate  between  peripheral  blood  and  tissue,  on 
contact  with  antigen  B  cells  undergo  their  final  stages  of  development 
(207;208).   
 
 
 
 
 
 
 
 
1.4.1 B Cell Gene Repertoire Development 
During the course of B cell development various gene segments rearrange to 
establish  the  repertoire  of  the  immunoglobulins  (Ig)  expressed  on  the  B  cell 
surface (Figure 1.5 & 1.6).  The Ig’s produced by B cells are composed of 2 
heavy  polypeptide  chains  and  2  light  polypeptide  chains,  kappa  or  lambda, 
made up by a combination of gene segments.  The germline variable (V) region 
of the IgH, heavy, chain are coded by the VH (variable), D (diversity) and JH 
(joining) gene segments located on chromosome 14 in humans (220-224).  The 
variable  and  joining  gene  segments  for  lambda  light  chains  are  located  on 
chromosome 22 while the kappa gene segments are located on chromosome 2.   
7 VH families exist based on sequence homology of at least 80% (225-228), 
with approximately 51 functional gene segments.  Approximately 27 functional 
DH gene segments make up 7 DH families based on sequence homology, which 
range from 11 to 37 base pairs in length (229), while 6 JH genes are present 
within the genome.  Kappa and lambda have 7 and 10 different V gene families 
respectively with approximately 40 and 30 gene segments respectively (Table 
1.2).  5 kappa J gene segments are found in the kappa locus with a single 
Figure 1.5 Differentiation Pathway of B Cells 
  
The maturation of B cells occurs in two phases, antigen-independent in the bone marrow and antigen-dependent in 
the periphery.  Stem cells diversify into lymphoid progenitors which further differentiate into pro-B cells before pre-B 
cells are formed where a rearranged VDJ unit is expressed at the cell surface with a surrogate light chain.  Immature B 
cells are formed, still within the bone marrow, that express IgM which evolve into mature B cells expressing IgM and 
IgD.  The terminal differentiation steps occur within germinal centre reactions in secondary lymphoid organs where 
naïve B cells are activated to differentiate into memory B cells and plasma cells.  Markers in red signify where loss of 
transcription factors arrests B cell development; the grey arrow represents the transition of B cells from the bone 
marrow to the peripheral compartments. Adapted from 217.  
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constant kappa gene while four pairs of functional J lambda and constant genes 
are found within the lambda locus.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene  segments  combine  to  form  functional  immunoglobulin  genes  in  a 
recombination  reaction  termed  V(D)J  recombination  (Figure  1.6)  (1;220;230-
234).    These  rearrangements  are  guided  by  conserved  non-coding  DNA 
sequences  that  are  found  adjacent  to  the  points  where  recombination  takes 
place.    These  conserved  sequences  consist  of  a  heptamer  (5’CACAGTG3’) 
followed by a nonconserved region, spacer, which is either 12 or 23 nucleotides 
long (Figure 1.7A).    The conserved length of the spacer corresponds to one or 
two  turns  of  the  DNA  double  helix  respectively.    This  is  then  followed  by  a 
second  conserved  nonamer  sequence  (5’ACAAAAACC3’).    The  heptamer-
spacer-nonamer  combination  is  also  known  as  the  recombination  signal 
sequences (RSSs).  Recombination of gene segments follows the 12/23 rule 
where only a gene segment flanked by a RSS with a 12 base pair (bp) spacer 
can be joined to one flanked by a 23 bp spacer RSS; DH gene segments can be 
Figure 1.6 A simplified Diagram of Gene Rearrangement Processes of Heavy (A) and Light (B) Chain 
Immunoglobulin Genes 
 
In the gene rearrangement process heavy chains are rearranged first (A).  Initially one of the D gene segments 
is translocated to one of the several J gene segments forming a DJ gene combination.  A V gene segment, 
with its own corresponding leader (L) sequence, is then translocated to the DJ segment to form a VDJ variable 
gene segment.  After completion of the heavy chain rearrangements light chain rearrangements are completed 
(B).  One of the V gene segments with its corresponding leader (L) sequence is translocated to a J gene 
segment creating a VJ gene segment encoding the complete light chain variable region.  The kappa chain is 
rearranged first, if this produces a non-functional rearrangement a lambda rearrangement then occurs.  A 
primary  RNA  transcript  is  then  produced  from  the  rearranged  DNA.    Splicing  then  occurs  to  remove  the 
intervening introns and bring together the VDJ/VJ segments with the constant (C) exons.  The kappa gene 
locus contains only one constant gene whereas each J segment of the lambda locus is associated with a 
different constant lambda region.  Adapted from 1. 
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joined to a JH gene segments and a VH gene segment to a DH gene segment 
but VH gene segments cannot be joined to JH gene segments as they are both 
flanked by 23 bp spacers whereas DH gene segments are flanked by 12 bp 
spacers.    The  mechanisms  of  V(D)J  recombination  bring  together  a  12  bp 
spaced and a 23 spaced RSS (Figure 1.7B&C).  The DNA molecule is then 
broken  in  two  places  and  rejoined  in  a  different  configuration.    The  gene 
segments join to form a coding joint while the remainder of the DNA in a hairpin 
loop form a signal joint creating a circular piece of chromosomal DNA which is 
lost during cell division.  Rearrangement of immunoglobulin genes is a multistep 
enzymatic  process  and  starts  with  the  binding  of  products  from  the 
recombination-activating genes, RAG1 and RAG2, whose expression is unique 
to lymphoid cells, and high-mobility group proteins (HMG) to RSSs, following 
the  12/23  rule.    The  endonuclease  activity  of  the  RAG  protein  complexes 
produces two single-strand DNA breaks just 5’ of the bound RSSs leaving a 
free  3’-OH  group  at  the  end  of  each  coding  segment.    This  3’-OH  then 
hydrolyses the phospodiester bond on the complementary uncut strand forming 
double-strand breaks, which are held tightly in a complex by the RAG proteins.  
These form a hairpin by joining to the cut end of its complementary strand on 
the other side of the break.  The two RSSs are precisely joined by DNA ligase 
IV  to  form  the  signal  joint.    To  complete  the  rearrangement  of  the  gene 
segments the DNA hairpin is nicked open by a single-stranded break by the 
RAG  proteins,  this  can  occur  at  various  points  along  the  hairpin  creating 
sequence variability when the sequences join.  The DNA repair enzymes, DNA-
dependent  protein  kinase  (DNA-PK)  and  the  Ku  heterodimer  (Ku70:Ku80) 
modify  the  opened  hairpins  by  removing  nucleotides by  exonuclease  activity 
and  adding  non-templated  (N)  nucleotides  by  terminal  deoxynucleotidyl 
transferase,  TdT,  or  templated  (P)  nucleotides.    DNA  ligase  IV  joins  the 
processed ends to generate a continuous double-stranded DNA, reconstituting 
a chromosome which includes the rearranged gene.   
 
The majority  of  gene segments  do  not  join  in  phase  with  the  reading frame 
resulting  in  non-functional  rearrangements.    Also  inappropriate  gene 
rearrangements,  approximately  75%,  produce  recognition  to  self  antigens 
resulting in apoptosis or anergy of cells at the pre-B stage.  These cells may be 48 
rescued  by  receptor  editing,  a  dominant  mechanism  in  B  cell  tolerance.  
Secondary Ig gene rearrangements occur, which are RAG-mediated, altering 
the  specificity  of  an  autoreactive  B  cell  at  the  immature  B  cell  stage 
(233;235;236). 
 
VH1  VH2  VH3  VH4  VH5  VH6  VH7  VH Family 
10  3  23  11  2  1  1 
DH1  DH2  DH3  DH4  DH5  DH6  DH7  DH Family 
5  4  5  4  4  4  1 
JH1  JH2  JH3  JH4  JH5  JH6  JH Family 
1  1  1  1  1   
Vκ1  Vκ2  Vκ3  Vκ4  Vκ5  Vκ6  Vκ Family 
19  9  7  1  1  3 
Jκ1  Jκ2  Jκ3  Jκ4  Jκ5  Jκ Family 
1  1  1  1  1 
Vλ1  Vλ2  Vλ3  Vλ4  Vλ5  Vλ6  Vλ7  Vλ8  Vλ9  Vλ10  Vλ Family 
5  5  9  3  3  1  2  1  1  1 
Jλ1  Jλ2  Jλ3  Jλ7  Jλ Family 
1  1  1  1 
          Vκ7, Jλ4, 5 and 6 are considered non-functional 
Table 1.2 Distribution of VH, Vκ and Vλ Functional Genes  
 
The  assembly  of  different  gene  segments  in  V(D)J  recombination  and  the 
random pairing of heavy and light chains provide the diverse gene repertoire of 
the B cell.  This diversity is further enhanced by exonuclease activity removing 
nucleotides and addition of up to 20 non-templated (N) or up to 4 templated (P) 
nucleotides, inverted repeats of V, D or J coding ends, at joining sequences 
within  the  CDR3  region  generating  the  most  diverse  region  of  the  Ig 
rearrangement  (Figure  1.7C)  (237;238).    Additional  mechanisms  are  also 
employed to further increase diversity following exposure to antigen, somatic 
hypermutation  leading  to  affinity  maturation  and  receptor  revision.    Receptor 
revision in the periphery, similar to that of receptor editing in the bone marrow, 
can also increase the diversity through secondary recombination of low affinity 
immunoglobulin  genes  to  alter  the  specificity  and  affinity  towards  antigen 
(233;239;240). 
 
1.4.2 VH Repertoire from Healthy Individuals 
Studies have been conducted within normal, healthy individuals to establish the 
normal repertoire of immunoglobulin genes which allow the modifications to the 
repertoire to be established within autoimmune diseases (241-250).  Some of 49 
these studies have demonstrated that the frequency of gene usage was similar 
to that of the germline complexity (241-243).  Guigou et al (245) first used in situ 
hybridization, on cDNA libraries from peripheral blood samples, using Ig DNA 
probes specific for VH1 to VH6 to analyse the expression pattern of VH families 
in  the human  adult  repertoire  of  two  healthy  patients.    Results  produced  an 
expression gradient for VH genes; VH3 (52%) > VH4 (19%) > VH1 (11%) > VH5 
(10%) > VH6 (5%) > VH2 (3%).  This gradient of gene usage is comparable to 
the complexity of functional germline genes within each family although bias for 
activated B cells is possible.  Brezinschek et al (241;242)  in subsequent studies 
used  single-cell  PCR  analysis  on  genomic  DNA  to  analyse  the  heavy  chain 
repertoire of human peripheral B cells.  In functional repertoires VH3 was used 
most frequently followed by VH4, VH1, VH5, VH2 and VH6, an ordering similar to 
the number of functional genes within each VH family.  This preferential use of 
VH3 gene segments was not found in non-functional repertoires.  Selection for 
particular  individual  VH  germline  genes  was  also  reported.    VH3-23,  VH4-59, 
VH4-39,  VH3-07,  VH3-30,  VH1-18,  VH3-30*03,  VH3-34  and  VH3-09  were  over-
represented in these repertoires and were found to be expressed by more than 
50% of B cells.  A limitation of these studies was the low number of patients 
involved which may not fully represent the true diversity of the Ig repertoire.  
 
The most recent study examining the VH gene repertoire was conducted using 
nearly 6,500 functional human Ig heavy chain genes which aimed to represent 
the natural Ig diversity and was compared to 325 non-functional genes (251).  
This  study  involves  a  larger  set  of  genes  than  was  previously  examined, 
including the previous studies by Brezinchek et al (241;242).  Clonally related 
gene duplicates and genes of autoimmune origin were filtered from the dataset 
of  sequences  isolated  from  the  Genbank  nucleotide  database  in  addition  to 
genes of perinatal origin, due to the known gene segments and CDR3 biases.  
The  study  established  that  functional  gene  rearrangements  more  closely 
resembled  the  genomic  complexity  compared  to  the  non-functional  gene 
rearrangements.    The  data  from  functional  genes  support  that  of  previous 
findings (241;242) that VH3 gene segments are used most frequently, followed 
in descending order by VH4, VH1, VH5, VH2, VH6 and VH7 which is also similar to 
the germline complexity.  Also in support of previous findings the gene segment 50 
VH3-23 was most frequently used followed by the VH4-34 gene segment in this 
study.  Analysis of DH gene segments demonstrated a significant departure of 
the  proportions  within  functional  and  non-functional  from  the  germline 
complexity at both the family and individual gene segments usage level.  The 
functional repertoire of DH demonstrated that DH3 gene segments were most 
frequently used followed by DH2, DH6, DH1, DH5, DH4 and finally DH7.  Due to 
the  difficulties  in  assigning  DH  gene  segments  in  rearranged  Ig  genes,  the 
normal repertoire of DH gene segments had not been extensively studied prior 
to this study.  The repertoire of JH gene segments was also found to correlate 
with  previous  studies  with  the  JH4  gene  segments  most  frequently  used 
followed by JH6, JH5, JH3, JH1 and JH2.  As very few JH gene segments are 
present within the genome, the repertoires observed within the functional, as 
well as the non-functional, were found to differ significantly from the germline 
complexity.  In addition to the repertoires of the individual gene segments the 
study also examined D-J segments pairings.  Several pairings were found to 
occur statistically above expected values, including DH2-2 to JH6 and JH2, DH1-
14to JH1 and JH5, DH5-24 to JH4 and DH7-27 to JH3.  Overall it was observed 
that several 5’DH gene segments paired with increase frequency to the most 
3’JH  gene  segments  (JH5  and  6)  while  with  decreased  frequency  to  closer 
chromosomal segments (JH1-4).  However, some 3’DH gene segments did show 
an increased frequency of pairings with the closest JH gene segments and a 
decreased frequency in pairing with the furthest JH5 and JH6 gene segments.  In 
addition  to  establishing  the  normal  repertoire  the  study  hypothesised  that 
multiple D-J successive recombinations may occur before translocation of the 
VH gene, although very little evidence for this mechanism had been found.           
 
Conversely  studies  have  been  conducted  in  healthy  individuals  that 
demonstrate that the peripheral B cell repertoire differs from the gene frequency 
within  the  germline  and  biased  expression  of  certain  VH  families  have  been 
observed in certain individuals (246-248;250).  Huang et al (246) demonstrated 
a selection for VH1 and VH5 gene segments with a selection against VH3 family 
genes  in  cDNA  libraries  from  2  patients.    Suzuki  et  al  (250)  assessed  the 
contribution  of  individual  VH3  and  4  gene  segments  to  the  human  antibody 
repertoire.  Synthetic oligonucleotide probes, which were specific to individual 51 
VH  gene  segments  within  rearranged  genomic  DNA,  were  used to  assess 8 
individual VH3 and 9 individual VH4 gene segments in the PBL repertoire of two 
healthy patients.  Of the eight individual VH3 gene segments assessed the VH3-
23 and VH3-30 gene segments were rearranged more frequently than expected 
based on germline complexity which accounted for approximately 17% and 20% 
of VH3 gene rearrangements in both subjects respectively.  In both subjects the 
eight  VH3  gene  segments  analysed  accounted  for  over  50%  of  the  VH 
rearrangements, an increase from the 16 to 30% predicted based on VH3 gene 
numbers.    VH4-34  was  shown  to  be  over-expressed  in  one  of  the  subjects, 
accounting for more than 25% of the sequences isolated. This rearrangement 
with another two VH4 rearrangements, VH4-31 and VH4-4b, accounted for more 
than 50% of the VH4 rearrangements.  Conversely VH4-17, VH4-55 and VH4-28 
were rarely found.  The work of this study suggests that a limited number of VH 
gene segments dominate the VH repertoire but due to the polymorphic nature of 
these  segments  the  dominance  of  individual  VH  gene  segments  will  differ 
between individuals.  The repertoire was analysed after an 8 month intermission 
and little change in the VH repertoire was observed indicating that the utilization 
of these VH gene segments was a stable feature in the VH repertoire of this 
subject.  The over-representation of the VH4-34 gene was also noted in another 
study into the normal adult human peripheral blood B cell repertoire.  Kraj et al 
(247) established the representation of the VH4-34 gene in the repertoire of two 
healthy individuals.  VH family distribution was found not to significantly differ 
from expected values based on the germline complexity but in both the cDNA 
library  and  rearranged  Ig  DNA  library  VH4-34  gene  segments  were  over-
represented relative to other VH4 gene segments accounting for 25 and 70% of 
DNA sequences in the two patients.  
 
Previous  work  on  biased  subsets  of  VH  gene  segments  within  peripheral 
repertoires led Kraj et al (248) to assess the human VH repertoire at different 
stages  of  B  cell  development.   The  study  compared the VH3  and  VH4  gene 
representation of pre-B, immature B and preimmune mature B cells from two 
healthy individuals.  Within pre-B cells there was a large representation of VH4 
gene segments.  VH4-34 was the most prominent and accounted for over 20% 
of  sequences  in  both  patients.   VH4-59  was  also  highly  prominent  within  VH 52 
repertoires  while  VH4-31,  VH4-4b  and  VH4-61  were  very  low  within  both 
repertoires.  For the VH3 repertoire a biased representation of certain VH3 gene 
segments, VH3-23 and VH3-30, was observed at the pre-B cell stage and this 
was carried through to mature B cell stages.  Other genes such as VH3-11 were 
highly prominent at early B cell stages but were rare in later B cells stages while 
VH3-20  were  very  infrequent  in  early  B  cell  stages  but  this  increased  in  the 
mature B cell population.  VH3-15 was shown to be highly frequent on immature 
B cells compared to pre-B cells but this was not observed at later stages of B 
cell  development.   The  authors  suggest  that  bias  within  the  VH  repertoire  is 
established  at  the  earliest  pre-B  cells  stage  resulting  from  preferential 
rearrangement which may later be modified by VH gene-mediated mechanisms 
such as effective surrogate light chain pairing and ligand mediated selection. 
 
Many mechanisms for these reported bias gene usage repertoires have been 
proposed (247;252;253).  These mechanisms include chromosomal positions, 
accessibility  to  recombinase  machinery,  and  the  presence  of  gene-specific 
promoter or enhancer sequences in addition to a greater number of gene copies 
in  the  germline.    It  has  also  been  shown  that  preferential  use  of  certain  VH 
elements may result from cellular selection due to antigen binding.  Gu et al 
(254) established that the recruitment of newly generated B cells into the long-
lived  peripheral  B  cell  population  is  mediated  through  positive  selection  by 
internal and/or external ligands.  Despite these previous studies the most recent 
and comprehensive study (251) has illustrated that the Ig repertoire is similar to 
the germline complexity. 
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1.4.3 Somatic Hypermutation (SHM) 
The release of B cells into the periphery from the bone marrow allows B cells to 
recirculate through peripheral lymphoid tissues and to come into contact with 
their cognate antigens resulting in B cell activation.  Activated B cells can enter 
primary lymphoid follicles leading to the formation of germinal centres (GCs), 
also containing antigen-specific T cells.  Within GCs the B cells undergo two 
distinct immunoglobulin gene diversification processes; somatic hypermutation 
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Figure 1.7 A simplified diagram of the mechanisms of V(D)J recombination 
 
Figure 1.7A – Conserved heptamer (     ) and nonamer (     ) sequences flank the gene segments of the heavy and 
light chains.  These are separated by a spacer of either 12 base pairs or 23 base pairs.  In V(D)J recombination a 
12/23 rule is in place to ensure that only a gene segment flanked with a 12bp spacer can be joined with a 23bp 
spacer.  Heptamer – spacer – nonamer combinations are known as recombination signal sequences (RSSs) 
 
Figure 1.7B&C – Ig rearrangement is a multistep process, initially RAGs and HMG bind to RSSs (    ) and bring the 
regions together before causing single stranded DNA breaks resulting in hairpin structures at the ends of the Ig 
gene segments.  A number of proteins (DNA-PK, Ku) bind to the hairpins and the sequences are cleaved at random 
and additional bases are added by TdT to generate diverse ends.  DNA ligase IV ligates the gene segments forming 
a coding joint.  The cleaved DNA circularises forming a signal joint which is lost during cell division.  Adapted from 1. 
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(SHM)  and  class  switch  recombination  (CSR),  although  SHM  has  been 
demonstrated to occur outside GCs in animal models that cannot develop GCs 
(255).  SHM introduces non-template point mutations in the variable region of Ig 
heavy  and  light  chains,  a  process  which  underlies  the  process  of  affinity 
maturation,  generating  an  immunoglobulin  with  an  altered,  higher  or  lower, 
affinity for its cognate antigen (256).  The full workings of SHM have yet to be 
established  although  some  mechanisms  have  been  elucidated.    Activation-
induced cytidine deaminase (AID) plays a significant role in SHM, as well as 
CSR.  AID is a B cell specific molecule that plays a central role in adaptive 
immunity  by  initiating  SHM  (257-261).    Although  AID  functions  as  a  DNA 
mutator  it  is  predominately  located  in  the  cytoplasm  of  B  cells  but  nuclear 
localisation  and  export  signals  allows  transfer  between  the  nucleus  and 
cytoplasm  (261).    Mutations  are  confined  to  a  1  to  2  kilobase  region  in  the 
rearranged immunoglobulin genes of which the variable region defined the 5’ 
boundary of the hypermutation region.  Mutations begin approximately 150 bp 
downstream of the transcription start site but the mutational frequency is not 
constant  and  decreases  exponentially  with  increasing  distance  from  the 
transcription start site (262).  Point mutations generally occur in SHM, although 
insertions and deletions are occasionally observed, at a rate of 1x10
-3 mutations 
per base per generation (261;263).  Transition mutations (a pyrimidine (C or T) 
to pyrimidine base change or a purine (A or G) to purine base change) occur 
approximately  twice  as  frequently  as  transversion  mutations  (a  pyrimidine  to 
purine base change and vice  versa) and a high proportion of these arise in 
mutational hotspot motifs.  Mutations are often seen in conjunction with WRCY 
motifs  (W=A/T,  R=A/G  and  Y=C/T)  or  its  complement  RGYW  (264).    AID 
initiates  SHM  by  the  deamination  of  C  nucleotides,  on  single  strand  DNA, 
resulting in a U.G mismatch.  Following this DNA polymerases can insert an A 
nucleotide  opposite  the  U  nucleotide  to  generate  C>T  or  G>A  transition 
mutations following replication, the mismatch could be removed by the UNG 
(uracil-DNA glycosylase), base-excision repair  (BER) mechanism, to create an 
abasic site that can then be bypassed by error-prone polymerases (η or ζ) to 
give rise to both transition and transversion mutations or the mismatch can be 
targeted by the mismatch repair (MMR) to initiate an error-prone polymerase 55 
mediated  mutation  process  that  introduces  A-T  and  G-C  mutations  that  are 
proximal but not located within hot spots. (257-259;262)    
 
1.4.4 Class Switching Recombination (CSR) 
Class switching recombination (CSR) is also initiated by AID, although the exact 
role of AID is unknown (257;261;265;266).  CSR is a process that changes the 
Cµ constant regions to another constant region (Cγ, Cα or Cε) to define the Fc 
mediated functions but allows the antibody to retain its specificity and affinity for 
antigen.  Tight regulation of CSR is required as abnormal levels of IgG, IgA or 
IgE favour the onset of autoimmune and allergic disorders such as SLE and 
asthma (265).  CSR results from DNA recombination between switch (S) region 
DNA segments located upstream of each C gene and deletion, circularisation, 
of the intervening DNA.  The choice of which S region serves as recipient for 
CSR is determined by which cytokines are released by the helper T cells that 
interact with the IgM-producing B cell (261).  Evidence suggests that once AID 
deaminates  C  to  U  in  both  the  donor  and  recipient  S  region,  the  resulting 
mismatch recruits all the same enzymes that are recruited during SHM to create 
ssDNA  breaks  with  CSR  a  result  of  DNA  repair  and  germline  transcription 
(257;261;265;266).    It  has  also  been  proposed  that  AID  generates  dsDNA 
breaks, generated by closely spaced single-strand breaks, with the recruited 
enzymes and additional enzymes are recruited to complete the process of CSR 
by nonhomologous end joining (261).  It has been recently demonstrated that 
AID is expressed in bone marrow pre-B cells and immature B cells initiated by 
the signalling through BCR and TLRs (266) providing an innate population of 
IgG and IgA expressing cells that could be involved in receptor editing of self-
reactive immature B cells.     
 
1.4.5 Germinal Centres  
GCs  are  composed  of  a  network  of  B  cells,  FDC  and  CD4
+  T  cells  whose 
interactions  result  in  the  B  cell  humoral  immune  response  in  secondary 
lymphoid  tissues  and  the  generation  of  antigen-specific  antibodies.    The 
microenvironments of GCs are essential in the development of normal B cell 
immune responses as they provide an infrastructure that captures and stores 
antigen,  drives  B  cell  division  and  maturation,  selects  B  cells  with  antigen 56 
specific high affinity receptors and differentiates cells into memory B cells and 
Ig-secreting  plasma  cells.    GCs  are  derived  from  1-3  B  cells  clones  (267).  
Small  recirculating  follicular  B  cells  are  displaced  to  the  outer  edge  of  the 
network of FDCs to form the follicular mantle (268).  GCs first appear at day 4-5 
postimmunisation, achieve maximum cell numbers by day 10-11 and decline 
after  about  3  weeks  (269).      Antigen  stimulated  B  cells  within  secondary 
lymphoid tissues migrate to the edges of B cell follicles where they interact with 
T helper cells and begin to form GCs (270).  Classically mature GC reactions 
are a two-stage process, firstly B cells form the GC dark zone and begin to 
proliferate,  during  proliferation  B  cells  undergo  somatic  hypermutation  to 
diversify the antibody variable region to produce variants with different affinities 
to  the  specified  antigen  (268;269;271-273).    Following  this,  B  cells  termed 
centroblasts  convert  to  smaller,  non-proliferating  centrocytes  with  surface 
expression  of  mutated  Igs  and  migrate  to  the  GC  light  zone  where  they 
encounter a network of FDC, that present native antigen in the form of immune 
complexes,  and  CD4
+  T  cells,  that  provide  helper  signals  to  promote  B  cell 
proliferation  and  differentiation,  and  undergo  intense  selection.    Selection  is 
based on competition for antigen; only those B cells with an increased affinity 
for antigen can undergo isotype switching and be selected to differentiate into 
memory B cells or plasma cells.  FDCs with successfully bound high affinity B 
cells switch off the apoptotic machinery of these high affinity B cells (273).  The 
majority  of  B  cells  die  through  apoptosis  and  are  immediately  taken  up  by 
germinal  centre  tingible-body  macrophages  as  somatic  mutations  result  in  a 
lower affinity for the specified antigen or the B cells may even become reactive 
with  self  antigens.    Over  the  course  of  the  GC  reaction  the  light  zone  is 
continuously replenished by migration of GC B cells from the dark zone.  It is 
also thought that selected centrocytes can return to the dark zone for further 
rounds of division and somatic mutations giving rise to the cyclic re-entry model 
(268;274).    The  organisation  of  light  and  dark  germinal  centre  zones  is 
mediated by CXCR4 and CXCR5.  Allen et al (275) demonstrated that CXCR4 
was essential for the segregation of dark and light zones, CXCR4 was more 
abundant  on  centroblasts  rather  than  centrocytes  and  was  required  for 
centroblast localization in the dark zone where its ligand, SDF1/CXCL12, was 
more abundant in comparison to the light zone.  Conversely CXCR5 helped 57 
direct  CXCL13-positive  cells  to  the  light  zone  but  this  was  not  essential  for 
segregation  of  zones.    The  study  proposed  that  centroblasts  downregulate 
CXCR4 and differentiate into centrocytes and migrate towards the light zone 
while centrocytes upregulate CXCR4 to allow re-entry into the dark zone.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recent studies have used two-photon laser-scanning fluorescent microscopy to 
capture the movement and behaviour of B cells in germinal centres and present 
GC mechanisms which are in contrast to the previous GC mechanisms (276-
278),  reviewed  (274;279;280)  (Figure  1.8).    Allen  et  al  (276;279)  tracked 
germinal centre B cells in mouse lymph nodes, in a perfusion chamber. Initially 
it  was  demonstrated  that  germinal  centre  B  cells  possessed  highly  dynamic 
Figure 1.8 Germinal Centre Organisation and Reactions 
 
Germinal Centre (GC) reactions occur within two distinct zones of the GC; the Light Zone (LZ) and the Dark Zone (DZ).  
The DZ is composed of GC B cells, a sparse network of stromal cells, GC T cells and tingible-body macrophages (TBM).  
The LZ is composed of GC B cells, a dense network of FDCs, GC T cells and TBMs.  GC B cells migrate within their 
respective compartments as well as moving between compartments by regulating CXCR4 levels.  Antigen is displayed on 
FDCs as immune complexes (IC).  GC B cells cycle within the DZ through cell proliferation and cell death.  Reducing 
CXCR4 levels cells from the DZ can migrate to the LZ where GC B cells rapidly move within the FDC network to be 
selected as high affinity GC B cells.  From the LZ, GC B cells either undergo apoptosis, exit the GC to differentiate into 
plasma cells or memory cells or they return to the LZ, a result of increasing CXCR4 levels.  Recent evidence had found 
that follicular B cells may enter GCs scanning the antigens present and may be recruited to an ongoing GC reaction if they 
have a higher affinity towards antigen. Adapted from 276. 
 
Classically  GC  mechanisms  defined  GC  B  cells  as  centroblasts  and  centrocytes  within  the  DZ  and  LZ  respectively.  
Centroblasts were thought to undergo a rapid process of proliferation and somatic mutation before differentiating into 
centrocytes  within  the  LZ  where  selection  of  high  affinity  antigen  B  cells  were  selected.    The  cycle  of  mutation  and 
selection required to isolate high-affinity GC B cells led to the cyclic re-entry model where GC B cells migrate between 
zones between each phase of mutation and selection.    
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shapes,  extending  dendritic  processes  when  they  moved  in  contrast  to  the 
spherical phenotype characteristic of naïve B cells.  Tracking analysis indicated 
that GC B cells were highly motile, similar to that of follicular mantle B cells and 
in contrast to plasma cells which demonstrated little motility.  This motility was 
partially  dependent  on  the  chemokine  CXCL13,  expressed  by  FDCs.    The 
behaviour  of  B  cells  in  the  dark  and  light  zones  were  examined  and  it  was 
demonstrated that GC B cells stayed within the dark or light zone although 5-
8% travelled from one zone to another per hour.  Cell division and cell death 
were observed in both regions of the germinal centre, in contrast to the classic 
model  of  germinal  centre  reactions  mentioned  previously.    Schwickert  et  al 
(278) and Hauser et al (277) also tracked the movement of germinal centre B 
cells,  but  these  were  conducted  in  live  mice  that  had  received  fluorescently 
labelled  antigen  specific  B  cells.    Similar  to  Allen  et  al  (276)  the  studies 
demonstrated that GC B cells were highly motile and re-circulate within the dark 
and light zones but Schwickert (278) demonstrated that bi-directional movement 
between zones occurred but at a higher frequency of 26% per hour in contrast 
to  5-8%  per  hour  described  by  Allen  et  al  (276)  and  Hauser  et  al  (277). 
Schwickert  et  al  (278)  also  demonstrated  that  the  contact  between  antigen 
bearing FDCs and antigen specific B cells was short lived, in the light zone, but 
frequent  suggesting  that  B  cells  were  crawling  along  FDCs  scanning  for 
antigen. This is in contrast to naïve B and T cells which stop moving when they 
initially encounter antigen.  The study also demonstrated that follicular B cells 
are frequent visitors to the GC compartment indicating that B cells may scan 
antigen trapped within the confines of germinal centres.  In addition to this it 
was  found  that  high-affinity  antigen-specific  B  cells  can  be  recruited  to  an 
ongoing germinal centre reaction which would enhance competition and ensure 
that  rare  high-affinity  B  cells,  not  initially  recruited  into  the  germinal  centre 
reaction, might gain the opportunity to participate within antibody responses.  
This is in contrast to lower-affinity B cells which could not easily colonise an 
established germinal centre.  This mechanism has recently been substantiated 
by Bende et al (281) who analysed the B cell composition of 48 GCs of reactive 
lymph  nodes  from  3  different  donors  and  demonstrated  that  single, 
hypermutated B cell clones were found in multiple GCs, along with the offspring 59 
from these clones.  These results indicated the repeat involvement of antigen-
experienced B cells within GC reactions.     
 
Allen et al (276) concluded that the rates of interchange between the two zones 
and the bi-directional movements were consistent with the cyclic re-entry model.  
Conversely Hauser et al (277) concluded that there was not sufficient migration 
between each cell division to substantiate the cyclic re-entry model and instead 
favoured the intrazonal model (Figure 1.9).  Within this model most cells stay 
resident in the dark or light zones and selection in each of the zones occurs 
independently.    In  a  more  recent  study  statistical  and  functional  modelling 
approaches were applied to the two-photon data to formulate a migration model 
which  also  incorporated  chemokine  receptor  expression  levels  (282).  
Collectively  these  results  demonstrate diverse  germinal  centre models  which 
differ from the conventional and classic models.   
 
 
 
 
 
 
 
 
 
Analogs of germinal centre structures with comparable proliferation, mutation 
and  apoptotic  reactions,  ectopic  GCs,  have  been  identified  in  non-lymphoid 
tissues in a variety of diseases, MG (52), SS (283), RA (284), HT (54) and 
breast cancer (285).  The biological functions of this lymphoid neogenesis have 
been implicated in the pathology of autoimmune diseases by the generation of 
autoantibodies  from  autoreactive  B  cells  although  the  steps  leading  to  auto-
antibody  production  remain  elusive.    Abnormal  GC  reactions  have  been 
observed in SLE which are thought to play a central role in SLE pathogenesis 
(286).    
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Figure 1.9 Migration Models for Germinal 
Centre Reactions 
 
Previous findings on GC reactions implied that 
GC  B  cells  which  succeed  in  the  selection 
process  return  to  the  dark  zone  for  further 
division  following  a  cyclic  re-entry  model  (A).  
Recent  studies  have  found  that  intra-zonal 
recirculation (B) may be the predominant mode 
of migration within GCs.  This model suggests 
that  GC  B  cell  migration  is  parallel  to,  rather 
than perpendicular to the DZ – LZ interface with 
infrequent exchanges between the zones.  
 
Solid arrows indicate strong movement of GC B 
cells, dashed arrows indicate a less prominent 
movement.  Blue arrows indicate cells exiting 
the GC.  Adapted from 277. 60 
1.4.6 Role of B cells in Myositis and Vasculitis  
The autoimmune origin and the role of B cells remain uncertain in myositis and 
vasculitis.  The autoimmune origins of these disorders are supported by the 
disease’s  association  with  other  autoimmune  diseases,  production  of 
autoantibodies,  formation  of  immune  complexes  and  the  response  of  the 
disease to B cell depletive therapies.  In a recent study the role of B cells has 
been established in myositis where the study aimed to distinguish DM from PM 
by B cell activation (287). The study examined RP105, a leucine-rich repeat 
molecule, structurally similar to Toll-like receptors, located on the surface of B 
cells that was found to transmit an activation signal for B cell proliferation and 
resistance to apoptosis, this molecule is lost upon activation.  SLE patients were 
found to have increased numbers of RP105 negative cells in peripheral blood, a 
phenotype of B cells consistent with that of activated B cells or germinal centre 
B cells, therefore the study investigated if DM and PM could be distinguished 
from  one  another  by  establishing  the  surface  expression  of  RP105  on 
circulating  B  cells  in  both  myopathies.    The  results  showed  a  noticeably 
increased percentage of RP105 negative cells in DM compared to PM, 33.0% 
compared to 5.8%, suggesting the expansion of RP105 negative B cells is a 
hallmark  of  DM  and  indicating  that  B  cells  have  a  fundamental  role  in  the 
pathogenesis of DM different from that of PM.  Recent studies indicate RP105 
regulates  antigen-presenting  functions  and  Treg  development  in  a  model  of 
collagen-induced  arthritis  (288).    In  vasculitis,    the  work  of  Baiu  et  al  (193) 
implicated a role for B cells in the pathophysiology of vasculitis as does the 
presence  of  immune-complex  formations  and  many  autoantibodies  within 
vasculitic lesions.    
 
Pathogenic  roles  for  B  cells  in  both  myositis  (DM)  and  vasculitis  are 
substantiated by the recent studies using the B cell depletive therapy, Rituximab 
(149-151).  Pilot studies indicated that Rituximab is an efficient treatment of DM 
as  the  resulting  B  cell  depletion  reduced  DM  symptoms  (150-152).  
Improvements in muscle strength were observed as well as decreased levels of 
creatine kinase and a reduction in skin rashes but these symptoms reappeared 
during  relapse  associated  with  a  return  of  circulating  B  cells.    Although 
preliminary, and from a small sample size, these results emphasise the role of B 61 
cells in the pathogenesis of DM.  A recent study has also demonstrated the use 
of  Rituximab  in  the  treatment  of  4  Juvenile  DM  patients,  with  and  without 
myositis specific autoantibody (MSA) production (152).  Clinical improvement 
was observed in three of the patients while the fourth had progression of the 
disease indicating that B cells are not fully accountable for the pathogenesis 
associated with myositis.  Similar results have also been observed in Rituximab 
use in SLE and RA (149).  Additional studies have demonstrated remission as a 
result  of  the  Rituximab  treatment  in  ANCA-associated  vasculitic 
(148;157;159;177;202-206).   
 
Collectively evidence from the studies described above substantiate a role for B 
cells in myositis and vasculitis but the exact mechanisms of B cells and their 
role in disease pathogenesis in these disorders remain unresolved.     
 
1.5 Hypothesis and Aim of Study 
The  core  objective  of  this  study  was  to  establish  a  role  for  B  cells  in  the 
autoimmune disorders of myositis and vasculitis.  By assessing the VH antibody 
repertoire and clonal diversification of infiltrating B cells and plasma cells this 
study  could  examine  the  hypothesis  that  infiltrating  lymphocytes  within  the 
muscle  and  vasculature  were  being  locally  stimulated  by  endogenous  or 
exogenous  antigens  contributing  to  the  pathological  mechanisms  of  these 
disorders.  Therefore the following main aims of this study were addressed: 
 
·  Identify infiltrating B cells and plasma cells within the inflammatory target 
tissue of myositis and vasculitis patients (Chapters 3 and 5). 
·  Establish the Ig gene repertoires of these muscle and skin infiltrating B 
cells and determine if gene selections are occurring (Chapters 4 and 5). 
·  Identify clonally related sets of sequences to indicate if B cell antigen-
driven responses occur in the target tissues of myositis and vasculitis 
patients (Chapters 4 and 5). 
·  Identify and characterise infiltrating antigen specific cells and determine 
the Ig repertoire of these cells (Chapter 6). 
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Chapter 2 – Materials and Methods 
 
2.1 Materials 
All chemicals were supplied by Sigma-Aldrich (St. Louis, MO, USA) and Griener 
Bio-One  (Kremsmuenster,  Austria),  Sarstedt  (Numbrecht,  Germany)  and 
StarLab (UK) supplied the plasticware unless otherwise stated.   
 
2.2 Identification of Cellular Infiltrates in Myositis and Vasculitis Biopsies  
 
2.2.1 Patients and Samples 
Muscle  and  skin  tissue  biopsies  were  obtained  from  patients  undergoing 
diagnostic  biopsies  for  myositis  or  vasculitis,  following  informed  consent.  
Ethical approval was obtained from North Glasgow Hospital Research Ethics 
Committee.  Samples, at time of biopsy, were embedded in Tissue-Tek OCT 
compound  (Sakura  Finetek,  Torrance,  CA)  and  snap-frozen  in  dry  ice  and 
ethanol  and  stored  at  -70° C.    Alternatively  archiva l  muscle  biopsies  from 
previous diagnostic procedures, conducted by Dr W Behan, were obtained from 
the  Pathology  Department, Western  Infirmary,  Glasgow.    Biopsies  had  been 
embedded in OCT and either stored in liquid nitrogen or at -70° C.  To obtain 
retrospective  consent  for  these  samples  to  be  used  for  research  purposes 
amendments to the original ethical approval were completed and the medical 
records  department  for  each  patient’s  hospital  was  contacted  to  obtain 
information of the patients General Practitioner to allow the patient’s contact 
information to be sought.    
 
A total of 28 myositis patients, plus a control biopsy from a healthy patient, were 
selected from archival records.  Sample MYO1 had already been selected and 
gave consent for the study.  From the 28 patients selected 9 were deceased at 
the commencement of the study.  To allow these samples to be used within the 
study the patient details were blinded and the samples number selected to the 
investigator  by  Linda  MacKinnon,  Pathology  Department,  Western  Infirmary, 
Glasgow.    From  the  9  samples  only  6  could  be  obtained  from  the  archival 
stores, 3 could not be located or had been sent away.  Four patients could not 
be found within any medical records departments therefore consent could not 
be sought from the patients and there was no confirmation if the patient was 
living or deceased therefore the samples were not included in the study.  For 63 
the remaining 15 patients, including the control patient, consent for the samples 
to be used in the study was requested.  From these requests consent was given 
by 13 patients.  From these, 10 of the samples could be obtained from archival 
stores, 3 could not be located or had been sent away.  For 2 patients, MYO5 
and  MYO18,  records  indicated  that  each  patient  had  2  separate  biopsies 
conducted. For patient MYO5 a further biopsy was conducted 3 years following 
a diagnostic biopsy and for patient MYO18 a second biopsy was conducted a 
year  following  the  diagnostic  biopsy.    For  these  patients  both  biopsies  were 
sought  but  only  the  biopsies  following  the  diagnostic  procedure  could  be 
obtained,  the  diagnostic  biopsies  could  not  be  located.    From  the  archival 
selection a total of 17 muscle samples from 16 different myositis patients and 1 
control patient (Table 2.1) were used within the study.  These samples, plus the 
sample  from  patient  MYO1  who  had  already  been  included  in  the  study, 
resulted in a total of 17 myositis biopsies being used within the study with the 
addition of a control sample.  A summary of the pathology reported in these 17 
myositis biopsies is shown in Table 2.2.  Each sample was examined using 
immunohistochemical techniques for the presence of B cells and plasma cells 
and those with evident cellular infiltrates were examined further.   
 
An additional muscle biopsy was obtained (MYO4) during the duration of the 
study but due to storage and transit conditions the sample was unable to be 
included in the study. 
 
8  skin  biopsies  were  obtained  during  diagnostic  procedures  from  the 
Dermatology Department, Royal Infirmary, Glasgow.  Only 3 of these biopsies 
could be used for the vasculitis study (Table 2.3).  Pathologists from the Royal 
Infirmary  hospital  reported  no  active  vasculitis  within  3  of  the  biopsies  and 
problems with sample handling meant an additional 2 could not be included in 
the study.  The remaining 3 skin biopsies had active vasculitis confirmed by the 
Pathology Department, Royal Infirmary.  As previously mentioned, each sample 
was  examined  using  immunohistochemical  techniques for  the  presence of  B 
cells and plasma cells and those with evident cellular infiltrates were examined 
further. 
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2.2.2 Tissue Sectioning 
Serial  frozen  sections  (8  µm)  were  cut  with  a  Shandon  cryostat  and  were 
mounted on positively charged slides (Menzel Glaser, Germany or VWR, UK).  
Sections were air dried for at least 1 hour, fixed in acetone for 10 minutes and 
stored at -70° C with a desiccant.                                        
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Sample  Diagnosis  M/F  Age at 
Diagnosis 
Disease 
Duration 
From 
Diagnosis 
CK at 
Biopsy 
IU/ml 
Normal 
Range up 
to 150 IU/ml 
CRP at 
Biopsy 
(mg/L) 
Normal 
Range 
<10 
Autoantibody 
Profile 
Therapies at time 
of Biopsy 
Family 
History  Other Features 
MYO1  DM  F  40  0  142  NR 
ANA NR, ENA 
Negative, Jo-1 
Negative, Weakly 
Positive Anti-DNA 
(52U/ml, normal 
range <30U/ml) 
No Prednisolone at 
biopsy, other 
medication unknown 
No 
Significant 
Family 
History 
Recorded 
Skin Rash for 8 months prior to biopsy.  
6 week history of weakness in 
shoulder muscles prior to biopsy. 
MYO3  PM  M  80  0  897  30 
ANA 1:2560, 
RNP/Sm Positive, 
Jo-1 Positive, RF 
and Centromere 
Negative 
Clopidogrel and 
NSAID (Name not 
apparent in notes) 
None 
Prostate Cancer (Previous Surgery, No 
medical treatment).  Died with 
pericarditis. 
MYO5 
PM (With 
Sjogren's 
Syndrome) 
F  40  3.5 years  1031  <6 
ANA 1:40 (2000) 
Pattern 
Homogenous       
ANA Negative 
(2001)                   
ENA Negative                        
RF 294 (2000) 
(Normal Range 1-15 
IU/ml) 
Prednisolone 2.5mg 
daily                 
IVIg every 8 weeks 
Brother - 
Reiter's 
Syndrome 
Cousin - 
SLE 
Diagnostic muscle biopsy conducted 
April 2000, CK 800 IU/ml. Patient also 
diagnosed with Sjogren's Syndrome 
(2000). Prednisolone started at 40mg 
daily, reduced to 2.5mg at second 
biopsy, October 2003.  IVIg therapy 
began September 2000 (2g/kg).  CK 
levels started to rise in January 2001 
and reached 650 IU/ml in October 
2001 despite steroid and IVIg therapy.  
Past Infection with EBV. 
MYO6  PM  M  63  0  919  <6 
ANA Negative       
ENA Negative  
RF<22 
GTN & Tildiem 
(Angina)         
Nexium (GI Upsets) 
Co-proximal 
(Analgesia) 
No 
Significant 
Family 
History 
Recorded 
Muscular pains began around 2 years 
prior to biopsy, CK levels increased 
from 260 IU/ml (18 months prior to 
biopsy) to 967 IU/ml (10 months prior 
to biopsy) with normal CKMB.  
Previous statin therapy, discontinued 2 
years prior to biopsy. Past medical 
history includes hiatus hernia, 
duodenal ulcer, angina, paraumbilical 
hernia, sleep apnoea syndrome 
MYO7  PM  M  50  0  8390  NR 
ANA Positive, ENA 
Negative, Jo-1 
Negative 
No Prednisolone at 
biopsy, other 
medication unknown 
No 
Significant 
Family 
History 
Recorded 
Pain and weakness noticed in shoulder 
and wrist a year prior to biopsy.  
Arthralgia 
Cont… 66 
Sample  Diagnosis  M/F  Age at 
Diagnosis 
Disease 
Duration 
From 
Diagnosis 
CK at 
Biopsy 
IU/ml 
Normal 
Range up 
to 150 IU/ml 
CRP at 
Biopsy 
(mg/L) 
Normal 
Range 
<10 
Autoantibody 
Profile 
Therapies at time 
of Biopsy 
Family 
History  Other Features 
MYO16  DM  F  33  0  1076  7 
ANA Positive 
(1:5120) Pattern 
Nucleolar (probable 
Topoisomerase 1), 
ENA Positive, Anti-
DNA Negative 
Oral Contraceptive 
Pill, Diclofenac 
No 
Significant 
Family 
History 
Recorded 
Past medical history of postural 
hypotension, no drug therapy received.  
Two year history of polyarthralgia and 
onset of Raynaud’s disease just prior 
to biopsy. 
MYO17 
PM  
 
Diagnosis 
reported as 
IBM, 6 years 
following 
biopsy.             
F  66  0  2716  NR 
Scleroderma / 
Myositis Screen 
Negative, ANA 
Negative, ENA Ro 
Negative, ENA 
La/Sm/RNP 
Negative, RF<22 
No Prednisolone at 
biopsy and no 
record of any other 
therapy at time of 
biopsy.  Patient 
received a 7 day 
trial 40mg 
Prednisolone (8 
months prior to 
biopsy) for 
Dyspnoea. 
No 
Significant 
Family 
History 
Recorded 
Pathologist noted that the degree of 
inflammatory cell infiltrate within the 
biopsy was greater than normal.  IBM 
also suspected.   Exacerbation of 
myositis occurred 4 years post biopsy, 
despite therapy. Biopsy was reviewed 
6 years post biopsy, Diagnosis IBM.  
Past medical history includes 
Rheumatic Fever as a child, 
Cholecystectomy (1975), 
Hysterectomy (1981), Bowens Disease 
(1996), treated surgically, Asthma 
(1997).  Following diagnosis, 
prednisolone therapy initiated.  
Additional therapies included 
Azathioprine, IVIg and Methotrexate 
were used but stopped due to lack of 
effect, patient continued with 
Cyclosporin therapy. 
MYO19  PM  F  62  0 
Elevated in 
a single 
occasion to 
400 but 
normal at 
time of 
biopsy 
NR 
ANA Positive 
(1:2560) Pattern 
Nucleolar, ENADNA 
Negative, ENA 
Negative 
Methotrexate 
15mg/week and oral 
corticosteroid (dose 
not specified) 
NR 
Past medical history includes 
seronegative inflammatory synovitis.  
Patient received corticosteroid injection 
following knee aspiration in July 2001.  
At this time recent medical history 
included excision of basal cell 
carcinoma at the right medial canthus.  
Previous to this past medical history 
includes appenicectomy (1957), 
anxiety and depression (1967-1969), 
Varicose vein injection (1972), hallux 
valgus repair (1986), hypertension 
(1992) and Potts fracture of left ankle 
(1996). 
Cont… 67 
Sample  Diagnosis  M/F  Age at 
Diagnosis 
Disease 
Duration 
From 
Diagnosis 
CK at 
Biopsy 
IU/ml 
Normal 
Range up 
to 150 IU/ml 
CRP at 
Biopsy 
(mg/L) 
Normal 
Range 
<10 
Autoantibody 
Profile 
Therapies at time 
of Biopsy 
Family 
History  Other Features 
MYO23  PM  F  45  0  5829  46 
Jo-1 Positive, ANA, 
ENA, RF and 
Centromere 
Negative 
Steroid therapy for 1 
week which was 
stopped 2 weeks 
prior to biopsy.  
Thyroxine 
No 
Significant 
Family 
History 
Recorded 
5 week history of diffuse swelling of 
both lower limbs with weakness prior 
to biopsy.  Hyperthyroidism (partial 
resection) 
MYO24  PM  F  59  0  6623 
No 
Record at 
Biopsy, 
Reported 
at 13, 6 
weeks 
after 
biopsy 
ANA negative   
Ro/La/Sm/RNP/Jo/ 
Scl70 Negative 
120mg 
Prednisolone (im) 
given 4 days prior to 
biopsy. 18 month 
treatment with 
statins, stopped a 
week prior to 
biopsy.  Losartan 
25mg, Metformin 
1.5gms, 
Bendrofluazide 
2.5mg, Glicazide 
160mg, Salbutamol. 
Previous treatment 
for pernicious 
anaemia. 
NR 
Past Medical History includes 
hypertension, asthma, Type II diabetes 
and pernicious anaemia.  Diagnosed 
with adenocarcinoma of endometrium 
(Grade II) April 2006.  Died May 2006, 
second day post op myocardial 
infarction. 
MYOC 
Patient 
deceased 
and 
clinical 
notes 
destroyed 
PM  M  66           
 (At Biopsy)  -  2500-3000  NR  NR 
Treatments at 
biopsy unknown.  
Previous statin and 
steroid therapy. 
No History 
of muscle 
disease 
Six month history of muscle weakness 
and cramping at time of biopsy.  Past 
medical history includes a long history 
of cardiac problems. 
 
 
 
 
 
Cont… 68 
Sample  Diagnosis  M/F  Age at 
Diagnosis 
Disease 
Duration 
From 
Diagnosis 
CK at 
Biopsy 
IU/ml 
Normal 
Range up 
to 150 IU/ml 
CRP at 
Biopsy 
(mg/L) 
Normal 
Range 
<10 
Autoantibody 
Profile 
Therapies at time 
of Biopsy 
Family 
History  Other Features 
MYOE 
Patient 
deceased 
and 
clinical 
notes 
destroyed 
Chronic 
Inflammatory 
Myopathy 
(Pathology 
consistent with 
PM) 
F  49  0  NR  46 
Anti-DNA + (Feb 03, 
10 months prior to 
biopsy),                             
Anti-Mitochondrial 
Negative (Dec 02), 
Anti-Smooth Muscle 
Negative (Dec 02), 
Anti-Gastric Parietal 
Cell Negative (Dec 
02) 
Had been on 
Prednisolone 
(40mg) for four 
months prior to 
biopsy.  Stopped 
Steroid therapy for 
around 6 weeks 
resumed on 20mg, 
at time of biopsy 
patients was on 
10mg.  Other 
medications include 
thyroxine (50mg), 
Clarithromycin 
(500mg), Citalopram 
(40mg) and 
Viscotears. 
NR 
8 month history of symmetrical joint 
pain in shoulders, elbows, wrists, 
hands, knees and feet prior to biopsy. 
Past medical history includes Bell's 
palsy, pneumonia and hypothyroidism.  
Patient was admitted with acute 
bronchitis approximately 4 weeks prior 
to biopsy. 
MY025    F  37              Control Sample from Healthy 
Volunteer 
MYO2 
Patient 
deceased 
and 
clinical 
notes 
destroyed 
Inflammatory 
Myopathy 
(Pathology 
consistent with 
PM) 
F  77 (At 
Biopsy)  -  17203  173  Not Known  Prednisolone 60mg 
(Just prior to biopsy)  NR 
At time of biopsy patient had a recent 
myocardial infarct, cardiac arrest and 
then resuscitation.  At this time patient 
had obvious proximal weakness.  CK 
was previously normal. 
MYOA 
Inflammatory 
Myopathy 
(possible IBM) 
F  70  0  694 
50 
(A month 
prior to 
biopsy) 
ANA 1/2560, 
Anti-mitochondria, 
Anti-smooth muscle 
and 
Anti-gastric parietal 
cell.  Anti-SRP 
Negative, Anti-Jo-1 
NR 
Atenolol, 
Dihydrocodeine, 
oxytetracycline, 
Vioxx, Frusemide 
No 
Significant 
History 
Medical History includes Fibromyalgia, 
Pulmonary TB, Primary biliary 
Cirrhosis, Hypertension, OA knees and 
Pulmonary fibrosis.  Died cerebral 
haemorrhage 15/01/04 
 
 
Cont… 69 
Sample  Diagnosis  M/F  Age at 
Diagnosis 
Disease 
Duration 
From 
Diagnosis 
CK at 
Biopsy 
IU/ml 
Normal 
Range up 
to 150 IU/ml 
CRP at 
Biopsy 
(mg/L) 
Normal 
Range 
<10 
Autoantibody 
Profile 
Therapies at time 
of Biopsy 
Family 
History  Other Features 
MYOD  DM  F  75  0  >3000  NR 
ENA Negative, DNA 
<30U/ml, ANCA 
Negative, ANA NR 
No Prednisolone at 
biopsy, other 
medication unknown 
NR 
Four week history of weakness in arms 
and legs.  Heliotrope rash on hands. 
One year post biopsy a chest x-ray 
revealed a lung tumour (Right hand 
side at the hilum).  Diagnosis of DM 
associated with underlying lung 
tumour. 
MYO18  PM  F  52  13 months  597 
NR (at 
time of 
biopsy) 
ANA 1:40, nucleolar 
RF Normal                                    
ENA Negative 
Prednisolone 15mg          
Co-Codamol  
Omeprazole 20mg  
Alendronate 70mg 
once weakly 
No 
Significant 
History 
Diagnostic Biopsy conducted January 
2001, CK 11226, CRP <5, 
Prednisolone started at 60mg daily, 
reduced to 15mg daily.  Second Biopsy 
conducted February 2002 
MYO21  PM  M  64  0  783  36 
ANCA Positive 
(pANCA-MPO) 
RF Negative 
ANA Negative 
Prednisolone 60mg 
(Just prior to biopsy) 
Other medications 
include: Enalapril 
(10mg od), 
Isosorbide 
Mononitrate (60mg 
od), Sertraline 
(50mg od), 
Simvastatin (40mg 
od), Nicorandil 
(20mg), 
Montellukast (10mg 
od), Serertide 500, 
Salbutamol 
NR 
Marked Eosinophilia (10, normal range 
<0.4110^9/l).  
 No deterioration in chest symptoms. 
 
Medical History includes Polyarteritis 
nodosa (PAN) with cutaneous 
involvement, asthma and Ischaemic 
heart disease.  Myocardial Infarction 6 
years prior. 
Table 2.1 Myositis Patients 
 M, Male; F, Female; CK, Creatine Kinase; CRP, C-Reactive Protein; NR, No Record. 
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Inflammatory Infiltrate 
Sample  Fibre Size 
Variation 
Necrotic Fibres 
(Undergoing 
Phagocytosis) 
Basophilic / 
Regenerating 
Fibres 
Internal 
Nuclei 
Perivascular 
Atrophy  HLA 
￿ ￿ ￿ ￿/￿ ￿ ￿ ￿        Location 
Invasion 
of 
Fibres 
Presence of 
Vacuoles 
Presence of 
Inclusions  Fibrosis 
MYO1  -  ￿  ￿  ￿  -  ￿  ￿  Perivascular  -  ￿  -  - 
MYO3  ￿  ￿  ￿ Occasional  -  -  -  ￿  -  -  -  -  Minimal 
MYO5  ￿  ￿  ￿ Occasional  ￿  ￿  ￿  ￿  Surrounding Necrotic 
Fibres  -  -  -  - 
MYO6  ￿ Mild  ￿ (￿)  -  ￿  ￿  ￿  ￿  Surrounding Necrotic 
Fibres & Perimysial BV  ￿  -  -  - 
MYO7  -  ￿ (￿)  ￿  ￿  ￿  -  ￿  Perimysial  -  -  ￿  - 
MYO16  ￿ Mild  ￿ (￿)  ￿ Rare  ￿ 
Occasional  ￿  -  ￿  Surrounding Necrotic 
Fibres  -  -  -  - 
MYO17  ￿  ￿  ￿  ￿  -  -  ￿ 
Endomysial, 
Surrounding Necrotic 
and Regenerating 
Fibres 
-  ￿ 
(￿ Reported 
2004, 6 years 
after biopsy) 
- 
MYO19  -  ￿ (￿)  ￿ Rare  -  ￿  ￿  ￿ 
Surrounding Necrotic 
Fibres & Perimysial BV. 
Not in Perifascicular 
region. 
-  -  ￿  - 
MYO23  ￿  ￿  ￿  -  ￿  ￿  ￿  -  -  -  -  - 
MYO24  ￿  ￿  ￿  ￿  -  ￿  ￿  Surrounding Necrotic 
Fibres  -  -  ￿  - 
MYOC  ￿  ￿  ￿  ￿  -  ￿  ￿  Surrounding necrotic 
fibres in each fascicle  ￿  -  ￿  ￿ 
MYOE  -  ￿ (￿)  ￿ Mild  -  -  ￿  ￿  Surrounding Necrotic 
Fibres and BV  -  -  -  ￿ 
MYO2  -  ￿  ￿  -  -  ￿  ￿  Endomysial  ￿    -  ￿ 
MYOA  ￿  ￿ Occasional  ￿ Occasional  ￿  ￿  ￿  ￿  Surrounding Necrotic 
Fibres  -  -  -  ￿ 
MYOD  ￿  ￿  -  ￿ Mild  ￿  -  ￿  -  -  ￿ Occasional  -  - 
MYO18  ￿  ￿ (￿)  ￿  -  -  -  ￿  -  -  -  -  - 
MYO21  ￿ Mild  ￿ (￿)  ￿  -  ￿  ￿  ￿  Endomysial  -  -  -  - 
Table 2.2 Myositis Pathological Summary 
- No record or discussion of feature in pathology report 71 
Sample  Diagnosis  M/F  Age at 
Diagnosis 
Disease 
Duration 
at Biopsy 
CK at 
Biopsy 
IU/ml 
Normal 
Range up 
to 150 IU/ml 
CRP at 
Biopsy 
(mg/L) 
Normal 
Range <10 
Autoantibody Profile  Therapies at time 
of Biopsy 
Family 
History  Other Features 
VAS1 
Cutaneous 
Vasculitis (With 
Sjogren's 
Syndrome) 
F  59  8 months  NR  NR  ANA 1:2560, speckled                   
Ro & La Positive 
Beclomethasome 
and Salbutamol 
Ischaemic 
heart 
disease & 
Thyroid 
Disease 
Diagnostic Biopsy conducted 
in Jun 04 and found features of 
leukocytoclastic vasculitis.  In 
June 04, RF positive and 
atypical c-ANCA positive.  Past 
Medical history includes 
childhood chest infections, 
hyperthyroidsm and asthma. 
VAS6 
Leukocytoclastic 
Vasculitis of 
lower limbs and 
scalp 
M  43  0  NR  7  ANA Negative      
ANCA negative 
Sulphasalazine 
500mg daily, 
Kenalog 40mg, 
Indocid, 
Imipramine, 
Diazepam, DF-118, 
Zantac 
Mother - 
Post-
traumatic 
epilepsy         
Father - 
Angina 
Background of Ankylosing 
Spondylitis 
VAS7 
Henoch-
Schonlein 
Purpura.       
Biopsy confirmed 
Leukocytoclastic 
Vasculitis 
M  49  0  NR  20 
ANA Negative          
RF Negative      
Atypical c-ANCA 
moderately positive 
(MPO and PR3 
negative) 
Mitochondrial Negative 
Smooth muscle 
Negative            
Gastric Parietal cell 
Negative                 
Liver kidney 
microsomal Negative           
Glomerular basement 
membrane Negative 
Spironalactone, 
Warfarin, Vitamin B 
Co Strong, 
Thiamine, Folate, 
Biprobase 
No 
Significant 
Family 
History 
Noted 
Polyarthralgia (Left Hand, 
Right Wrist, Both elbows, 
knees and ankles)                                        
IgA 9.9g/l (Normal Range 0.8-
4) IgG 21.5g/l (Normal Range 
6-16) IgM 6.7 (Normal Range 
0.5-2)  Positive E Coli Blood 
culture - May 05                                                     
Long History of excess alcohol.  
Past Medical History includes 
Liver Cirrhosis,Recurrent 
DVT's, Pleural Effusion, Folate 
Deficiency and Borderline 
Protein C Deficiency 
 
Table 2.3 Vasculitis Patients 
M, Male; F, Female; CK, Creatine Kinase; CRP, C-Reactive Protein; NR, No Record.72 
2.2.3 Immunohistochemistry 
Slides from -70° C were thawed at room temperature f or 30 minutes in a staining 
vessel containing anhydrous silica gel.  To fix sections slides were transferred 
to acetone for 10 minutes and then allowed to dry.  Sections were circled with a 
PAP  pen  (Immedge  Pen,  Vector  Laboratories,  Burlingame,  CA,  USA)  and 
allowed to dry for 5 minutes.  100 µl of 2% bovine serum albumin/ Tris-buffered 
saline (2%BSA/TBS) was added to each section to block for 30 minutes.  All 
incubations  were  carried  out  at  room  temperature  in  a  humidified  chamber.    
Blocking solution was poured off and 100 µl of 2% BSA/TBS containing mouse 
anti-human  primary  antibody  (DAKO,  Denmark)  was  added  to  each  section 
(Table  2.4).    Negative  control  experiments  were  performed  using  antibodies 
with  matched  isotypes.    Sections  were  incubated  for  1  hour.  The  primary 
antibody  solution  was  poured  off  and  sections  were  washed  twice  in  TBS 
(Section  2.5)  for  5  minutes.    Following  washing  100  µl  of  2%  BSA/TBS 
containing 5 µl of rabbit anti-mouse IgG secondary antibody (DAKO) was added 
to  each  section  and  was  incubated  for  30  minutes.    After  the  secondary 
antibody was poured off and sections were washed twice in TBS for 5 minutes 
100 µl  of 2%  BSA/TBS  containing  2  µl of alkaline  phosphatase anti-alkaline 
phosphatase (APAAP) was added to each section and was incubated for 30 
minutes.  Sections were again washed twice in TBS for 5 minutes. 100 µl of 
substrate  was  then  added  to  each  section  and  allowed  to  develop  for  20 
minutes.  Substrate solution contained 10 µl of 5% New Fuchsin in 2 M HCl, 25 
µl of 0.7 M sodium nitrite, 3.5 ml of Buffer E (0.05 M Tris, 0.9% NaCl, pH 9.7), 
1.25 ml of 0.2M 2-amino-2-methyl-1,3-propanediol (AMPD), 50 µl of 40 mg/ml 
levamisol, 30 µl of Naphthol AS-BI phosphate and 100 µl of 2M HCl.  Following 
substrate incubation sections were washed twice in TBS for 5 minutes and once 
in  sterile  distilled  water  for  5  minutes.      Sections  were  counter-stained  with 
Mayer’s Haemotoxylin and washed in Scotts tap water substitute (Section 2.5) 
to allow proper colour development, except for sections with Ki67 staining. As 
this  is  a  nuclear  marker  haemotoxylin  staining  would  camouflage  the  signal.  
Sections were viewed using a Nikon (Melville, NY) Diaphot inverted microscope 
and images were taken using a JVC 3-CCD camera.  The analog signal from 
the camera was converted into a digital signal using an ADS Tech (Ireland) 
Pyro A/V link convertor and images were taken using Adobe Premier Elements 73 
software.  Sections were stored in a wet chamber at 4° C for microdissection.  
Sections not used for microdissection were mounted using glycerol gelatine. 
 
Initially sections at intervals of between 40 to 80 mm were stained for CD20
+ B 
cells  and  plasma  cells  to  determine  the  presence  of  these  cell  phenotypes 
throughout  the  collection  of  serial  sections  obtained  from  the  biopsy;  n=3-7 
depending on tissue availability.  Serial sections surrounding areas of infiltrating 
B cells and/or plasma cells were then used to establish the infiltration of the 
other cell phenotypes.  Representative images of these cellular infiltrations are 
presented in this thesis.   Semi quantitative analysis of cellular infiltration of the 
various cell phenotypes was conducted, described further in Tables 3.1 and 5.1. 
Antibody 
Specificity  Source  Species  Clone  Isotype  Dilution 
CD20  DAKO
a  Mouse 
Monoclonal  L26  -IgG2a  1:50 
FDC  DAKO  Mouse 
Monoclonal  CAN.42  -IgM  1:100 
Plasma Cell  DAKO  Mouse 
Monoclonal  V538c  -IgG1  1:200 
CD3  DAKO  Mouse 
Monoclonal  T3-4B5  -IgG1  1:100 
CD4  DAKO  Mouse 
Monoclonal  MT310  -IgG1  1:20 
CD8  DAKO  Mouse 
Monoclonal  Dk25  -IgG1  1:100 
Ki67  DAKO  Mouse 
Monoclonal  MIB-1  -IgG1  1:100 
FoxP3  AB CAM
b  Mouse 
Monoclonal  236A/E7  -IgG1  1:40 
CD68 
(Macrophage)  DAKO  Mouse 
Monoclonal  EMB11  -IgG1  1:100 
-IgG1 Isotype 
Control  DAKO  Mouse 
Monoclonal  DAK-G01 
  Same as 
primary 
antibody 
concentration 
-IgG2a 
Isotype 
Control 
(Anti-
Aflatoxin) 
Kind gift 
from Prof 
Stimpson, 
Strathclyde 
University, 
Glasgow 
   
 
1:50 
-IgM Isotype 
Control  DAKO  Mouse 
Monoclonal  DAK-G08    1:100 
a – Denmark, b – Cambridge, UK 
Table 2.4 Primary Antibodies used in Immunohistochemistry 74 
2.2.4 Immunofluorescence 
Double immunofluorescent staining on frozen serial sections was carried out 
using the Mouse on Mouse (M.O.M) Immunodetection Immunofluorescent Kit 
(Vector Laboratories, Burlingame, CA, USA) designed to fluorescently detect 
several mouse primary antibodies on the same tissue whether or not the tissue 
is of mouse origin.  Primary antibodies used for fluorescent staining were the 
same as those described in Table 2.4 of section 2.2.3, although some antibody 
concentrations were optimized for multiple immunofluorescent staining, Table 
2.5.   Frozen sections were thawed at room temperature for 30 minutes in a 
staining  vessel  containing  anhydrous  silica  gel.    To  fix  sections  slides  were 
transferred to acetone for 10 minutes and then allowed to dry.  Sections were 
circled with a PAP pen (Vector Laboratories) and allowed to dry for 5 minutes.  
All incubations were carried out at room temperature in a humidified chamber.  
Sections were incubated for 15 minutes with avidin blocking solution (Vector 
Laboratories) and briefly washed in TBS before a 15 minute incubation with 
biotin blocking solution (Vector Laboratories).  They were then washed twice for 
2 minutes in TBS before a 5 minute incubation with a working solution of M.O.M 
diluent to allow all non-specific protein sites to be blocked. After a 5 minute 
incubation excess M.O.M diluent was removed and sections were incubated for 
30 minutes with the first primary antibody, Table 2.5, in M.O.M diluent.  Sections 
were  again  washed  twice  in  TBS  for  2  minutes.    A  working  solution  of 
biotinylated Horse Anti-Mouse Ig reagent in M.O.M diluent was then applied to 
each section and incubated for 10 minutes followed by two washes in TBS for 2 
minutes.  A working solution of fluorescein avidin DCS was then applied to each 
section for 5 minutes before two 5 minute washes in TBS.  For staining of the 
second  antigen  sections  were  again  blocked  with  avidin  and  biotin  blocking 
solutions for 15 minutes to prevent the interaction of the second set of labelling 
reagents with the first set of labelling reagents.  Sections were washed twice for 
2 minutes in TBS before sections were incubated for 1 hour with a working 
solution  of  M.O.M  mouse  Ig  blocking  reagent.    After  two  2  minute  washes 
sections were again incubated with a working solution of M.O.M diluent for 5 
minutes to block any non-specific protein binding sites.  Excess M.O.M diluent 
was removed and sections were incubated for 30 minutes with M.O.M diluent 
containing the second primary antibody.  After two 2 minute washes in TBS 75 
sections were incubated for 10 minutes with a working solution of Anti-Mouse Ig 
reagent  in  M.O.M  diluent.    Following  two  2  minute  washes  sections  were 
incubated for 10 minutes with Texas Red Avidin DCS (20 µg/ml). After two final 
5 minute washes sections were mounted in VECTASHIELD hardset mounting 
medium  (Vector  Laboratories)  and  viewed  using  a  Zeiss  Axiovert  S100 
microscope with a Zeiss Plan-NEOFLUAR 63x lens (Carl Zeiss Ltd., Welwyn 
Garden City, UK).  For each view, 5 images were taken at 0.5 micron intervals 
and Openlab software (Improvision) was used to deconvolve the images.  
 
Antibody 
Specificity  Source  Species  Clone  Isotype  Dilution 
CD20  DAKO
a  Mouse 
Monoclonal  L26  -IgG2a  1:100 
Plasma Cell  DAKO  Mouse 
Monoclonal  V538c  -IgG1  1:200 
CD3  DAKO  Mouse 
Monoclonal  T3-4B5  -IgG1  1:100 
CD4  DAKO  Mouse 
Monoclonal  MT310  -IgG1  1:100 
CD8  DAKO  Mouse 
Monoclonal  Dk25  -IgG1  1:100 
Ki67  DAKO  Mouse 
Monoclonal  MIB-1  -IgG1  1:100 
FoxP3  AB CAM
b  Mouse 
Monoclonal  236A/E7  -IgG1  1:20 
CD68 
(Macrophage)  DAKO  Mouse 
Monoclonal  EMB11  -IgG1  1:100 
-IgG1  DAKO  Mouse 
Monoclonal  DAK-G01 
  Same as 
primary 
antibody 
concentration 
-IgG2a  
(Anti-
Aflatoxin) 
Kind gift 
from Prof. 
Stimpson, 
Strathclyde 
University, 
Glasgow 
   
 
1:100 
a – Denmark, b – Cambridge, UK 
Table 2.5 Primary Antibodies used in Immunofluorescence 
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2.3   VH-Gene Repertoire of Infiltrating B Cells in Myositis and Vasculitis 
Samples 
2.3.1 Microdissection and DNA preparation 
To establish the antibody repertoire of the B cells and/or plasma cells in the 
cellular  infiltrates  the  stained  areas  resembling  B  cell  and  plasma  cell 
aggregates  were  microdissected under  a  Nikon  Diaphot  inverted  microscope 
(Melville, NY).  To avoid contamination a fresh lancet was used for each section 
excised and discarded if it came into contact with any other site.  DNA was 
released by proteinase K digestion using the QIAGEN DNA Micro Kit (QIAGEN, 
Sussex,  UK)  according  to  manufactures  instructions.    Briefly,  microdissected 
tissue  was  added  to  180  µl  Lysis  Buffer  ATL  and  20  µl  Proteinase  K.  
Microdissected samples were incubated at 56° C for a pproximately 4 hours to 
allow lysis.  Following lysis 200 µl of Buffer AL containing 1 µg of carrier RNA 
was added to each sample and mixed by pulse vortexing for 15 seconds.  200 
µl of 100% ethanol was then added to each sample and after mixing thoroughly 
samples were incubated at room temperature for 5 minutes.  Lysates were then 
transferred to a QIAamp MinElute column and centrifuged at 8000 rpm for 1 
minute to allow binding of the DNA to the column membrane.  The DNA bound 
to the column was washed firstly with 500 µl of Buffer AW1 by centrifugation at 
8000 rpm for 1 minute and then 500 µl of Buffer AW2 by centrifugation at 8000 
rpm for 1 minute.  Columns were then centrifuged at 14, 000 rpm for 3 minutes 
to dry the membrane.  To elute the DNA 20 µl of PCR Grade Water (Roche, 
Mannheim, Germany) was added to each column and allowed to incubate for 5 
minutes at room temperature before a final centrifugation at 14, 000 rpm for 1 
minute to release the DNA from the membrane.  For extremely small areas that 
were  microdissected,  cell  lysis  occurred  in  a  total  volume  of  25  µl  Buffer 
ATL/Proteinase K containing 10 µl Proteinase K.  An additional 25 µl of Buffer 
ATL was added to each sample following a 3 hour incubation at 56° C.  50 µl of 
Buffer AL was then added to each sample which again contained 1 µg of carrier 
RNA.    After  pulse-vortexing  for  15  seconds  samples  were  mixed  with  50  µl 
100% ethanol and allowed to incubate at room temperature for 5 minutes.  The 
remainder of the protocol was as described above.  Alternatively excised tissue 
was digested in 30 µl of Proteinase K (0.7 mg/ml, Roche, Mannheim, Germany) 
at 50° C for 1 hour and the enzyme was inactivated a t 95° C for 10 minutes.  This 77 
method was used for analysis of sample MYO1.  Samples were either stored at 
-20° C or used directly in nested PCR reactions.  
 
2.3.2 Peripheral Blood Mononuclear Cell (PBMC) Isolation 
For  positive  control  PCR  and  analysis  of  patient’s  peripheral  blood,  PBMCs 
were isolated from blood samples containing the anticoagulant heparin using 
Lymphoprep (Axis Shield, Oslo, Norway), a sterile and endotoxin tested solution 
for  the  isolation  of  pure  lymphocyte  suspensions.    Lymphoprep  results  in 
aggregation of erythrocytes, increasing their sedimentation rate allowing them 
to be isolated after centrifugation, as leukocyte sedimentation is only slightly 
affected and can therefore be removed from the upper layer (Figure 2.1).  An 
equal volume (6 mls) of 0.9% NaCl was used to dilute the blood.  6 mls of the 
diluted blood was then layered over 3 mls of lymphoprep and centrifuged at 800 
x g for 20 minutes without brake, or 30 minutes without brake if the blood had 
been collected over a 2 hour time frame.  After centrifugation PBMCs form a 
distinct band at the sample/medium interface, also known as the buffy coat, and 
were  removed  using  a  glass  Pasteur  pipette.    The  upper  serum  layer  was 
removed  and  stored  at  -20° C  after  PBMCs  were  remove d.    The  fraction  of 
PBMCs was diluted in 10 mls 0.9% NaCl and centrifuged at 250 x g for 10 
minutes twice. The pellet was then resuspended in 200 µl PBS (Section 2.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood 
Lymphoprep 
Lymphocytes 
(Buffy Coat) 
Serum 
Erythrocytes 
800 x g 
Before 
Centrifugation 
After 
Centrifugation 
Figure 2.1 Removal of lymphocytes from peripheral blood 
 
To  establish  the  repertoire  of  lymphocytes  from  peripheral  blood  samples,  lymphocytes  were 
separated with the use of Lymphoprep (Axis Shield, Norway).  Lymphoprep is a ready made, sterile, 
and endotoxin tested solution which allows the isolation of pure lymphocyte suspensions.  The mixing 
of blood with lymphoprep causes aggregation of the erythrocytes, increasing their sedimentation rate.  
The lymphoprep solution only slightly affects the sedimentation rates of lymphocytes and therefore 
after centrifugation the erythrocytes, with their increased sedimentation rate, collect at the base of 
tube while lymphocytes form a distinct band at the sample/medium interface allowing the lymphocyte 
suspension to be removed.  Adapted from Lymphoprep (Axis Shield, Norway) datasheet. 78 
2.3.3 Lymphocyte Cryopreservation 
In cases where additional blood samples were taken from patients, lymphocytes 
were extracted as described in section 2.3.2 but were either resuspended in 1 
ml  Foetal  Bovine  Serum  (FBS)  supplemented  with  10%  dimethyl  sulfoxide 
(DMSO)  or  1  ml  60%  wash  buffer  (RPMI  supplemented  with  1% 
Penicillin/Streptomycin and 1% 200 mM L-Glutamine) supplemented with 30% 
Foetal  Bovine  Serum  and  10%  DMSO  and  transferred  to  a  1.5  ml  cryovial 
(Starstedt,  Numbrecht,  Germany).    The  lymphocytes  were  cooled  at 
approximately 1°C a minute in a freezing container (Nalgene Nunc, Abingdon, 
UK) containing isopropanol to a final temperature of -80°C.  The lymphocytes 
were kept at -80°C for 24 hours before being transferred to liquid nitrogen for 
long-term storage.  The tissue culture medium and supplements were obtained 
from Invitrogen (Paisley, UK).   
 
2.3.4 Sera Isolation 
Blood collected from patients in the absence of any anticoagulant was stored at 
4° C for at least 30 minutes to allow the clot to re duce.  The blood clot was then 
removed and the remaining serum was centrifuged at 3000 rpm for 10 minutes 
to  remove  any  remaining  erythrocytes.    The  serum  supernatant  was  then 
removed and stored at -20° C. 
 
2.3.5 Genomic DNA Isolation 
PBMC DNA was extracted from the resuspended fraction after PBMC isolation, 
section 2.3.2, using a QIAamp DNA mini kit (QIAGEN, Sussex, UK), according 
to manufacturers instructions.  In summary, 20 µl of QIAGEN proteinase K was 
added to 200 µl of buffy coat sample.  200 µl of Buffer AL was then added to 
sample  and  mixed  by  pulse  vortexing  for  15  seconds.    Samples  were  then 
incubated for 10 minutes at 65° C to ensure maximum  lysis.  200 µl of 100% 
ethanol  was  then  added  to  the  sample  and  mixed  for  15  seconds  by  pulse 
vortexting.  The sample mixture was then added to the QIAamp spin column 
and columns were centrifuged at 8,000 rpm for 1 minute.  500 µl of Buffer AW1, 
wash buffer, was added to the column and the column was again centrifuged for 
1 minute at 8, 000 rpm.  500 µl of Buffer AW2, wash buffer, was then added to 
the  column  and  the  column  was  centrifuged  for  1  minute  at  13,  000  rpm.  79 
Columns were then centrifuged at 13, 000 rpm for an additional 3 minutes to 
remove  any  residual  Buffer  AW2.    Columns  were  transferred  to  1.5  ml 
microcentrifuge tubes and 200 µl Buffer AE was added and allowed to stand for 
1  minute  before  being  centrifuged  for  1  minute  at  13,  000  rpm.    DNA 
concentration  was  measured  as  described  in  section  2.3.11  and  DNA  was 
stored at -20° C.  10 µl of DNA, for positive contro l purposes or for analysing a 
patient PBL, was used in each PCR reaction as described in Section 2.3.7.  
 
2.3.6 Primers 
Primers  for  nested  PCR  were  synthesised  by  Operon  Biotechnologies 
(Huntsville,  AL,  USA),  Tables  2.7  and  2.8.    For  use  in  PCR,  primers  were 
synthesised  at  0.2  µmole,  desalted  and  arrived  lyophilized  and  were 
reconstituted in PCR grade H2O (Roche, Mannheim, Germany) to produce a 
stock concentration of 100 µM (100 pmol/µl).  Primer stock concentrations were 
stored  at  -20° C.    For  use  in  PCR,  working  solutions   of  a  total  combined 
concentration  of  20  µM  (20  pmol/µl)  were  prepared  as  per  Table  2.6.    For 
primary PCR reactions all VH leader sequences were combined in one working 
solution but for secondary PCR reactions each set of VH family primers were 
combined to produce family specific working solutions to allow for family specific 
amplification.  All J family primers were also combined.  Working concentrations 
of primers were also stored at -20° C. 
 
Number of 
primers in 
working solution 
µl of each primer 
required for final 
concentration of 
20 µM 
µl of 50 mM Tris-
HCl pH 8.0 
µl of sterile PCR 
grade H20 
1  4  6  10 
2  2  6  10 
3  1.33  6  10 
4  1  6  10 
5  0.8  6  10 
11  1  27.5  37.5 
 
Table 2.6 Volumes for preparing primer working concentrations (20 µM) 
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2.3.7 Nested PCR 
Immunoglobulin genes from infiltrating B cells and plasma cells were amplified 
by  a  nested  PCR  system  (Figure  2.2)  that  ensures  that  only  rearranged  Ig 
V-genes were amplified and has been used previously within the laboratory to 
successfully  analyse  the  repertoire  of  Ig  V-genes  from  B  cell  clusters  and 
germinal centres in SS (283), MG (52), breast cancer (285) and SLE (289).  
Primers were designed to amplify all known functional, rearranged human VH 
genes  and  are  shown  in  Tables  2.7  and  2.8.    To  avoid  contamination  of 
samples and PCR reagents all procedures prior to primary PCR amplification 
were performed in a clean laboratory prior to where post amplification steps 
were  carried  out.    All  PCR  reactions  were  prepared  in  a  Captair™Bio 
Biocap™RNA/DNA hood (Erlab, France).  Filter tips were also used in sample 
preparation to limit PCR contamination as well as the use of a Microman M10 
pipette  with  sterilised  and  disposable  pipette  capillaries  and  pistons  in 
transferring DNA from primary to secondary PCR reactions.  Microman pipettes 
are  equipped  with  a  positive  displacement  mechanism  that  isolates  the 
aspirated liquid from the body of the pipette with prevents the sample-to-sample 
contamination that can result from aerosols (290).  The disposable pistons and 
capillaries  are  the  only  feature  to  make  contact  with  the  aspirated  liquids 
therefore protecting against contamination from one sample to another. 
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Figure 2.2 A simplified Diagram of Nested Polymerase Chain Reaction (PCR) 
 
 
The Polymerase Chain Reaction (PCR) was used to amplify a specific sequence of DNA 
using primers, each complementary to the DNA target sequence (    ).  Target DNA was 
amplified  through  a  series  of  cycles  of  denaturation  to  separate  target  DNA,  primer 
annealing to target DNA and polymerisation of the target DNA  For this series of cycles 
Mg
2+, each deoxynucleoside triphosphate (dNTP), PCR buffer and the thermostable DNA 
polymerase, Taq, are required in addition to the template DNA.  To increase the specificity 
of immunoglobulin gene amplification a second round of PCR was carried out in a process 
of nested PCR.  In the second phase of cycles a new set of primers (    ) were used that 
anneal within the fragments produced in the first round of PCR.  The use of nested PCR 
increased the specificity by ensuring that only the target sequence was amplified from the 
mixture from the first round; as only the target sequence should contain both sets of primer-
binding sites. 
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2.3.7.1 Nested PCR – VH Chain Amplification 
For primary amplification 10 µl of DNA was amplified in a reaction volume of 50 
µl with 10 pmole of VH leader primer mixture, 10 pmole of universal JH primer, 
2.6 U DNA polymerase, 2.5 mM MgCl2 and 200 µM dNTP’s in conjunction with 
hot-start ampli-wax Gem 50 beads (Applied Biosystems, Foster City, CA).  The 
conditions used for 35 cycles were, after an initial 2 minute hot start, 94° C for 1 
minute, 50° C for 1 minute and 72° C for 2 minutes fo llowed by one cycle of 72° C 
for  15  minutes.    The  reactions  were  conducted  on  a  Trio-Thermoblock 
(Biometra,  Tampa,  FL)  or  Tprofessional  Thermocycler  (Biometra)  using  the 
Expand High Fidelity PCR System (Roche, Mannheim, Germany). The Expand 
High Fidelity PCR System contains a unique combination of thermostable Taq 
DNA  polymerase  and  Tgo  DNA  polymerase,  providing  a  thermostable  DNA 
polymerase with proofreading activity to generate PCR products of high yield, 
fidelity and specificity.  For secondary amplification 2 µl of primary amplification 
product was used as a template in reactions similar to primary PCR reactions 
except 20 pmole of each VH family and JH primer mixes were used.  Conditions 
for 40 cycles were 94° C for 1 minute, after an init ial 2 minute hot start at 94° C, 
61° C for 1 minute for V H 1, 2 and 3 primers or 65° C for 1 minute for V H 4, 5 and 
6 primers and 72° C for 2 minutes followed by one cycle of 72° C for 15 minutes.     
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      Primer Name                             Sequence 
 
VH Leader primers        HUVH1L               TCA CCA TGG ACT GGA CCT GGA G  
  HUVH1L.2               TCA CCA TGG ACT GGA TTT GGA GG  
  HUVH2L               ACC ATG GAT ATA CTT TGT TCC ACG  
  HUVH2L.2               ACC ATG GAC ACA CTT TGC TCC ACG  
  HUVH2L.3               ACC ATG GAC ACA CTT TGC TAC ACA  
  HUVH3L               ACC ATG GAG TTT GGG CTG AGC TG  
  HUVH3L.2               ACC ATG GAA CTT GGG CTC CGC TG  
  HUVH4L               AAG AAC ATG AAA CAC CTG TGG TTC  
  HUVH4L.2                  AAG AAC ATG AAG CAC CTG TGG TTT  
  HUVH5L               ATC ATG GGG TCA ACC GCC ATC CT  
  HUVH6L               ACA ATG TCT GTC TCC TTC CTC ATC  
 
 
Universal JH primer         HUJHUNI               CTC ACC TGA GGA GAC GGT GAC CGG  
 
 
Table 2.7 Leader Primer Sequences for primary amplification round in Nested PCR 
 
 
 
                            Primer Name        Sequence   
VH Family primers 
 
VH 1                              HUVH1.1                 CAG GTG CAG CTG GTG CAG TCT GG  
  HUVH1.2  CAR ATG CAG CTG GTG CAG TCT GG  
  HUVH1.3  GAG GTC CAG CTG GTA CAG TCT GG  
 
VH 2  HUVH2  CAG ATC ACC TTG AAG GAG TCT GG  
  HUVH2.1  CAG GTC ACC TTG ARG GAG TCT GG 
  
VH 3  HUVH3.1  GAG GTG CAG CTG GTG GAG TCT GG  
  HUVH3.2  GAG GTG CAG CTG TTG GAG TCT GG  
  HUVH3.3  GAG GTG CAG CTG GTG GAG ACT GG  
  HUVH3.4  GAG GTG CAG CTG GTG GAG TCT CG 
 
VH 4  HUVH4  CAG GTG CAG CTG CAG GAG TCG GG  
  HUVH4.1  CAG CTG CAG CTG CAG GAG TCS GG  
  HUVH4.2  CAG GTG CAG CTA CAR CAG TGG GG  
 
VH 5/ VH 7  HUVH5/7  SAG GTG CAG CTG GTG CAR TCT GG  
 
VH 6  HUVH6.1  CAG GTA CAG CTG CAG CAG TCA GG  
 
JH primers  HUJH1  TGA GGA GAC GGT GAC CAG GGT GC  
  HUJH3  TGA AGA GAC GGT GAC CAT TGT CCC  
  HUJH4  TGA GGA GAC GGT GAC CAG GGT TCC  
  HUJH6  TGA GGA GAC GGT GAC CGT GGT CC  
 
 
Table 2.8 Family Primer Sequences for secondary amplification round in Nested PCR 
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2.3.8 Agarose Gel Electrophoresis 
PCR products were separated through 1.5% electrophoresis grade Ultra Pure 
Agarose  (Invitrogen,  Paisley,  UK)  in  TBE  (Section  2.5)  and  visualised  with 
ethidium bromide (0.5 µg/ml) under UV light.  Samples were diluted with 6X 
Blue-Orange Gel loading dye (Promega, Madison, WI, USA) and the size of 
products was determined using a 10 KB ladder (Bioline, London UK).  PCR 
products  were  visualised  under  UV  light  using  KODAK  Gel  logic  200  and 
KODAK 1D Image Analysis software (KODAK, Rochester, NY, USA).  Products 
of approximately 350-400 base pairs were expected. 
 
2.3.9 Gel Extraction 
DNA  (20  µl)  to  be  extracted  and  purified  was  run  on  a  1.5%  agarose  gel 
(Section 2.5) and DNA fragments were excised with a sterile sharp scalpel.  To 
eliminate  any  cross  contamination  a  fresh  scalpel  was  used  for  each  DNA 
sample.  DNA was extracted using the QIAquick Gel Extraction Kit (QIAGEN, 
Sussex,  UK)  according  to  manufactures  instructions.    In  summary,  after  the 
weight of the gel slice was determined, 3 volumes of Buffer QG was added to 1 
volume of gel (100 mg ~ 100 µl) and gel extracts were incubated at 50° C for 10 
minutes to allow the gel slice to completely dissolve.  To aid dissolution of the 
agarose gel slice samples were vortexed every 2-3 minutes.  After incubation 1 
gel volume of isopropanol was added to each sample and mixed.  Samples 
were then applied to the QIAquick column and centrifuged at 13, 000 rpm for 1 
minute  to  allow  DNA  to  bind  to  the  column  membrane.    QIAquick  columns 
contain  uniquely-designed  silica  gel  membranes  which  adsorb  DNA  in  the 
presence  of  high  salt  concentrations  and  at  approximately  pH  7.5.    This 
uniquely-designed  membrane  allows  the  removal  of  unwanted  primers  and 
impurities.  0.5 ml Buffer QG was applied to each column and centrifuged for 1 
minute at 13, 000 rpm to remove all traces of agarose.  0.75 ml Buffer PE was 
then applied to the QIAquick column and allowed to stand for 5 minutes before 
a  1  minute  centrifugation  at  13,  000  rpm.    Buffer  PE,  containing  ethanol, 
removes the high salt concentrations from the column to allow for DNA elution.  
Columns were then centrifuged for an additional minute to remove any residual 
ethanol  from  Buffer  PE.    Columns  were  then  transferred  to  1.5  ml 
microcentrifuge tube and 30 µl of Buffer EB (10 mM Tris-Cl, pH 8.5) was added 85 
to  the  membrane  to  elute  DNA.    After  a  1  minute  incubation  samples  were 
centrifuged for 1 minute at 13, 000 rpm and eluted DNA was stored at -20° C.  
 
2.3.10 Cloning of Rearranged Immunoglobulin Genes 
The TA cloning kit Dual promoter with pCR
®II vector (Invitrogen, Paisley, UK) 
provided  a  one-step  cloning  approach  for  the  direct  insertion  of  VH  PCR 
products into a plasmid vector. Taq polymerase used in PCR reactions provided 
a  nontemplate-dependent  addition  of  a  single  deoxyadenosine  (A)  to  the  3’ 
ends of each PCR product.  The linearized plasmid vector was supplied with 
additional  single  3’  deoxythymidine  (T)  residues  allowing  effective  ligation  of 
PCR  product  with  the  plasmid  vector.    The  use  of  the  TA  cloning  kit  Dual 
promoter with pCR
®II vector eliminates the use of PCR primers that contain 
restriction sites, eliminates any enzymatic modifications of the PCR product and 
allows transcription from either direction of the insert. 
 
2.3.10.1 Ligation into Dual Promoter pCR
®II Vector 
Ligation efficiencies were optimised within a 10 µl ligation reaction to contain 6 
µl DNA, 2 µl pCR
®II vector (25 ng/µl) (Figure 2.3), 1 µl 10X Ligation buffer and 
1  µl  T4  DNA  Ligase  (4.0  Weiss  units).    Ligation  reactions  were  incubated 
overnight  at  14° C  using  the  Trio-Thermoblock  (Biome tra,  Tampa,  FL)  PCR 
machine. 
 
2.3.10.2  Transformation into One Shot TOP10F’ Chemically Competent E.                                      
coli 
2 µl of the ligation reaction was pipetted into one 50 µl vial of One shot TOP10F’ 
chemically competent cells (Invitrogen, Paisley, UK) and was mixed by gentle 
stirring.  Vials were incubated for 30 minutes on ice before being heat shocked 
at 42° C for 30 seconds.  250 µl of room temperature  S.O.C medium (Invitrogen) 
was added to each vial of competent cells and vials were shaken at 37° C for 1 
hour at 225 rpm in a shaking incubator.  LB plates (25 g/l Miller’s Lab Broth 
Base  (Invitrogen)  supplemented  with  15  g/l  agar  (Oxoid,  Basingstoke,  UK) 
containing  Kanamycin  (Gibco)  (50  µg/ml))  were  equilibrated  at  37°   for  30 
minutes then 40 µl 100 mM IPTG (Roche, Mannheim, Germany) and 40 µl 40 
mg/ml  X-Gal  (Roche,  Mannheim,  Germany)  were  spread  on  each  plate  and 86 
allowed to soak into plates.  Following the 1 hour incubation 50 µl and 200 µl of 
each transformation vial was plated onto LB plates and plates were incubated 
overnight  at  37° C  before  being  moved  to  4° C  to  allo w  proper  colour 
development.  Alternatively 75 µl from each transformation vial was plated onto 
LB plates. 
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Figure 2.3  pCR
®II Vector 
 
The TA cloning kit Dual promoter with pCR
®II vector provided a one-step cloning approach for the 
direct insertion of VH PCR products into a plasmid vector.  The linearized plasmid vector was 
supplied with additional single 3’ deoxythymidine (T) residues allowing effective ligation of PCR 
product  with  the  plasmid  vector  as  Taq  polymerase  used  in  PCR  reactions  provides  a 
nontemplate-dependent  addition  of  a  single  deoxyadenosine  (A)  to  the  3’  ends  of  each  PCR 
product. 
 
The disruption of the lacZ gene by the PCR product allows for colour screening of colonies as 
vectors  containing  a  PCR  insert  would  not  be  able  to  transcribe  the  lacZ  gene  therefore  the 
colonies  would  be  white  whereas  empty  colonies  with  no  PCR  insert  would  be  blue  as 
transcription  could  occur  from  the  lacZ  promoter.    lacZ  encodes  the  enzyme  β-galactosidase 
enzyme  which  can  be  induced  by  isopropyl-β-D-thiogalactopyranoside  (IPTG)  and  utilizes  the 
substrate 5-bromo-4-chloro-3-inodyl-β-D-galactopyranoside (X-gal) to yield a blue product. 
 
pCR
®II vector also contains a number of primer annealing sites for sequencing of the PCR insert, 
M13F and M13R, as well as a number of restriction sites, i.e. EcoR1, to allow for the presence 
and size of inserts within each plasmid to be determined.  Restriction digestion of the pCR
®II 
vector containing the appropriate insert produced digested fragments of approximately 400 base 
pairs.  Adapted from TA cloning kit Dual promoter with pCR
®II vector User Guide (Invitrogen, 
Paisley, UK). 
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2.3.11 Nucleic Acid Concentration 
The concentration of nucleic acids was determined using a Beckman DU640 
spectrophotometer by measuring the absorbance of the sample at a wavelength 
of 260 nm.  The absorbance at 280 nm was also determined and the ratio of 
260 nm / 280 nm assesses the purity of the sample.  A range of 1.6 to 1.9 was 
expected  for  DNA  samples,  a  lower  value  of  ratio  indicated  protein 
contamination as protein absorbs more strongly at 280 nm. To determine the 
nucleic acid concentration (µg/ml) the absorbance at 260 nm was multiplied by 
50 and then by the dilution factor.  
 
2.3.12 Sequencing and Analysis of Rearranged VH Genes 
 
2.3.12.1 Analysis of Transformants 
2.3.12.1.1 Overnight Cultures 
For analysis of positive clones single white colonies were picked from LB plates 
and were grown overnight in 3 mls LB broth (25 g/l, Invitrogen, Paisley, UK) 
supplemented with 50 µg/ml kanamycin (Gibco). Cultures were incubated and 
shaken at 37° C at 225 rpm.  After an overnight incu bation glycerol stocks were 
produced from each culture for long-term storage.  1 ml glycerol stocks were 
produced containing 15% sterile glycerol and stored at -80° C.  Plasmid DNA 
was purified using QIAprep Miniprep kit (QIAGEN, Sussex, UK), as described in 
section  2.3.12.1.2,  from  the  remaining  culture  after  bacterial  cells  were 
harvested after a 10 minute centrifugation at 13, 000 rpm.  
2.3.12.1.2 Plasmid DNA Extraction (Miniprep) 
Plasmid DNA was isolated using QIAprep Miniprep kit (QIAGEN, Sussex, UK), 
a system based on alkaline lysis of bacterial cells which utilises a unique silica-
gel membrane system. After harvesting and resuspension of bacterial cells in 
Buffer P1 (50 mM Tris-Cl, pH8.0, 10 mM EDTA, 100 µg/ml RNase A), the cells 
were lysed in Buffer P2 (200 mM NaOH, 1%SDS (w/v)) by gently inversion of 
microcentrifuge tube.  The lysate was then neutralised by the addition of Buffer 
N3  (acidic  potassium  acetate)  and  gently  mixed  until  the  solution  became 
cloudy.  Samples were then centrifuged for 10 minutes at 13, 000 rpm resulting 
in  a  compact  white  pellet.  The  remaining  supernatants  were  applied  to  the 
QIAprep  spin  columns  and  centrifuged  for  1  minute  at  14,  000  rpm.    The 
columns were washed with 0.5 ml Buffer PB and centrifuged again for 1 minute 89 
at 13, 000 rpm.  After addition of 0.75 ml Buffer PE columns were left to stand 
for 3 minutes before a 1 minute centrifugation at 13, 000 rpm.  Columns were 
then centrifuged for an additional minute at 13, 000 rpm to remove residual 
wash buffer.  Columns were then transferred to 1.5 ml microcentrifuge tubes 
and 50 µl of filter sterile distilled water was added to each column to elute the 
plasmid  DNA  from  the  column.    After  a  1  minute  incubation  columns  were 
centrifuged for 1 minute at 13, 000 rpm and eluted DNA was stored at -20° C. 
 
2.3.12.1.3 EcoR1 Restriction Digestion of Plasmid DNA 
 To  check  the  presence  and  size  of  inserts  within  each  plasmid  EcoR1 
restriction digest (G↓AATTC) was conducted on each plasmid after purification.  
In a 10 µl reaction 5 µl of each purified plasmid was mixed with 3 µl water and 1 
µl  reaction  buffer  and  1  µl  EcoR1  Restriction  enzyme  (10  U/µl)  (Invitrogen, 
Paisley, UK).  Reactions were incubated at 37° C for  1 hour.  The presence of 
an  insert  was  determined  by  agarose  gel  electrophoresis,  as  described  in 
Section 2.3.8.  1.5% agarose gel was used and inserts approximately 400 bp 
were expected. 
 
2.3.12.1.4 Measurement of DNA Concentration 
A DNA concentration for each purified plasmid was calculated as described in 
section 2.3.11. 
 
2.3.12.2 Sequencing 
DNA sequencing was performed by The Sequencing Service (School of Life 
Sciences,  University  of  Dundee,  Scotland,  www.dnaseq.co.uk)  using  Applied 
Biosystems Big-Dye Ver 3.1 chemistry on an Applied Biosystems model 3730 
automated capillary DNA sequencer.  200-300 ng of each plasmid DNA sample 
was sent for each sequencing reaction and plasmids were sequenced from the 
M13F and M13R regions of the plasmid using primers, Table 2.9, supplied by 
The Sequencing Service, Dundee.  The Sequencing Service also included a gc 
melt within the sequencing reactions to ensure efficient sequencing. 
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     Primer Name                       Sequence 
    Sequencing   M13F  GTAAAACGACGGCCAGTG 
    Primers  M13R  GGAAACAGCTATGACCATG 
 
     
Table 2.9 Primers used for sequencing of pCR
®II plasmid 
 
 
 
2.3.12.3 Sequence Analysis 
Sequence  results,  text  files  and  electropherograms,  obtained  from  The 
Sequencing Service, Dundee were checked and analysed using Chromas Lite 
software (Technelysium Pty Ltd, Australia).  The text file sequence was checked 
against the electropherogram for each sequence to ensure no anomalies had 
occurred during reading of the sequence.  The corresponding human germline 
genes were identified by searching the IMGT database using the JOINSOLVER 
software (http://joinsolver.niams.nih.gov) for the best matching genes in a Kabat 
data format  (291).    JOINSOLVER  was  specifically  developed  to  analyze  the 
CDR3 region of the immunoglobulin genes, a region fundamental in identifying 
clonally related sequences, and to provide a more accurate assessment of D 
segments.    JOINSOLVER  initially  searches  for  D  germline  sequences.    The 
human D germline gene database employed includes all D gene segments from 
the  IMGT  database  in  addition  to  the  reverse  and  DIR  germline  genes.  
JOINSOLVER identifies codon 93 as the beginning of CDR3 by searching for 
the conserved motif sequence TAT TAC TGT which comprises codons 90 to 92 
of the VH gene.  If this conserved motif is not found the search is reinitiated with 
an  allowance  for  one  base  change,  if  this  fails  homologies  to  the  germline 
genes are used to find the most likely start of the CDR3 region.  Once the VH 
end  of  the  CDR3  had  been  identified,  the  JH  border  of  the  CDR3  was 
determined using the conserved motif C TGG GG at the 3’ end of the CDR3 
region.    Once  the  CDR3  region  has  been  established  VH,  JH  and  D  gene 
assignment  was  conducted.    The  VH  and  JH  regions  are  scored  with  an 
alignment score, a score of +5 is assigned for a nucleotide match with a score 
of -4 for a mismatch between the unknown sequence and germline sequence. 
Following VH and JH assignment, the D segment assignment is conducted using 
a  consecutive  nucleotide  matching  system.    Matches  to  the  D  segment  are 91 
scored  and  sorted  based  on  the  VH-JH  distance,  the  distance  in  nucleotides 
between the end of the VH segment and the beginning of the JH segment.  A 
Monte Carlo simulation was used to establish the minimal D segment match 
length required to assign a D segment (Table 2.10), this was found to depend 
on the VH-JH distance.  These minimal match lengths were used in conjunction 
with the VH-JH distance of the sequence to determine if the highest scored D 
segment could be statistically assigned to the immunoglobulin rearrangement 
with a 95% probability that the match was not from random chance.  In some 
instances  a  mismatch  was  found  within  the  D  segment,  disrupting  the 
consecutive  match  length.    To  allow  a  higher  percentage  of  D  genes  to  be 
assigned statistically advice was sought and followed according to the criteria 
kindly  provided  by  Dr  Gary  Sims,  a  contributor  to  the  development  of  the 
JOINSOLVER software (Figure 2.4).     JOINSOLVER also conducts junction 
analysis at the VD and DJ junctions to assign P nucleotides, inverted repeats at 
germline encoded ends and N nucleotides, nontemplated junctional additions.   
 
Assignment of VH, D and JH gene segments and mutational numbers were also 
analysed  for  all  sequences  using  IMGT/V-QUEST  software 
(http://imgt.cines.fr)(292;293) with a search for insertions and deletions.  Any 
deviations  from  JOINSOLVER  assignments  were  noted.    IMGT,  the 
international ImMunoGeneTics information system® was created in 1989 by the 
Laboratoire  d’ImmunoGénétique  Moléculaire  (LIGM)  (Université  Montpellier  II 
and CNRS) at Montpellier, France.  It is a high-quality integrated knowledge 
resource specialising in immunoglobulins (IG), T cell receptors (TR) and major 
histocompatibility complex’s (MHC) and deals with all the IG and TR nucleotide 
sequences published in the DDBJ, EMBL and GenBank databases.  IMGT/V-
QUEST  (V-QUEry  and  STandardization)  is  an  integrated  on-line  software 
programme  which  analyses  IG  and  TR  rearranged  nucleotide  sequences.  
IMGT/V-QUEST first identifies the locus to which the sequence belongs and 
then identifies the V, D and J genes and alleles by best alignment score of the 
input sequence with the IMGT reference directory.  The programme first aligns 
the V-region, then the J-region and finally the D-region.  The junction of these 
sequences,  CDR3,  encompasses  the  sequence  between  the  V-region 
conserved  cysteine  (2
nd-  CYS)  at  position  104  and  the  J-region  conserved 92 
tryptophan (J-TRP) at position 118 found within the Trp-Gly-X-Gly conserved 
motif.    IMGT/JunctionAnalysis,  an  integrated  system  in  IMGT/V-QUEST 
performs analysis of the V-D-J junction. 
 
VH-JH Distance 
(bp) 
Minimal D Segment Match Length 
Required (bp) at a stringency of 0.05 
(To allow a 95% probability that the match was not 
from random chance) 
8  8 
9-11  8 
12-23  9 
24-27  9 
28-75  10 
76-79  10 
 
Table 2.10 Assignment of D gene segments based on VH-JH distance and D segment match 
length 
 
For each sequence the VH-JH distance is calculated using the JOINSOLVER software, in order 
to assign the best matching D gene segment with a 95% probability the associated number of 
minimal match lengths must be observed within the D segment sequence. 
 
 
 
 
 
 
 
 
 
Figure 2.4 Additional Criteria for assignment of D gene segments 
 
Figure 2.4 demonstrates supplementary criteria used in the statistical assignment of D gene 
segments  in  immunoglobulin  rearrangements  found  within  myositis  and  vasculitis  samples, 
kindly  provided  by  Dr  Gary  Sims,  a  contributor  to  the  development  of  the  JOINSOLVER 
software.    These  criteria  describe  the  additional  match  length  required  when  a  mismatch 
disrupts  the  consecutive  match  length  observed  within  the  segment  to  allow  a  D  gene 
assignment with a 95% probability that the match was not from random chance. 
 
The VH, D, JH gene usage distribution of functional gene rearrangements was 
analysed  by  determining  the  percentage  usage  of  each  gene  family  within 
infiltrating B cells and/or plasma cells of myositis and vasculitis samples. These 
gene distributions were compared to the baseline germline complexity and to 
published  normal  distributions  from  studies  conducted  by  Volpe  and  Kepler 
(251).  The number of single point mutations within each variable gene segment 
of  functional  gene  rearrangements  were  also  analysed  and  given  as  a 
For each mismatch in a sequence add 2 to the minimal D segment match length. 
 
eg. if the consecutive match required is 8. (x=match; o=mismatch) 
oxxxxxxxo 7 match = not significant 
oxxxxxxxxo 8 match = significant 
oxxxxxoxxxo 8/9 match = not significant 
oxxxxxxoxxxo 9/10 match = not significant 
oxxxxxxxoxxxo 10/11 match = significant 
oxxxxxoxxoxxxxxo 12/14 match = significant 
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percentage of the total number of sequences.  Base differences within the first 
24 bases of sequence were disregarded as this part of the sequence binds the 
5’ VH primer.  In addition to mutational numbers, the location of mutations were 
analysed between Framework regions (FR) and Complementary Determining 
Regions (CDR).  The number of mutations in each segment was expressed as 
a percentage of the total length of the segment to correct for the longer lengths 
observed  within  the  framework  regions.    The  approximate  base  positions  of 
each region is summarised in Figure 2.5.  As well as analysing the location of 
mutations  within  variable  gene  segments  the  types  of  mutation  were  also 
analysed.    The  numbers  of  mutations  resulting  in  an  amino  acid  change 
(replacement, R, mutation) were calculated in VH gene segments along with the 
number of silent, S, mutations where a nucleotide change does not result in an 
amino acid change within the sequence. Each mutation within the sequence 
was handled independently on a base-by-base method (Figure 2.6) rather than 
a  codon-by-codon  method.    This  corresponds  to  the  method  used  by  the 
JOINSOLVER software for calculating R and S mutational numbers; confirmed 
in consultation with Dr Nancy Longo and Dr Daniel Russ (National Institute of 
Health, Bethesda, MD, USA), two authors of the JOINSOVLER software (291).  
Statistical  analysis  of  these  R  and  S  mutational  numbers  for  antigen-driven 
selection  was  conducted  according  to  Hershberg  et  al  (294)  and  the 
corresponding  computer  programme  (http://clip.med.yale.edu/selection)  which 
demonstrates  an  improved  method  for  detecting  selection  by  mutational 
analysis of Ig V region sequences.  The software uses a focused binomial test 
which accounts for known biases of somatic hypermutation at two levels, the 
impact of local sequence context on mutability and the transition bias, in order 
to establish positive or negative mutational selections within the sequence with 
high specificity and increased sensitivity. Use of this software required the VH 
gene  segments  of  the  immunoglobulin  sequences  obtained  from  The 
Sequencing Service to be converted to a FASTA format with the IMGT unique 
format including gaps.  These sequences were initially analysed using IMGT/V-
QUEST software (292;293) to confirm the VH gene segment assignment and 
were  aligned  with  the  corresponding  germline  gene.    Both  sequences  were 
entered  into  the  software  with  the  germline  gene  following  the  input  query 
sequence and the CDR regions were selected manually to correspond to Kabat 94 
nomenclature.  The software calculated the number of R and S mutations within 
FR and CDR1 and 2 regions independently as well as testing for positive and 
negative selections for each of these mutations in both the FR and CDRs.  The 
use  of  this  software  also  allowed  the  number  of  independent  mutations  and 
selection to be analysed in sets of clonally related sequences.  All sequences 
were  entered  into  the  software  with  the  germline  VH  sequence following  the 
clonally related sequences.  CDR3 lengths in addition to P and N nucleotides 
and exonuclease activity at the VD and DJ junctions were also calculated and 
expressed as a mean value ± SEM.  For assignment of P and N nucleotides 
these  values  were  checked  for  each  sequence  as  the  criteria  for  handling 
mismatches  within  the  D  segment,  as  previously  described,  resulted  in  a 
change to the P and N nucleotide numbers.  Clonally related sequences were 
identified on the basis of identical VDJ gene rearrangements, CDR3 regions 
and junctional sequences.  Genealogical trees were constructed by analysis of 
shared and unshared mutations within these sequences.  In some instances the 
best matching and highest scoring VH gene alignment for clonally related sets 
were  not  always  assigned,  some  alternative  and  lower  scoring  sequence 
matches were used to correlate with clonally related sequence sets where the 
same CDR3, junctional rearrangements and common mutational patterns as the 
other isolated sequences were found, the clonally related gene was generally 
found to be the 4-6
th best matching gene segment.   
 
The  text  file  sequence  and  gene  alignments  for  all  sequences  are  given  in 
Appendix 1. 
  
2.3.12.3.1 PCR Error Rate 
The number of base changes regarded as significant was based on the PCR 
error rate for the polymerase, previously calculated (52), as less than one base 
per 4 VH genes. 
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Figure 2.6 Calculation of Replacement (R) and Silent (S) mutations on a base-by-base 
method 
 
Figure 2.6 demonstrates the criteria used to assign each point mutation as Replacement (R) or 
Silent  (S)  with  the  VH  segment  of  rearrangements.    For  this  study  each  mutation  is  taken 
independently on a base-by-base method, in this example this concluded with 1 R and 1 S 
mutation within the codon.  If the assignment of R and S mutations had been on a codon-by-
codon basis this would only represent 1 R mutation. 
VH  D  JH 
CDR1  CDR2  CDR3 
31  35  56  65  93  102 
Vκ  Jκ 
CDR1  CDR2  CDR3 
24  34  50  56  89  97 
Vλ  Jλ 
CDR1 CDR2  CDR3 
24  34  50  56  89  97 
A 
B 
C 
Figure 2.5 A simplified Diagram of Immunoglobulin Gene Segments for Sequence Analysis 
 
Figure 2.5 demonstrates the different gene segments that form the rearranged VH (A), Vλ (B) and 
Vκ  (C)  genes.  Within  these  rearrangements  there  are  areas  of  variability  known  as 
Complementarity  Determining  Regions  (CDR)  which  are  flanked  by  less  variable  Framework 
Regions (FR).  Figures represent approximate codon locations of CDRs.  CDRs constitute the 
antigen  binding  site  with  CDR3  being  the  most  hypervariable  as  it  is  generated  by  the 
recombination of different gene segments, VDJ in heavy chains and VJ in light chains.   
 
For sequence analysis the number and type of mutations within variable gene segments, FR and 
CDRs were compared.  Base differences within the first 24 bases of sequence were disregarded 
as this part of the sequence binds the 5’ VH primer.  CDR3 was not incorporated into mutational 
analysis due to the difficulty in distinguishing point mutations and junctional variation as a result of 
gene  recombination.  Clonally  related  sequences  were  identified  on  the  basis  of  identical  VDJ 
gene rearrangements, CDR3 regions and junctional sequences. 
 
 
Sequence mutation 
 
 GGA->GAC  (Gly->Asp) 
 
Base-by-base method 
 
GGA -> GAA - mutation in the 2nd base (Gly->Glu) 1 R 
GGA -> GGC - mutation in the 3rd base (Gly -> Gly) 1 S 
 
Codon-by-codon method would only generate 1 R mutation  
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2.3.13 Statistical Analysis 
Statistical  analysis  was  conducted  using  GraphPad  Prism  4  (GraphPad 
Software  Inc.,  San  Diego  CA,  USA)  and  after  consultation  with  Dr  Tony 
Speekenbrink  (Statistics  Analyses  Advisor  to  the  Clinical  Microbiology 
Department, University of Glasgow).   P  values less than 0.05 were deemed 
significant.  All p values are given in Appendix 2. 
    
The distribution of VH, DH and JH family usage, as well as individual VH and DH 
gene  usage,  was  compared  to  published  normal  PBL  values  (251)  and  the 
germline  complexity  using  Pearson’s  Chi  square  analysis  to  determine  a 
statistical selection for or against particular gene families, or individual genes, 
expressed  on  infiltrating  cells  from  the  muscle  or  skin.    Absolute  values 
obtained for each VH, DH and JH family, as well as individual genes, were used 
to construct contingency tables in the GraphPad software for each VH, DH and 
JH family and tested for selection against the values of the corresponding family 
in the normal PBL and the germline complexity.    
 
CDR3 lengths, P and N nucleotides and exonuclease activity were analysed in 
functional and non-functional sequences using a two-tailed unpaired t-test.  The 
One-way analysis of variance test was used in conjunction with Tukey-Kramer 
multiple comparison post test to determine any statistical difference between 
mean CDR3 lengths in mutated sequences.  These statistical tests allowed any 
statistical  difference  in  the mean  CDR3  lengths  of  the  4 different  mutational 
groups (0-2, 3-10, 11-20 and 20+) to be established as well as correcting for 
multiple comparisons within the same data set, this eliminates the Type 1 errors 
that occur when statistical tests are used repeatedly. 
 
Statistical  analysis  of  R  and  S  mutations  was  conducted  as  described 
previously  in  section  2.3.12.3.    Briefly  a  focused  binomial  test  was  used  to 
calculate the parameters of the null model of mutation and test for positive and 
negative selection in the CDR and FW separately.  P values less than 0.05 
were deemed significant.    
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2.4 Identification of Antigens Driving the Immune Response in Myositis    
Patients 
2.4.1  Protein Biotinylation 
50 µg of recombinant proteins to be biotinylated, Table 2.11, were mixed and 
incubated  for  2  hours  with  5  µl  of  1  mg/ml  Biotin  (Long  Arm)    N 
hydroxysuccinimide  ester  –  water  soluble  (NHS)  (Vector  Laboratories), 
dissolved in 100 mM bicarbonate buffer pH 8.5 or 1X PBS.  After 2 hours the 
biotinylation reaction was stopped by the addition of 1 ml 10% glycine in H20.  
To remove excess biotin, samples were dialyzed against 100 mM bicarbonate 
buffer pH 8.5 or 1X PBS using 0.5 ml-3 ml Slide-A-Lyzer Dialysis cassettes 
(Pierce, Rockford, IL, USA).  Initially cassette membranes were rehydrated in 
dialysis  buffer  for  30  seconds  to  increase  the  flexibility  of  the  membrane.  
Cassettes  were  checked  for  leaks  by  injecting  sterile  distilled  water  into  the 
cassette immediately prior to the addition of the sample.  After removal of the 
distilled water samples were injected into cassettes using a syringe filled with 
the sample and an 18-gauge 1-inch beveled needle.  Excess air was removed 
from the cassette to allow maximal sample solution contact with the dialysis 
buffer.  Dialysis was carried out at 4° C and dialys is buffer was changed after 3 
hours, then after overnight followed by a further 2 hour incubation in dialysis 
buffer.  To remove samples syringes with an 18-gauge 1-inch beveled needle 
were filled with air at least equal in volume to the sample.  The air was then 
discharged  into  the  cassette  to  allow  the  membranes  of  the  cassette  to 
separate.  The cassette was then rotated to allow the biotinylated sample to be 
drawn back into the syringe.  Biotinylated proteins were aliquoted and stored at 
-20° C.  BSA was also biotinylated by the above proc edure to use as a control in 
experiments. 
 
2.4.2 Dot Blot 
To  verify  biotinylation  of  recombinant  proteins  an  aliquot  of  the  protein  was 
serially diluted 1:10 until a final dilution of 1:100, 000.  10 µl neat biotinylated 
protein (50 µg/ml) and each serial dilution were spotted onto Hybond™-N nylon 
membrane  (Amersham  Life  Sciences,  Buckinghamshire,  England).    Proteins 
were allowed to soak into the membrane before the membrane was blocked 
with 1X Casein in TBS/Tween (Section 2.5) for 30 minutes.  The membrane 98 
was washed twice for 10 minutes each in TBS/Tween then for 10 minutes in 
TBS.  The membrane was then incubated with 5 ml ABComplex AP reagent 
(Vector Laboratories) for 30 minutes.  The reagent consists of 5 ml TBS with 2 
drops of Reagent A, Avidin DH, and 2 drops of Reagent B, biotinylated alkaline 
phosphatase H.  The reagent was mixed 30 minutes prior to use and allowed to 
stand at room temperature.  Membrane was washed twice for 10 minutes each 
in TBS/Tween then for 10 minutes in TBS before incubating with 5 ml Alkaline 
phosphatase substrate as described in section 2.2.3 and 2.5 or 5 ml of Vector 
Blue  Alkaline  Phophatase  Substrate  III  (Vector  Laboratories).    A  working 
solution of Vector Blue substrate consisting of 5 mls 100  mM Tris-HCl pH 8.2, 2 
drops Reagent 1, 2 drops Reagent 2 and 2 drop of Reagent 3 was prepared 
immediately prior to use and membrane was incubated for 20 minutes of until 
colour  development.    Membranes  were  then  washed  3  times  in  TBS  for  10 
minutes.    All  incubations  were  carried  out  at  room  temperature.    Non-
biotinylated BSA was used as a negative control. 
 
RECOMBINANT PROTEIN  SOURCE 
Jo-1 
A kind gift from Prof. Paul Plotz, National 
Institute of Health, Bethesda, MD, USA 
Calf Thymus DNA  Sigma (St. Louis, MO, USA) 
Sm/RNP  The Binding Site (UK) 
Scl-70  The Binding Site (UK) 
 
Table 2.11 Recombinant Proteins for biotinylation to identify antigen specific cells 
 
2.4.3 Antigen Specific Staining 
Slides from -70° C were thawed at room temperature f or 30 minutes in a staining 
vessel containing anhydrous silica gel.  To fix sections slides were transferred 
to acetone for 10 minutes and then allowed to dry.  Sections were circled with a 
PAP pen (Immedge Pen, Vector Laboratories) and allowed to dry for 5 minutes.  
They were then incubated for 15 minutes with avidin blocking solution (Vector 
Laboratories) and briefly washed in TBS before a 15 minute incubation with 
biotin blocking solution (Vector Laboratories).  Sections were then washed twice 
for 5 minutes in TBS.  100 µl of 1X Casein (Vector Laboratories) was added to 99 
each section to block for 15 minutes.  Blocking solution was poured off and 100 
µl  of  20  µg/ml  biotinylated  recombinant  protein  was  added  to  sections,  with 
appropriate negative  controls, and  incubated for 1  hour.   The  sections  were 
then washed 3 times in TBS for 5 minutes and then incubated with 100 µl of 
ABComplex  AP  Reagent  (Vector  laboratories)  solution  for  30  minutes.    The 
reagent consists of 5 mls TBS with 2 drops of Reagent A, Avidin DH, and 2 
drops of Reagent B, biotinylated alkaline phosphatase H.  Reagent was mixed 
30 minutes prior to use and allowed to stand at room temperature.  Sections 
were washed 3 times in TBS for 5 minutes then incubated with 5 mls Alkaline 
phosphatase  substrate  as  described  in  section  2.2.3  and  2.5.    Following 
substrate incubation sections were washed twice in TBS for 5 minutes and once 
in sterile distilled water for 5 minutes.  All incubations were carried out at room 
temperature in a humidified chamber.  Biotinylated BSA as a negative control 
on myositis sections and biotinylated antigen was also used on tonsil sections 
as a negative control. 
 
2.4.4 Double Immunofluorescent Antigen Specific Staining 
Double Immunofluorescent immunohistochemistry for antigen specific cells was 
performed  as  described  in  section  2.2.4  using  2  µg/ml  recombinant  protein 
(Table 2.11).  Use of the biotinylated recombinant proteins eliminated the need 
for  using  M.O.M  biotinylated  Anti-Mouse  Ig  reagent  therefore  this  step  was 
eliminated  where  appropriate  before  the  appropriate  detecting  solution  was 
applied to each section.  Biotinylated BSA was used on sample sections as a 
negative control. 
 
2.4.5 Laser Capture Microdissection 
Laser capture microdissection (LCM) was performed using a PixCell
® IIe Laser 
Capture Microdissection System (Arcturus Bioscience Inc, Mountain View, CA) 
to direct the low-powered infrared laser through the CapSure
® HS (Arcturus) 
caps to melt the film onto the cell of interest (Figure 2.7A).  CapSure
® HS caps 
are coated with a special thermoplastic film which melts onto the surface of the 
target cell when pulsed with the infrared light from the laser.  This film also 
absorbs  the  laser  radiation  ensuring  that  any  infrared  radiation  that  does 
penetrate the polymer does not create or catalyse any chemical alterations to 100 
the  DNA/RNA  of  the  sample  ensuring  its  integrity  for  further  downstream 
applications.  CapSure
® HS caps contain a 12 µm discontinuous circular ridge 
that sits on the surface of the tissue ensuring the cap is elevated above the 
sample microdissection (Figure 2.7B). This ensures that the only part of the film 
that comes into contact with the sample is that which has been melted by the 
laser onto the cell of interest.  The ExtracSure Extraction device is placed on 
the caps after capture of the cells of interest and seals around the perimeter of 
the  cap  surface  and  covers  the  circular  ridge  that  was  in  contact  with  the 
sample during LCM.  Extraction buffer can then be safely added to ExtracSure 
device to allow extraction of DNA (Figure 2.7C-A).  For RNA extraction the 
ExtracSure device was not required.  100 µl of lysis buffer is placed in a 0.5 ml 
microcentrifuge  tube  and  inverted  to  allow  cell  lysis  (Figure  2.7C-B).  Taken 
from PixCell
® IIe Laser Capture Microdissection System User Guide, Arcturus 
Bioscience Inc, Mountain View, CA.  
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Figure 2.7 A simplified diagram of Laser Capture Microscopy (LCM) 
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Figure 2.7 A simplified diagram of Laser Capture Microscopy (LCM) 
 
Laser capture microdissection (LCM) to isolate single cells was performed using a PixCell
® IIe 
Laser Capture Microdissection System (Arcturus Bioscience Inc, Mountain View, CA). A low-
powered infrared laser is passed through CapSure
® HS caps (Figure 2.7A) over the cell which 
is to be dissected.  CapSure
® HS caps are coated with a special thermoplastic film which melts 
onto the surface of the target cell when pulsed with the infrared light from the laser (Figure 
2.7B).  For extraction of genomic DNA the ExtracSure Extraction device is placed on the caps 
after capture of the cells of interest and seals around the perimeter of the cap surface and filled 
with DNA extraction buffer (Figure 2.7C-A).  The ExtracSure Extraction device is not required 
for  RNA  isolation  (Figure  2.7C-B);  alternatively  100  µl  of  lysis  buffer  is  placed  in  a  0.5  ml 
microcentrifuge tube and inverted to allow cell lysis.  Adapted from (295) and PixCell
® IIe Laser 
Capture Microdissection System User Guide, Arcturus Bioscience Inc, Mountain View, CA. 
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2.4.5.1 Immunohistochemistry for LCM 
Immunohistochemical staining for LCM was performed as described in section 
2.2.3,  although  incubation  times  were  reduced  and  antibody  concentrations 
were increased. This was to ensure efficient transfer and quality of nucleic acid 
obtained during microdissection.   Sections were also dehydrated as moisture 
present within the sample can impede transfer efficiency.  Briefly, slides from -
70° C  were  thawed  at  room  temperature  for  15  minutes   in  a  staining  vessel 
containing  anhydrous  silica  gel.    To  fix  sections  slides  were  transferred  to 
acetone for 10 minutes and then allowed to dry.  Sections were circled with a 
PAP pen (Immedge Pen, Vector Laboratories) and allowed to dry for 5 minutes.  
Sections were rehydrated in TBS for 30 seconds.  100 µl of 2% BSA/TBS was 
added to each section to block for 15 minutes.  Blocking solution was poured off 
and  100  µl  of  2%  BSA/TBS  containing  mouse  anti-human  primary  antibody 
(DAKO) was added to each section (Table 2.12) and incubated for 15 minutes.  
Negative control experiments were performed using antibodies with matched 
isotypes.    The  primary  antibody  solution  was  poured  off  and  sections  were 
washed  twice  in  TBS  for  30  seconds.    Following  washing  100  µl  of  2% 
BSA/TBS containing 10 µl of rabbit anti-mouse IgG secondary antibody (DAKO) 
was added to each section and was incubated for 10 minutes.  After secondary 
antibody was poured off and sections were washed twice in TBS for 30 seconds 
100 µl of 2% BSA/TBS containing 4 µl of alkaline phosphatase anti- alkaline 
phosphatase (APAAP) was added to each section and was incubated for 10 
minutes.  Sections were again washed twice in TBS for 30 seconds. 100 µl of 
substrate solution, as per section 2.2.3 and 2.5, was then added to each section 
and allowed to develop for 20 minutes.  Following substrate incubation sections 
were washed twice in TBS for 5 minutes and once in sterile distilled water for 1 
minute.  Sections were counter-stained with Mayer’s Haemotoxylin and washed 
in  Scotts  tap  water  substitute  to  allow  proper  colour  development.    All 
incubations were carried out at room temperature in a humidified chamber.  For 
laser microdissection sections were dehydrated in 75% ethanol for 1 minute, 
followed  by  95%  ethanol for  1 minute  and then 100% ethanol  for  1  minute.  
Finally  sections  were  incubated  for  5  minutes  with  Histoclear  (National 
Diagnostics).  They were then allowed to air dry, under a fume hood, and stored 104 
desiccated.  For antigen-specific cells staining was carried out as described in 
section 2.4.3. 
 
 
Antibody 
Specificity  Source  Species  Clone  Isotype  Dilution 
CD20  DAKO  Mouse 
Monoclonal  L26  -IgG2a  1:25 
Plasma Cell  DAKO  Mouse 
Monoclonal  V538c  -IgG1  1:100 
-IgG1 Isotype 
Control  DAKO  Mouse 
Monoclonal  DAK-G01    1:100 
-IgG2a 
Isotype 
Control 
(Anti-
Aflatoxin) 
Kind gift 
from Prof 
Stimpson, 
Strathclyde 
University, 
Glasgow 
      1:25 
 
Table 2.12 Primary Antibodies used for staining LCM sections 
 
2.4.5.2 Laser Microdissection 
Microdissection  for  single  cells  was  performed  using  a  spot  size  of  7.5  µM, 
power of 70 mV and 1 ms duration.   Cells were transferred to CapSure
® HS 
caps. 
 
2.4.5.3 RNA Purification 
Isolation  of  RNA  from  microdissected  single  cells  was  performed  using 
Absolutely RNA Nanoprep Kit (Stratagene, La Jolla, CA. USA).    The nanoprep 
RNA purification method utilizes a guanidine thiocyanate lysis buffer which acts 
as  a  strong  protein  denaturant  to  allow  cell  lysis  and  prevention  of  RNA 
degradation by ribonucleases (RNases).  After transfer to the nano-spin cup, 
RNA is bound to the silica-based fibre matrix and RNA sample is treated with 
DNase to remove contaminating DNA and several washes removes DNase and 
other proteins resulting in RNA suitable for cDNA synthesis.   Briefly, 0.7 µl β-
Mercaptoethanol (14.2 M) was added to 100 µl lysis buffer for each sample in a 
0.5 ml Eppendorf.  The CapSure
® cap containing laser-captured cell is snapped 
onto each microcentrifuge tube.  Each tube was inverted and vortexed for 30 
seconds to allow cell lysis.  100 µl of 70% ethanol was then added to each 
sample and mixed by pulse vortexing.  The entire lysate was then transferred to 105 
an  RNA-binding  nano-spin  cap  and  centrifuged  for  60  seconds  at  12,000  g.  
After discarding the filtrate 300 µl of 1x Low-Salt Wash Buffer was added to 
each cap and centrifuged at 12, 000 g for 60 seconds.  After removal of the 
filtrate the cap was centrifuged for 2 minutes to dry out the fibre matrix.  Each 
sample  was  then  incubated  with  15  µl  DNase  solution  (2.5  µl  reconstituted 
RNase-Free  DNase  1  with  12.5  µl  DNase  Digestion  Buffer)  at  37° C  for  15 
minutes.  300 µl 1x High-Salt Wash Buffer was then added to each sample and 
centrifuged for 60 seconds at 12, 000 g.  This was repeated twice with 300 µl 
Low-Salt  Wash  Buffer  before  a  3  minute  centrifugation  to  dry  out  the  fibre 
matrix.  10 µl Elution Buffer was then added to each sample and incubated for 2 
minutes  at  room  temperature.    Total  RNA  was  eluted  after  centrifugation  at 
12,000 g for 5 minutes. 
 
2.4.5.4 cDNA Synthesis 
cDNA  synthesis  was  performed  using  the AffinityScript  Multiple Temperature 
cDNA  synthesis  Kit  (Stratagene,  La  Jolla,  CA.  USA).    First  strand  cDNA 
synthesis  reaction  was  performed  using  the  total  RNA  sample  from  section 
2.4.5.3; 5.7 µl RNase-free water was added to the purified RNA before 1 µl of 
constant region gene specific primers (100 ng/µl) were added.  The reaction 
was  incubated  at  65° C  for  5  minutes.    Constant  regi on  primers  were 
synthesised  by  Operon  Biotechnologies  (Huntsville,  AL,  USA)  and  were  as 
previously described by Wang and Stollar (296) (Table 2.13).  After 5 minutes 
reactions were allowed to cool to room temperature to allow primers to anneal 
to RNA.  Once cooled to room temperature 2 µl of 10x AffinityScript RT buffer 
was added to each reaction followed, in order, by 0.8 µl dNTP mix (25 mM 
each),  0.5  µl  RNase  Block  Ribonuclease  Inhibitor  (40  U/µl)  and  1  µl  of 
AffinityScript  Multiple  Temperature  Reverse  Transcriptase.    Reactions  were 
incubated for 60 minutes at 42° C. Reactions were st opped by incubating for 15 
minutes at 70° C.  cDNA synthesis reactions were sto red on ice for subsequent 
PCR reactions. 
 
 
 
 106 
 
     Primer Name                       Sequence 
    Constant Region   HuCmu  GCAGGAGACGAGGGGGA 
    Primers  HuCgamma  AGGGYGCCAGGGGGAA 
  HuCkappa  AACAGAGGCAGTTCCAGA 
  HuClambda  TGTGGCCTTGTTGGCTTG 
 
                               Table 2.13 Constant Region Primers for cDNA synthesis 
 
 
2.4.5.5 VH Nested PCR on single cells 
 
VH amplification from cDNA isolated from single infiltrating cells was carried out 
as  previously  described  in  section  2.3.7.    PCR  products  were  visualised  as 
described  in  section  2.3.8  and  extraction  and  cloning  were  performed  as 
described in sections 2.3.9, 2.3.10 and 2.3.12. 
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2.5 Buffers 
 
Tris-Buffered Saline 
(TBS) 
20 mM Tris Base 
137 mM NaCl 
2.7 mM KCl 
pH 7.4 
TBS/Tween  20 mM Tris Base 
137 mM NaCl 
2.7 mM KCl 
pH 7.4 
0.1% Tween 20 
Phosphate Buffered 
Saline (PBS) 
137 mM NaCl 
10 mM phosphate 
2.7 mM KCl 
Buffer E  0.05 M Tris Base 
0.9% NaCl 
pH 9.7 
Alkaline Phosphate 
Substrate for 
Immunohistochemistry 
10 µl of 5% New Fuchsin in 2 M HCl 
25 µl of 0.7 M sodium nitrite 
3.5 mls of Buffer E 
1.25 mls of 0.2 M 2-amino-2-methyl-1,3-propanediol 
(AMPD) 
50 µl of 40 mg/ml levamisol 
30 µl of Naphthol AS-BI phosphate 
100 µl of 2 M HCl 
 
Scotts Tap Water 
Substitute 
0.35% NaHCO3 
0.2% MgSO4 
 
 
Complete RPMI  RPMI Medium 
1% Penicillin/Streptomycin 
1% 200mM L-Glutamine) 
30% Foetal Bovine Serum 
 
+10% DMSO for Lymphocyte Cryopreservation 
 
TBE Electrophoresis 
Buffer 
 
45 mM Tris base 
45 mM Boric Acid 
1 mM EDTA 
Agarose Gel  1.5% electrophoresis grade Ultra Pure Agarose 
(Invitrogen) 
1 x TBE 
0.5 µg/ml Ethidium Bromide 
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Chapter 3 - Phenotypic Characterisation of Cellular Infiltrates in Myositis 
Patients 
3.1 Introduction 
As discussed in Chapter 1 the presence and phenotypes of cellular infiltrates 
have  previously  been  studied  in  myositis  (87-89;297;298).    The  roles, 
interactions, degree of infiltration and organisation of these cells have yet to be 
fully understood in these autoimmune disorders.  Including myositis, a variety of 
different  cellular  phenotypes  have  been  identified  in  different  autoimmune 
inflammatory reactions, these include B cells, either in their B cell state or in 
their differentiated plasma cell state.  These cells have been implicated in the 
pathogenesis of autoimmune disorders but their precise role in contributing to 
autoimmune pathology is largely unknown.   
 
To investigate the role of B cells in myositis and examine the Ig gene repertoire 
and clonal diversification of infiltrating cells the occurrence of these B cells and 
plasma cells within the target tissues of these disorders was initially determined.  
Therefore immunohistochemical studies were conducted to address the central 
aim of this chapter; 
 
·  Establish the occurrence and organisation of CD20
+ B cells and plasma 
cells within the infiltrating cellular population of the muscle. 
·  Identify  proliferating  Ki67
+  B  cells  within  the  muscle  to  indicate  the 
possible expansion and clonal diversification of these cells within the 
muscle.  
·  Determine  the  degree  of  infiltration,  organisation  and  proliferation  of 
additional  cell  phenotypes  (T  cells  (CD3,  CD4,  CD8),  macrophages 
(CD68),  Follicular  dendritic  cells  (FDC),  proliferating  cells  (Ki67)  and 
regulatory T cell (FoxP3)) within muscle samples. 
 
The work described in this chapter demonstrates that a large variety of cellular 
phenotypes  was  present  within  inflammatory  reactions  in  myositis  and  are 
summarised in Table 3.1. 
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Sample  Diagnosis  Germinal 
Centre 
Formation 
Cellular 
Aggregation  CD20  Plasma 
Cell  FDC  CD3  CD4  CD8  FoxP3  CD68  Ki67  -IgG1  -IgG2a  -IgM 
MYO1  DM  -  +++  ++  ++  -  ++  ++  +  ++  ++  ++  -  -  - 
MYO3  PM  -  +++  +  ++  +  ++  +++  +  -  ++  +  -  -  - 
MYO5  PM  -  -  +  ++  +  ++  ++  ++  -  ++  +  -  -  - 
MYO6  PM  -  ++  +  +  -  ++  +  +  -  ++  +  -  -  - 
MYO7  PM  -  ++  +  ++  -  +  +++  +  -  +++  +  -  -  - 
MYO16  DM  -  +++  +++  ++  -  ++  ++  +  -  +++  +  -  -  - 
MYO17  PM/IBM  -  ++  +  ++  +  +++  ++  +  +  ++  +  -  -  - 
MYO19  PM  -  ++  +  ++  -  ++  ++  +  -  ++  +  -  -  - 
MYO23  PM  -  +  +  ++  +  +  ++  +  -  ++  +  -  -  - 
MYO24  PM  -  ++ 
- (+ IF 
only)  +++  -  ++  ++  +  +  ++  +  -  -  - 
MYOC   PM  -  +  +  ++  -  ++  +++  ++  -  ++  +  -  -  - 
MYOE  Myopathy 
(PM) 
-  +  +  ++  -  ++  ++  ++  -  ++  ++  -  -  - 
MYO25  Control  -  N/A  -  -  -  -  -  -  -  +  -  -  -  - 
 
MYO2  Myopathy 
(PM)  -  +  -  -                       -  -    
MYOA  Myopathy 
(IBM)  -  N/A  -  -                       -  -    
MYOD  DM  -  N/A  -  -                       -  -    
MYO18  PM  -  -  -  -                       -  -    
MYO21  PM  -  +  -  -                       -  -    
Table 3.1 Immunohistochemistry Summary Table from Myositis Samples 
   
Table 3.1 provides a summary overview of the immunohistochemistry profiles observed from each sample for each myositis patient.  The table summarises the infiltration 
of each cell phenotype observed throughout the entire biopsy (n=3-7 sections for each cell phenotype depending on tissue availability) and is not based solely on the 
representative images presented in Figures 3.1, 3.5, 3.7, 3.9, 3.11, 3.13, 3.15, 3.17, 3.19, 3.21, 3.23, 3.25, 3.27 and 3.28.  Comparisons were made between cell 
phenotypes in the same patient and not between different patients.  For germinal centre formation, – represents the absence of these structures within the muscle 
sections.  The extent of cellular aggregation of infiltrating cells was established for each sample and was based on semi quantitative observations; - represents no cellular 
aggregation with a widespread scattering of lymphocytes throughout the muscle section; +, ++, +++ represents an increasing degree of aggregation of lymphocytes 
respectively observed within the muscle sections.  N/A was applied to samples where no or very little infiltration was present.  Immunohistochemistry summary profiles 
were based on semi-quantitative observations of cellular infiltration; - indicates where cell phenotypes were absent from the infiltrating population while +, ++, +++ 
represent increasing numbers of cell phenotypes respectively within the muscle infiltrating population.  Areas highlighted in yellow indicate where proliferating cell 
phenotypes were observed from fluorescent double immunohistochemistry (IF) experiments, these experiments were not included in the semi quantitative analysis and 
were used solely to establish the population of proliferating cells.  Areas in grey indicate where cell phenotypes were not tested for.          110 
3.2 Characterisation of Cellular Infiltrates in Inflammatory Myopathies 
3.2.1 Sample MYO1 
Six  extensive  regions  of  cellular  infiltration  were  observed  through  serial 
sections of sample MYO1  with additional scattered infiltration throughout the 
section between the muscle fibres.  No characteristic germinal centre structures 
were  observed;  areas  of  infiltration  appeared  as  loose  aggregates  of  cells 
situated  between  muscle  fibres,  mainly  in  perimysial  and/or  perifascicular 
regions of the muscle.  In region 1 (Figure 3.1), as well as other regions of 
infiltration,  CD20
+ (A), CD3
+ (D), CD4
+ (E), CD8
+ (F) and Ki67
+ (G) cells were 
identified with plasma cell staining (C) mostly concentrated in the six regions but 
were  also  identified  lightly  scattered  throughout  the  section  in  endomysial 
locations.  Very few FDCs (B) appeared to be present within the infiltrating cell 
population.  In addition, a large infiltration of CD68
+ (H) cells was observed as 
well as an infiltration of FoxP3
+ cells (I) throughout sections examined.  These 
cell markers were observed in each of the areas of cell aggregation as well as 
additional scattered staining throughout the muscle section.  Staining sections 
with the appropriate negative controls (J-L) identified virtually no staining in the 
regions  identified  by  the  other  cellular  stains  although  small  amounts  were 
observed throughout the section.  A large proportion of B cells, CD4
+ cells and 
plasma cells were observed which may suggest a humoral, ectopic germinal 
centre  response  was  occurring  within  the  sample  but  no  germinal  centre 
structures or FDCs were observed.  Although CD8 staining was observed cell 
numbers appeared reduced in comparison to other cell types.   
 
Double  staining  experiments  to  characterise  the  nature  of  proliferating  cells 
within sample MYO1 showed that the majority of proliferating cells were CD3
+ 
(B) or CD4
+ (C) cells (Figure 3.2).  There was the presence of an occasional 
proliferating CD20
+ cell throughout the MYO1 sections.  Figure 3.3 (A & B) 
shows  that  FoxP3
+  cells  are  included  in  the  population  of  proliferating  cells.  
Negative control experiments with the antibody isotype controls showed no non-
specific staining within sections (Figure 3.4). 
 
 
 
 
 111 
 
       
 
        
 
       
 
       
 
 
 
 
 
 
 
 
 
  
 
   
 
 
 
 
Figure 3.1 Immunohistochemistry of serial muscle sections of sample MYO1 
 
A representative example of serial muscle sections from sample MYO1 stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 
(H), FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative 
control (L) and visualised by APAAP and New Fuschin substrate to establish cellular 
infiltrates within the muscle section.  Images A – I: 400X; Images J-L: 100X 
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K  L 112 
 
 
 
 
CD3 
CD20  Ki67 
Ki67 
Ki67 
Ki67 
CD4 
CD8 
CD20 Ki67 
 
CD3 Ki67 
 
CD4 Ki67 
 
CD8 Ki67 
 
CD68  Ki67  CD68 Ki67 
 
A 
B 
C 
D 
E 
Figure 3.2 Double Immunohistochemical staining of serial muscle sections of sample 
MYO1  
 
A representative example of serial muscle sections from sample MYO1 stained for CD20 
(A), CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all 
sections were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the 
type of proliferating cells within the myositis sample to be identified.  Images were taken at 
630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 113 
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Figure 3.3 Double Immunohistochemical staining of serial muscle sections of sample 
MYO1 with Anti-FoxP3 
 
A representative example of serial muscle sections from sample MYO1 stained for FoxP3 
(A&B) and visualised by Fluorescein Avidin D before all sections were stained with Ki67 and 
visualised by Texas Red Avidin D.  This allowed any FoxP3 proliferating cells within the 
myositis sample to be identified.  Images were taken at 630X (A) and 1000X (B). Scale Bar 
(A) represents 15 µm, no Scale Bar was calibrated at 1000X.  Arrows identify proliferating 
cells within the sections. 
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Figure 3.4 Double Immunohistochemical staining of serial muscle sections of sample 
MYO1 with negative control isotype antibodies  
 
A representative example of serial muscle sections from sample MYO1 stained with –IgG2a 
isotype  control  (A)  or  –IgG1  isotype  control  (B)  and  visualised  by  Fluorescein  Avidin  D 
before all sections were stained with –IgG1 isotype control and visualised by Texas Red 
Avidin D.  This allowed any non-specific staining within the myositis sample to be identified.  
Images were taken at 630X.  Scale Bar represents 15 µm.   114 
3.2.2 Sample MYO3 
 
Immunohistochemical staining of sample MYO3 produced a different pattern of 
staining in comparison to sample MYO1 (Figure 3.5).  Two distinct regions of 
infiltration at endomysial locations were observed with varied degrees of cellular 
infiltration in addition to scattered staining throughout the section.  Staining for 
CD20
+ (A) cells and FDCs (B) produced a very diffuse pattern of staining but 
there appeared to be a low infiltration of these cell classes present within the 
sample.  A large infiltration of plasma cells (C) was observed throughout the 
section.  These were aggregated in the regions of distinct infiltration but plasma 
cells  were  also  observed  scattered  throughout  the  entire  section.  A  large 
proportion  of  cells  appeared  to  be  CD3
+  (D)  and  CD4
+  (E)  cells,  in  some 
instances  the  occurrence  of  CD4
+  cells  appeared  to  be  greater  than  that  of 
CD3
+  cells.    CD8
+  (F)  cells  were  present  within  sample  MYO3  but  these 
appeared to be reduced in comparison to the numbers of CD3
+ and CD4
+ cells.  
A large infiltration of CD68
+ (H) cells was also present within the sample; in 
addition to being aggregated in dense areas of infiltration, these cells were also 
scattered throughout the whole section.  Proliferating cells were observed within 
the  sample  using  the  Ki67  proliferation  marker  (G),  as  with  the  other  cell 
markers  staining  was  observed  within  the  cellular  aggregates  as  well  as 
throughout the whole section.  No FoxP3
+ (I) cells were evident within sample 
MYO3.  Staining of section with negative control isotype antibodies showed no 
non-specific staining (J-L). 
 
Identification  of  Ki67
+  cells  by  double  staining  experiments  showed  the 
presence of CD3
+ (B) and CD8
+ (D) proliferating cells throughout the section at 
the areas of cellular aggregation (Figure 3.6).  Figure 3.6 represents a small 
area of the whole section but these proliferating cells were observed in other 
areas of cellular aggregation.  No other type of proliferating cell was observed 
within the sections stained.  Negative control staining produced no non-specific 
staining.  
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Figure 3.5 Immunohistochemistry of serial muscle sections of Sample MYO3. 
 
A representative example of serial muscle sections from sample MYO3 stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H), 
FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative control 
(L)  and  visualised  by  APAAP  and  New  Fuschin  substrate  to  establish  cellular 
infiltrates within the muscle section.  Images A – L: 400X 
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Figure 3.6 Double Immunohistochemical staining of serial muscle sections of sample 
MYO3 
 
A representative example of serial muscle sections from sample MYO3 stained for CD20 (A), 
CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all sections 
were  stained  with  Ki67  and  visualised  by  Texas  Red  Avidin  D.    This  allowed  the  type  of 
proliferating cells within the myositis sample to be identified.  Images were taken at 630X; Scale 
Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 117 
3.2.3 Sample MYO5  
Analysis  of  cellular  infiltrates  within  sample  MYO5  produced  a  largely 
endomysial  pattern  of  staining,  characterisation  of  cellular  phenotypes  was 
similar to that of sample MYO3 (Figure 3.7).  There was very little evidence of 
CD20
+  (A)  cells  and  FDCs  (B)  within  the  sample.    A  large  proportion  of 
infiltrating cells were plasma cells (C) or CD3
+ (D), CD4
+ (E) and CD8
+ (F) cells.  
As seen in MYO3 a large infiltrate of CD68
+ (H) cells was observed.  Ki67
+ (G) 
cells  were  present  within  the  myositis  biopsy  but  no  FoxP3
+  (I)  cells  were 
evident throughout the sections examined.  Negative control experiments were 
clear with no non-specific staining (J-L).  In contrast to sample MYO3 cells were 
not formed in loose aggregates with additional scattered staining throughout the 
section.  In  sample  MYO5  there  was  a  large  endomysial  infiltrate  of  cells 
throughout  the  entire  section  which  did  not  appear  to  aggregate  at  any 
particular region within the muscle biopsy. 
 
Proliferating CD3
+ (B), CD8
+ (D) and CD68
+ (E) cells were observed within the 
sample (Figure 3.8).  No proliferating CD20
+ cells were observed within the 
sections  examined  but  proliferating  cells  were  found  to  be  located  next  to 
CD20
+ cells (Figure 3.8A).  Negative control staining produced no non-specific 
staining. 
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Figure 3.7 Immunohistochemistry of serial muscle sections of Sample MYO5. 
 
A representative example of serial muscle sections from sample MYO5 stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 
(H), FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative 
control  (L)  and  visualised  by  APAAP  and  New  Fuschin  substrate  to  establish 
cellular infiltrates within the muscle section.  Images A – L: 400X 
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Figure 3.8 Double Immunohistochemical staining of serial muscle sections of sample 
MYO5 
 
A representative example of serial muscle sections from sample MYO5 stained for CD20 
(A), CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all 
sections were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the 
type of proliferating cells within the myositis sample to be identified.  Images were taken at 
630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 120 
3.2.4 Sample MYO6 
In sample MYO6 there was no extensive region of cellular infiltration.  Cells 
present  within  the  sample  appear  to  surround  the  muscle  fibres  in  an 
endomysial pattern (Figure 3.9).  Immunohistochemistry experiments produced 
largely diffuse areas of staining but some of the cells stained were identified as 
CD20
+  (A)  cells  in  addition  to  CD3
+  (D),  CD4
+  (E)  and  CD8
+  (F)  cells.    No 
staining was observed for FDCs (B) but plasma cells (C) were evident amongst 
the infiltrating cells.  No proliferating cells (G) were evident within this area of 
aggregation in sample MYO6; a few proliferating cells were observed in other 
areas of infiltration.  There was a large infiltration of CD68
+ (H) cells within the 
sample.  FoxP3
+ (I) cells were not present. Negative control isotype antibodies 
produced no non-specific staining (J-L). 
 
Although few proliferating cells were present within sample MYO6, those that 
were present appeared to be CD68
+ cells (Figure 3.10E).  No other proliferating 
cell type was observed in the serial sections analysed of sample MYO6.  As 
with the previous staining experiments no non-specific staining was present. 
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Figure 3.9 Immunohistochemistry of serial muscle sections of Sample MYO6. 
 
A representative example of serial muscle sections from sample MYO6 stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H), 
FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative control 
(L)  and  visualised  by  APAAP  and  New  Fuschin  substrate  to  establish  cellular 
infiltrates within the muscle section.  Images A – L: 400X 
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Figure 3.10 Double Immunohistochemical staining of serial muscle sections of sample 
MYO6  
 
A representative example of serial muscle sections from sample MYO6 stained for CD20 
(A), CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all 
sections were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the 
type of proliferating cells within the myositis sample to be identified.  Images were taken at 
630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 123 
3.2.5 Sample MYO7 
 
Immunohistochemical  staining  of  sample  MYO7  (Figure  3.11)  demonstrated 
that infiltrating cells were present throughout the entire section, between muscle 
fibres,  but  did  appear  to  form  approximately  three  regions  of  aggregation, 
although some of these areas appeared to be damaged during section cutting.  
Within the cellular infiltrates very few CD20
+ (A) cells or FDCs (B) were present.  
A large proportion of the cells were identified as plasma cells (C) or CD4
+ (E) 
cells.  The number of cells observed using the CD4 marker appeared to be 
greater than that observed for both CD3
+ (D) and CD8
+ (F) cells, as observed in 
sample MYO3.  There was a large infiltrate of CD68
+ (H) cells present within 
sample  MYO7.    Very  few  Ki67
+  (G)  cells  were  present  with  no  evidence  of 
FoxP3
+  (I)  cells.    Negative  control  experiments  were  clear  from  non-specific 
staining (J-L).   
 
Double staining experiments showed that the proliferating cells present within 
the muscle sample were CD3
+ (B), CD8
+ (D) and CD68
+ (E) cells (Figure 3.12).  
Occasionally a proliferating CD4
+ (C) cell was observed throughout the section.  
Negative control staining was clear. 
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Figure 3.11 Immunohistochemistry of serial muscle sections of Sample MYO7. 
 
A  representative  example  of  serial  muscle  sections  from  sample  MYO7  stained  for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H), 
FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative control 
(L) and visualised by APAAP and New Fuschin substrate to establish cellular infiltrates 
within the muscle section.  Images A – L: 400X 
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Figure 3.12 Double Immunohistochemical staining of serial muscle sections of sample 
MYO7  
 
A representative example of serial muscle sections from sample MYO7 stained for CD20 
(A), CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all 
sections were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the 
type of proliferating cells within the myositis sample to be identified.  Images were taken at 
630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 126 
3.2.6 Sample MYO16 
 
Within sample MYO16 three main regions of perimysial/perifascicular cellular 
infiltration  were  observed  with  additional  scattered  infiltration  (Figure  3.13).  
Although  infiltrates  were  largely  focused  at  the  fascicle  edges,  a  number  of 
individual  muscle  fibres  at  one  area  of  aggregation  were  surrounded  by 
infiltrating  cells.    One  of  the  main  regions  of  cellular  infiltration  displayed 
considerable  CD20
+  (A),  CD3
+  (D),  CD4
+  (E)  cells  and  plasma  cell  (C) 
infiltrates, as well as Ki67
+ (G) cells with reduced cellular CD8
+ (F) staining in 
comparison to other cell types.  The CD20
+ cells formed a very dense follicle of 
cells  situated between  muscle fibres.    In  other  regions  the  infiltrating  CD20
+ 
cells were more loosely aggregated.  A large infiltration of CD68
+ (H) cells was 
also present within sample MYO16.  These cells types were evident within the 
regions of aggregation but were also dispersed throughout the entire section.  
No FoxP3
+ (I) cells or FDCs (B) were present within the infiltrating population.  
This  pattern  of  infiltration  was  observed  in  the  other  regions  of  cellular 
aggregation but there was a reduction in the presence of CD20
+ cells in the 
other  regions  compared  to  that  observed  in  the  region  mentioned  above.  
Negative  control  stains  with  appropriate  isotype  controls  produced  no  non-
specific staining (J-L).  
 
Identification of the proliferating cells by double staining identified the Ki67
+ cells 
as  CD3
+  (B),  CD4
+  (C),  CD8
+  (D)  and  CD68
+  (E)  cells  (Figure  3.14).    No 
proliferating  CD20
+  (A)  cells  were  observed  in  serial  sections  of  the  sample 
although the large areas of aggregation observed within immunohistochemistry 
experiments, Figure 3.13, could not be located in the later sections used for the 
immunofluorescence  experiments.    As  previously  described  no  non-specific 
staining was observed within the sample. 
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Figure 3.13 Immunohistochemistry of serial muscle sections of Sample MYO16. 
 
A  representative  example  of  serial  muscle  sections  from  sample  MYO16  stained  for 
CD20  (A),  FDC  (B),  Plasma  cells  (C),  CD3  (D),  CD4  (E),  CD8  (F),  Ki67  (G),  IgG1 
Negative control (H), IgG2a Negative control (I), IgM Negative control (J) and visualised 
by APAAP to establish cellular infiltrates within the muscle section.  Images A – J 400X 
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Figure 3.14 Double Immunohistochemical staining of serial muscle sections of sample 
MYO16  
 
A representative example of serial muscle sections from sample MYO16 stained for CD20 
(A), CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all 
sections were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the 
type of proliferating cells within the myositis sample to be identified.  Images were taken at 
630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 129 
3.2.7 Sample MYO17 
 
Identification  of  cellular  infiltrates  within  sample  MYO17  showed  many  small 
areas of aggregation as well as scattered areas of cellular infiltration throughout 
the section at endomysial locations.  One extensive area of cellular infiltration 
between  muscle  fibres  was  observed  within  sample  MYO17  (Figure  3.15). 
CD3
+ (D), CD4
+ (E) cells and plasma cells (C) dominated the cellular infiltrate 
with positive but reduced numbers of CD8
+ (F) cells.  Very few CD20
+ (A) cells 
or FDCs (B) were observed within the sample in comparison to CD3
+, CD4
+ and 
plasma  cell  staining.    Proliferating  Ki67
+  (G)  cells  were  present  within  the 
sample  as  well  as  a  large  infiltrate  of  CD68
+  (H)  cells.    FoxP3
+  (I)  staining 
showed the presence of an occasional positive cell.  Some light diffuse staining 
was observed with the negative control isotype antibodies but the staining for 
cell markers are clearly specific due to the differences in staining intensity (J-L). 
 
Proliferating cells were shown to include CD20
+ (A), CD3
+ (B), CD4
+ (C), CD8
+ 
(D) and CD68
+ (E) cells (Figure 3.16).  Negative control experiments with the 
antibody isotype controls showed no non-specific staining within sections.   
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Figure 3.15 Immunohistochemistry of serial muscle sections of Sample MYO17. 
 
A representative example of serial muscle sections from sample MYO17 stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H), 
FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative control 
(L) and visualised by APAAP and New Fuschin substrate to establish cellular infiltrates 
within the muscle section.  Images A – L: 400X 
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Figure 3.16 Double Immunohistochemical staining of serial muscle sections of sample 
MYO17  
 
A representative example of serial muscle sections from sample MYO17 stained for CD20 
(A), CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all 
sections were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the 
type of proliferating cells within the myositis sample to be identified.  Images were taken at 
630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 132 
3.2.8 Sample MYO19 
 
Numerous small areas of endomysial infiltration were observed within sample 
MYO19 which appeared to vary in cell density, with additional scattered staining 
throughout  the  sample.    As  demonstrated  in  Figure  3.17  all  the  regions 
displayed positive staining for CD20 (A), CD3 (D), CD4 (E), CD8 (F), Ki67 (G) 
cell  markers  and  plasma  cells  (C).    As  previously  observed  in  some  other 
myositis samples no staining was observed for FDCs (B) and CD8 staining was 
reduced in comparison to other cell types.  A large infiltration of CD68
+ (H) cells 
but no FoxP3
+ (I) cells were observed throughout sections examined for this 
sample.  Staining sections with the appropriate negative controls (J-L) identified 
virtually no staining in the regions identified by the other cellular stains. 
 
Double staining identified the proliferating cells within the muscle as a collection 
of  CD20
+  (A),  CD3
+  (B),  CD4
+  (C)  and  CD8
+  (D)  cells  (Figure  3.18).    No 
proliferating CD68
+ (E) cells were observed throughout the sample.  Negative 
control experiments were clear of non-specific staining. 
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Figure 3.17 Immunohistochemistry of serial muscle sections of Sample MYO19. 
 
A representative example of serial muscle sections from sample MYO19 stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H), 
FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative control 
(L)  and  visualised  by  APAAP  and  New  Fuschin  substrate  to  establish  cellular 
infiltrates within the muscle section.  Images A – L: 400X 
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Figure 3.18 Double Immunohistochemical staining of serial muscle sections of sample 
MYO19  
 
A representative example of serial muscle sections from sample MYO19 stained for CD20 
(A), CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all 
sections were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the 
type of proliferating cells within the myositis sample to be identified.  Images were taken at 
630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 135 
3.2.9 Sample MYO23 
 
For sample MYO23 no dense region of cellular infiltration was observed and 
infiltrating  cells  appeared  to  be  in  very  small  numbers  throughout  the  entire 
section between muscle fibres in endomysial locations (Figure 3.19).  Of the 
cells that were present a large proportion were identified as plasma cells (C), 
CD4
+ (E) and CD68
+ (H) cells.  Some of the infiltrating cells were identified as 
CD20
+ (A), CD3
+ (D) and CD8
+ (F) cells as well as FDCs (B).  Some of the 
infiltrating  cells  were  proliferating  with  the  presence  of  Ki67
+  (G)  cells.  No 
FoxP3
+  (I)  cells  were found  within  the  section.   The use of negative  control 
isotype antibodies produced no non-specific staining (J-L). 
 
Double immunohistochemical experiments demonstrated that proliferating cells 
within  sample  MYO23  were  CD3
+  (B),  CD8
+  (D)  or  CD68
+  (E)  cells  (Figure 
3.20).  Negative control experiments were clear of non-specific staining.      
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Figure 3.19 Immunohistochemistry of serial muscle sections of Sample MYO23. 
 
A representative example  of serial muscle sections from sample MYO23 stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H), 
FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative control 
(L) and visualised by APAAP and New Fuschin substrate to establish cellular infiltrates 
within the muscle section.  Images A – L: 400X 
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Figure 3.20 Double Immunohistochemical staining of serial muscle sections of sample 
MYO23  
 
A representative example of serial muscle sections from sample MYO23 stained for CD20 
(A), CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all 
sections were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the 
type of proliferating cells within the myositis sample to be identified.  Images were taken at 
630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 138 
3.2.10 Sample MYO24 
 
For  sample  MYO24  plasma  cells  (C)  and  CD68
+  (H)  cells  dominated  the 
population of infiltrating cells (Figure 3.21).  Diffuse staining was observed for 
CD20
+ cells (A) and FDCs (B) with no clear representation of these cells being 
present  within  sample  MYO24,  although  CD20
+  cells  were  later  identified  in 
immunofluorescent experiments (Figure 3.22).  CD3
+ (D) and CD4
+ (E) cells 
were  evident  within  the  sample.    These  cells  formed  a  few  small  areas  of 
cellular  aggregation  but  additional  cells  were  dispersed  through  the  whole 
section between the muscle fibres.  CD8
+ (F) cells were also present within the 
sample but the staining was reduced in comparison to that of CD3 and CD4 cell 
markers.    Ki67
+  (G)  cells  were  present  within  the  sample  with  also  the 
occasional FoxP3
+ (I) cell.  All negative control staining experiments were clear 
of non-specific staining (J-L). 
 
Identification of the proliferating cells within sample MYO24 by double staining 
showed  that  some  of  the  infiltrating  CD20
+  (A)  and  CD4
+  (C)  cells  were 
proliferating within sample MYO24 (Figure 3.22).  Negative control experiments 
with  the  antibody  isotype  controls  showed  no  non-specific  staining  within 
sections 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 139 
 
       
 
       
 
       
 
       
 
 
 
 
 
 
 
CD20 
A 
FDC  Plasma Cell 
CD3  CD4  CD8 
Ki67  FoxP3  CD68 
B  C 
D  E  F 
G  H  I 
-IgG1 
J 
-IgG2a  -IgM 
K  L 
Figure 3.21 Immunohistochemistry of serial muscle sections of Sample MYO24. 
 
A representative example of serial muscle sections from sample MYO24 stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H), 
FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative control 
(L) and visualised by APAAP and New Fuschin substrate to establish cellular infiltrates 
within the muscle section.  Images A – L: 400X 
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Figure 3.22 Double Immunohistochemical staining of serial muscle sections of sample 
MYO24  
 
A representative example of serial muscle sections from sample MYO24 stained for CD20 
(A), CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all 
sections were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the 
type of proliferating cells within the myositis sample to be identified.  Images were taken at 
630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 141 
3.2.11 Sample MYOC 
 
MYOC  cellular  infiltration  was  observed  throughout  the  entire  section,  in  an 
endomysial pattern, with small areas of aggregation (Figure 3.23).  No FDCs 
(B) were observed within the section and there was very little staining observed 
for CD20
+ (A) cells.  CD3
+ (D) and CD8
+ (F) cells were found within the muscle 
as well as CD4
+ (E) cells but the staining of CD4
+ cells was greater than that 
observed for the CD3 cell marker, similar to that observed in other samples.  
Also present within sample MYOC were CD68
+ (H) and a small number of Ki67
+ 
(G) cells.  For sample MYOC no FoxP3
+ (I) staining was observed within the 
section.    Negative  control  experiments  produced  no  non-specific  within  the 
section (J-L). 
 
Very  few  proliferating  Ki67
+  cells  were  evident  within  sample  MYOC,  the 
phenotype of those that were present could not be identified from the sections 
examined  (Figure  3.24).    Negative  control  experiments  produced  no  non-
specific staining. 
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Figure 3.23 Immunohistochemistry of serial muscle sections of Sample MYOC. 
 
A representative example of serial muscle sections from sample MYOC stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H), 
FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative control 
(L) and visualised by APAAP and New Fuschin substrate to establish cellular infiltrates 
within the muscle section.  Images A – L: 400X 
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Figure 3.24 Double Immunohistochemical staining of serial muscle sections of sample 
MYOC  
 
A representative example of serial muscle sections from sample MYOC stained for CD20 
(A), CD3 (B), CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all 
sections were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the 
type of proliferating cells within the myositis sample to be identified.  Images were taken at 
630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within the sections. 144 
3.2.12 Sample MYOE 
 
Immunohistochemical  staining  within  sample  MYOE  showed  that  there  were 
small  numbers  of  CD20
+  (A)  cells  within  the  cellular  infiltrate  of  the  sample 
(Figure 3.25).  Cells infiltrating the sample were quite diffuse with small areas of 
aggregation which were distributed between the muscle fibres. As with previous 
myositis samples no FDCs (B) were present within the infiltrating population of 
cells but plasma cells (C), CD3
+ (D), CD4
+ (E), CD8
+ (F), Ki67
+ (G), and CD68
+ 
(H)  cells  were  present.    Comparing  the  CD4
+  staining  with  CD3
+  staining 
showed  that  again  there  was  a  slightly  greater  infiltration  of  CD4
+  cells  in 
comparison to that of CD3
+ cells.  FoxP3
+ (I) infiltrating cells were not found 
within the sample.  Non-specific staining was not observed by the use of isotype 
negative control antibodies (J-L). 
 
Double staining experiments identified that some of the proliferating cells were 
CD20
+ (A) cells but a large proportion of the proliferating cells were of other cell 
phenotypes  (Figure  3.26).    CD3
+  (B),  CD4
+  (C)  and  CD68
+  (E)  proliferating 
cells were identified within sample MYOE as were a few CD8
+ (D) proliferating 
cells.  Negative control experiments were clear of non-specific staining.  The 
large  cluster  of  CD20
+  cells  observed  by  immunofluorescent  staining 
experiments  could  not  be  found  in  the  remaining  serial  sections  of  sample 
MYOE to allow for possible microdissection.  
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Figure 3.25 Immunohistochemistry of serial muscle sections of Sample MYOE. 
 
A representative example of serial muscle sections from sample MYOE stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H), 
FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative control 
(L) and visualised by APAAP and New Fuschin substrate to establish cellular infiltrates 
within the muscle section.  Images A – L: 400X 
 146 
 
 
 
 
 
CD3 
CD20 
CD20 
CD4 
CD8 
CD68 
Ki67 
Ki67 
Ki67 
Ki67 
Ki67 
Ki67 
CD20 Ki67 
 
CD20 Ki67 
 
CD3 Ki67 
 
CD4 Ki67 
 
CD8 Ki67 
 
CD68 Ki67 
 
A 
B 
C 
D 
E 
F 
Figure 3.26 Double Immunohistochemical staining of serial muscle sections of sample 
MYOE  
 
A representative example of serial muscle sections from sample MYOE stained for CD20 (A-B), 
CD3 (C), CD4 (D), CD8 (E), CD68 (F) and visualised by Fluorescein Avidin D before all sections 
were stained with Ki67 and visualised by Texas Red Avidin D.  This allowed the type of proliferating 
cells within the myositis sample to be identified.  Images were taken at 630X; Scale Bar represents 
15 µm.  Arrows identify proliferating cells within the sections. 147 
3.2.13 Sample MYO25 
 
Sample  MYO25  was  obtained  from  a  healthy  volunteer  and  was  used  as  a 
control  to  identify  any  infiltrating  cells  within  normal  muscle.    As  shown  in 
Figure 3.27 no cell marker was identified within the normal muscle sections 
apart from the presence of some CD68
+ cells (H).  As very few cell types were 
identified within sample MYO25 and with no Ki67
+ (G) cells found within the 
control section no double staining experiments were conducted. 
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Figure 3.27 Immunohistochemistry of serial muscle sections of Sample MYO25. 
 
A representative example of serial muscle sections from sample MYO25 stained for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H) 
denoted by circle, FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), 
IgM  Negative  control  (L)  and  visualised  by  APAAP  and  New  Fuschin  substrate  to 
establish cellular infiltrates within the muscle section.  Images A – L: 40X 
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3.2.14 Samples MYO2, MYOA, MYOD, MYO18 and MYO21 
 
From the 17 myositis samples included in this study 5 samples did not contain a 
sufficient cellular infiltrate in serial sections that warranted further experiments 
(Figure 3.28).  As the central aim of the work described in this chapter was to 
identify  B  cells  and  plasma  cells  to  allow  Ig  gene  repertoires  and  clonal 
diversification to be established, no further immunohistochemical analysis was 
conducted on these samples after the use of the CD20 and plasma cell markers 
revealed  that  these  cell  phenotypes  were  absent  from  the  inflammatory 
infiltrating population.  For sample MYO2 a large cellular infiltrate was observed 
in the muscle sections although this was very widespread between the muscle 
fibres in an endomysial pattern with no definite areas of aggregation observed.  
No B cells or plasma cells were clearly evident in the infiltrating population, a 
very light diffuse staining was observed while using the CD20 marker but this 
was non-specific and the same diffuse staining was also evident using in the 
negative control experiments.  This may be the result of tissue damage that was 
observed in the sections as a result of tissue sectioning.  Cellular infiltrates were 
also observed in samples MYO18 and MYO21, the degree of infiltration in these 
samples was substantially reduced in comparison to sample MYO2 but areas of 
cellular  aggregation  were  observed.    As  previously  mentioned  no  CD20
+  or 
plasma  cells  were  evident  within  these  samples.  Use  of  additional  cellular 
markers on these samples would have characterised the cellular phenotypes of 
the  infiltrating  population  in  these  samples  but  as  the  aim  of  the  study  and 
central objective of this chapter was to identify B cells and plasma cells these 
experiments were not concluded.  The identification of a cellular infiltrate within 
sample MYO18 is in contrast to the biopsy pathology report (Table 2.2) which 
indicated that no inflammatory infiltrate was observed.  An inflammatory infiltrate 
was  absent  from  the  sections  analysed  for  samples  MYOA  and  MYOD, 
therefore  no  CD20
+  or  plasma  cells  were  found  within  these  samples.    The 
absence of an inflammatory infiltrate in sample MYOA was again in contrast to 
that reported within the biopsy pathology report which did report the presence of 
cells infiltrating the muscle biopsy.  As with MYO18, the sections used in the 
analysis  of  MYOA  were  obtained  from  a  different  depth  of  muscle  tissue 
compared to that used in the initial pathological assessment and may therefore 
account for the differences observed.    150 
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Figure 3.28 Immunohistochemistry of serial muscle sections of samples MYO2, 
MYOA, MYOD, MYO18 and MYO21 
 
A representative example of serial muscle sections from the above samples stained for 
CD20, IgG2a Negative control, Plasma cells and IgG1 Negative control and visualised by 
APAAP  and  New  Fuschin  substrate  to  establish  cellular  infiltrates  within  the  muscle 
section.  From consecutive staining experiments from these serial sections no CD20
+ or 
plasma  cells  were  observed  within  these  sections,  therefore  no  further  analysis  was 
conducted.  Images at 400X. 151 
3.3 Discussion 
Identification and characterisation of B cells and plasma cells within the muscle 
infiltrating inflammatory population of cells was the main objective of the work 
presented in this chapter, this would allow further experiments to establish the 
Ig gene rearrangements expressed on muscle infiltrating B cells and plasma 
cells  and  determine  if  these  cells  were  being  locally  stimulated  within  the 
muscle  by  assessing  the  somatic  hypermutation  and  clonal  diversification 
mechanisms.  As well as these initial experiments to identify B cells, additional 
cell markers and double immunohistochemical experiments were conducted to 
identify and characterise follicular dendritic cells, macrophages, various T cell 
subsets and proliferating cells.  The results of this chapter demonstrate that 
CD20
+ B cells and plasma cells were a substantial part of the muscle infiltrating 
population  but  that  the  infiltration  of  these  cells  as  well  as  the  other  cell 
phenotypes identified was different between patients and myositis subsets. 
 
Characterisation  of  inflammatory  infiltrates  in  different  myositis  subsets  have 
previously been established (87-89;297;298) with continuous studies facilitating 
the classification of muscle infiltrating populations to improve the understanding 
in the role of these cells within the disease mechanisms of the inflammatory 
myopathies.  The current study supports the traditional observations as well as 
implicating additional roles for newly classified cells subsets, based on recent 
studies, of cellular infiltrates within inflammatory myopathies.  Identification of 
proliferating cell phenotypes within the muscle disorders may also indicate the 
active participation of these cells in the pathogenesis of these disorders. 
 
Unlike other studies investigating ectopic germinal centre type responses and 
the  stimulation  of  B  cells  within  the  target  tissues  of  various  autoimmune 
disorders, such as MG (52), SS (283) and RA (284), no characteristic germinal 
centre  type  structures  were  observed  within  this  study.    Previous  studies  in 
muscle  have  not  reported  these  structures  and  infiltrates,  as  previously 
described  in  Chapter  1,  localise  between  or  around  muscle  fibres  either  at 
perivascular, perimysial or endomysial sites depending on the myositis subset.  
Cellular infiltrates within this study were found to either form dense follicles of 
cells or loose aggregations, either perimysial or endomysial depending on the 152 
myositis subset, with no distinct structure or pattern and additional scattered 
staining throughout the entire sample. 
 
In the current study B cells were found to constitute a significant component of 
the inflammatory infiltrate in all samples examined, regardless of the myositis 
subset.  These cells were either in their CD20
+ B cells state or differentiated 
plasma cell state and some of the CD20
+ B cells were found to be proliferating 
within  the  muscle.    The  heaviest  infiltration  of  CD20
+  B  cells  were  found  in 
samples MYO1 and MYO16 corresponding to the diagnosis of these patients 
(Table 2.1).  Both patients had a diagnosis of DM where larger populations of B 
cells are generally found in comparison to PM and IBM, as previously described 
in  Chapter  1.    Although  at  smaller  and  limited  populations,  CD20
+  B  cell 
populations were observed in the majority of the patients who were diagnosed 
as PM and/or IBM.  In 4 of these patients proliferating CD20
+ B cells were also 
observed which may indicate their active participation in an immune response.  
 
In addition to these correlations plasma cells were evident within all samples of 
this study in varying degrees, regardless of the myositis diagnosis implicating a 
role for these variant B cell derived cells within these disorders.  These results 
concur with recent studies further characterising inflammatory infiltrates within 
the  myositis  subsets  as  well  as  microarray  studies  which  identified  Ig 
transcripts,  only  transcribed  in  B  cells  and  their  progeny,  in  IBM  and  PM 
(89;299;300).  Although B cells were identified in DM biopsies in earlier studies 
with very few present in PM and IBM (87;88), plasma cells were not identified in 
these studies for either myositis subset.  The presence of plasma cells within 
inflammatory infiltrates was only recently studied in PM and IBM.  Greenberg et 
al  (89)  identified  few  or  no  B  cells  within  the  infiltrating  cell  repertoire  of 
inflammatory myopathies but did demonstrate the presence of CD138
+ plasma 
cells  in  the  IBM  and PM  samples,  confirmed  by  sequence  analysis  of  Ig  V-
genes expressed by single laser dissected cells.  These studies show that in 
IBM  and  PM  plasma  cells  outnumber  B  cells  by  a  factor  of  4.    A  greater 
infiltration of plasma cells was observed within IBM samples in comparison to 
PM samples.  It was also calculated that IBM had a mean of 0.84 times as 
many  B  cells  and  4.3  times  as  many  plasma  cells  compared  to  untreated 153 
patients with DM.  The numbers of CD138
+ plasma cells were also found to be 
smaller than the number of CD3
+ T cells.  Recent studies have demonstrated 
the  occurrence  of  autoantibodies  in  IBM  reactive  to  a  muscle  constituent 
suggesting the involvement of a humoral immune response (97).  The role of 
these plasma cells in this humoral immune response remains unclear.  Despite 
implicating  the  participation  of  plasma  cells  in  inflammatory  myopathies  the 
study did not show if plasma cell antibody production was a primary effector 
mechanism  for  muscle  damage,  any  antigen  specificity  of  the  response  and 
where the maturation of B cells into these plasma cells occurs.  A question 
therefore  remains  on  the  role  of  these  matured  B  cells  within  inflammatory 
myopathies.  As plasma cells traditionally reside and secrete antibodies from 
the bone marrow (1) the presence of these cells within inflamed muscle may 
suggest an active pathological mechanism in these disorders, but why these 
cells locate to the inflamed muscle remains unresolved.  Further studies would 
establish if non-specific infiltration of these cells occurs due to the formation of a 
suitable niche as a result of the inflammatory reaction, if antigen-specific cells, 
plasmablasts,  are  recruited  and  mature  within  the  inflamed  muscle  or  if 
complete  ectopic  germinal  centre  type  responses  occur  within  the  muscle 
resulting in selection, diversification and maturation of B cells within the muscle. 
 
The  main  objective  of  this  study  was  to  establish  if  B  cell  antigen-driven 
responses were occurring within inflamed muscle, reactions similar to germinal 
centre  responses  characterised  by  Ig  gene  selection,  SHM  and  clonal 
diversification.  For such reactions a population of FDCs would be expected 
similar to that observed in other studies of ectopic germinal centre responses 
(52;283;284) in order for antigen presentation and activation of high affinity B 
cells.  Very few FDCs were identified within the samples of the current study; 
immunohistochemical analysis only identified these cells in 4 myositis patients 
within the study and demonstrated no distinct relationship with other cell types.  
These patients were diagnosed within PM or IBM and not DM where B cells are 
traditionally thought to play a greater role compared to PM and IBM.  These 
findings may implicate that additional cell phenotypes substitute and take over 
the antigen presenting role of FDCs in muscle inflammatory reactions or may 
suggest that antigen-driven, germinal centre responses may not be occurring 154 
within the target tissue of these myositis disorders although somatic mutation 
and  activation  of  autoreactive  B  cells  has  been  found  to  occur  outwith  the 
germinal centre response (301). 
 
While  the  main  intention  of  the  work  presented  in  this  chapter  was  the 
identification  of  B  cells  and  plasma  cells  in  the  muscle,  additional  cell 
phenotypes  were  also  studied  to  examine  the  complexity  of  the  immune 
response.  Within myositis subsets CD8
+ cells are largely found in IBM and PM, 
demonstrating  an  endomysial  pattern  of  infiltration  while  CD4
+  cells  are 
generally characteristic of DM and display a perivascular/perimysial pattern of 
infiltration (87;88).  In this study CD3
+, CD4
+ and CD8
+ cells, some proliferating 
(Ki67
+),  were  found  in  all  autoimmune  disorders  studied  and  generally 
correlated  with  previous  studies.    CD4
+  cells  are  known  to  function  through 
molecular mechanisms during contact with antigen presenting cells, in particular 
activation  and  maturation  of  B  cells  and  production  of  cytokines  while  the 
function of CD8
+, cytotoxic, cells is largely undefined.  These cells induce cell 
death, which is largely absent from muscle biopsies (302), through Fas, perforin 
and granzyme mechanisms.  Perforin has been implicated in the pathogenesis 
of myositis with an increased expression in DM and PM compared to controls 
(85).  In this study an additional subset of infiltrating T cells was examined, 
FoxP3
+ regulatory T cells (Tregs).  The exact mechanisms of these cells are 
unknown  but  they  are  believed  to  play  a  pivotal  role  in  controlling  immune 
responses, maintenance  of T  cell homeostasis  and  controlling  organ-specific 
autoimmune disorders.  This T cell subset has not been extensively studied in 
inflammatory myopathies and the results of this chapter demonstrate that they 
are  largely  absent  from  the  muscle  infiltrating  population.    A  considerable 
infiltration of these cells was only evident in 1 myositis specimen (MYO1, Figure 
3.1) while a limited population were evident in 1 other patient (MYO24, Figure 
3.21).  Studies have occurred within other systems and have suggested that 
regulatory T cells may affect the maturation and antigen presentation capacity 
of DCs (27) and have also been shown to be defective in SLE patients (43).  A 
novel  type  of  regulatory  T  cells,  CD4
+  CD57
+  FoxP3
-,  has  recently  been 
reported  in  germinal  centres  of  human  tonsil  tissues  (303)  and  found  to 
enhance  the  survival  of  GC  B  cells  and  have  suppressive  effects  on 155 
conventional CD4
+ CD57
- T cells; an 80% reduction in cellular proliferation was 
observed.  This collection of results established the dual role of CD4
+ CD57
+ T 
cells  in  promoting  germinal  centre  B  cell  responses  while  suppressing 
conventional T cell responses.  The presence or absence of regulatory T cells 
from inflammatory populations in muscle may play a role in the mechanisms in 
the muscle but additional studies would be required.     
 
Although exact figures of cellular infiltrations were not calculated, some samples 
appeared to have greater staining for CD3
+ and CD4
+ cells in comparison to 
CD8
+  staining,  regardless  of  the  diagnosis.    This  is  in  contrast  to  previous 
studies where a larger population of CD8
+ cells were observed in PM and IBM 
(87;88).  In some cases CD4
+ cells were more abundant than CD3
+ cells which 
is clearly illustrated for samples MYO3 (Figure 3.5), MYO7 (Figure 3.11) and 
MYOC (Figure 3.23).  This correlates with other studies investigating cellular 
infiltrates  in  autoimmune  inflammatory  reactions  (297).    These  studies  have 
demonstrated that these CD4
+ cells may not all be the predicted CD4
+ T helper 
cells and may in fact be plasmacytoid dendritic cells (PDCs) which may be an 
important  component  in  the  myositis  pathological  mechanisms.    While 
conventional or myeloid DCs are potent antigen-presenting cells and assist the 
adaptive immune response, PDCs play an important role in the innate immune 
response and are capable of producing interferon-α/β in quantities 200-1000 
fold  greater  than  other  cell  types  which  stimulates  production  of  intracellular 
proteins capable of providing defence against pathogens (298).  Greenberg et 
al (297) identified and studied CD123
+ BDCA-2
+ IFN-α
+ PDCs in DM muscle 
specimens and implicated these cells to the pathophysiology of DM.  These cell 
types were abundant in 10 of 14 DM patients and were also present in muscle 
sections  that  lacked  inflammatory  cells  with  standard  hematoxylin  and  eosin 
stains in routine clinical histopathological studies.  These immunohistochemical 
results  demonstrate  that  infiltrating  PDCs  are  characteristic  of  DM.    An 
upregulation of 86% of interferon-α and –β inducible genes was also observed 
in DM patients compared to 15% in other inflammatory myopathies in addition 
to the identification of MxA, an interferon-α/β-inducible protein in DM patients.  
These interferon signatures have recently been observed in peripheral blood 
samples of DM patients (304;305) and were also observed in PM patients in 156 
one study (305).  Qualitative analysis of 14 DM patients showed that 13 of these 
patients  produced  greater  expression  of  CD4  compared  to  CD3.   The  study 
showed that there were approximately 5.3 times more CD4
+ cells than CD3
+ 
cells, suggesting that PDCs account for at least 30-90% of CD4
+ cells and they 
outnumber CD4
+ T cells by at least a factor of 2.  More recent studies (306;307) 
identified these cells within the skin of DM patients.  Wenzel et al (306) used 
anti-CD123 monoclonal antibodies and MxA to analyse the PDC infiltrating DM 
skin  lesions  and  established  that  there  was  a  significant  increase  of  MxA 
expression in the epidermis and in the inflammatory infiltrate.  CD123
+ cells, 
with  plasmacytoid  morphology,  were  found  to  heavily  infiltrate  the  DM  skin 
lesions compared to low levels observed in normal samples.  McNiff et al (307) 
also identified PDCs within skin lesions of DM patients and established that this 
pattern was distinct from that observed in lupus erythematosus.  Recently DCs 
have  been  identified  in  IBM,  in  addition  to DM  and PM  (298),  as  well  as  in 
Juvenile  DM  (308).    Greenberg  et  al  (298)  identified  BDCA-1  positive  cells 
(myeloid DCs) in IBM and PM specimens, widely distributed as well as loose 
aggregations of cells.  Loose aggregations of cells were typically endomysial, 
which  surrounded  or  invaded  myofibres.    Very  few  PDCs  (BDCA-2  positive) 
were  observed  in  these  cell  aggregations, myeloid  DC  numbers were  3  fold 
higher than that of PDCs.  Similar numbers of myeloid and plasmacytoid cells 
were observed in perivascular and perimysial locations.  Conversely in DM PDC 
numbers were 16 fold and 3 fold higher than myeloid DCs in endomysial and 
perivascular  sites  respectively.    The  precise  role  of  DCs  in  inflammatory 
myopathies and other disorders has yet to be fully established.  Myeloid DCs 
are generally believed to return to lymph nodes where they present antigen and 
activate,  or  suppress,  helper  T  cells.    PDCs  are  thought  to  have  an 
immunomodulation role but have also been shown to act as antigen presenting 
cells (309) and have been shown to be critical for the generation of plasma cells 
and  antibody  responses  (310),  which  may  play  a  significant  role  in  the 
pathophysiology of inflammatory myopathies.  
 
The PDCs from Greenberg et al (297;298) were characterised as CD4
+, CD68
+, 
CD123
+ and BDCA-2
+ but CD68 was used as a cellular marker for infiltrating 
macrophages within this study therefore no definitive distinction can be made 157 
between the two cellular phenotypes in this study.  Further clarification of these 
cells types, with the use of additional cell markers, would be required to fully 
establish  and  evaluate  the  impact  of  both  cell  phenotypes  on  inflammatory 
myopathies.    Double  immunohistochemical  studies  within  the  current  study 
demonstrated  the  presence  of  proliferating  CD68
+  cells  in  some  myositis 
patients, suggesting an active participation in the immune response.  Previous 
studies  (311)  have  found  increased  numbers  of  proliferating  alveolar 
macrophages  were  observed  in  DM,  PM  patients  as  well  as  in  systemic 
sclerosis patients compared to healthy volunteers.  Recently macrophages in 
the lesion areas of atherosclerosis and RA patients have been found to express 
granzyme  B,  a  cytotoxic  protein  thought  to  contribute  to  muscle  pathology 
commonly found in CD8
+ T cells (312).  A recent study has also demonstrated 
that human B cells can transfer BCR-targeted antigen to human macrophages 
and  that  the  macrophages  were  able  to  capture  B  cell-derived  membrane 
and/or intact intracellular proteins along with the antigen by a mechanism other 
that  phagocytosis  which  is  mediated  by  SR-A,  class  A  scavenger  receptors 
(313).  The study postulates that this transfer of antigen from specific B cells to 
other APCs results in a more focused immune response and may indicate a 
possible immune mechanism within inflamed muscle.   
  
Although  characterisation  of  the  muscle  infiltrating  populations  provides 
valuable insights into inflamed muscle immune reactions, the effects of therapy 
on the inflammatory infiltrates needs to be considered.  Under ideal conditions 
muscle  specimens  would  be  obtained  from  patients  who  had  not  received 
immunomodulatory therapy but as shown in Table 2.1 various patients were 
receiving various therapies at the time of biopsy which may alter the infiltration 
of inflammatory cells in muscle or the degree of muscle pathology observed 
within the specimens.  As described in Chapter 1 statin therapy has been found 
to contribute to muscle pathology (49;69;70), although the mechanism of this 
has not been determined.  Patients MYO24 and MYOC were both receiving 
statin therapy which may impact on the degree of muscle damage as well as 
the degree of cellular infiltration.  The degree of muscle damage observed in 
sample MYO24 was found to exceed the damage observed by statin therapy, 
as  observed  by  the  reporting  pathologist.    Within  the  same  report  the  non-158 
conspicuous  infiltrate  observed  in  this  sample  was  attributed  to  the  steroid 
therapy, 120 mg prednisolone intra-muscular injection.  Corticosteroid therapy 
suppresses  both  cell-mediated  and  humoral  immunity.    In  humoral  immunity 
corticosteroids have been shown to reduce Ig concentrations (314;315) as well 
as influence the function of various cell phenotypes including PDCs and T cells 
(316).  The use of steroid therapy could reduce or alter the cellular infiltrates 
observed  within  muscle  inflammation  and  alter  the  true  heterogeneity  of  the 
immune reactions.  In this study 8 patients (MYO 5, 19, 23, 24, C, E, 2, 18) 
were receiving steroid therapy at the time of biopsy.  Despite the influence of 
therapy significant inflammatory infiltrates, in particular B cells and plasma cells 
were observed in a number of these samples (MYO5, 19, 23, C, E).  Other 
immunosuppressive  therapies,  such  as  methotrexate,  may  also  disguise  the 
true heterogeneity of the response.  Underlying medical conditions and family 
history may also play a role in the results presented in this chapter.  3 of these 
patients (MYO3, 24, D – Table 2.1) had underlying carcinomas while patient 
MYO19  was  treated  for  inflammatory  synovitis.    Patient  MYO5  also  had  a 
background of Sjögrens syndrome and a strong family history of autoimmune 
disease  which  may  come  into  play  while  assessing  the  mechanism  of  the 
muscle inflammation observed within such patients.  A final consideration would 
be  the  area  selected  for  biopsy,  due  to  the  large  area  affected  by  the 
inflammation and the small specimen obtained for diagnosis and these studies, 
considerable difference may be observed between different muscle sites.      
  
To summarise, the work presented in this chapter demonstrates that B cells and 
their  differentiated  counterpart’s  plasma  cells  are  substantial  within  the 
infiltrating inflammatory population of myositis disorders.  The characterisation 
of proliferating B cells may indicate the active participation of these cells in the 
muscle response.  B cells and plasma cells were identified in association with a 
number  of  additional  cell  phenotypes,  illustrating  the  complexity  of  immune 
reactions within muscle.  The identification of B cells and plasma cells within 
these samples allowed further work to be conducted to determine if B cells play 
an active role in antigen-driven responses within the inflamed muscle.     159 
Chapter  4  -  VH-Gene  Repertoire  and  Clonal  Diversification  of  Muscle 
Infiltrating B Cells in Myositis 
4.1 Introduction 
As previously discussed in Chapter 1, the role of B cells and plasma cells, and 
the  antibodies  they  produce,  in  the  autoimmune  disease  of  myositis  is  still 
unresolved although B cells have been thought to contribute to the pathological 
immune  response  at  these  sites  of  inflammation.    The  work  conducted  in 
Chapter 3, in addition to previously published work, classified the phenotypes of 
infiltrating cells in the inflammatory reactions of myositis of which B cells, and 
their  differentiated  counter-parts  plasma  cells,  were  prominent.    Despite  the 
presence  of  these  cells  within  the  inflammatory  infiltrate  no  characteristic 
germinal  centre  formations,  the  typical  sites  of  somatic  hypermutation  and 
clonal  diversification,  were  observed  at  these  ectopic  sites.    What  remains 
unclear is the role of these B cells and plasma cells within the inflammatory 
infiltrate; therefore the work of this chapter aims to establish a role for these 
cells  within  myositis  samples.    To  determine  if  infiltrating  lymphocytes  were 
being stimulated locally to respond to an endogenous antigen resulting in tissue 
damage, areas of significant B cell and plasma cell infiltration established in 
Chapter 3 were microdissected from tissue sections.  The rearranged Ig gene 
amplification from the DNA of these cells was used to address the following key 
aims of the chapter; 
 
·  Establish the Ig gene repertoire of infiltrating B cells and plasma cells to 
determine if positive, or negative, gene selection was occurring within 
infiltrating cells. 
·  Analyse VH gene point mutations (number, location and category) to 
establish  if  clonally  related  B  cells,  with  shared  VDJ  and  CDR3 
sequences,  are  present  within  the  muscle  inflammatory  infiltrate 
undergoing an antigen-driven B cell response. 
 
For the results of this chapter the patients were studied individually in addition 
to collective myositis analysis.     
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4.2 VH Repertoire and Sequence Analysis in Myositis 
4.2.1 Sample MYO1 
4.2.1.1 VH Gene Repertoire of Infiltrating B Cells from MYO1 
B cell aggregates from frozen sections from sample MYO1 were microdissected 
and the Ig rearrangements were amplified by nested PCR (Figure 4.1), cloned 
and  sequenced.    Over  150  sequences  were  analysed  from  the  6  different 
regions of cellular infiltration observed and the best matching germline genes 
were  identified  (Table  4.1).    The  gene  usage  distribution  of  functional  gene 
rearrangements was analysed from 57 sequences as multiple copies of genes 
arose  within  the  same  regions  of  cellular  infiltration  (Figure  4.2).    Using 
absolute values in Chi square analysis, significant selections were observed for 
VH2 and VH3 genes against the normal control values (Figure 4.2A). No other 
selections  were  observed  against  normal  control  values  or  the  germline 
composition.    Despite  the  selection  for  VH2  and  VH3  genes,  the  VH  gene 
distribution  followed  the  distribution  pattern  of  that  described  in  the  normal 
control data, VH3>VH4>VH1>VH2>VH5>VH6>VH7 (251).  DH gene assignments 
were conducted as described in section 2.3.12.3, V-J lengths and consecutive 
D match lengths are shown in Table 4.1.  DH genes could be assigned to 66.7% 
of the sequences isolated from sample MYO1.  Comparing the distribution of 
these genes to both the normal control values and the germline composition 
demonstrated that there was no selection for or against any DH gene families 
(Figure 4.2B).  Selections against JH1 and JH2 genes were observed within the 
sequences (Figure 4.2C), but these were only significant against the germline 
composition.  Analysis of the JH gene usage compared to normal control values 
revealed  no  positive  or  negative  JH  gene  selections  within  the  infiltrating 
repertoire.    
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Before Microdissection  After Microdissection 
A 
B 
C 
400 bp 
400 bp 
VH1  VH2  VH3 
VH4  VH5  VH6 
_  MYO 
1  +  _  MYO 
1  +  _  MYO 
1  + 
Figure 4.1 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample MYO1 
 
Six areas of B cell and plasma cell infiltration were microdissected from sample MYO1.  
Figure  4.1A  and  B  demonstrates  the  microdissection  of  2  regions  of  cellular  infiltration.  
Images  were  taken  at  400X.    DNA  released  from  these  microdissections  was  amplified 
using  a  Nested  PCR  system  (Figure  4.1C),  as  previously  described  in  Chapter  2.    – 
indicates negative control PCR reactions where DNA was substituted with water while + 
indicates positive control PCR reactions using peripheral blood mononuclear cells isolated 
from peripheral blood of a healthy individual.  Results show amplification of all 6 VH families. 162 
Region  VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches)  
1  1-46*01  3-10*01  5*02  1  1  ARSVWFRELLEVQNWFDP  33  18(+1) 
  3-07*01  No D gene 
Assignment  6*02  1  12  AREGKEGYGMDV  12  10(+3) 
  3-23*01  5-12*01  3*02  1  0  AKGGGYDWGDDAFDI  24  12 
  3-30*04  4-17*01  3*02  1  11  AKDFGYDYGDYLYDAFDI  34  16 
  3-43*01  3-10*01  5*02  (1)  1  AKDPYSGSYYATGST  28  22 
  3-48*01  3-22*01  3*02  (1)  0  ARGSMVL**WDLI  27  12 
  3-66*01  No D gene 
Assignment  6*02  1  0  ARERALYYYGMDV  10  5 
  4-39*01  No D gene 
Assignment  4*02  1  0  ARHGLSEPYQQPPGYRFDY  40  12(+3) 
  4-59*01  3-22*01  5*02  (1)  0  ARA*TYYYDSSGYYSTTGST  38  29 
  4-59*01  6-13*01  6*02  1  2  ARHGKKQQLTRNYYYGMDV  28  11 
  5-51*03  No D gene 
Assignment  6*02  1  27  VRHAPYYFYGMDV  22  5 
                 
2  3-09*01  6-13*01  4*02  (1)  0  AKDIPF*GIAAAGTLPPPGTS*L  53  20 
  3-33*01  3-22*01  4*02  4  10, 11, 11, 12  AREFYDTSGYWEDC  33  19(+1) 
  4-59*01  1-1*01  5*02  1  0  ARVLYNWNGGFGRFDP  30  13 
                 
3  3-30*04  No D gene 
Assignment  3*02  (1)  29  AIDRLAG*  17  7 
  3-30*04  No D gene 
Assignment  4*02  4  11, 12, 12, 14  ARDRRGGWEGYFDY  21  6 
  3-30*04  No D gene 
Assignment  4*02  (1)  13  ARDRGGGMGGLL*L  22  8 
  3-30*04  No D gene 
Assignment  6*01  1  11  ARDR  3  6 
  3-30*04  No D gene 
Assignment  6*01  1  11  ARDRRGG  13  6 
                 
4  2-05*01  No D gene 
Assignment  2*01  1  0  AHSRARLEGYFDL  17  6 
  3-07*02  6-19*01  6*02  2  12, 13  ARDLGSSGWHVNPEMFYYHAMDV  54  13 
  4-04*02  No D gene 
Assignment  4*02  1  19  ARGQLGNFDS  22  8 
  4-31*03  3-22*01  5*01  1  8  ARGNYDMTSDS  20  9 
  5-a*01  4-23*01  5*01  1  10  ARHGADYGGNPEGFDS  31  15 
                 
5  1-46*01  1-26*01  4*02  1  0  ARTRIVGATRSIDY  32  18 
  1-69*04  1-26*01  4*03  1  0  ARTRIVGATRSIDY  32  18 
  1-69*04  3-16*02  4*02  1  0  ARDVWEIFGSGSYPYFDY  34  10 
  1-69*09  3-16*02  4*02  1  0  ARDVWEIFGSGSYPYFDY  34  10 
  2-05*10  1-1*01  5*02  2  20, 21  AHRLGGYSWNDGWFDP  31  14(+1) 
  2-05*01  No D gene 
Assignment  6*02  2  7, 8  ARREFSWGMDV  17  7 
  3-15*01  3-10*01  4*02  4  11, 12, 13, 13  TTDTRPRLGEFFYFWVGYFDP  54  10 
  3-23*01  No D gene 
Assignment  6*02  2  33, 44  VKNSGSGKPYYYAMDV  37  7 
  3-30*03  6-19*01  4*02  2  0, 1  AFSDNSGYHN  25  11(+1) 
  3-30*04  3-3*01  4*02  2  0, 1  ARDVHDFWSGYHFDY  26  19 
  3-48*02  2-21*01  3*02  1  0  ARDYPDCGGDCSPYDAFDI  33  18 
  3-66*01  2-21*01  3*02  2  26, 31  ARDYPDCGGDCSPYDAFDI  33  18 
                 
Cont… 163 
Region  VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
6  1-08*01  2-8*02  6*02  1  0  ARGRYCTGGVCYRDASYYYYGMDV  42  27 
  1-18*01  No D gene 
Assignment 
6*02  1  15  ARTQTPDLYAIFGHYYGMDV  40  10(+1) 
  2-05*01  3-3*01  4*02  (1)  12  AHILAYYDFCSA*SPLLALT  54  15 
  3-11*03  4-17*01  6*02  2  0, 1  ARDKPYGDSRNNWYYYYYGMDV  33  11 
  3-23*01  1-26*01  4*02  1  0  AKDEGWVVGATKAPFDY  33  15 
  3-30*03  6-19*01  4*02  1  0  AKLGSYNSGRDY  25  11 (+1) 
  3-49*03  2-2*01  4*02  1  17  TRGNHLYCSSHSCYWDS  48  21(+4) 
  4-b*02  No D gene 
Assignment  5*02  1  14  ARDDLPIRFDP  16  5 
  4-04*02  No D gene 
Assignment 
4*02  1  5  ARVTTGFFFDY  18  7 
  4-59*01  5-12*01  5*02  1  17  ARQGTVGSAYSGSDP  35  14(+1) 
  4-59*01  6-19*01  6*02  1  5  ARRRGGWYSSGHRGNYGMDV  37  14 
 
 
 
 
 
 
In  addition  to  determining  the  gene  assignments  using  the  JOINSOLVER 
software,  the  IMGT/V-QUEST  algorithm  was  also  used  to  verify  the  gene 
assignments for this sample as well as all other samples in the study.  For the 
majority  of  sequences  the  gene  assignments  matched  the  JOINSOLVER 
software but in some cases IMGT/V-QUEST determined a different match for 
part of the gene rearrangement or detected deletions or insertions within the 
sequence  altering  the  gene  assignment  (Appendix  1).    In  cases  where 
JOINSOLVER was unable to assign a D gene with statistical significance the 
region was also examined using the IMGT/V-QUEST software but no additional 
D  gene  assignments  could  be  made  with  confidence.    In  contrast  to 
JOINSOLVER, IMGT/V-QUEST failed to find a rearrangement for the sequence 
in region 3 using VH3-30*04 (CDR3-ARDRRGG) and was only able to identify 
the same VH gene segment.  Also in region 3 with another Ig using the VH3-
30*04  (CDR3-ARDR)  IMGT/V-QUEST  categorised  this  sequence  as  non-
functional and was not able to identify any D gene segments.  In region 5 for the 
Ig  using  the  VH1-69*09  DH3-16*01  JH4*02  rearrangement  IMGT/V-QUEST 
assigned the D gene as 3-10*01 which was the 2
nd highest matching score in 
Table 4.1 Heavy chain genes identified from myositis sample MYO1 
 
Best matching germline sequences were identified from aligning sequences in the IMGT database 
using  JOINSOLVER  software  from  regions  1  to  6  within  the  MYO1  myositis  section.    The  total 
number of sequences isolated is given in the 5
th column of the table; non-functional rearrangements 
indicated in brackets.  Identical sequences with the same VH, DH, JH, CDR3 and base mutations were 
only  counted  once.    CDR3  amino  acid  sequences  were  also  identified  using  the  JOINSOLVER 
software; * indicates the presence of a stop codon within the CDR3. V-J lengths and consecutive D 
match lengths (bp) were also identified using the JOINSOLVER software and allowed assignment of 
the DH genes as described in section 2.3.12.3.    164 
JOINSOLVER but DH3-16*01 had a higher consecutive match.  If mismatches 
were incorporated into the analysis of the DH3-10*01 gene it would have a D 
consecutive match length of 14 with 1 mismatch which may therefore indicate 
that the DH3-10*01 gene should be assigned although no mismatch analysis 
had to be conducted on the DH3-16*01 gene for it to be statistically assigned.  
The DH3-16*01 gene was not identified in the top 5 matched using the IMGT/V-
QUEST software.  Also IMGT/V-QUEST assigned the JH segment as 2P*01 but 
also suggested the gene segments of 6*01 and 6*02, these genes were found 
to be outwith the 6 best matching genes in JOINSOLVER with the 6*01 and 
6*02 genes generating negative alignment scores.  The 4*02 gene segment 
identified by JOINSOLVER was the 4
th best matching gene in IMGT/V-QUEST.  
For  the  Ig  rearrangement  VH3-15*01  DH3-10*01  JH4*02  in  region  5  both 
JOINSOLVER and IMGT/V-QUEST identified two JH genes that could possibly 
be  assigned  to  the  rearrangement,  4*02  and  5*02.    In  JOINSOLVER  and 
IMGT/V-QUEST the 4*02 gene had a score of 195 while the 5*02 gene had a 
score of 192.  Although the 5*02 gene had a greater number of consecutive 
matches  both  sequences  exhibited  a  higher  number  of  germline  matches 
therefore either gene could be assigned, mismatches could be interpreted as 
mutations.  Insertions and deletions were detected in Ig rearrangement VH3-
23*01 DH3-10*01 JH6*02 with 44 mutations.  Once these had been resolved the 
gene rearrangement was revealed to be non-functional in IMGT/V-QUEST with 
the same gene assignments but with 34 mutations. 33 of these mutations were 
common between this sequence and the other sequence with the same gene 
rearrangement  shown  in  Table  4.1  but  an  additional  silent  mutation  was 
observed  in  codon  88  at  the  3
rd  nucleotide  position.    A  deletion  was  also 
detected in the CDR2 for both sequences with the VH3-66*01 DH2-21*01 JH3*02 
in  region  5.    Once  the  deletions  had  been  restored  the  Ig  rearrangement 
obtained  was  VH3-48*02  DH2-21*01  JH3*02  in  both  the  JOINSOLVER  and 
IMGT/V-QUEST  software  although  IMGT/V-QUEST  also  determined  the  JH 
segment may also be assigned as JH6*02 which exhibited a higher consecutive 
match in IMGT/V-QUEST.   These sequences contained 1 and 11 mutations 
with no common mutations between the sequences.  
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Figure 4.2 VH Gene Family Usage of MYO 1 
 
VH gene family usage.  Distribution of functional genes was compared with published normal 
control values from Volpe and Kepler (251) as well as the germline complexity assuming every 
germline gene is capable of producing a functional rearrangement.  Absolute values were used 
in Chi Square Analysis to determine gene selections.  § represent a significant difference from 
normal control values; * represent a significant difference from the germline (p<0.05).  
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4.2.1.2 Mutational Analysis of B Cell Ig Sequences of Sample MYO1 
Numbers  of  mutations  within  the  VH  gene  segment  of  the  functional  gene 
rearrangements  were  analysed  (Figure  4.3A).    Results  demonstrate  that 
approximately 30 to 40% of sequences are virtually non-mutated with only 0 to 
2 mutations within the VH segment of the gene rearrangement while a further 30 
to  40%  contains  11  to  20  mutations  within  the  VH  segment.    Sequences 
containing 3 to 10 and over 20 mutations were found in approximately 10% of 
the infiltrating cells respectively.  In addition to mutational numbers, the location 
of  mutations  was  analysed  between  Framework  regions  (FR)  and 
Complementarity  Determining  Regions  (CDR)  regions  (Figure  4.3B).    The 
number of mutations in each segment was expressed as a percentage of the 
total  length  of  the  segment.    Results  demonstrate  a  higher  percentage  of 
mutations within CDR regions compared to framework regions for rearranged 
genes.  A higher percentage of mutations were observed in CDR1 compared to 
CDR2. 
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The type of mutations, replacement and silent, in the VH gene segment of the 
immunoglobulin gene were also analysed (Table 4.2), according to the revised 
method by Hershberg et al (294) described in section 2.3.12.3.  This updated 
A 
B 
Figure 4.3 Numbers of Mutations and 
Mutational  Distribution  of  Functional 
Sequences in MYO1 
 
Figure 4.3A - The number of mutations 
within functional rearranged genes were 
analysed collectively from all 6 regions of 
cellular  infiltration.    Base  differences 
within  the  first  24  bases  of  sequence 
were  disregarded  as  this  part  of  the 
sequence binds the 5’ VH primer.  Graph 
demonstrates  sequences  within  cellular 
infiltrates  show  a  diverse  distribution  of 
mutational numbers. 
 
 Figure 4.3B - The locations of mutations 
observed  within  functional  rearranged 
genes were categorised as being within 
FR  or  CDR  regions.    The  numbers  of 
mutations  within  these  regions  were 
expressed as a percentage of the entire 
length  of  the  region  to  correct  for  the 
longer  lengths  observed  within  the 
framework regions.  Graph demonstrates 
a higher percentage of mutations within 
CDR  regions  compared  to  framework 
regions. 167 
analysis determined if positive or negative mutational selections were occurring 
within each sequence of the infiltrating repertoire.  A significant selection was 
only observed in 8 of the sequences from all 6 regions.  The only sequence 
which demonstrated selection in the CDRs was a non-functional rearrangement 
in region 3; results revealed a negative selection within the CDR.  All remaining 
sequences with a significant selection also demonstrated negative selection but 
in  these  sequences  the  negative  selection  was  observed  in  the  framework 
regions of the sequences. 
 
4.2.1.3 CDR3 Analysis 
Analysis of the VDJ junctional area within the sequences demonstrated that the 
mean  amino  acid  CDR3  length  within  functional  sequences  was  15.3  ±  0.5 
(ranging from 4 to 24 amino acids) which was not significant against the non-
functional repertoire (ranging from 8 to 23 amino acids) (Table 4.3).  The CDR3 
length was also analysed in relation to the number of VH mutations observed 
within the sequence (Figure 4.4). The average CDR3 length was calculated for 
sequences in particular mutational ranges, as previous studies have shown a 
reduced CDR3 length in highly mutated sequences (238).  For this sample no 
significant  changes  in  the  CDR3  length  were  observed  for  the  different 
mutational groups.  The numbers of P and N nucleotides at the VD and DJ 
junctions were also analysed (Table 4.3), from the sequences isolated in this 
sample no significant difference in these nucleotides was observed between the 
functional  and  non-functional  sequences.    There  was  also  no  significant 
difference in the numbers of P and N nucleotides between the VD region of the 
junction  and  the  DJ  region.    Exonuclease  activity  at  the  3’  of  the  VH  gene 
segment  was  shown  to  be  significantly  lower  from  the  5’DH  and  5’JH 
exonuclease activity in the functional repertoire.  No significant differences in 
exonuclease activity between the functional and non-functional repertoires were 
observed at any point of the junction. 
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Region  VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
1  1-46*01  3-10*01  5*02  1  1  0  0  0.47626  -0.52374  0  1  0.674002  -0.326 
  3-07*01  No D gene 
Assignment  6*02  1  12  4  2  0.44397  0.988952  3  3  0.670119  -0.1031 
  3-23*01  5-12*01  3*02  1  0  -  -  -  -  -  -  -  - 
  3-30*04  4-17*01  3*02  1  11  6  0  0.47645  0.141781  3  2  0.672622  -0.7284 
  3-43*01  3-10*01  5*02  (1)  1  0  0  0.45644  0  1  0  0.678704  0.6787 
  3-48*01  3-22*01  3*02  (1)  0  -  -  -  -  -  -  -  - 
  3-66*01  No D gene 
Assignment  6*02  1  0  -  -  -  -  -  -  -  - 
  4-39*01  No D gene 
Assignment  4*02  1  0  -  -  -  -  -  -  -  - 
  4-59*01  3-22*01  5*02  (1)  0  -  -  -  -  -  -  -  - 
  4-59*01  6-13*01  6*02  1  2  0  0  0.44001  -0.31358  0  2  0.656452  -0.118 
  5-51*03  No D gene 
Assignment  6*02  1  27  6  2  0.43118  -0.66779  11  8  0.700775  -0.0924 
                           
2  3-09*01  6-13*01  4*02  (1)  0  -  -  -  -  -  -  -  - 
  3-33*01  3-22*01  4*02  4  10  3  1  0.46759  -0.6274  2  4  0.673935  -0.0473 
          11  3  1  0.46759  -0.44768  2  5  0.673935  -0.0198 
          11  3  1  0.46759  -0.6274  3  4  0.673935  -0.0982 
          12  3  1  0.46759  -0.44768  3  5  0.673935  -0.0453 
  4-59*01  1-1*01  5*02  1  0  -  -  -  -  -  -  -  - 
                           
3  3-30*04  No D gene 
Assignment  3*02  (1)  29  2  3  0.47645  -0.02004  16  8  0.672622  -0.3824 
  3-30*04  No D gene 
Assignment  4*02  4  11  2  3  0.47645  -0.34645  4  2  0.672622  -0.1747 
          12  3  3  0.47645  -0.59353  4  2  0.672622  -0.1747 
          12  2  3  0.47645  -0.22438  4  3  0.672622  -0.0883 
          14  3  3  0.47645  -0.59353  6  2  0.672622  -0.3876 
Cont… 169 
Region  VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
  3-30*04  No D gene 
Assignment  4*02  (1)  13  2  3  0.47645  -0.34645  6  2  0.672622  -0.3876 
  3-30*04  No D gene 
Assignment  6*01  1  11  2  3  0.47645  -0.34645  4  2  0.672622  -0.1747 
  3-30*04  No D gene 
Assignment  6*01  1  11  2  3  0.47645  -0.34645  4  2  0.672622  -0.1747 
                           
4  2-05*01  No D gene 
Assignment  2*01  1  0  -  -  -  -  -  -  -  - 
  3-07*02  6-19*01  6*02  2  12  6  2  0.44221  0.338457  2  2  0.668099  -0.1162 
          13  6  2  0.44221  0.338457  3  2  0.668099  -0.2156 
  4-04*02  No D gene 
Assignment  4*02  1  19  6  2  0.43349  0.8366  6  5  0.665093  -0.1415 
  4-31*03  3-22*01  5*01  1  8  3  0  0.43271  0.253968  4  1  0.653402  0.55407 
  5-a*01  4-23*01  5*01  1  10  1  2  0.45272  -0.1871  4  3  0.702728  -0.1197 
                           
5  1-46*01  1-26*01  4*02  1  0  -  -  -  -  -  -  -  - 
  1-69*04  1-26*01  4*03  1  0  -  -  -  -  -  -  -  - 
  1-69*04  3-16*02  4*02  1  0  -  -  -  -  -  -  -  - 
  1-69*09  3-16*02  4*02  1  0  -  -  -  -  -  -  -  - 
  2-05*10  1-1*01  5*02  2  20  2  2  0.44387  -0.08592  9  7  0.6816  -0.1155 
          21  2  3  0.44387  -0.05531  9  7  0.6816  -0.0652 
  2-05*01  No D gene 
Assignment  6*02  2  7  4  1  0.44837  0.320677  1  1  0.681376  -0.2722 
          8  5  1  0.44837  0.185831  1  1  0.681376  -0.2722 
  3-15*01  3-10*01  4*02  4  11  5  1  0.43976  0.320397  4  2  0.659501  -0.6303 
          12  5  1  0.43976  0.320397  4  2  0.659501  -0.6303 
          13  5  1  0.43976  0.320397  5  2  0.659501  -0.8228 
          13  5  2  0.43976  0.505038  4  2  0.659501  -0.369 
  3-23*01  No D gene 
Assignment  6*02  2  33  9  6  0.45266  -0.45643  9  9  0.650002  -0.0071 
          44  9  6  0.45266  -0.28386  18  11  0.650002  -0.1018 
Cont… 170 
Region  VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
  3-30*03  6-19*01  4*02  2  0  -  -  -  -  -  -  -  - 
          1  0  1  0.46606  -0.53394  0  0  0.674321  -0.3257 
  3-30*04  3-3*01  4*02  2  0  -  -  -  -  -  -  -  - 
          1  0  1  0.476452  -
0.523548 
0  0  0.672622  -
0.327378 
  3-48*02  2-21*01  3*02  1  0  -  -  -  -  -  -  -  - 
  3-66*01  2-21*01  3*02  2  26  12  4  0.46522  0.340486  5  5  0.668169  -0.0208 
          31  15  3  0.46522  0.185352  6  7  0.668169  -0.0193 
                           
6  1-08*01  2-8*02  6*02  1  0  -  -  -  -  -  -  -  - 
  1-18*01  No D gene 
Assignment  6*02  1  15  6  2  0.47674  0.279322  6  1  0.688086  -0.8666 
  2-05*01  3-3*01  4*02  (1)  12  3  2  0.44837  0.807761  6  1  0.681376  -0.8999 
  3-11*01  4-17*01  6*02  2  0  -  -  -  -  -  -  -  - 
          1  1  0  0.47238  0.472384  0  0  0.664488  0 
  3-23*01  1-26*01  4*02  1  0  -  -  -  -  -  -  -  - 
  3-30*03  6-19*01  4*02  1  0  -  -  -  -  -  -  -  - 
  3-49*01  2-2*01  4*02  1  17  5  2  0.44618  0.529547  8  2  0.663604  1.00709 
  4-b*02  No D gene 
Assignment  5*02  1  14  3  0  0.42687  0.474147  9  2  0.653301  0.26984 
  4-04*02  No D gene 
Assignment  4*02  1  5  1  0  0.44897  -0.74359  2  2  0.659438  -0.5379 
  4-59*01  5-12*01  5*02  1  17  4  3  0.44001  -0.18652  2  8  0.656452  -0.0003 
  4-59*01  6-19*01  6*02  1  5  1  1  0.44001  -0.50574  1  2  0.656452  -0.1343 
 
Table 4.2 Analysis of Replacement and Silent Mutations and Positive and Negative Selection in Sample MYO1 
 
Replacement and silent mutations within the immunoglobulin sequences and antigen-driven selection were determined according to Hershberg et al (294) and the corresponding computer 
programme (http://clip.med.yale.edu/selection).  This improved method of analysis uses a focused binomial test to establish positive or negative mutational selections within the sequence 
with high specificity and increased sensitivity accounting for known biases within the immunoglobulin gene sequence.  R-CDR and S-CDR represents the number of replacement and silent 
mutations within the CDR respectively.  pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while 
p-CDR is the p-value of the focused binominal test on the CDR.  Conversely R-FW and S-FW represents the number of replacement and silent mutations within the FW respectively. pFW 
represent the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR while p-FW is the p-value of the focused binominal 
test on the FW.  If the number of R mutations is less than expected the software will test for negative selection and p-values will be preceded by a negative sign or if the number of 
mutations  is  more  than  expected  the  software  will  test  for  positive  selection.    p-values  <0.05  are  highlighted  in  yellow  and  were  deemed  significant  for  selection.171 
 
Functional  15.3 ± 0.5  CDR3 Length 
Non-Functional  16.1 ± 1.9 
  VD Junction  DJ Junction 
Functional  0.6 ± 0.1  0.4 ± 0.1  P Nucleotide 
Non-Functional  1.4 ± 0.7  0.4 ± 0.4 
Functional  8.7 ± 0.8  7.7 ± 0.9  N Nucleotide 
Non-Functional  6 ± 1.5  10.2 ± 4.1 
  3’ VH  5’ DH  3’ DH  5’JH 
Functional  1.2 ± 0.2  5.6 ± 0.8
 θ  4.7 ± 0.5  4.9 ± 0.6
θ  Exonuclease 
Activity  Non-Functional  2 ± 0.7  2.2 ± 1.2  6.2 ± 2.9  4.6 ± 1.6 
 
Table 4.3 CDR3 and Junctional Analysis in Sample MYO1 
 
The mean amino acid length of the CDR3, the mean nucleotide numbers corresponding to P and N 
nucleotides as well as the mean number of germline nucleotides lost due to exonuclease activity 
were calculated from the junctional regions of all immunoglobulin sequences from sample MYO1.  
Results are given as the Mean ± SEM, statistical significance was established using an unpaired t-
test.  Θ represents a significant difference from 3’VH. 
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4.2.1.4 Clonal Diversification in MYO1  
 
Two  clonally  related  sequences  were  identified  in  region  5  of  sample  MYO1 
(Figure 4.5A&B).  These sequences shared the same VDJ gene segments, the 
same  CDR3  amino  acid  sequence,  the  same  junctional  sequences  and  also 
contained  14  common  replacement  mutations  and  8  common  silent  mutations.  
Analysis  of  the  common  and  independent  mutations  (Table  4.4)  of  these  two 
clonally  related  sequences  demonstrated  that  there  was  a  significant  negative 
Figure  4.4  Mean  CDR3  Lengths  in 
Relation to VH Mutational Numbers  
 
The mean  CDR3  length  was  calculated 
for immunoglobulin sequences according 
the  number  of  mutations  within  the  VH 
segment  of  the  gene  rearrangement  to 
establish  any  relationship  between 
mutational  number  and  CDR3  length.  
Results  are  given  as  Mean  amino  acid 
CDR3  length  ±  SEM.    Groups  were 
compared  for  statistical  significance 
using the Tukey-Kramer test for multiple 
comparisons.    The  graph  demonstrates 
that  no  significant  changes  in  CDR3 
length  were  observed  at  the  various 
number  of  mutations.    p-values  <0.05 
would have been deemed significant. 172 
selection within the framework regions of these sequences.  A positive selection 
was  occurring  within  the  CDRs  but  this  was  not  significant.    As  previously 
described, IMGT/V-QUEST detected deletions within these sequences, which not 
only changed the VH gene assignment but also the number of point mutations.  
Taking  the  sequence  alignments  and  changes  suggested  by  IMGT/V-QUEST 
indicates that these sequences would not be clonally related.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Germline3-66*01      GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTC 
CloneA               GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTTAGAGTC  
CloneB               GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTC  
                      
                              CDR1 
Germline3-66*01      TCCTGTGCAGCCTCTGGATTCACCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGCT  
CloneA               TCCTGTGCAGCCTCTGGATTCACTTTCACTAAGGCCTGGATGAACTGGGTCCGCCAGGCT  
CloneB               TCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGGGTCCGCCAGGCT  
                      
                         ↓ AGT    CDR2 
Germline3-66*01      CCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGCACATACTACGCA  
CloneA               CCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTAGTACCATATACTACGCA  
CloneB               CCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTAGTACCATATACTACGCA  
                      
 
Germline3-66*01      GACTCCGTGAAGGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTT  
CloneA               GACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTG  
CloneB               GACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTG  
                    
                                 CDR3 
Germline3-66*01      CAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGA  
CloneA               CAAATGAACAGCCTGAGAGACGAGGACACGGCTGTGTATTACTGTGCGAGAGA 
CloneB               CAAATGAACAGCCTGAGAGACGAGGACACGACTGTGTATTACTGTGCGAGAGA 
 
 
 
 
 
 
 
 
3 (1) 
14 (8) 
A  B 
7 (2) 
VH3-66*01 
Figure 4.5 Clonal Proliferation in Sample MYO1 
 
2 B cell sequences isolated from sample MYO1 demonstrated somatic hypermutation and clonal proliferation 
(A&B).  Figure A - The letters in the circles refer to individual sequences isolated from each B cell clone.  
Numbers indicate the minimum number of mutations required between each sequence with bracketed figures 
representing  additional  silent  mutations.   The  dashed  circle  represents  a  hypothetical  intermediate  whose 
sequence was not found amongst the isolated sequences.  Figure B - The DNA sequences of the clonally 
related sequences were aligned using ClustalW software to highlight the common and independent mutations.  
CDR regions are highlighted in yellow, replacement mutations in blue and silent mutations in purple.  The 
sequence in red above the alignment within the CDR2 regions indicated the deletion detected by the IMGT/V-
QUEST software. 
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Table 4.4 Analysis of Replacement and Silent Mutations and Positive and Negative Selection 
in Clonally Related B Cells in Sample MYO1 
 
The number of replacement and silent mutations and the presence of any positive and negative 
selection were conducted as per Hershberg et al (294) as previously described in section 2.3.12.3 
and Table 4.2.  For clonally related sequences mutations shared across the sequences are only 
counted  once  and  p  values  are  calculated  for  the  clone  as  a  single  entity.  R-CDR/FW  and  S-
CDR/FW  represent  the  number  of  replacement  and  silent  mutations  in  the  CDR  and  FW 
respectively.  pCDR represents the probability of having a R mutation in the CDR given all the 
mutations in the sequence except R mutations within the FW while pFW represents the probability 
of having a R mutation in the FW given all the mutations in the sequence except R mutations within 
the CDR and p-CDR/FW represent the p-value of the focused binominal test on the CDR and FW 
respectively.  A negative sign indicates negative selection.  p-values <0.05 are highlighted in yellow 
and were deemed significant. 
 
 
 
As shown in Table 4.1 a number of sequences demonstrated different mutational 
patterns  but  shared  common  gene  segment  usage  and  CDR3  and  junctional 
sequences;  these  were  not  deemed  to  be  clonally  related  as  the  rate  of  base 
changes fell within the PCR error rate of one base per 4 VH genes (52).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
17  4  0.46522  0.139067  7  7  0.668169  -0.0177 174 
4.2.2 Sample MYO3 
4.2.2.1 VH Gene Repertoire of Infiltrating B Cells  
For  sample  MYO3  one  large  area  of  infiltrating  cells  was  microdissected  and 
amplification of VH1-6 families was carried out by nested PCR (Figure 4.6).  From 
the extensive region of infiltration in sample MYO3 sequence results produced 17 
functional  sequences  (Table  4.5)  which  showed  a  selection  for  VH1  gene 
segments,  approximately  60%  of  the  sequences  isolated  belonged  to  the  VH1 
family, which was significant against both normal control values and the germline 
complexity  (Figure  4.7A).    Figure  4.7A  demonstrates  an  apparent  reduced 
selection for VH3 and VH4 gene segments but this reduction was not significant 
against normal control values or the germline complexity when the absolute values 
were used in the Chi square analysis.  No gene segments were observed within 
the infiltrating repertoire for VH2, VH5, VH6 and VH7 families, similarly this was not 
significant against both sets of control values.  DH genes could be assigned to 
41.2% of the genes from the infiltrating repertoire.  The repertoire of these genes 
almost  mirrors  the  distribution  of  the  normal  control  values  and  the  germline 
complexity (Figure 4.7B); no significant selections were observed within the genes 
isolated from the muscle sections from sample MYO3 except for the selection of 
DH3 genes which were significant against the germline complexity but were not 
significant against the normal control values.  For JH family segments a selection 
for JH5 gene segments was observed which was significant against normal control 
values  but  not  the  germline  complexity  (Figure  4.7C).    No  other  significant 
selections were observed for any other JH gene family within cellular infiltrates of 
MYO3.  
 
Comparing the V, D and J gene assignments from the JOINSOLVER software to 
that  from  the  IMGT/V-QUEST  produced  no  discrepancies  between  the  two 
softwares.  
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Before Microdissection  After Microdissection 
A 
B 
400 bp 
400 bp 
VH1  VH2  VH3 
VH4  VH5  VH6 
_  MYO 
3  + 
Figure 4.6 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample MYO3 
 
The region of B cell and plasma cell infiltration was microdissected from sample MYO3.  
Figure 4.6A demonstrates the microdissection of the region of cellular infiltration.  Images 
were taken at 200X.  DNA released from these microdissections  was amplified using a 
Nested PCR system (Figure 4.6B), as described in Chapter 2.  – indicates negative control 
PCR reactions  where DNA  was substituted  with  water while + indicates positive control 
PCR reactions using peripheral blood mononuclear cells isolated from peripheral blood of a 
healthy individual.  Results show amplification of all 6 VH families. 
_  MYO 
3  +  _  MYO 
3  + 176 
VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
1-03*01  3-22*01  4*02  2  0  ASGDSSGYTLDY  23  14 
        2  ASGDSSGYTLDY  23  14 
1-46*01  No D gene 
Assignment  5*02  2  10  AARVPVDSVMSSDH  39  6 
        11  AARVPVDSVMSSDH     
1-69*01  5-24*01  4*02  1  14  ARDTRRDVYNSGYDY  36  17 (+1) 
1-69*02  No D gene 
Assignment  5*02  1  23  AARVPVDSVMSSDH  39  6 
1-69*04  No D gene 
Assignment  4*02  1  10  ARDSVGGTGY  18  6 
1-69*09  No D gene 
Assignment  4*02  1  22  AARIASGDSSYFDY  27  8 
1-69*09  No D gene 
Assignment  5*02  1  24  AARVPVDSVMSSDH  39  6 
1-69*09  No D gene 
Assignment  4*02  1  25  ANGAAGYYDD  24  5 
3-07*02  2-15*01  6*03  1  15  ARKTGRGGSRPWYNRYYYMDV  39  11 
3-11*03  No D gene 
Assignment  6*02  1  1  ARDLSMVYYYYGMDV  14  5 
3-30*03  No D gene 
Assignment 
4*02  1  18  AKEEEVRSSAPPVFDY  35  8 
3-49*03  No D gene 
Assignment  5*02  1  19  CRYYPSWFDP  30  7 
4-34*12  3-10*01  6*02  1  12  ARGPRNYYRTGRRERDFYYYYGMDV  44  17 (+2) 
4-39*01  1-26*01  4*02  1  5  ARRKARVGASQAFDY  29  11 
4-59*01  3-22*01  2*01  1  12  ARTPYYYDSTGYYYPLVGFDL  47  30(+1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.5 Heavy chain genes identified from myositis sample MYO3 
 
Best matching germline sequences were identified from aligning sequences in the IMGT database 
using JOINSOLVER software from the MYO3 myositis section.  The total number of sequences 
isolated is given in the 4
th column of the table; non-functional rearrangements indicated in brackets.  
Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  
CDR3 amino acid sequences were also identified using the JOINSOLVER software.  V-J lengths 
and consecutive D match lengths (bp) were also identified using the JOINSOLVER software and 
allowed assignment of the DH genes as described in section 2.3.12.3.    177 
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Figure 4.7 VH Gene Family Usage of MYO3 
 
VH gene family usage.  Distribution of functional genes was compared with published normal control 
values from Volpe and Kepler (251) as well as the germline complexity assuming every germline 
gene is capable of producing a functional rearrangement.  Absolute values were used in Chi Square 
Analysis to determine gene selections.  § represent a significant difference from normal control 
values; * represent a significant difference from the germline (p<0.05).  
 
A 
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4.2.2.2 Mutational Analysis of B Cell Ig Sequences of Sample MYO3 
Over 50% of the sequences isolated from sample MYO3 were highly mutated with 
mutational numbers over 11 per sequence (Figure 4.8A), which may indicate the 
infiltration of memory cells.  Just fewer than 20% of sequences were virtually non-
mutated  with  only  0  to  2  per  sequence  indicating  the  presence  of  a  naïve 
population of cells with the remainder of sequences containing between 3 and 10 
mutations throughout the VH segment of the gene rearrangement.  Examining the 
percentage of mutations within framework and CDR regions demonstrates, like the 
previous sample, that there were a higher percentage of mutations within CDR 
regions of gene sequences, with the highest percentage of these mutations found 
within the CDR1 region (Figure 4.8B). 
      
0-2 3-10 11-20 21+
0
10
20
30
40
50
Number of Mutations
%
 
o
f
 
S
e
q
u
e
n
c
e
s
 
      
Framework CDR1 CDR2
0
5
10
15
N
u
m
b
e
r
 
o
f
 
M
u
t
a
t
i
o
n
s
 
(
%
 
o
f
 
L
e
n
g
t
h
)
 
Analysis  of  replacement  and  silent  ratios  in  the  VH  region  were  analysed  as 
previously described.   From 17 sequences significant selections were only found 
within 2 of the sequences; positive selection within the CDR was observed within 1 
of the sequences while negative selection in the FW was observed within the other 
sequence (Table 4.6).  All other positive and negative selections within the CDR 
and regions were not significant.   
Figure 4.8 Numbers of Mutations and 
Mutational  Distribution  of  Functional 
Sequences in MYO3 
 
Figure 4.8A - The number of mutations 
within functional rearranged genes were 
analysed  in  sample  MYO3.    Base 
differences  within  the  first  24  bases  of 
sequence were disregarded as this part 
of the sequence binds the 5’ VH primer.  
Graph  demonstrates  sequences  within 
cellular  infiltrates  show  a  diverse 
distribution of mutational numbers. 
 
 Figure 4.8B - The locations of mutations 
observed  within  functional  rearranged 
genes were categorised as being within 
FR  or  CDR  regions.    The  numbers  of 
mutations  within  these  regions  were 
expressed as a percentage of the entire 
length  of  the  region  to  correct  for  the 
longer  lengths  observed  within  the 
framework regions.  Graph demonstrates 
a higher percentage of mutations within 
CDR  regions  compared  to  framework 
regions. 
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Table 4.6 Analysis of Replacement and Silent Mutations and Positive and Negative Selection in Sample MYO3 
 
Replacement and silent mutations within the immunoglobulin sequences and antigen-driven selection were determined according to Hershberg et al (294) and the corresponding computer 
programme (http://clip.med.yale.edu/selection).  This improved method of analysis uses a focused binomial test to establish positive or negative mutational selections within the sequence 
with high specificity and increased sensitivity accounting for known biases within the immunoglobulin gene sequence.  R-CDR and S-CDR represents the number of replacement and silent 
mutations within the CDR respectively.  pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while 
p-CDR is the p-value of the focused binominal test on the CDR.  Conversely R-FW and S-FW represents the number of replacement and silent mutations within the FW respectively. pFW 
represent the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR while p-FW is the p-value of the focused binominal 
test on the FW.  If the number of R mutations is less than expected the software will test for negative selection and p-values will be preceded by a negative sign or if the number of 
mutations is more than expected the software will test for positive selection.  p-values <0.05 are highlighted in yellow and were deemed significant for selection. 
 
VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number 
of Point 
Mutations 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
1-03*01  3-22*01  4*02  2  0  -  -  -  -  -  -  -  - 
        2  0  0  0.47127  0  2  0  0.70269  0.49377 
1-46*01  No D gene 
Assignment  5*02  2  10  0  0  0.47626  -0.0752  6  4  0.674  -0.6191 
        11  1  0  0.47626  -0.1539  5  5  0.674  -0.2677 
1-69*01  5-24*01  4*02  1  14  7  1  0.44858  0.05775  5  1  0.67095  0.85185 
1-69*02  No D gene 
Assignment  5*02  1  23  9  1  0.46421  0.599  6  7  0.67462  -0.065 
1-69*04  No D gene 
Assignment  4*02  1  10  8  1  0.46613  0.01279  1  0  0.67556  -0.6489 
1-69*09  No D gene 
Assignment  4*02  1  22  6  4  0.4646  -0.6319  7  5  0.67435  -0.0566 
1-69*09  No D gene 
Assignment  5*02  1  24  10  1  0.4646  0.45103  6  7  0.67435  -0.0654 
1-69*09  No D gene 
Assignment  4*02  1  25  8  3  0.4646  0.95751  8  6  0.67435  -0.089 
3-07*02  2-15*01  6*03  1  15  2  2  0.44221  -0.2033  6  5  0.6681  -0.1353 
3-11*03  No D gene 
Assignment  6*02  1  1  0  0  0.47238  -0.5276  0  1  0.66449  -0.3355 
3-30*03  No D gene 
Assignment  4*02  1  18  9  2  0.46606  0.31422  3  4  0.67432  -0.0451 
3-49*03  No D gene 
Assignment  5*02  1  19  9  2  0.44618  0.08515  6  2  0.6636  -0.6685 
4-34*12  3-10*01  6*02  1  12  3  0  0.41289  0.92298  5  4  0.65315  -0.5497 
4-39*01  1-26*01  4*02  1  5  0  0  0.42497  -0.1901  2  3  0.66224  -0.264 
4-59*01  3-22*01  2*01  1  12  2  1  0.44001  -0.3081  4  5  0.65645  -0.1109 180 
4.2.2.3 CDR3 Analysis 
Analysis  of  the  CDR3  in  these  sequences  could  only  be  conducted  within  the 
functional  repertoire  as  no  non-functional  sequences  were  isolated  (Table  4.7).  
For these sequences the mean amino acid CDR3 length was 14.8 ± 1 (ranging 
from  10  to  25  amino  acids).    The  mean  CDR3  lengths  were  also  compared 
between the different mutational groups but no significant differences in the CDR3 
length was observed (Figure 4.9).  Comparison of the P and N nucleotides at the 
VD and DJ junctions were not significant but a significant increase in exonuclease 
activity  was  observed  at  the  5’  of  the  JH  gene  segment  compared  to  the 
exonuclease activity observed a the 3’ end of the VH gene.  No further significant 
differences were observed. 
Functional  14.8 ± 1  CDR3 Length 
Non-Functional  N/A 
  VD Junction  DJ Junction 
Functional  0.9 ± 0.4  0.4 ± 0.2  P Nucleotide 
Non-Functional  N/A  N/A 
Functional  6.9 ± 1.1  9.4 ± 1.7  N Nucleotide 
Non-Functional  N/A  N/A 
  3’ VH  5’ DH  3’ DH  5’JH 
Functional  1.9 ± 0.5  5.1 ± 1.7  5.8 ± 1.4  6.1 ± 0.7
θ  Exonuclease 
Activity  Non-Functional  N/A  N/A  N/A  N/A 
Table 4.7 CDR3 and Junctional Analysis in Sample MYO3 
The mean amino acid length of the CDR3, the mean nucleotide numbers corresponding to P and N 
nucleotides as well as the mean number of germline nucleotides lost due to exonuclease activity 
were calculated from the junctional regions of all immunoglobulin sequences from sample MYO3.  
Results are given as the Mean ± SEM, statistical significance was established using an unpaired t-
test.    Instances  where  no  non-functional  sequences  were  identified  and  values  could  not  be 
calculated were recorded as non applicable (N/A).  Θ represents a significant difference from 3’VH. 
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Figure  4.9  Mean  CDR3  Lengths  in 
Relation to VH Mutational Numbers  
 
The mean  CDR3  length  was  calculated 
for immunoglobulin sequences according 
the  number  of  mutations  within  the  VH 
segment  of  the  gene  rearrangement  to 
establish  any  relationship  between 
mutational  number  and  CDR3  length.  
Results  are  given  as  Mean  amino  acid 
CDR3  length  ±  SEM.    Groups  were 
compared  for  statistical  significance 
using the Tukey-Kramer test for multiple 
comparisons.    The  graph  demonstrates 
that  no  significant  changes  in  CDR3 
length  were  observed  at  the  various 
number  of  mutations.    p-values  <0.05 
would have been deemed significant. 181 
4.2.2.4 Clonal Diversification in MYO3  
Two clonally related sequences from sample MYO3 were observed (Figure 4.10).  
In addition the common VDJ gene segments, CDR3 composition and junctional 
sequences, these clonally related sequences shared 4 replacement mutations and 
3  silent  mutations.    No  other  clonally  related  sequences  were  observed  within 
sample MYO3.  Analysis of the R and S mutations (Table 4.8) showed that there 
was no significant selection observed within the CDR and FW regions although a 
non-significant negative selection was observed in both regions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Germline1-46*01      CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTT  
CloneA               CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTT  
CloneB               CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCGTCGGTGAAGGTT  
                      
                               CDR1 
Germline1-46*01      TCCTGCAAGGCATCTGGATACACCTTCACCAGCTACTATATGCACTGGGTGCGACAGGCC  
CloneA               TCCTGCAAGGCGTCTGGATACACCTTCACCAGCTACTATATGCACTGGGTGCGACAGGCC  
CloneB               TCCTGCAAGGCATCTGGATACACCTTCACCAGCTACTATATGCACTGGGTGCGACAGGCC  
                      
                                    CDR2 
Germline1-46*01      CCTGGACAAGGGCTTGAGTGGATGGGAATAATCAACCCTAGTGGTGGTAGCACAAGCTAC  
CloneA               CCTGGACAAGGGCTTGAGTGGATGGGAATAATCAACCCTAGTGGTGGTAGCACAAGCTAC  
CloneB               CCTGGACAAGGGCTTGAGTGGATGGGAATAATCAACCCTAGTGGTGGTAGCACAGGCTAC  
                      
 
Germline1-46*01      GCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTAC  
CloneA               GCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGCCTAC  
CloneB               GCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTAC  
                     
                   CDR3 
Germline1-46*01      ATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGA  
CloneA               ATGCAGCTGAGCAGCCTGAGTCAGGAGGACACGGCCATATATTATTGTGCAGCCAG  
CloneB               ATGGAGCTGAGCAGCCTGAGTCAGGAGGACACGGCCATATATTATTGTGCAGCCAG  
 
 
 
 
 
 
 
VH1-46*01 
4(3) 
A  B 
2 (1)  2 (2) 
A 
B 
Figure 4.10 Clonal Proliferation in Sample MYO3 
 
Two  B  cell  sequences  isolated  from  sample  MYO3  demonstrated  somatic  hypermutation  and  clonal 
proliferation (A&B).  Figure A - The letters in the circles refer to individual sequences isolated from each B cell 
clone.  Numbers indicate the minimum number of mutations required between each sequence with bracketed 
figures representing additional silent mutations.  The dashed circle represents a hypothetical intermediate 
whose sequence was not found amongst the isolated sequences.  Figure B - The DNA sequences of the 
clonally related sequences were aligned using ClustalW software to highlight the common and independent 
mutations.  CDR regions are highlighted  in  yellow, replacement mutations in blue  and silent mutations in 
purple. 182 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
1  0  0.47626  -0.0904  7  6  0.674  -0.3167 
 
Table 4.8 Analysis of Replacement and Silent Mutations and Positive and Negative Selection 
in Clonally Related B Cells in Sample MYO3 
 
The number of replacement and silent mutations and the presence of any positive and negative 
selection were conducted as per Hershberg et al (294) as previously described.  For clonally related 
sequences  mutations  shared  across  the  sequences  are  only  counted  once  and  p  values  are 
calculated for the clone as a single entity. R-CDR/FW and S-CDR/FW represent the number of 
replacement  and  silent  mutations  in  the  CDR  and  FW  respectively.    pCDR  represents  the 
probability of having a R mutation in the CDR given all the mutations in the sequence except R 
mutations within the FW while pFW represents the probability of having a R mutation in the FW 
given  all  the  mutations  in  the  sequence  except  R  mutations  within  the  CDR  and  p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative 
sign indicates negative selection.  p-values <0.05 were deemed significant. 
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4.2.3 Sample MYO5 
4.2.3.1 VH Gene Repertoire of Infiltrating B Cells  
Biopsy  material  from  patient  MYO5  used  in  this  study  was  a  second  biopsy 
conducted 3 years after the initial diagnostic biopsy due to a flare up of myositis.  
As described in Chapter 3 no well-defined areas of infiltration were observed within 
sections,  cellular  infiltration  was  observed  throughout  the  entire  sample.  
Consequently the whole section was used to establish the gene repertoire used by 
infiltrating B and plasma cells (Figure 4.11).  22 functional gene rearrangements 
were used to establish the gene usage distribution (Table 4.9), multiple copies of 
the same gene were isolated from the repertoire but these were only counted as 
one.  A  selection  against  VH1  gene  segments  and  a  selection  for  VH5  gene 
segments were observed significant against both normal control values and the 
germline  complexity  (Figure  4.12A).  A  difference  of  approximately  20%  was 
observed for each family respectively.  No other gene family displayed significant 
differences between the two sets of control data.  DH genes could be identified in 
40.9% of the sequences isolated from the inflammatory infiltrate in sample MYO5.  
The distribution mirrored the normal control distribution as well as the germline 
complexity  and  no  significant  selections  were  observed for  any DH  gene  family 
(Figure 4.12B).  Similarly no selection was observed for any of the JH gene family 
segments  and  the  repertoire  of  the  inflammatory  infiltrate  mirrored  the  gene 
distribution of normal control values and the germline complexity (Figure 4.12C).   
 
From the sequences isolated from the inflammatory infiltrate in sample MYO5 no 
discrepancies in gene assignment was observed between the JOINSOLVER and 
IMGT/V-QUEST software’s. 
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Figure 4.11 Amplification of VH-gene rearrangements from Sample MYO5 
 
As  no  distinct  aggregation  of  infiltrating  cells  was  observed  within  sample  MYO5  and 
infiltrating cells were observed throughout the whole section, the whole section was used to 
obtain DNA.  DNA released from the section was amplified using a Nested PCR system, as 
described in Chapter 2. PCR reactions were conducted for DNA isolated from the muscle 
sections (Figure 4.11A) in addition to DNA isolated from PBL (Figure 4.11B).  – indicates 
negative control PCR reactions where DNA was substituted with water while + indicates 
positive  control  PCR  reactions  using  peripheral  blood  mononuclear  cells  isolated  from 
peripheral blood of a healthy individual.  Results show amplification of all 6 VH families for 
both types of DNA tested. 
A 
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VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number 
of Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
2-70*04  No D gene 
Assignment  5*02  1  14  SRTYLTNGYDP  26  6 
3-30*04  1-7*01  4*02  2  4, 5  ARGGGYNWTYRVSGYCDS  46  14(+1) 
3-30*04  3-22*01  4*02  1  13  ARDITYSDDDTGGYYYPI  43  25 (+4) 
3-30*04  5-12*01  6*02  2  16, 19  ARGVGGSSGYDLPWYSSYGMDV  43  17(+2) 
3-30*09  No D gene 
Assignment  6*02  1  21  ARDRYSHAYYSGVDV  29  9 
3-30*09  No D gene 
Assignment  6*02  1  21  ARDRYSHAYYSGMDV  28  8 
3-53*01  3-22*01  4*02  2  18, 18  ARDHDANSYYYEGSAY  42  10 
3-72*01  No D gene 
Assignment  5*02  1  17  ARDLNGLGRN  21  8 
3-73*02  No D gene 
Assignment  4*02  1  26  TRWAPKTGGLDY  30  7 
4-34*01  No D gene 
Assignment  4*02  3  25, 27, 28  ARCLMGNYLH  22  6 
4-59*01  No D gene 
Assignment  4*02  1  10  AKGGGDTALLFGN  35  6 
5-51*01  No D gene 
Assignment  3*02  4  12, 25, 31, 
32  ARAKCSAGQCRLPEAFDM  51  8 
5-51*01  6-19*01  4*02  2  4, 5  ARQGRSSGWYWSDFDY  31  16 
Table 4.9 Heavy chain genes identified from myositis sample MYO5 
 
Best matching germline sequences were identified from aligning sequences in the IMGT database 
using JOINSOLVER software from the MYO5 myositis section.  The total number of sequences 
isolated is given in the 4
th column of the table; non-functional rearrangements indicated in brackets.  
Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  
CDR3 amino acid sequences were also identified using the JOINSOLVER software.  V-J lengths 
and consecutive D match lengths (bp) were also identified using the JOINSOLVER software and 
allowed assignment of the DH genes as described in section 2.3.12.3.    186 
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Figure 4.12 VH Gene Family Usage of MYO5 
 
VH gene family usage.  Distribution of functional genes was compared with published normal control 
values from Volpe and Kepler (251) as well as the germline complexity assuming every germline 
gene is capable of producing a functional rearrangement.  Absolute values were used in Chi Square 
Analysis to determine gene selections.  § represent a significant difference from normal control 
values; * represent a significant difference from the germline (p<0.05).  
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4.2.3.2 Mutational Analysis of B Cell Ig Sequences of Sample MYO5 
Mutational numbers within functional rearrangements demonstrated that a highly 
mutated  population  was  present  within  sample  MYO5  which  may  represent  a 
memory  cell  population,  approximately  75%  of  cells  isolated  from  the  muscle 
contained over 11 mutations (Figure 4.13A).  There was a very low presence of 
naïve  cells  within  the  muscle  with  no  sequences  being  isolated  with  0  to  2 
mutations,  all  remaining  sequences  had  between  3  and  10  mutations  per 
sequence.  Analysis of mutation locations demonstrated a higher percentage of 
mutations within CDR regions in comparison to framework regions (Figure 4.13B), 
a higher percentage of mutations was observed within CDR1 regions.  
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Based on the replacement and silent mutations within the sequences (Table 4.10) 
selection was observed in 5 of the 22 sequences isolated from sample MYO5.  
Two of these sequences demonstrated positive selection within the CDR while the 
remaining 3 sequences demonstrated negative selection in the FW regions.  In the 
other  17  sequences  positive  and  negative  selection  were  observed  in  both  the 
CDR and FW region but these selections were not significant. 
A 
B 
Figure  4.13  Numbers  of  Mutations  and 
Mutational  Distribution  of  Functional 
Sequences in MYO5 
 
Figure  4.13A  -  The  number  of  mutations 
within  functional  rearranged  genes  were 
analysed  in  sample  MYO5.    Base 
differences  within  the  first  24  bases  of 
sequence were disregarded as this part of 
the sequence binds the 5’ VH primer. Graph 
demonstrates  sequences  within  cellular 
infiltrates of sample MYO5 do not contain 
any  naïve  cells  and  that  the  population 
within sample MYO5 are highly mutated.  
 
Figure 4.13B - The locations of mutations 
observed  within  functional  rearranged 
genes were categorised as being within FR 
or  CDR  regions.    The  numbers  of 
mutations  within  these  regions  were 
expressed  as  a  percentage  of  the  entire 
length of the region to correct for the longer 
lengths  observed  within  the  framework 
regions.    Graph  demonstrates  a  higher 
percentage  of  mutations  within  CDR 
regions compared to framework regions. 188 
VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
2-70*04  No D gene 
Assignment  5*02  1  14  8  1  0.46004  0.03713  4  1  0.67539  -0.9339 
3-30*04  1-7*01  4*02  2  4  3  0  0.47645  0.32957  0  1  0.67262  -0.3274 
        5  3  0  0.47645  0.61536  0  2  0.67262  -0.1072 
3-30*04  3-22*01  4*02  1  13  5  0  0.47645  0.23822  6  2  0.67262  0.68795 
3-30*04  5-12*01  6*02  2  16  6  2  0.47645  0.4565  6  2  0.67262  -0.6256 
        19  6  2  0.47645  0.87298  7  4  0.67262  -0.3219 
3-30*09  No D gene 
Assignment  6*02  1  21  12  3  0.47758  0.06524  4  2  0.67244  -0.1751 
3-30*09  No D gene 
Assignment  6*02  1  21  12  3  0.47758  0.06524  4  2  0.67244  -0.1751 
3-53*01  3-22*01  4*02  2  18  8  3  0.45711  0.08369  7  0  0.65885  0.81907 
        18  8  3  0.45711  0.16134  6  1  0.65885  -0.6915 
3-72*01  No D gene 
Assignment  5*02  1  17  3  3  0.45531  -0.3487  7  4  0.65729  -0.2354 
3-73*02  No D gene 
Assignment  4*02  1  26  14  1  0.47416  0.04699  6  5  0.66265  -0.2564 
4-34*01  No D gene 
Assignment  4*02  3  25  6  1  0.42123  0.76861  12  6  0.65376  -0.8267 
        27  7  2  0.42123  -0.7963  9  9  0.65376  -0.0672 
        28  7  2  0.42123  -0.6576  9  10  0.65376  -0.0385 
4-59*01  No D gene 
Assignment  4*02  1  10  3  0  0.44001  0.51005  5  2  0.65645  0.79209 
5-51*01  No D gene 
Assignment  3*02  4  12  1  1  0.43137  -0.2215  6  4  0.70065  -0.2864 
        25  5  5  0.43137  -0.4626  10  5  0.70065  -0.0642 
        31  7  6  0.43137  -0.4775  11  7  0.70065  -0.0148 
        32  7  6  0.43137  -0.4775  12  7  0.70065  -0.023 
5-51*01  6-19*01  4*02  2  4  1  1  0.43137  0.86274  2  0  0.70065  -0.8712 
        5  1  1  0.43137  0.86274  3  0  0.70065  0.89384 
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Table 4.10 Analysis of Replacement and Silent Mutations and Positive and Negative Selection in Sample MYO5 
 
Replacement and silent mutations within the immunoglobulin sequences and antigen-driven selection were determined according to Hershberg et al 
(294) and the corresponding computer programme (http://clip.med.yale.edu/selection).  This improved method of analysis uses a focused binomial 
test to establish positive or negative mutational selections within the sequence with high specificity and increased sensitivity accounting for known 
biases within the immunoglobulin gene sequence.  R-CDR and S-CDR represents the number of replacement and silent mutations within the CDR 
respectively.  pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within 
the FW while p-CDR is the p-value of the focused binominal test on the CDR.  Conversely R-FW and S-FW represents the number of replacement 
and silent mutations within the FW respectively. pFW represent the probability of having a R mutation in the FW given all the mutations in the 
sequence except R mutations within the CDR while p-FW is the p-value of the focused binominal test on the FW.  If the number of R mutations is less 
than expected the software will test for negative selection and p-values will be preceded by a negative sign or if the number of mutations is more than 
expected the software will test for positive selection.  p-values <0.05 are highlighted in yellow and were deemed significant for selection. 
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4.2.3.3 CDR3 Analysis 
As  no  non-functional  sequences  were  identified  in  the  infiltrating  repertoire  in 
sample MYO5 no comparisons could be made between these sequences and the 
functional sequences of the cells infiltrating the muscle.  The mean amino acid 
CDR3 length was calculated at 15.5 ± 0.8 (ranging from 10 to 22 amino acids) 
(Table 4.11).  As demonstrated in Figure 4.13A no non-mutated sequences were 
found within the infiltrating repertoire therefore the mean CDR3 length could only 
be examined for the 3 different ranges of highly mutated sequences (Figure 4.14).  
Using the Tukey-Kramer multiple comparison test no significant difference in the 
CDR3  length  was  observed  between  the  different  mutational  groups.    Like  the 
previous  samples  no  significant  differences  were  observed  for  the  P  and  N 
nucleotides  at  the  VD  and  DJ  junctions  but  in  similarity  to  the  other  myositis 
samples a significant difference was observed for the exonuclease activity between 
the two junctional areas with a significant increase in exonuclease at the 5’ end of 
the JH gene segments and the 5’DH region compared to the 3’VH region (Table 
4.11).  There is also a significant difference in the DJ junction between the genes 
with an increased exonuclease activity at the 5’JH compared to the 3’ DH.   
 
Functional  15.5 ± 0.8  CDR3 Length 
Non-Functional  N/A 
  VD Junction  DJ Junction 
Functional  0.3 ± 0.2  0.2 ± 0.1  P Nucleotide 
Non-Functional  N/A  N/A 
Functional  8.2 ± 1.3  9.6 ± 0.5  N Nucleotide 
Non-Functional  N/A  N/A 
  3’ VH  5’ DH  3’ DH  5’JH 
Functional  0.2 ± 0.1  6.3 ± 2.8
θ  0.9 ± 0.6  6.2 ± 1.4 
θЖ  Exonuclease 
Activity  Non-Functional  N/A  N/A  N/A  N/A 
 
Table 4.11 CDR3 and Junctional Analysis in Sample MYO5 
 
The mean amino acid length of the CDR3, the mean nucleotide numbers corresponding to P and N 
nucleotides as well as the mean number of germline nucleotides lost due to exonuclease activity 
were calculated from the junctional regions of all immunoglobulin sequences from sample MYO5.  
Results are given as the Mean ± SEM, statistical significance was established using an unpaired t-
test.    Instances  where  no  non-functional  sequences  were  identified  and  values  could  not  be 
calculated were recorded as non applicable (N/A).  Θ represents a significant difference from 3’VH 
while Ж represents a significant difference from 3’ DH. 
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4.2.3.4 Clonal Diversification in MYO5  
Four  clonally  related sets of  genes were  observed from sample MYO5  (Figure 
4.15A-H).  These clonally related sets of genes utilise VH gene segments from VH 
families 3, 4 and 5 and indicate a B cell antigen-driven response.  The use of 
varying  VH  families  may  also  indicate  an  antigen-driven  response  to  different 
antigens.    Each  set  of  clonally  related  sequences  share  the  same  VDJ  gene 
rearrangement, CDR3 and junctional composition as well as common replacement 
and  silent  mutations.    For  clonal  tree  A  clonal  variants  A  and  E  share  1 
replacement mutation between them but do not share the other R and S mutations 
indicated  within  the  genealogical  tree  indicating  that  they  are  formed  during 
different  clonal  lineages.      The  only  sets  of  clonally  related  sequences  which 
demonstrated  a  significant  selection  was  the  clonally  related  sequences  from 
Figure 4.15A (Table 4.12); a significant negative selection was observed within the 
framework region when all the mutations from the clone were analysed as a single 
entity.  Despite the individual sequence of clone D from Figure 4.15D exhibiting 
negative selection in the framework regions when analysed individually this was no 
longer  significant  when  the  other  mutations  of  the  clone  were  taken  into 
consideration.  
 
 
Figure  4.14  Mean  CDR3  Lengths  in 
Relation to VH Mutational Numbers  
 
The mean  CDR3  length  was  calculated 
for immunoglobulin sequences according 
the  number  of  mutations  within  the  VH 
segment  of  the  gene  rearrangement  to 
establish  any  relationship  between 
mutational  number  and  CDR3  length.  
Results  are  given  as  Mean  amino  acid 
CDR3  length  ±  SEM.    Groups  were 
compared  for  statistical  significance 
using the Tukey-Kramer test for multiple 
comparisons.    The  graph  demonstrates 
that  no  significant  changes  in  CDR3 
length  were  observed  at  the  various 
number  of  mutations.    p-values  <0.05 
would have been deemed significant. 192 
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E 
Germline5-51*01      GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATC  
CloneA               GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATC  
CloneB               GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATC  
CloneC&D             GAGGTGCAGCTGGTGCAGTCTGGAGTAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATC  
CloneE               GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTCTGAAGATC  
                    
                                CDR1 
Germline5-51*01      TCCTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCGGCTGGGTGCGCCAGATG  
CloneA               TCCTGTAAGGCTTCTGGATACAGCTTTACCAGCTACTGGATCGGCTGGGTGCGCCAGATG  
CloneB               TCCTGTAAGGGTTCTGGATATAGTTTTCCCAACTTTTGGATCGGCTGGGTGCGCCAGCTG  
CloneC&D             TCCTGTAAGGGTTCTGGATATAGTTTTCCCAACTTTTGGATCGGCTGGGTGCGCCAGCTG  
CloneE               TCCTGTAAGGCTTCTGGATACAGCTTTACCAGCTACTGGATCGGCTGGGTGCGCCAGATG  
                      
                                    CDR2 
Germline5-51*01      CCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATAC  
CloneA               CCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATAGTAGATAC  
CloneB               CCCGGGAAAGGCCTGCAGTACGTGGGTATGATTCATCCTGGTGAATCTGACACCAGATAT  
CloneC&D             CCCGGGAAAGGCCTGCAGTACGTGGGTATGATTCATCCTGGTGAATCTGACACCAGATAT  
CloneE               CCCGGGAAAGGCCTGCAGTACGTGGGTATGATTCATCCTGGTGAATCTGACACCAGATAT  
                    
 
Germline5-51*01      AGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTAC  
CloneA               AGCCCGTCCTTCCAAGGCCAGGTCACCATCTCAGCCGACAAGTCCCTGAGGACAGCCTAT  
CloneB               AGTCCAGCCTTCCAAGACCAGGTCACCATCTCAGCCGACAAGTCCCTGAGGACAGCCTAT  
CloneC&D             AGTCCAGCCTTCCAAGACCAGGTCACCATCTCAGCCGACAAGTCCCTGAGGACAGCCTAT  
CloneE               AGTCCAGCCTTCCAAGACCAGGTCACCATCTCAGCCGACAAGTCCCTGAGGACAGCCTAT  
                      
                    CDR3 
Germline5-51*01      CTGCAGTGGAGCAGCCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGACA  
CloneA               CTGCAGTGGAGCAGCCTGAAGGCCTCGGACACTGCCGTGTTTTATTGTGCGCGGGC  
CloneB               CTGCAGTGGAGCAGCCTGAAGGCCTCGGACACTGCCGTGTTTTATTGTGCGCGGGC  
CloneC&D             CTGCAGTGGAGCAGCCTGAAGGCCTCGGACACTGCCGTGTTTTATTGTGCGCGGGC  
CloneE               CTGCAGTGGAGCAGCCTGAAGGCCTCGGACACTGCCGTGTTTTATTGTGCGCGGGC  
 
 
F 
Germline3-30*04      CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTC  
CloneA               CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTC  
CloneB               CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTC  
                      
                               CDR1 
Germline3-30*04      TCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATGCTATGCACTGGGTCCGCCAGGCT  
CloneA               TCCTGTGCAGCCTCTGGGTTCATCTTCAGTAACTTTGCTATGCACTGGGTCCGCCAGGCT  
CloneB               TCCTGTGCAGCCTCTGGATTCACCTTCAGTGACTATGCTATGCACTGGGTCCGCCAGGCT  
                      
                                    CDR2     
Germline3-30*04      CCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATATGATGGAAGTAATAAATACTAC  
CloneA               CCAGGCAAAGGGCTGGAGTGGGTGGCAGTTATATCGTATGCTGGAACTAATAAAGACTAC  
CloneB               CCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCGTATGCTGGAACTAATAAAGACTAC  
                      
 
Germline3-30*04      GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTAT  
CloneA               GCAGACTCCGTTAAGGACCGATTCACCATCTCGAGAGACAATTCCAAGAACACGCTGTAT  
CloneB               GCAGACTCCGTTAAGGACCGATTCACCATCTCGAGAGACAATTCCAAGAACACGCTGTAT  
                      
                   CDR3 
Germline3-30*04      CTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGA  
CloneA               CTGGAAATGAACAACCTGAGACTTGAAGACACGGCTTTGTTTTACTGTGCGAGAGG  
CloneB               CTGGAAATGAACAACCTGAGACTTGAAGACACGGCTTTGTTTTACTGTGCGAGAGG  
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G 
Germline3-53*01      GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTC  
CloneA               GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGCGACTC  
CloneB               GAGGTGCAGCTGGTGGAGTCTGGAGGAGGCTTGGTCCAGCCTGGGAGGTCCCTGAGACTC  
                      
                               CDR1 
Germline3-53*01      TCCTGTGCAGCCTCTGGGTTCACCGTCAGTAGCAACTACATGAGCTGGGTCCGCCAGGCT  
CloneA               TCCTGTACAGCCTCTGGGTTCACCGTCAGGAATTACTACATGAACTGGGTCCGCCAGGCT  
CloneB               TCCTGTGCAGCCTCTGGGTTCACCGTCAGGAATTACTACATGAACTGGGTCCGCCAGGCT  
                     
                                     CDR2 
Germline3-53*01      CCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGCACATACTACGCA  
CloneA               CCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATTATGATGGTAACACAGACTATGCA  
CloneB               CCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATTATGATGGTAACACAGACTATGCA  
                   
 
Germline3-53*01      GACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTT  
CloneA               GACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACGTTCCCAAGAACACGGTGTATCTT  
CloneB               GACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACGTTCCCAAGAACACGGTGTATCTT  
                     
                                  CDR3 
Germline3-53*01      CAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGAGA  
CloneA               CAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCTAGAGA  
CloneB               CAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCTAGAGA  
 
H 
Germline4-34*01      CAGGTGCAGCTACAGCAGTGGGGCGCAGGACTGTTGAAGCCTTCGGAGACCCTGTCCCTC  
CloneA               CAGGTGCAGCTACAGCAGTGGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTC  
CloneB&C             CAGGTGCAGCTACAGCAGTGGGGCGCTGGGCTGTTGAAGCCTTCGGAGACCCTGTCCCTC  
CloneD               CAGGTGCAGCTACAGCAGTGGGGCGCTGGGCTGTTGAAGCCTTCGGAGACCCTGTCCCTC  
                      
                               CDR1 
Germline4-34*01      ACCTGCGCTGTCTATGGTGGGTCCTTCAGTGGTTACTACTGGAGCTGGATCCGCCAGCCC  
CloneA               ATCTGCACTGTCTCTGGTGGCTCCTTCAGTGGTTACTACTGGAACTGGATCCGGCAGCCC  
CloneB&C             ACGTGCACTGTCCATGGTGGGTCGTTCAGTGGATTCTTCTGGAGCTGGATTCGCCAGCCC  
CloneD               ACGTGCACTGTCCATGGTGGGTCGTTCAGTGGATTCTTCTGGAGCTGGATTCGCCAGCCC  
                     
                                    CDR2 
Germline4-34*01      CCAGGGAAGGGGCTGGAGTGGATTGGGGAAATCAATCATAGTGGAAGCACCAACTACAAC  
CloneA               CCAGGGAAGGGGCTGGAGTGGATTGGGGAAATTAATTTTAATGGATCCACCAACTACAAC  
CloneB&C             CCAGGGAAGGGGCTGGAGTGGATTGGGGAAATTAATTTTAATGGATCCACCAACTACAAC  
CloneD               CCAGGGAAGGGGCTGGAGTGGATTGGGGAAATTAATTTTAATGGATCCACCAACTACAAC  
                     
 
Germline4-34*01      CCGTCCCTCAAGAGTCGAGTCACCATATCAGTAGACACGTCCAAGAACCAGTTCTCCCTG  
CloneA               CCGTCCCTCAAGAGTCGAGTCTCCATCTTACGAGACACGTCCAAGAAGCAGTTCTCCCTG  
CloneB&C             CCGTCCCTCAAGAGTCGAGTCTCCATCTTACGAGACACGTCCAAGAAGCAGTTCTCCCTG  
CloneD               CCGTCCCTCAAGAGTCGAGTCTCCATCTTACGAGACACGTCCAAGAAGCAGTTCTCCCTG  
                      
                                  CDR3 
Germline4-34*01      AAGCTGAGCTCTGTGACCGCCGCGGACACGGCTGTGTATTACTGTGCGAGAGG  
CloneA               AATTTGAGGTCTGTGACCGCCGCGGACACGGCTGTCTATTATTGTGCGAGATG  
CloneB&C             AATTTGAGGTCTGTGACCGCCGCGGACACGGCTGTCTATTATTGTGCGAGATG  
CloneD               AATTTGAGGTCTGTGACCGCCGCGGACACGGCTGTCTATTATTGCGCGAGATG  
                   
 
 
 
 
 
 
 
 
Figure 4.15 Clonal Proliferation in Sample MYO5 
 
4  sets  of  sequences  were  isolated  from  sample  MYO5  demonstrated  somatic  hypermutation  and  clonal 
proliferation (A-H).  Figure A-D - The letters in the circles refer to individual sequences isolated from each B 
cell  clone.    Numbers  indicate  the  minimum  number  of  mutations  required  between  each  sequence  with 
bracketed  figures  representing  additional  silent  mutations.    The  dashed  circle  represents  a  hypothetical 
intermediate  whose  sequence  was  not  found  amongst  the  isolated  sequences.    Figure  E-H  -  The  DNA 
sequences of the clonally related sequences were aligned using ClustalW software to highlight the common 
and independent mutations.  CDR regions are highlighted in yellow, replacement mutations in blue and silent 
mutations in purple. 195 
 
VH Gene  DH Gene  JH Gene  R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
5-51*01  No D gene 
Assignment  3*02  9  7  0.44751  -0.6002  12  7  0.69597  -0.0142 
3-30*04  5-12*01  6*02  7  2  0.47645  0.66553  7  4  0.67262  -0.3219 
3-53*01  3-22*01  4*02  8  3  0.45711  0.16134  8  1  0.65885  0.97999 
4-34*01  No D gene 
Assignment  4*02  8  2  0.42123  -0.5993  13  12  0.65376  -0.0699 
 
Table 4.12 Analysis of Replacement and Silent Mutations and Positive and Negative 
Selection in Clonally Related B Cells in Sample MYO5 
 
The number of replacement and silent mutations and the presence of any positive and negative 
selection were conducted as per Hershberg et al (294) as previously described.  For clonally related 
sequences  mutations  shared  across  the  sequences  are  only  counted  once  and  p  values  are 
calculated for the clone as a single entity. R-CDR/FW and S-CDR/FW represent the number of 
replacement  and  silent  mutations  in  the  CDR  and  FW  respectively.    pCDR  represents  the 
probability of having a R mutation in the CDR given all the mutations in the sequence except R 
mutations within the FW while pFW represents the probability of having a R mutation in the FW 
given  all  the  mutations  in  the  sequence  except  R  mutations  within  the  CDR  and  p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative 
sign indicates negative selection.  p-values <0.05 were deemed significant. 
 
4.2.3.5 VH Repertoire from Myositis PBL 
A  blood  sample  was  obtained  from  patient  MYO5  allowing  the  gene  repertoire 
within the blood to be determined (Figure 4.11); although this was taken 3 years 
after the second biopsy was conducted.  Approximately 50 sequences have been 
isolated from the PBL repertoire (Table 4.13).  Within the PBL a selection for gene 
segments VH1 and 2 was observed which were significant against the published 
normal  control  values  but  were  not  significant  against  the  germline  complexity 
(Figure  4.16A).    A  selection  against  VH4  segments  was  observed  within  the 
patient’s  blood  sample  which  was  significantly  decreased  in  comparison  to 
published normal control values and the selection was also significant against the 
germline complexity.  The DH gene repertoire was assessed from the 41.9% of 
sequences where a D gene could statistically be assigned (Figure 4.16B).  As 
shown in Figure 4.16B this gene repertoire almost mirrors that of the normal control 
repertoire  as  well  as  the  germline  complexity,  the  only  significant  difference 
observed was a selection for the DH3 gene segments but this was only significant 
against the germline complexity and not the normal control values.  Analysis of the 
JH gene repertoire demonstrated a selection for JH2 and JH4 gene segments which 196 
were used significantly higher in the MYO5 PBL repertoire compared to the normal 
control values (Figure 4.16C).  A selection against the use of JH1 and JH6 gene 
segments was also observed within the PBL repertoire.  For JH6 this decline was 
significant against normal control values but not the germline complexity whereas 
the decline in JH1 family usage was only significant against the germline complexity 
and not the normal control repertoire.   
 
For some sequences isolated from the PBL from patient MYO5 anomalies were 
detected between the JOINSOLVER and IMGT/V-QUEST software.  For the VH1-
69*01 DH5-12*01 JH5*02 gene rearrangement IMGT/V-QUEST identified a different 
highest  DH  gene  match  and  assigned  DH3-22*01  to  the  rearrangement.    In 
JOINSOLVER this gene was the 3
rd best matching gene with only 8 consecutive 
nucleotides  compared  to  the  9  observed  for  the  DH5-12*01  gene  which  were 
sufficient to assign the DH gene statistically.  Using the IMGT/V-QUEST software 
the DH5-12*01 gene was the 2
nd best matching gene and had a match score of 25 
compared  to  69  for  the  DH3-22*01  gene.    For  the  non-functional  gene 
rearrangement  using  the  VH2-26*01  gene  with  30  mutations,  IMGT/V-QUEST 
assigned a different DH gene segment to this rearrangement.  Instead of assigning 
the DH2-21*02 gene a DH2-15*01 gene was assigned, this was found to be the 3
rd 
best matching DH gene segment using JOINSOLVER.  Another difference was also 
observed  with  another  non-functional  gene,  IMGT/V-QUEST  failed  to  find  a 
rearrangement for the VH3-23*01 JH1*01 identified using JOINSOLVER and was 
only able to identify the VH segment of the rearrangement.  IMGT/V-QUEST was 
also able to detect a deletion within the functional VH3-66*01 DH6-19*01 JH5*02 
rearrangement with 56 mutations.  This single codon deletion was observed within 
the CDR2.  When this deletion had been restored into the rearrangement both 
JOINSOLVER  and  IMGT/V-QUEST  aligned  the  sequence  to  a  VH3-21*01  DH6-
19*01  JH5*02  rearrangement with a  total of  44  mutations,  junctional  sequences 
were common between both alignments. 
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VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
1-03*01  No D gene 
Assignment  4*02  1  0  ARIHQEGPDY  17  8 
1-03*01  No D gene 
Assignment  3*02  1  19  ARAGHTVPNNAFDI  23  6 
1-18*01  2-21*02  3*02  1  17  ARDNVVVTVTTAFDI  24  14 
1-46*01  2-21*02  4*02  (1)  46  AECGGDCLYFD*  33  15 
1-46*01  3-22*01  2*01  1  2  ARVWNYYDSSGYYVGYFDL  36  26 
1-46*01  No D gene 
Assignment  5*02  1  31  ARGGGYGYIWFDP  19  6 
1-69*01  3-22*01  4*01  1  10  ARAYYSDSSGYGPFDN  39  24(+1) 
1-69*01  3-3*02  2*01  1  1  ARTEWLLSSYWYFDL  21  14 
1-69*01  3-3*02  6*02  2  37, 38  ARSSPFQNFWSALSYREAFYYAMDV  60  12 
1-69*01  3-9*01  4*02  1  19  ARCSTHYDDLSGYNMAYYFDY  43  20(+3) 
1-69*01  No D gene 
Assignment  1*01  (1)  25  ARDYRPKTSS  13  5 
1-69*01  5-12*01  5*02  1  21  ARNFYDNSGYNWFDP  24  9 
1-69*01  No D gene 
Assignment  6*02  1  25  ARAQFSYVAYIYYFYAMDV  40  8 
1-69*06  No D gene 
Assignment  3*02  1  33  ARGRGNNSEGFDI  31  6 
1-69*06  No D gene 
Assignment  5*02  1  10  ARDERYIGEVMTTNWFDP  31  7 
1-69*06  2-8*01  4*02  1  0  ARAPQGRKNCTNGVCYTGGT  49  25 
2-05*01  No D gene 
Assignment  4*02  1  2  AHRSNGPLFDY  20  6 
2-26*01  2-15*01  6*02  (1)  0  ARTDIVVVVAANPPSLLTTVWT  44  23 
2-26*01  2-21*02  5*02  (1)  30  TRTTESWWWLLRDDRGST(cc)  48  15(+1) 
2-26*01 
No D gene 
Assignment  4*02  2  0, 1  ARIPELDRWYLFDY  23  8 
2-26*01  No D gene 
Assignment  5*02  2  19, 20  ARINREGWIGLG  30  6 
3-07*02  No D gene 
Assignment  4*02  1  0  ARDWWLDNY  17  7 
3-21*01  2-2*01  3*02  1  30  ARDGLPAARDI  22  11 
3-21*01  No D gene 
Assignment  5*02  1  30  ARGVGMPGNPVFRFDP  32  5 
3-21*01  No D gene 
Assignment  3*02  1  0  ARDDSTSPGSAFDI  21  8 
3-21*01  6-19*01  5*02  1  21  ARGVAMAGTRVCTFDP  36  12(+1) 
3-23*01 
No D gene 
Assignment  1*01  (1)  15  ARWRGIS(cg)  21  5 
3-23*01  3-10*01  2*01  1  0  AKNPNMVRDLRGVWYFDL  33  11 
3-23*01  4-17*01  2*01  1  1  AKDSGVDYGAHGGLWYFDL  34  10 
3-30*04  No D gene 
Assignment  3*01  2  23, 26  ARESVPNCGAGTCHPRDRAFDV  45  9 
3-30*04  3-3*01  4*02  1  30  AREEGRQNTDFWSGYVFDC  54  17 
3-30*04  3-3*02  2*01  1  1  ARTEWLLSSYWYFDL  21  14 
3-48*01  No D gene 
Assignment  4*02  1  21  ARAGFFEPHFDF  33 
7 
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VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
3-66*01  6-19*01  5*02  1  56  TRGLAVAGTGVLCFDP  39  11 
3-73*01 
No D gene 
Assignment  4*02  1  23  ARPSAAYTSTWPGDY  45  7 
4-34*01  4-17*01  5*02  1  4  ARGGYGDYLKWFDP  22  12 
4-34*01  No D gene 
Assignment  6*02  1  13  ARALGF  11  6 
5-51*01  No D gene 
Assignment  4*02  1  35  AAFDTHAGARFLY  33  7 
5-51*01  No D gene 
Assignment  4*02  1  22  TRLDTDAGAKFEY  36  7 
5-51*01  No D gene 
Assignment  3*02  1  15  ARHSMYTFPDDALDK  37  6 
5-51*01  5-24*01  4*02  1  0  ARQDSRDGYNPFDY  25  17 
6-01*01 
No D gene 
Assignment  4*02  2  0, 7  ARGGAGEDFDY  15  7 
6-01*01  No D gene 
Assignment  5*02  1  23  ARGFLKLGFDP  28  8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
Table 4.13 Heavy chain genes identified from the PBL sample of myositis patient MYO5 PBL 
 
Best matching germline sequences were identified from aligning sequences in the IMGT database 
using JOINSOLVER software from the MYO5 PBL sample.  The total number of sequences isolated 
is given in the 4
th column of the table; non-functional rearrangements indicated in brackets.  Identical 
sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  CDR3 
amino  acid  sequences  were  also  identified  using  the  JOINSOLVER  software;  *  indicates  the 
presence of a stop codon within the CDR3. V-J lengths and consecutive D match lengths (bp) were 
also  identified  using  the  JOINSOLVER  software  and  allowed  assignment  of  the  DH  genes  as 
described in section 2.3.12.3.    199 
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Figure 4.16 VH Gene Family Usage of MYO5 PBL 
 
VH gene family usage.  Distribution of functional genes was compared with published normal control 
values from Volpe and Kepler (251) as well as the germline complexity assuming every germline 
gene is capable of producing a functional rearrangement.  Absolute values were used in Chi Square 
Analysis to determine gene selections.  § represent a significant difference from normal PBL values; 
* represent a significant difference from the germline (p<0.05).  
A 
B 
C 200 
4.2.3.6 Mutational Analysis of B Cell Ig Sequences Isolated from PBL 
Mutational numbers within rearranged genes demonstrated a variety of mutational 
numbers within PBL sequences (Figure 4.17A).  Over 40% of sequences were 
highly mutated with over 21 mutations within VH gene segments.  Over 30% of 
cells  were  from  a  naïve  population  with  between  0  and  2  mutations.    The 
remainder  of  sequences  contain  between  3  and  20  mutations.    Mutational 
distribution (Figure 4.17B) percentages within framework and CDR regions show 
that there were a higher percentage of mutations within CDR regions compared to 
framework  regions.    Comparing  mutational  distributions  between  CDR  regions 
show that there were a higher percentage of mutations within CDR1. 
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Analysis of the R and S mutations from Ig sequences isolated from the PBL (Table 
4.14) demonstrated negative selection within the framework regions of 10 of the 
sequences.  Positive selection in the CDR was observed in 3 of the sequences 
while 1 sequence demonstrated negative selection within the CDR.  This sequence 
also exhibited negative selection in the FW regions.  
 
A 
B 
Figure 4.17 Numbers of Mutations and 
Mutational  Distribution  of  Functional 
Sequences in MYO5 PBL 
 
Figure 4.17A - The number of mutations 
within functional rearranged genes were 
analysed  in  the  PBL  sample  of  MYO5.  
Base differences within the first 24 bases 
of  sequence  were  disregarded  as  this 
part  of  the  sequence  binds  the  5’  VH 
primer.  Graph demonstrates sequences 
within  cellular  infiltrates  show  a  diverse 
distribution of mutational numbers. 
 
 Figure  4.17B  -  The  locations  of 
mutations  observed  within  functional 
rearranged  genes  were  categorised  as 
being  within  FR  or  CDR  regions.    The 
numbers  of  mutations  within  these 
regions were expressed as a percentage 
of  the  entire  length  of  the  region  to 
correct  for  the  longer  lengths  observed 
within  the  framework  regions.    Graph 
demonstrates  a  higher  percentage  of 
mutations within CDR regions compared 
to framework regions. 201 
VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
1-03*01  No D gene 
Assignment  4*02  1  0  -  -  -  -  -  -  -  - 
1-03*01  No D gene 
Assignment  3*02  1  19  6  1  0.47127  0.63617  8  4  0.70269  -0.4975 
1-18*01  2-21*02  3*02  1  17  7  0  0.47674  0.31052  6  4  0.68809  -0.5539 
1-46*01  2-21*02  4*02  (1)  46  11  2  0.47626  -0.7247  21  12  0.674  -0.3563 
1-46*01  3-22*01  2*01  1  2  0  0  0.47626  -0.5237  1  1  0.674  -0.652 
1-46*01  No D gene 
Assignment  5*02  1  31  9  5  0.47626  -0.672  10  7  0.674  -0.037 
1-69*01  3-22*01  4*01  1  10  4  2  0.44858  -0.9895  1  3  0.67095  -0.0181 
1-69*01  3-3*02  2*01  1  1  0  0  0.44858  -0.5514  0  1  0.67095  -0.3291 
1-69*01  3-3*02  6*02  2  37  11  1  0.44858  0.77525  14  11  0.67095  -0.1641 
        38  10  2  0.44858  -0.7636  14  12  0.67095  -0.0644 
1-69*01  3-9*01  4*02  1  19  9  2  0.44858  0.15835  5  3  0.67095  -0.2767 
1-69*01  No D gene 
Assignment  1*01  (1)  25  10  2  0.44858  0.1692  9  4  0.67095  -0.5608 
1-69*01  5-12*01  5*02  1  21  7  4  0.44858  0.88572  6  4  0.67095  -0.0695 
1-69*01  No D gene 
Assignment  6*02  1  25  11  1  0.44858  0.26589  6  7  0.67095  -0.0695 
1-69*06  No D gene 
Assignment  3*02  1  33  7  4  0.44956  -0.492  14  8  0.67148  -0.1623 
1-69*06  No D gene 
Assignment  5*02  1  10  2  1  0.44956  -0.8508  5  2  0.67148  -0.7688 
1-69*06  2-8*01  4*02  1  0  -  -  -  -  -  -  -  - 
2-05*01  No D gene 
Assignment  4*02  1  2  1  0  0.44387  0.44387  1  0  0.6816  0.6816 
2-26*01  2-15*01  6*02  (1)  0  -  -  -  -  -  -  -  - 
2-26*01  2-21*02  5*02  (1)  30  10  4  0.46263  0.44118  12  4  0.68432  -0.4245 
2-26*01  No D gene 
Assignment  4*02  2  0  -  -  -  -  -  -  -  - 
        1  0  0  0  -  1  0  0.74726  0.74726 
Cont… 202 
VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
2-26*01  No D gene 
Assignment  5*02  2  19  9  1  0.46263  0.1913  5  4  0.68432  -0.2384 
        20  9  1  0.46263  0.30178  5  5  0.68432  -0.126 
3-07*02  No D gene 
Assignment  4*02  1  0  -  -  -  -  -  -  -  - 
3-21*01  2-2*01  3*02  1  30  12  5  0.5135  0.93998  7  6  0.65938  -0.0219 
3-21*01  No D gene 
Assignment  5*02  1  30  10  3  0.5135  -0.5886  8  9  0.65938  -0.0202 
3-21*01  No D gene 
Assignment  3*02  1  0  -  -  -  -  -  -  -  - 
3-21*01  6-19*01  5*02  1  21  7  6  0.49658  -0.6483  5  3  0.66123  -0.0241 
3-23*01  No D gene 
Assignment  1*01  (1)  15  6  1  0.45266  0.22144  6  2  0.65  0.94618 
3-23*01  3-10*01  2*01  1  0  -  -  -  -  -  -  -  - 
3-23*01  4-17*01  2*01  1  1  0  0  0.45265  -  1  0  0.65000  0.65000 
3-30*04  No D gene 
Assignment  3*01  2  23  10  1  0.47645  0.03902  10  2  0.67262  0.48789 
        26  6  1  0.47645  -0.5693  11  8  0.67262  -0.2576 
3-30*04  3-3*01  4*02  1  30  11  3  0.47645  0.98399  7  9  0.67262  -0.0079 
3-30*04  3-3*02  2*01  1  1  0  0  0.47645  -0.5235  0  1  0.67262  -0.3274 
3-48*01  No D gene 
Assignment  4*02  1  21  5  3  0.51637  -0.1685  6  7  0.6621  -0.0222 
3-66*01  6-19*01  5*02  1  56  17  7  0.46522  -0.9478  19  13  0.66817  -0.0209 
3-73*01  No D gene 
Assignment  4*02  1  23  3  4  0.47416  -0.0347  8  8  0.66265  -0.0186 
4-34*01  4-17*01  5*02  1  4  0  0  0.42123  -0.5788  3  1  0.65376  0.75232 
4-34*01  No D gene 
Assignment  6*02  1  13  3  0  0.42123  -0.8171  5  5  0.65376  -0.3309 
5-51*01  No D gene 
Assignment  4*02  1  35  14  3  0.43137  0.0339  14  4  0.70065  -0.7216 
5-51*01  No D gene 
Assignment  4*02  1  22  8  1  0.43137  0.00717  13  0  0.70065 
0.05484 
Cont… 203 
VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
5-51*01  No D gene 
Assignment  3*02  1  15  2  2  0.43137  -0.4749  8  3  0.70065  -0.5078 
5-51*01  5-24*01  4*02  1  0  -  -  -  -  -  -  -  - 
6-01*01  No D gene 
Assignment  4*02  2  0  -  -  -  -  -  -  -  - 
        7  5  0  0.47248  0.09678  1  1  0.65538  -0.6893 
6-01*01  No D gene 
Assignment  5*02  1  23  9  2  0.47248  0.81772  5  7  0.65538  -0.0272 
 
 
 
Table 4.14 Analysis of Replacement and Silent Mutations and Positive and Negative Selection in Sample MYO5 PBL 
 
Replacement and silent mutations within the immunoglobulin sequences and antigen-driven selection were determined according to Hershberg et al 
(294) and the corresponding computer programme (http://clip.med.yale.edu/selection).  This improved method of analysis uses a focused binomial 
test to establish positive or negative mutational selections within the sequence with high specificity and increased sensitivity accounting for known 
biases within the immunoglobulin gene sequence.  R-CDR and S-CDR represents the number of replacement and silent mutations within the CDR 
respectively.  pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within 
the FW while P-CDR is the p-value of the focused binominal test on the CDR.  Conversely R-FW and S-FW represents the number of replacement 
and silent mutations within the FW respectively. pFW represent the probability of having a R mutation in the FW given all the mutations in the 
sequence except R mutations within the CDR while p-FW is the p-value of the focused binominal test on the FW.  If the number of R mutations is less 
than expected the software will test for negative selection and p-values will be preceded by a negative sign or if the number of mutations is more than 
expected the software will test for positive selection.  p-values <0.05 are highlighted in yellow and were deemed significant for selection. 
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4.2.3.7 CDR3 Analysis 
No  significant  changes  were  observed  in  the  CDR3  length  between  the 
functional and non-functional populations (Table 4.15) as well as between the 
different  mutational  groups  within  the  functional  population  (Figure  4.18).  
Similarly no significant differences were observed for the P and N nucleotide 
additions between the two populations or between the two different junctional 
regions within each population.  As seen within the Ig sequences of the myositis 
infiltrating repertoire a significant difference was observed for the exonuclease 
activity.  A significant increase in this activity was observed at the 5’ end of the 
DH and JH gene in comparison to the 3’VH gene in the functional population.  A 
significant change was also observed at the 3’VH gene junction between the 
functional and non-functional populations.  A significant increase in exonuclease 
activity  was  observed  in  the  non-functional  sequences  at  the  3’VH  region 
compared to the functional sequences.  This increase in exonuclease activity 
may have resulted in a frameshift resulting in a non-functional rearrangement.   
 
Functional  15.2 ± 6  CDR3 Length 
Non-Functional  13.8 ± 2.7 
  VD Junction  DJ Junction 
Functional  1.0 ± 0.2  0.8 ± 0.2  P Nucleotide 
Non-Functional  0.3 ± 0.3  0 
Functional  7.8 ± 1.5  7.9 ± 1.4  N Nucleotide 
Non-Functional  4.7 ± 2.2  12 ± 5.1 
  3’ VH  5’ DH  3’ DH  5’JH 
Functional  1.6 ± 0.3*  5.1 ± 0.9
θ  5.8 ± 1.0  4.9 ± 0.7
 θ  Exonuclease 
Activity  Non-Functional  3.7 ± 0.7  5.3 ± 1.8  5.3 ± 0.7  7.3 ± 3.3 
 
Table 4.15 CDR3 and Junctional Analysis in Sample MYO5 PBL 
 
The mean amino acid length of the CDR3, the mean nucleotide numbers corresponding to P 
and N nucleotides as well as the mean number of germline nucleotides lost due to exonuclease 
activity were calculated from the junctional regions of all PBL immunoglobulin sequences from 
sample MYO5.  Results are given as the Mean ± SEM.  * indicates a significant difference 
between  functional  and  non-functional  sequences  established  using  an  unpaired  t  test.      Θ 
represents a significant difference from 3’VH. 
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No clonally related sets of genes were isolated from the PBL population but as 
the  sequences  isolated  represent  only  a  small  fraction  of  the  overall  PBL 
population  the  presence  of  clones  within  the  isolated  sequences  was  not 
anticipated.    In  cases  where  multiple  genes  were  isolated  from  the  PBL 
repertoire which shared VDJ gene assignments and junctional sequences these 
sequences only differed or shared 1 mutation and were therefore not deemed 
clonally related.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.18  Mean  CDR3  Lengths  in 
Relation to VH Mutational Numbers  
 
The mean  CDR3  length  was  calculated 
for immunoglobulin sequences according 
the  number  of  mutations  within  the  VH 
segment  of  the  gene  rearrangement  to 
establish  any  relationship  between 
mutational  number  and  CDR3  length.  
Results  are  given  as  Mean  amino  acid 
CDR3  length  ±  SEM.    Groups  were 
compared  for  statistical  significance 
using the Tukey-Kramer test for multiple 
comparisons.    The  graph  demonstrates 
that  no  significant  changes  in  CDR3 
length  were  observed  at  the  various 
number  of  mutations.    p-values  <0.05 
would have been deemed significant. 206 
4.2.3.8 Comparison of Myositis Muscle VH Repertoire with Myositis PBL 
Repertoire 
Comparing the infiltrating cell repertoire from the muscle to that of the published 
repertoire  of  normal  control  values  demonstrated  selections  for  and  against 
certain gene segments (Figure 4.12).  As a blood sample was obtained from 
this patient the VH gene repertoire of the muscle infiltrating B cells was also 
compared to the patients own PBL repertoire (Figure 4.19).  Although this is 
from a small percentage of the whole PBL repertoire, and a larger number of 
sequences  would  be  required  for  a  more  accurate  comparison,  it  does 
demonstrate  a  selection  for  and  against  gene  families.    For  VH  gene  family 
segments  there  was  a  selection  against  VH1  in  the  muscle  repertoire  in 
comparison with the PBL repertoire as there was a significant increase of these 
gene families evident within the PBL (Figure 4.19A).  No other selections were 
significant for the VH gene families despite the appearance of selection for VH3, 
VH4 and VH5 family genes; these were not significant when the absolute values 
were used in Chi square analysis although a p-value of 0.0574 (Appendix 2) 
was observed for VH5 family genes which may represent a significant selection 
for these genes segments if a larger population of sequences had been isolated 
from each sample.  DH1 gene segments were significantly selected for within 
the muscle repertoire and this selection for DH1 was not observed within the 
PBL repertoire (Figure 4.19B).  No significant changes in the JH repertoire was 
observed between the muscle and PBL Ig populations (Figure 4.19C).   
 
A larger number of sequences from the PBL repertoire is required to provide a 
more accurate representation of entire PBL repertoire and to fully determine if 
the  selections  for  and  against  gene  segments  are  in  fact  present  between 
muscle  and  PBL  repertoires.    In  addition  to  comparing  the  VH  repertoires 
between the muscle infiltrating population and the PBL population, comparing 
the individual gene rearrangements used in each population demonstrated that 
no similar gene rearrangements were found in both the muscle and blood B cell 
populations. 
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Figure 4.19 VH Gene Family Usage of MYO5 muscle and PBL 
VH gene family usage.  Distribution of functional genes from infiltrating cells within the muscle 
were compared to the patients own PBL repertoire.  * represent a significant difference from 
myositis PBL values (p<0.05).  
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4.2.4 Sample MYO6 
Areas of cellular infiltration within sample MYO6 were microdissected and the 
DNA released was amplified for all 6 VH families by nested PCR (Figure 4.20).  
Despite  the  presence  of  B  cells  and  plasma  cells  within  the  infiltrating 
population only 1 sequence could be found within various regions of the sample 
(Table 4.16A).  This sequence utilised the VH3-72*01 gene segment, in addition 
to  the  JH4*02  gene  segment;  no  D  gene  assignment  could  be  statistically 
assigned.    The  isolated  sequence  contained  15  mutations,  with  the  higher 
percentage of these mutations being present within the CDR2 region.  Analysis 
of the R and S mutations indicates a negative selection in the FW regions of this 
sequence (Table 4.16B), negative selection was also found within the CDR but 
this was not significant.  Analysis of the junctional region of this sequence could 
not be completed as no DH gene could be statistically assigned.  No changes in 
gene assignments were observed using the IMGT/V-QUEST software. 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Before Microdissection  After Microdissection 
A 
Figure 4.20 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample MYO6 
 
The region of B cell and plasma cell infiltration was microdissected from sample MYO6.  Figure 
4.20A demonstrates the microdissection of the region of cellular infiltration.  Images were taken 
at 400X.  DNA released from these microdissections was amplified using a Nested PCR system 
(Figure 4.20B), as described in Chapter 2.  – indicates negative control PCR reactions where 
DNA  was  substituted  with  water  while  +  indicates  positive  control  PCR  reactions  using 
peripheral blood mononuclear cells isolated from peripheral blood of a healthy individual.  
Results show amplification for VH1, 2, 3, 5 and 6 families. 
400 bp 
400 bp 
VH1  VH2  VH3 
VH4  VH5  VH6 
_  MYO 
6  +  _  MYO 
6  + 
_  MYO 
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Mutational Distribution  
(% of length)  VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3  
CDR3 
Length 
(aa)  Framework  CDR1  CDR2 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
3-72*01  No D gene 
Assignment  4*02  1  15  ARVVEGVVSRDVLDY  15  3.6  0  8.3  30  8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
3  2  0.45531  -0.2424  4  6  0.65729  -0.0271 
Table 4.16 A&B Sequence Analysis from Sample MYO6 
 
Table 4.16A - Best matching germline sequences were identified from aligning sequences in the IMGT database using JOINSOLVER software from the MYO6 
myositis section.  Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  V-J lengths and consecutive D match 
lengths (bp) were also identified using the JOINSOLVER software and allowed assignment of the DH genes as described in section 2.3.12.3.    
 
The number of mutations within functional rearranged genes were analysed collectively from all region of dissected cellular infiltration.  Base differences within 
the first 24 bases of sequence were disregarded as this part of the sequence binds the 5’ VH primer.   
 
The locations of mutations observed within functional rearranged genes were categorised as being within FR or CDR regions.  The numbers of mutations 
within these regions were expressed as a percentage of the entire length of the region to correct for the longer lengths observed within the framework regions. 
 
Table 4.16B - The number of replacement and silent mutations and the presence of any positive and negative selection was conducted as per Hershberg et al 
(294) as previously described.   R-CDR/FW and S-CDR/FW represent the number of replacement and silent mutations in the CDR and FW respectively.  
pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while pFW 
represents the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative sign indicates negative selection.  p-values <0.05 were 
deemed significant. 
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4.2.5 Sample MYO7 
Areas of cellular infiltration microdissected from MYO7 (Figure 4.21) produced 
only  2  different  functional  gene  rearrangements  (Table  4.17A).    Both 
sequences isolated were from the VH3 gene family, VH3-66*01 and VH3-74*01.  
DH3-3*01 was the only D gene that could be statistically assigned in the VH3-
66*01 rearrangement along with the JH5*02 gene segment while the other gene 
rearrangement utilised the JH6*02 segment.  No changes were observed using 
IMGT/V-QUEST.    The  VH3-74*01  was  non-mutated  but  the  other  functional 
gene contained 9 VH mutations, with the higher percentage of these mutations 
present within the CDR2 region. Analysis of R and S mutations demonstrated 
no significant selection was present in either the CDR or FW regions (Table 
4.17B).  As no D gene could be assigned to the VH3-74*01 rearrangement no 
junctional  analysis  could  be  conducted.    Analysis  in  the  VH3-66*01 
rearrangement found that 0 and 1 P nucleotides and 1 and 9 N nucleotides 
were present at the VD and DJ junctions respectively.  Exonuclease activity was 
calculated to have removed 2, 1, 9 and 4 nucleotides from the 3’ VH, 5’DH, 3’DH 
and 5’JH regions of the junction respectively. 
                   
 
 
 
 
 
 
 
 
 
 
 
 
 
Before Microdissection  After Microdissection 
A 
Figure 4.21 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample MYO7 
The region of B cell and plasma cell infiltration was microdissected from sample MYO7.  Figure 
4.21A demonstrates the microdissection of the region of cellular infiltration.  Images were taken 
at 400X.  DNA released from these microdissections was amplified using a Nested PCR system 
(Figure 4.21B), as described in Chapter 2.  – indicates negative control PCR reactions where 
DNA  was  substituted  with  water  while  +  indicates  positive  control  PCR  reactions  using 
peripheral blood mononuclear cells isolated from peripheral blood of a healthy individual.  
Results show amplification for VH1, 3, 4 and 5 families. 
B 
400 bp 
400 bp 
_  MYO 
7  +  _  MYO 
7  + 
_  MYO 
7  + 
VH1  VH2  VH3 
VH4  VH5  VH6 211 
  
Mutational Distribution 
 (% of length)  VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number 
of Point 
Mutations 
CDR3 
CDR3 
Length 
(aa)  Framework  CDR1  CDR2 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
3-66*01  3-3*01  5*02  1  9  ARILRSLEWSTGGWFDP  17  2.3  0  7.8  32  20 (+1) 
3-74*01  No D gene 
Assignment  6*02  1  0  ARGELVKRADYYYGMDV  17  0  0  0  22  8 
 
 
VH Gene  DH Gene  JH Gene  R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
3-66*01  3-3*01  5*02  3  1  0.46522  0.87  3  2  0.66817  -0.4153 
3-74*01  No D gene 
Assignment  6*02  -  -  -  -  -  -  -  - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.17 A&B Sequence Analysis from Sample MYO7 
 
Table 4.17A - Best matching germline sequences were identified from aligning sequences in the IMGT database using JOINSOLVER software from the MYO7 
myositis section.  Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  V-J lengths and consecutive D match 
lengths (bp) were also identified using the JOINSOLVER software and allowed assignment of the DH genes as described in section 2.3.12.3.    
 
The number of mutations within functional rearranged genes were analysed collectively from all region of dissected cellular infiltration.  Base differences within 
the first 24 bases of sequence were disregarded as this part of the sequence binds the 5’ VH primer.   
 
The locations of mutations observed within functional rearranged genes were categorised as being within FR or CDR regions.  The numbers of mutations 
within these regions were expressed as a percentage of the entire length of the region to correct for the longer lengths observed within the framework regions. 
 
Table 4.17B - The number of replacement and silent mutations and the presence of any positive and negative selection was conducted as per Hershberg et al 
(294) as previously described.   R-CDR/FW and S-CDR/FW represent the number of replacement and silent mutations in the CDR and FW respectively.  
pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while pFW 
represents the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative sign indicates negative selection.  p-values <0.05 were 
deemed significant. 
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4.2.6 Sample MYO16 
 
4.2.6.1 VH Repertoire of Infiltrating B Cells 
As shown in Figure 4.22, two significant areas of infiltration within sample MYO16 
were microdissected and the DNA released from these areas was amplified in a 
nested  PCR  protocol  for  VH  amplification.    The  sequences  isolated  from  these 
areas, as well as a third area of infiltration, are shown in Table 4.18.  To establish 
the gene repertoire within sample MYO16, and to allow comparisons with normal 
control values and the baseline germline complexity, the sequence data from all 
regions  was  combined.  From  36  functional  gene  rearrangements  there  was  a 
significant selection for VH3 family gene segments against both the normal control 
values  and  the  germline  complexity  (Figure  4.23A).    No  significant  differences 
were  observed  for  the  other  VH  gene  families  against  either  set  of  the  control 
values.  In this sample DH gene assignments could be completed in 47.2% of the 
sequences. From this repertoire a selection for DH6 genes was observed which 
was  significant  against  both the  normal  control  values  and  germline  complexity 
(Figure 4.23B), no other selection was observed.  A positive selection for JH3 gene 
segments was observed within JH family members (Figure 4.23C).  This selection 
was  significant  against  normal  control  values  but  not  against  the  germline 
complexity.  Other selections observed within the infiltrating muscle repertoire in 
sample MYO16 was a decreased selection for the JH1 and JH2 genes but these 
were only significant against the germline complexity and not the normal control 
values.  
 
The discrepancies observed between JOINSOLVER and IMGT/V-QUEST for these 
sequences was observed for the VH3-15*01 JH6*03 gene rearrangement with 1 
mutation from region 5, IMGT/V-QUEST also suggest the 2P*01, 4*03 and 4*01 JH 
gene  assignment  (Appendix  1).    These  three  genes  were  the  only  genes  that 
IMGT/V-QUEST  could  assign  and  they  were  not found  to  be  within  the  best  5 
matches  using  the  JOINSOLVER  software.    For  the  VH3-11*01  JH6*03  gene 
rearrangements  in  region  6  with  11  and  13  mutations  the  best  matching  VH 
germline gene  in  both JOINSOLVER  and IMGT/V-QUEST  was  VH3-48*01, with 
fewer mutations, which resulted in an increased score of 1389 compared to 1326 in 213 
JOINSOLVER and 1372 compared to 1309 in IMGT/V-QUEST.  In these instances 
the VH3-11*01 gene was shown to be the 4
th and 6
th best matching gene but as 
these genes were rearranged with the same D and J gene segments in addition to 
the same CDR3 and junctional sequence composition as the other VH3-11*01 gene 
rearrangements these sequences were considered to be assigned the VH3-11*01 
gene segment instead of the VH3-48*01 gene segment.  
    
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
Before Microdissection  After Microdissection 
A 
B 
C 
Figure 4.22 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample MYO16 
 
Three regions of B cell infiltration were microdissected from sample MYO16.  Figure 4.22A 
and B demonstrates the microdissection of 2 regions of cellular infiltration.  Images were 
taken at 400X.  DNA released from these microdissections was amplified using a Nested 
PCR system (Figure 4.22C), as described in Chapter 2.  – indicates negative control PCR 
reactions  where DNA  was substituted  with  water  while  + indicates positive control  PCR 
reactions  using  peripheral  blood  mononuclear  cells  isolated  from  peripheral  blood  of  a 
healthy individual.  Results show amplification of all 6 VH families. 
400 bp 
400 bp 
VH1  VH2  VH3 
VH4  VH5  VH6 
_  MYO 
16  +  _  MYO 
16  +  _  MYO 
16  + 214 
Region  VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
1  3-09*01  6-6*01  4*02  5  0, 1, 1, 1, 1  AKDIGGQLVLGGVHYFDY  32  11 
  4-59*01  6-13*01  4*02  2  0, 2  ARVIAAAGKAAAYFDY  28  14 
  4-59*03  6-13*01  4*02  1  1  ARVIAAAGKAAAYFDY  32  14 
                 
5  1-46*01  No D gene 
Assignment  4*03  (1)  2  SRVIPGFPLDRFD  41  7 
  1-46*01  6-6*01  4*02  1  1  ARGGYSSSSGDY  28  15 
  3-07*01  No D gene 
Assignment 
3*02  10 
24, 32, 32, 
33, 33, 33, 
33, 33, 33, 
34 
SRVIPGFPLDRFDI  33  7 
  3-07*01  3-3*01  4*03  1  1  ARVGYYDFWGGWGFDY  31  22(+1) 
  3-15*01  3-3*01  4*02  1  13  ARVGYYDFWSGWGFDY  38  23 
  3-15*01  No D gene 
Assignment 
6*03  1  1  TTDLGELPYYYYYMDV  16  8 
  3-15*01  No D gene 
Assignment 
6*03  1  2  TTDLGELPYYYYMDV  16  6 
  4-34*01  3-10*01  5*02  1  0  ARVSKITMVRGVIIKRGWFDP  43  27(+1) 
                 
6  1-18*01  3-9*01  4*02  1  0  ARVRYDGILTGYDDY  34  15 
  3-11*01  No D gene 
Assignment  6*03  6  0, 1, 3, 3, 
11, 13  AREYGRSLWLTQYYYYMDV  28  9 
  3-48*01  2-21*01  6*03  2  0,1  AREVVVVIATPLSDYYYMDV  32  18 
  3-48*01  No D gene 
Assignment 
6*03  1  1  AREYGRSLWLTQYYYYMDV  28  9 
  3-48*03  4-4*01  4*02  1  6  ARGFFPNYSNYGNLLGS  44  12 
  4-61*01  6-13*01  6*03  1  2  ARETSPGYSSSWYGSYYYYYMDV  36  21 
 
 
 
 
 
 
 
 
 
 
 
Table 4.18 Heavy chain genes identified from myositis sample MYO16 
 
Best matching germline sequences were identified from aligning sequences in the IMGT database 
using JOINSOLVER software from the MYO16 myositis section.  The total number of sequences 
isolated is given in the 5
th column of the table; non-functional rearrangements indicated in brackets.  
Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  
CDR3 amino acid sequences were also identified using the JOINSOLVER software.  V-J lengths 
and consecutive D match lengths (bp) were also identified using the JOINSOLVER software and 
allowed assignment of the DH genes as described in section 2.3.12.3.    215 
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Figure 4.23 VH Gene Family Usage of MYO16 
 
VH gene family usage.  Distribution of functional genes was compared with published normal control 
values from Volpe and Kepler (251) as well as the germline complexity assuming every germline 
gene is capable of producing a functional rearrangement.  Absolute values were used in Chi Square 
Analysis to determine gene selections.  § represent a significant difference from normal control 
values; * represent a significant difference from the germline (p<0.05).  
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4.2.6.2 Mutational Analysis of B Cell Ig Sequences of Sample MYO16 
Results  of mutational numbers  within functional  rearrangements show  that  over 
60% of sequences isolated from sample MYO16 were essentially non-mutated (0-2 
mutations) while over 20% of sequences were highly mutated,  containing over 21 
mutations (Figure 4.24A).  The remainder of the sequences contain between 3 
and 20 mutations.  Results suggest the presence of a largely naïve population, 
possibly due to a recent migration from the PBL, as well as the presence of a 
number of highly mutated, possibly memory cells.  As seen with previous samples 
there were a higher percentage of mutations within CDR regions (Figure 4.24B) in 
comparison to framework regions.  There were a similar percentage of mutations 
between CDR1 and CDR2 regions. 
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Negative  selection  was  observed  in  the  FW  regions  of  two  of  the  isolated 
sequences; both of these sequences share the same VDJ gene rearrangement 
and junctional composition.  Negative selection in the FW was also observed in a 
3
rd sequence in sample MYO16 but in contrast to the other 2 sequences a negative 
selection was also observed in the CDR of this sequence.  All other sequences 
demonstrated both positive and negative selection within the CDR and FW regions 
but these were not statistically significant. 
Figure  4.24  Numbers  of  Mutations  and 
Mutational  Distribution  of  Functional 
Sequences in MYO16 
 
Figure  4.24A  -  The  number  of  mutations 
within  functional  rearranged  genes  were 
analysed  collectively  from  all  3  regions  of 
cellular  infiltration  within  sample  MYO16.  
Base differences within the first 24 bases of 
sequence were disregarded as this part of the 
sequence  binds  the  5’  VH  primer.  Graph 
demonstrates  sequences  within  cellular 
infiltrates  were  primarily  from  a  naïve 
population of infiltrating cells with some highly 
mutated sequences also present. 
 
Figure  4.24B  -  The  locations  of  mutations 
observed within functional rearranged genes 
were categorised as being within FR or CDR 
regions.    The  numbers  of  mutations  within 
these  regions  were  expressed  as  a 
percentage of the entire length of the region 
to  correct  for  the  longer  lengths  observed 
within  the  framework  regions.    Graph 
demonstrates  a  higher  percentage  of 
mutations  within  CDR  regions  compared  to 
framework regions. 
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Region  VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
1  3-09*01  6-6*01  4*02  5  0  -  -  -  -  -  -  -  - 
          1  0  0  0.46314  -0.53685  0  1  0.67146  -0.3285 
          1  0  0  0.46314  -0.53685  0  1  0.67146  -0.3285 
          1  0  0  0.46314  -  1  0  0.67146  -0.6714 
          1  0  0  0.46314  -  1  0  0.67146  -0.6714 
  4-59*01  6-13*01  4*02  2  0  -  -  -  -  -  -  -  - 
          2  1  0  0.44001  0.44001  1  0  0.65645  0.65645 
  4-59*03  6-13*01  4*02  1  1  0  0  0.44024  -  1  0  0.65722  0.65722 
                           
5  1-46*01  No D gene 
Assignment  4*03  (1)  2  0  0  0.47626  -0.5237  1  1  0.674  -0.652 
  1-46*01  6-6*01  4*02  1  1  0  0  0.47626  0  1  0  0.674  0.674 
  3-07*01  No D gene 
Assignment  3*02  10  24  11  2  0.44397  0.16557  6  5  0.67012  -0.1312 
          32  14  2  0.44397  0.17902  8  8  0.67012  -0.0537 
          32  14  2  0.44397  0.12036  9  7  0.67012  -0.1422 
          33  14  3  0.44397  0.3412  7  9  0.67012  -0.0084 
          33  14  2  0.44397  0.17902  9  8  0.67012  -0.0829 
          33  14  2  0.44397  0.17902  9  8  0.67012  -0.0829 
          33  14  2  0.44397  0.17902  9  8  0.67012  -0.0829 
          33  15  2  0.44397  0.12446  8  8  0.67012  -0.0537 
          33  14  2  0.44397  0.17902  9  8  0.67012  -0.0829 
          34  14  2  0.44397  0.25277  9  9  0.67012  -0.0468 
  3-07*01  3-3*01  4*03  1  0  -  -  -  -  -  -  -  - 
          1  0  0  0.44397  0  1  0  0.67012  0.67012 
  3-15*01  3-3*01  4*02  1  13  0  0  0.43976  -0.0097  5  8  0.6595  -0.0496 
  3-15*01  No D gene 
Assignment  6*03  1  1  0  0  0.43976  -0.5602  0  1  0.6595  -0.3404 
  3-15*01  No D gene 
Assignment  6*03  1  2  2  0  0.43976  0.19339  0  0  0.6595  0 
  4-34*01  3-10*01  5*02  1  0  -  -  -  -  -  -  -  - 
Cont… 218 
Region  VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
6  1-18*01  3-9*01  4*02  1  0  -  -  -  -  -  -  -  - 
  3-11*01  No D gene 
Assignment  6*03  6  0  -  -  -  -  -  -  -  - 
          1  0  0  0.48848  -  1  0  0.66592  0.66592 
          3  0  0  0.48848  -0.2617  1  2  0.66592  -0.2975 
          3  0  0  0.48848  -0.5115  2  1  0.66592  1.03506 
          11  6  1  0.48848  0.31078  2  2  0.66592  -0.2566 
          13  6  1  0.48848  0.71789  2  4  0.66592  -0.0526 
  3-48*01  2-21*01  6*03  2  0  -  -  -  -  -  -  -  - 
          1  0  0  0.51636  -  1  0  0.6621  0.6621 
  3-48*01  No D gene 
Assignment  6*03  1  1  0  0  0.49992  -0.5001  0  1  0.66392  -0.3361 
  3-48*03  4-41*01  4*02  1  6  4  1  0.49491  0.43894  0  1  0.66764  -0.1105 
  4-61*01  6-13*01  6*03  1  2  1  0  0.4489  0.4489  1  0  0.65022  0.65022 
 
Table 4.19 Analysis of Replacement and Silent Mutations and Positive and Negative Selection in Sample MYO16 
 
Replacement and silent mutations within the immunoglobulin sequences and antigen-driven selection were determined according to Hershberg et al 
(294) and the corresponding computer programme (http://clip.med.yale.edu/selection).  This improved method of analysis uses a focused binomial 
test to establish positive or negative mutational selections within the sequence with high specificity and increased sensitivity accounting for known 
biases within the immunoglobulin gene sequence.  R-CDR and S-CDR represents the number of replacement and silent mutations within the CDR 
respectively.  pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within 
the FW while p-CDR is the p-value of the focused binominal test on the CDR.  Conversely R-FW and S-FW represents the number of replacement 
and silent mutations within the FW respectively. pFW represent the probability of having a R mutation in the FW given all the mutations in the 
sequence except R mutations within the CDR while p-FW is the p-value of the focused binominal test on the FW.  If the number of R mutations is less 
than expected the software will test for negative selection and p-values will be preceded by a negative sign or if the number of mutations is more than 
expected the software will test for positive selection.  p-values <0.05 are highlighted in yellow and were deemed significant for selection. 
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4.2.6.3 CDR3 Analysis 
The muscle infiltrating population of B cells in this sample only produced 1 non-
functional rearrangement, as a result the unpaired t-test could not be used to 
determine  if  a  significant  difference  occurs  between  the  CDR3  lengths  and 
junctional  sequences  of  these  sequences;  the  unpaired  t-test  requires  more 
than 1 value in the non-functional group.  As shown in Table 4.20 the mean 
CDR3 length of functional sequences was 16.7 ± 0.4 amino acids (ranging from 
12 to 23 amino acids), while the non-functional gene had a CDR3 length of 13 
amino acids.  Analysis of the CDR3 lengths in correlation with the VH mutations 
of the sequences demonstrated a significant decrease in the CDR3 length in 
highly  mutated,  21+,  sequences  (Figure  4.25).    This  significant  decrease  in 
CDR3 length was observed for all 3 previous mutational groups.  The different 
sequence  features  of  the  junctional  regions  were  also  analysed.    In  the 
functional population of sequences a significant difference was observed for the 
removal  of  nucleotides  by  exonuclease  activity  between  the  VD  and  DJ 
junctional regions but not for the addition of P or N nucleotides in the junctions.  
As  only  1  non-functional  sequence  was  isolated  in  this  sample  a  statistical 
comparison  between  functional  and  non-functional  sequences  could  be 
conducted.    Within  the  functional  population  a  significant  increase  of 
exonuclease activity at the 5’DH and 5’JH regions of the junction was observed 
compared to the 3’VH region.        
 
Functional  16.7 ± 0.4  CDR3 Length 
Non-Functional  13 
  VD Junction  DJ Junction 
Functional  0.4 ± 0.2  0.6 ± 0.2  P Nucleotide 
Non-Functional  N/A  N/A 
Functional  6.2 ± 0.9  8.9 ± 1.1  N Nucleotide 
Non-Functional  N/A  N/A 
  3’ VH  5’ DH  3’ DH  5’JH 
Functional  1.1 ± 0.4  4.3 ± 0.7
θ  2.7 ± 0.7  4 ± 0.6
 θ  Exonuclease 
Activity  Non-Functional  N/A  N/A  N/A  N/A 
   
  Table 4.20 CDR3 and Junctional Analysis in Sample MYO16 
 
The mean amino acid length of the CDR3, the mean nucleotide numbers corresponding to P 
and N nucleotides as well as the mean number of germline nucleotides lost due to exonuclease 
activity  were  calculated  from  the  junctional  regions  of  all  immunoglobulin  sequences  from 
sample MYO16.  Results are given as the Mean ± SEM, statistical significance was established 
using an unpaired t-test.  Θ represents a significant difference from 3’VH. 220 
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4.2.6.4 Clonal Diversification in MYO16  
Within sample MYO16 two clonally related sets of sequences were discovered 
(Figure 4.26). This provides evidence of B cell clonal proliferation and mutation 
within cellular infiltrates of muscle inflammation.  These clones contained VH3 
family  gene  segments,  VH3-07*01  and  VH3-11*01,  within  the functional  gene 
rearrangements.  These  clones  were  isolated  from  different  regions  of  the 
muscle section; there was no evidence from the sequences isolated to suggest 
that clonally related B cells were migrating between different cellular aggregates 
suggesting that clones were generated independently in different cell clusters.  
In the clonal genealogical tree in Figure 4.26A 1 silent mutation was observed in 
the  clonal  branch  consisting  of  clones  C-J  but  this  silent  mutation  was  also 
observed in clone L.  As clones C-J did not contain the additional replacement 
mutation found in clones K and L this would suggest that the mutations were 
formed during different and branch mutational lineages.    
 
 
 
 
 
 
 
Figure  4.25  Mean  CDR3  Lengths  in 
Relation to VH Mutational Numbers  
 
The mean  CDR3  length  was  calculated 
for immunoglobulin sequences according 
the  number  of  mutations  within  the  VH 
segment  of  the  gene  rearrangement  to 
establish  any  relationship  between 
mutational  number  and  CDR3  length.  
Results  are  given  as  Mean  amino  acid 
CDR3  length  ±  SEM.    Groups  were 
compared  for  statistical  significance 
using the Tukey-Kramer test for multiple 
comparisons.    The  graph  demonstrates 
significant  changes  in  CDR3  length  for 
sequences containing over 20 mutations.  
This  reduction  in  CDR3  length  was 
significant against sequences containing 
0-2 mutations (*), 3-10 mutations (**) and 
11-20  mutations  (***).  p-values  <0.05 
were  deemed  significant.  *  was 
calculated at <0.001. 221 
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Germline3-07*01      GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTC 
CloneA               GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTC  
CloneB               GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTAAAGCCTGGGGGGTCCCTTAGACTC  
CloneC_D_E           GAGGTGCAGCTGGTGGAGTCTGGGGGGGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTC  
CloneF               GAGGTGCAGCTGGTGGAGTCTGGGGGGGGCTTGGTACAGCCTGGGGGGTCCCCGAGACTC  
CloneG               GAGGTGCAGCTGGTGGAGTCTGGGGGGGGCTCGGTACAGCCTGGGGGGTCCCTGAGACTC  
CloneH               GAGGTGCAGCTGGTGGAGTCTGGGGGGGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTC  
CloneI               GAGGTGCAGCTGGTGGAGTCTGGGGGGGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTC  
CloneJ               GAGGTGCAGCTGGTGGAGTCTGGGGGGGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTC  
CloneK               GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTC  
CloneL               GAGGTGCAGCTGGTGGAGTCTGGGGGGGGCTTGGTACAGCCTGGGGGGTCCCTGAGGCTC  
                      
                   CDR1 
Germline3-07*01      TCCTGTGCAGCCTCTGGATTCACCTTTAGTAGCTATTGGATGAGCTGGGTCCGCCAGGCT  
CloneA               TCCTGTGCAGCCTCTGGATTCACCTTTAGTAGCTATTGGATGAGCTGGGTCCGCCAGGCT  
CloneB               TCCTGTGCAGCCTCTGGATTCACTTTCAGTAACGCCTGGATGAGCTGGGTCCGCCAGGCT  
CloneC_D_E           TCCTGTGCACCCTCTGGATTCAGCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCT  
CloneF               TCCTGTGCACCCTCTGGATTCAGCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCT  
CloneG               TCCTGTGCACCCTCTGGATTCAGCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCT  
CloneH               TCCTGTGCACCCTCTGGATTCAGCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCT  
CloneI               TCCTGTGCACCCTCTGGATTCAGCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCT  
CloneJ               TCCTGTGCACCCTCTGGATTCAGCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCT 
CloneK               TCCTGTGCACCCCCTGGATTCAGCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCT  
CloneL               TCCTGTGCACCCCCTGGATTCAGCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCT  
                      
                CDR2 
Germline3-07*01      CCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAAGCAAGATGGAAGTGAGAAATACTAT  
CloneA               CCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCACGATGACAGGCGACATTACTAT  
CloneB               CCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCACGATGACAGGCGACATTACTAT  
CloneC_D_E           CCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCACGATGACAGGCGACATTACTAT  
CloneF               CCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCACGATGACAGGCGACATTACTAT  
CloneG               CCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCACGATGACAGGCGACATTACTAT  
CloneH               CCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCACGATGACAGGCGACATTACTAT  
CloneI               CCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCACGATGACAGGCGACATTACTAT  
CloneJ               CCAGGGAAGGGGCTGCAGTGGGTGGCCAACATAAACCACGATGACAGGCGACATTACTAT  
CloneK               CCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCACGATGACAGGCGACATTACTAT  
CloneL               CCAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCACGATGACAGGCGACATTACTAT  
                      
 
Germline3-07*01      GTGGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTGTAT  
CloneA               CTGCAGTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGGCAGAAACTTACTTTAT  
CloneB               CTGCAGTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGGCAGAAACTTACTTTAT  
CloneC_D_E           CTGCAGTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGGCAGAAACTTACTTTAT  
CloneF               CTGCAGTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGGCAGAAACTTACTTTAT  
CloneG               CTGCAGTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGGCAGAAACTTACTTTAT  
CloneH               CTGCAGTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGGCAGAAACTTACTTTAT  
CloneI               CTGCAGTCTGCGAAGGGCCGATTCACCATCTCCAGAGACAATGGCAGAAACTTACTTTAT  
CloneJ               CTGCAGTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGGCAGAAACTTACTTTAT  
CloneK               CTGCAGTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGGCAGAAACTTACTTTAT  
CloneL               CTGCAGTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGGCAGAAACTTACTTTAT  
                       
                CDR3 
Germline3-07*01      CTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGA  
CloneA               CTGGAAATGAACAGCCTGAAAGTCGAGGACACGGCCGTCTATTACTGTTCGAGGGT  
CloneB               CTGGAAATGAACAGCCTGAAAGTCGAGGACACGGCCGTCTATTACTGTTCGAGGGT  
CloneC_D_E           CTGGAAATGAACAGCCTGAAAGTCGAGGACACGGCCGTCTATTACTGTTCGAGGGT  
CloneF               CTGGAAATGAACAGCCTGAAAGTCGAGGACACGGCCGTCTATTACTGTTCGAGGGT  
CloneG               CTGGAAATGAACAGCCTGAAAGTCGAGGACACGGCCGTCTATTACTGTTCGAGGGT  
CloneH               CTGGAAATGAACAGCCTGAAAGTCGAGGACACGGCCGCCTATTACTGTTCGAGGGT  
CloneI               CTGGAAATGAACAGCCTGAAAGTCGAGGACACGGCCGTCTATTACTGTTCGAGGGT  
CloneJ               CTGGAAATGAACAGCCTGAAAGTCGAGGACACGGCCGTCTATTACTGTTCGAGGGT  
CloneK               CTGGAAATGAACAGCCTGAAAGTCGAGGACACGGCCGTCTATTACTGTTCGAGGGT  
CloneL               CTGGAAATGAACAGCCTGAAAGTCGAGGACACGGCCGTCTATTACTGTTCGAGGGT  
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Germline3-11*01      CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTC  
CloneA-D             CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCTGAGACTC  
CloneE               CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCAAGCCTGGAGGGTCCCCGAGACTC  
CloneF               CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGAGGGTCCCTGAGACTC 
CloneG               CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTC 
CloneH               CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTC  
CloneI               CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTC  
                      
                   CDR1 
Germline3-11*01      TCCTGTGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCT  
CloneA-D             TCCTGTGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCT  
CloneE               TCCTGTGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCT  
CloneF               TCCTGTGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCT 
CloneG               TCCTGTGCAGCCTCTGGATTCACCTTCAGTGACTACTACATGAGCTGGATCCGCCAGGCT  
CloneH               TCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGGGTCCGCCAGGCT  
CloneI               TCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGGGTCCGCCAGGCT  
                      
                CDR2 
Germline3-11*01      CCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTGGTAGTACCATATACTAC  
CloneA-D             CCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTGGTAGTACCATATACTAC  
CloneE               CCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTGGTAGTACCATATACTAC  
CloneF               CCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTGGTAGTACCATATACTAC  
CloneG               CCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTGGTAGTACCATATACTAC  
CloneH               CCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTAGTAGTACCATATACTAC  
CloneI               CCAGGGAAGGGGCTGGAGTGGGTTTCATACATTAGTAGTAGTAGTAGTACCATATACTAC  
                    
 
Germline3-11*01      GCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTAT  
CloneA-D             GCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTAT  
CloneE               GCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTAT  
CloneF               GCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTAT  
CloneG               GCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTAT  
CloneH               GCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTAT  
CloneI               GCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTAT  
                      
                   CDR3 
Germline3-11*01      CTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGAGA  
CloneA-D             CTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGAGA  
CloneE               CTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGAGA  
CloneF               CTGCAAATGAACAGCCTGAGAGTCGAGGACACGGCCGTGTATTACTGTGCGAGAGA  
CloneG               CTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGAGA  
CloneH               CTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGAGA  
CloneI               CTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGAGA  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.26 Clonal Proliferation in Sample MYO16 
 
Two sets of sequences were isolated from sample MYO16 demonstrated somatic hypermutation and clonal 
proliferation (A-D).  Figure A&B - The letters in the circles refer to individual sequences isolated from each B 
cell  clone.    Numbers  indicate  the  minimum  number  of  mutations  required  between  each  sequence  with 
bracketed  figures  representing  additional  silent  mutations.    The  dashed  circle  represents  a  hypothetical 
intermediate  whose  sequence  was  not  found  amongst  the  isolated  sequences.    Figure  C&D  -  The  DNA 
sequences of the clonally related sequences were aligned using ClustalW software to highlight the common 
and independent mutations.  CDR regions are highlighted in yellow, replacement mutations in blue and silent 
mutations in purple. 224 
Analysis of the replacement and silent mutations of these clones indicates that 
positive selection occurs within the CDR while negative selection occurs in the 
FW  regions  of  the  sequences  (Table  4.21).    These  selections  were  only 
significant  for  the  VH3-07*01  clone  for  negative  selections  in  the  framework 
regions; no other selection was statistically significant.  This negative selection 
was also observed in two of the individual sequences of this clone when the 
sequences were analysed independently (Table 4.19). 
 
VH Gene  DH Gene  JH Gene  R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
3-07*01  No D gene 
Assignment  3*02  18  3  0.44397  0.24823  14  12  0.67012  -0.0397 
3-11*01  No D gene 
Assignment  6*03  6  1  0.41326  0.39307  4  4  0.69174  -0.1382 
 
Table 4.21 Analysis of Replacement and Silent Mutations and Positive and Negative 
Selection in Clonally Related B Cells in Sample MYO16 
 
The number of replacement and silent mutations and the presence of any positive and negative 
selection was conducted as per Hershberg et al (294) as previously described.  For clonally 
related sequences mutations shared across the sequences are only counted once and p values 
are calculated for the clone as a single entity. R-CDR/FW and S-CDR/FW represent the number 
of replacement and silent mutations in the CDR and FW respectively.  pCDR represents the 
probability of having a R mutation in the CDR given all the mutations in the sequence except R 
mutations within the FW while pFW represents the probability of having a R mutation in the FW 
given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent  the  p-value  of  the  focused  binominal  test  on  the  CDR  and  FW  respectively.    A 
negative sign indicates negative selection.  p-values <0.05 were deemed significant. 
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4.2.7 Sample MYO17 
From sample MYO17 only two functional sequences were isolated from multiple 
microdissections and DNA amplification (Figure 4.27).  Table 4.22A details the 
characteristics of the two different isolated sequences.  VH3-30*03 and VH6-
01*01 gene segments were used in these sequences along with JH4*02 and 
JH5*02 respectively.  A DH gene, DH3-9*01, could only be assigned to the VH3-
30*03 gene rearrangement; the consecutive D match length was not sufficient 
in the VH6*01 gene rearrangement for a gene to be statistically assigned.  Both 
VH3 and VH6 genes isolated from this sample were mutated, as shown in Table 
4.22; they contained 12 and 5 mutations respectively.  Examination of these 
mutations demonstrated that they were congregated mostly within CDR regions 
of the sequence.  For the VH3 gene these were mostly within the CDR1 region 
of  the  sequence  while,  conversely  for  the  VH6  gene,  mutations  were  solely 
located  within  the  CDR2  region  of  the  sequence.    Negative  selection  was 
observed in both the CDR and FW regions of both sequences (Table 4.22B) 
after  analysis  of  the  R  and  S  mutations  but  these  selections  were  not 
statistically significant.  Analysis of the junctional characteristics from the VH3-
30*03  gene  rearrangement  where  a  statistical  DH  match  could  be  made 
revealed that no P nucleotides were present at with the VD or DJ junctions for 
either sequence.  The number of N nucleotides assigned was 7 and 9 at the VD 
and DJ regions respectively while the mean exonuclease activity at the 3’VH, 
5’DH, 3’DH and 5’JH region was 4, 0, 9 and 5 respectively.  
 
The gene assignments using the JOINSOLVER software match those of the 
IMGT/V-QUEST software for both sequences isolated from sample MYO17. 
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Before Microdissection  After Microdissection 
A 
B 
C 
Figure 4.27 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample MYO17 
 
Regions of B cell and plasma cell infiltration  were microdissected from sample MYO17.  
Figure 4.27A and B demonstrates the microdissection of 2 regions of cellular infiltration.  
Images  were  taken  at  400X.    DNA  released  from  these  microdissections  was  amplified 
using  a  Nested  PCR  system  (Figure  4.27C),  as  described  in  Chapter  2.    –  indicates 
negative control PCR reactions where DNA was substituted with water while + indicates 
positive  control  PCR  reactions  using  peripheral  blood  mononuclear  cells  isolated  from 
peripheral blood of a healthy  individual. Results show  amplification of VH 3,  4, 5 and 6 
families. 
400 bp 
400 bp 
VH1  VH2  VH3 
VH4  VH5  VH6 
_  MYO 
17  +  _  MYO 
17  + 
_  MYO 
17  + 227 
 
Mutational Distribution 
 (% of length)  VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Mutations  CDR3 
CDR3 
Length 
(aa)  Framework  CDR1  CDR2 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
3-30*03  3-9*01  4*02  1  12  ATGAYYDILSGARPFDY  17  3.2  13.3  5.6  38  20(+2) 
6-01*01  No D gene 
Assignment  5*02  1  5  VRSPLKQWLEP  11  1.8  0  1.8  29  6 
 
VH Gene  DH Gene  JH Gene  R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
3-30*03  3-9*01  4*02  4  1  0.46606  -0.908  3  4  0.67432  -0.0977 
6-01*01  No D gene 
Assignment  5*02  0  1  0.47248  -0.1468  2  2  0.65538  -0.278 
 
 
 
 
 
 
 
 
 
 
A 
B 
Table 4.22 A&B Sequence Analysis from Sample MYO17 
 
Table 4.22A - Best matching germline sequences were identified from aligning sequences in the IMGT database using JOINSOLVER software from the 
MYO17 myositis section.  Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  V-J lengths and consecutive D 
match lengths (bp) were also identified using the JOINSOLVER software and allowed assignment of the DH genes as described in section 2.3.12.3.    
 
The number of mutations within functional rearranged genes were analysed collectively from all region of dissected cellular infiltration.  Base differences within 
the first 24 bases of sequence were disregarded as this part of the sequence binds the 5’ VH primer.   
 
The locations of mutations observed within functional rearranged genes were categorised as being within FR or CDR regions.  The numbers of mutations 
within these regions were expressed as a percentage of the entire length of the region to correct for the longer lengths observed within the framework regions. 
 
Table 4.22B - The number of replacement and silent mutations and the presence of any positive and negative selection was conducted by Hershberg et al 
(294) as previously described.   R-CDR/FW and S-CDR/FW represent the number of replacement and silent mutations in the CDR and FW respectively.  
pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while pFW 
represents the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative sign indicates negative selection.  p-values <0.05 were 
deemed significant. 
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4.2.8 Sample MYO19 
As described in Chapter 3 both CD20
+ cells and plasma cells were identified 
within  sample  MYO19.    Despite  the  microdissection  and  DNA  amplification 
(Figure  4.28)  of  various  areas  of  infiltration  within  sample  MYO19  only  1 
functional rearranged sequence could be isolated (Table 4.23A).  This gene 
used the 3-21*01 VH gene segment along with DH3-22*01 and JH3*02 in this 
functional rearrangement.  As described in Table 4.14 the sequence isolated 
from  sample  MYO19  only  contained  4  mutations  throughout  the  entire 
sequence.    These  mutations  were  solely  within  framework  regions  of  the 
sequence with CDR regions remaining non-mutated. Based on these mutations 
negative selection was observed within both the CDR and FW regions but these 
were not significant selections (Table 4.23B).  Only 1 P nucleotide was present 
in this rearrangement at the DJ region of the junction.  14 and 15 N nucleotides 
were  present  at  the  VD  and  DJ  junctions  respectively  while  2,  6,  13  and  4 
nucleotides  were  removed  respectively  from  the  3’VH,  5’DH,  3’DH  and  5’JH 
region. 
 
No changes in gene assignment were observed for this sequence using the 
IMGT/V-QUEST software. 
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Before Microdissection  After Microdissection 
A 
B 
C 
Figure 4.28 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample MYO19 
 
Regions of B cell and plasma cell infiltration  were microdissected from sample MYO19.  
Figure 4.28 A and B demonstrates the microdissection of 2 regions of cellular infiltration.  
Images  were  taken  at  400X.    DNA  released  from  these  microdissections  was  amplified 
using  a  Nested  PCR  system  (Figure  4.28C),  as  described  in  Chapter  2.    –  indicates 
negative control PCR reactions where DNA was substituted with water while + indicates 
positive  control  PCR  reactions  using  peripheral  blood  mononuclear  cells  isolated  from 
peripheral blood of a healthy individual. Results show amplification of VH 3,4 and 6 families. 
400 bp 
400 bp 
VH1  VH2  VH3 
VH4  VH5  VH6 
_  MYO 
19  +  _  MYO 
19  +  _  MYO 
19  + 230 
Mutational Distribution  
(% of length)  VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3 
CDR3 
Length 
(aa)  Framework  CDR1  CDR2 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
3-21*01  3-22*01  3*02  1  4  ARPLSTPYDSRSASAAAFDI  20  1.8  0  0  42  12 
 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
0  0  0.5135  -0.1151  1  3  0.65938  -0.1312 
 
 
 
 
 
 
 
 
 
 
Table 4.23 A&B Sequence Analysis from Sample MYO19 
 
Table 4.23A - Best matching germline sequences were identified from aligning sequences in the IMGT database using JOINSOLVER software from the 
MYO19 myositis section.  Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  V-J lengths and consecutive D 
match lengths were also identified using the JOINSOLVER software and allowed assignment of the DH genes as described in section 2.3.12.3.    
 
The number of mutations within functional rearranged genes were analysed collectively from all region of dissected cellular infiltration.  Base differences within 
the first 24 bases of sequence were disregarded as this part of the sequence binds the 5’ VH primer.   
 
The locations of mutations observed within functional rearranged genes were categorised as being within FR or CDR regions.  The numbers of mutations 
within these regions were expressed as a percentage of the entire length of the region to correct for the longer lengths observed within the framework regions. 
 
Table 4.23B - The number of replacement and silent mutations and the presence of any positive and negative selection was conducted as per Hershberg et al 
(294) as previously described.   R-CDR/FW and S-CDR/FW represent the number of replacement and silent mutations in the CDR and FW respectively.  
pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while pFW 
represents the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative sign indicates negative selection.  p-values <0.05 were 
deemed significant. 
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4.2.9 Sample MYO23 
4.2.9.1 VH Repertoire of Infiltrating B Cells 
Due  to  the  low  numbers  of  infiltrating  cells  within  sample  MYO23  and  with  no 
distinctive region of cellular aggregation it was not possible to obtain information 
from specific areas of the MYO23 sample.  As a result the gene repertoire of the 
whole  section  was  determined  after  nested  PCR  reactions  amplified  the  VH 
rearrangements from infiltrating cells (Figure 4.29).  A total of 9 different functional 
genes were isolated from the infiltrating population which consisted of 4 different 
gene rearrangements with different mutational patterns (Table 4.24).  Despite the 
small number of genes identified the repertoire of these genes was compared to 
both sets of control values (Figure 4.30), except for the DH genes as there was not 
enough DH genes (4) identified to allow a statistical comparison to be conducted.  
For  VH  genes  only  VH3  and  VH4  gene  segments  were  used  within  these 
rearrangements which resulted in a significant selection for the VH3 gene segments 
which  was  significant  against  both  the  normal  control  values  and  the  germline 
complexity.  A significant selection for JH2 and JH5 genes was observed which was 
only  significant  against  normal  control  values  and  not  the  germline  complexity 
when  the  absolute  values  were  used  in  the  Chi  square  analysis.  A  selection 
against JH4 gene segments was also observed which again was only significant 
against the normal control values and not the germline complexity.  As only a small 
number of sequences could be isolated from the muscle section these selections 
may  not  be  representative  of  the  entire  population  within  the  whole  area  of 
inflammation.     
 
For  all  sequences  isolated  from  sample  MYO23  the  gene  assignments  by 
JOINSOLVER  matched  those  of  IMGT/V-QUEST.    The  only  change  to  gene 
assignments arose in the VH3-33*01 JH5*02 sequence with 18 mutations.  This 
gene  sequence  was  the  4
th  best  matching  gene  for  this  sequence  in  both 
JOINSOLVER  and  IMGT/V-QUEST.    The  difference  between  these  sequences 
was a score of 10 using JOINSOLVER and a score of 9 using IMGT/V-QUEST, 
which represented 1 base difference.  The 4
th best matching gene was used as this 
gene shared CDR3, junctional and JH compositions with other sequences.  232 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
3-07*01  6-19*01  2*01  3  5, 6, 7  ARGYTSGWYSANWYFDL  27  19(+2) 
3-33*01  No D gene 
Assignment  5*02  4  8, 9(X2), 18  AKDSNRARPGWFDP  25  6 
3-33*03  6-19*01  2*01  1  9  ARGYTSGWYSATWYFDL  28  19(+2) 
4-04*07  No D gene 
Assignment  2*01  1  10  ARVDSRRQVWSPNWYFDL  34  6 
 
 
 
 
 
 
 
 
400 bp 
400 bp 
VH1  VH2  VH3 
VH4  VH5  VH6 
Figure 4.29 Amplification of VH-gene rearrangements from Sample MYO23 
 
As no distinct area of aggregation from infiltrating cells was observed within sample MYO23 
and infiltrating cells were observed throughout the whole section, the whole section was 
used to obtain DNA.  DNA released from the section was amplified using a Nested PCR 
system, as described in Chapter 2.  – indicates negative control PCR reactions where DNA 
was substituted with water while + indicates positive control PCR reactions using peripheral 
blood mononuclear cells isolated from peripheral blood of a healthy individual. Results show 
amplification of all 6 VH families. 
_ 
MYO 
23 
+  _ 
MYO 
23 
+  _ 
MYO 
23 
+ 
Table 4.24 Heavy chain genes identified from myositis sample MYO23 
 
Best matching germline sequences were identified from aligning sequences in the IMGT database 
using JOINSOLVER software from the MYO23 myositis section.  The total number of sequences 
isolated is given in the 4
th column of the table; non-functional rearrangements indicated in brackets.  
Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  
CDR3 amino acid sequences were also identified using the JOINSOLVER software.  V-J lengths 
and consecutive D match lengths (bp) were also identified using the JOINSOLVER software and 
allowed assignment of the DH genes as described in section 2.3.12.3.    233 
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Figure 4.30 VH Gene Family Usage of MYO23 
 
VH gene family usage.  Distribution of functional genes was compared with published normal control 
values from Volpe and Kepler (251) as well as the germline complexity assuming every germline 
gene is capable of producing a functional rearrangement.  Absolute values were used in Chi Square 
Analysis to determine gene selections.  § represent a significant difference from normal control 
values; * represent a significant difference from the germline (p<0.05).  
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4.2.9.2 Mutational Analysis of B Cell Ig Sequences of Sample MYO23 
Examining  the  number  of  mutations  within  functional  rearrangements  (Figure 
4.31A)  showed  that  the  majority  of  sequences  contained  between  3  to  10 
mutations while a small percentage, approximately 10% contained between 11 and 
20 mutations.  Sequences with 0 to 2 mutations or over 21 mutations were not 
found  within  the  infiltrating  repertoire.    Analysis  of  mutational  location  (Figure 
4.31B) demonstrated that there were a higher percentage of mutations within CDR 
regions of the gene in comparison to framework regions.  Between CDR regions 
CDR1 possessed a higher percentage of mutations in comparison to CDR2. 
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From these mutations positive and negative selections were observed in both the 
CDR  and  FW  regions,  the  only  significant  selections  were  found  in  the  gene 
rearrangements using the VH3-33*01 and VH3-33*03 gene segments (Table 4.25).  
These selections were shown to be negative within the framework regions of the 
sequences. 
 
A 
B 
Figure  4.31  Numbers  of  Mutations  and 
Mutational  Distribution  of  Functional 
Sequences in MYO23 
 
Figure  4.31A  -  The  number  of  mutations 
within  functional  rearranged  genes  were 
analysed collectively from the whole sample 
of  cellular  infiltration  within  sample  MYO23.  
Base differences within the first 24 bases of 
sequence were disregarded as this part of the 
sequence  binds  the  5’  VH  primer.    Graph 
demonstrates  sequences  within  cellular 
infiltrates are not from a naïve population 
but rather a highly mutated population. 
 
Figure  4.31B  -  The  locations  of  mutations 
observed within functional rearranged genes 
were categorised as being within FR or CDR 
regions.    The  numbers  of  mutations  within 
these  regions  were  expressed  as  a 
percentage of the entire length of the region 
to  correct  for  the  longer  lengths  observed 
within  the  framework  regions.    Graph 
demonstrates  a  higher  percentage  of 
mutations  within  CDR  regions  compared  to 
framework regions. 235 
VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
3-07*01  6-19*01  2*01  3  5  2  0  0.44397  0.50381  2  1  0.67012  -0.9537 
        6  3  0  0.44397  0.27233  2  1  0.67012  -0.9537 
        7  2  0  0.44397  0.50381  4  1  0.67012  0.60288 
3-33*01  No D gene 
Assignment  5*02  4  8  2  2  0.46759  -0.2431  0  4  0.67394  -0.0012 
        9  2  2  0.46759  -0.2431  1  4  0.67394  -0.0065 
        9  2  2  0.46759  -0.2431  1  4  0.67394  -0.0065 
        18  6  2  0.46759  -0.7825  4  6  0.67394  -0.0195 
3-33*03  6-19*01  2*01  1  9  2  2  0.46654  -0.3726  2  3  0.67113  -0.0491 
4-04*07  No D gene 
Assignment  2*01  1  10  5  1  0.43938  0.31935  2  2  0.65629  -0.2761 
 
Table 4.25 Analysis of Replacement and Silent Mutations and Positive and Negative Selection in Sample MYO23 
 
Replacement and silent mutations within the immunoglobulin sequences and antigen-driven selection were determined according to Hershberg et al 
(294) and the corresponding computer programme (http://clip.med.yale.edu/selection).  This improved method of analysis uses a focused binomial 
test to establish positive or negative mutational selections within the sequence with high specificity and increased sensitivity accounting for known 
biases within the immunoglobulin gene sequence.  R-CDR and S-CDR represents the number of replacement and silent mutations within the CDR 
respectively.  pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within 
the FW while p-CDR is the p-value of the focused binominal test on the CDR.  Conversely R-FW and S-FW represents the number of replacement 
and silent mutations within the FW respectively. pFW represent the probability of having a R mutation in the FW given all the mutations in the 
sequence except R mutations within the CDR while p-FW is the p-value of the focused binominal test on the FW.  If the number of R mutations is less 
than expected the software will test for negative selection and p-values will be preceded by a negative sign or if the number of mutations is more than 
expected the software will test for positive selection.  p-values <0.05 are highlighted in yellow and were deemed significant for selection. 
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4.2.9.3 CDR3 Analysis 
The mean amino acid CDR3 length from these sequences is shown in Table 
4.26.  No non-functional sequences were isolated from the infiltrating repertoire 
and therefore the CDR3 lengths in the two populations could not be compared.  
Previous analysis with the CDR3 lengths in this study has examined the CDR3 
lengths  in  different  mutational  groups.    As  shown  in  Figure  4.31A  all  the 
mutations from these sequences fell into only 2 of the mutational groups which 
did not allow the statistical multiple comparison test to be conducted as 3 or 
more  groups  are  required  for  the  comparison.    Analysis  of  the  P  and  N 
nucleotides as well as the exonuclease activity can only be conducted on gene 
rearrangements where a D gene has been assigned.  As this was the case for 
only 4 sequences which exhibited the same junctional composition no statistical 
comparisons could be conducted but the number of the different nucleotides are 
shown in Table 4.26. 
 
Functional  15.7 ± 0.6  CDR3 Length 
Non-Functional  N/A 
  VD Junction  DJ Junction 
Functional  0  0  P Nucleotide 
Non-Functional  N/A  N/A 
Functional  0  7.3 ± 0.3  N Nucleotide 
Non-Functional  N/A  N/A 
  3’ VH  5’ DH  3’ DH  5’JH 
Functional  2 ± 0  0  0  2.3 ± 0.3  Exonuclease 
Activity  Non-Functional  N/A  N/A  N/A  N/A 
 
Table 4.26 CDR3 and Junctional Analysis in Sample MYO23 
 
The mean amino acid length of the CDR3, the mean nucleotide numbers corresponding to P 
and N nucleotides as well as the mean number of germline nucleotides lost due to exonuclease 
activity  were  calculated  from  the  junctional  regions  of  all  immunoglobulin  sequences  from 
sample MYO23.  Results are given as the Mean ± SEM, statistical significance was established 
using an unpaired t-test.  Instances  where no non-functional sequences were identified and 
values could not be calculated were recorded as non applicable (N/A).   
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4.2.9.4 Clonal Diversification in MYO23  
Despite  the  low  numbers  of  isolated  sequences  from  sample  MYO23,  four 
clonally related sequences were found within the infiltrating repertoire (Figure 
4.32).  These sequences shared the same VDJ gene rearrangement as well as 
common  junctional  areas.    In  these  clonally  related  sequences  clone  K  and 
clone L share 1 replacement mutation but do not contain the other additional 
mutations,  after  branching  of  the  clonal  tree,  indicated  in  Figure  4.32  which 
indicates that the mutations were formed during different and branch mutational 
lineages.    As  shown  in  Table  4.27  these  mutations  indicate  that  negative 
selection was occurring in both the CDR and FW regions but this selection was 
only significant in the framework regions.  
 
 
 
Table 4.27 Analysis of Replacement and Silent Mutations and Positive and Negative 
Selection in Clonally Related B Cells in Sample MYO23 
 
The number of replacement and silent mutations and the presence of any positive and negative 
selection were conducted as per Hershberg et al (294) as previously described.  For clonally 
related sequences mutations shared across the sequences are only counted once and p values 
are calculated for the clone as a single entity. R-CDR/FW and S-CDR/FW represent the number 
of replacement and silent mutations in the CDR and FW respectively.  pCDR represents the 
probability of having a R mutation in the CDR given all the mutations in the sequence except R 
mutations within the FW while pFW represents the probability of having a R mutation in the FW 
given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent  the  p-value  of  the  focused  binominal  test  on  the  CDR  and  FW  respectively.    A 
negative sign indicates negative selection.  p-values <0.05 were deemed significant. 
 
 
 
 
 
 
 
 
 
 
VH Gene  DH Gene  JH Gene  R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
3-33*01  No D gene 
Assignment  5*02  6  3  0.46759  -0.4743  5  7  0.67394  -0.0086 238 
 
 
 
 
 
 
 
 
 
 
 
 
 
Germline3-33*01      CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTC  
CloneA-I             CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTC  
CloneJ               CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTC  
CloneK               CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGAGGTCCCTGAGACTC  
CloneL               CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTC  
                      
                               CDR1 
Germline3-33*01      TCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCT  
CloneA-I             TCCTGTGCAGCGTCTGGATTTACCTTCAGTAGTTATGGCATGCACTGGGTCCGCCAGGCT  
CloneJ               TCCTGTGCAGCGTCTGGATTTACCTTCAGTAGTTATGGCATGCACTGGGTCCGCCAGGCT  
CloneK               TCCTGTGCAGCGTCTGGATTTACCTTCAGTAGTTATGGCATGCACTGGGTCCGCCAGGCT  
CloneL               TCCTGTGTAGCCTCTGGACTCACCTTTAGTAACTATTGGATGAGCTGGGTCCGCCAGGCT  
                     
                CDR2 
Germline3-33*01      CCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATAAATACTAT  
CloneA-I             CCAGGCAAGGGGCTGGAGTGGGTGGCAACTATATGGTATGATGGCAGTAATAAATACTAT 
CloneJ               CCAGGCAAGGGGCTGGAGTGGGTGGCAACTATATGGTATGATGGCAGTAATAAATACTAT  
CloneK               CCAGGCAAGGGGCTGGAGTGGGTGGCAACTATATGGTATGATGGCAGTAATAAATACTAT  
CloneL               CCAGGGAAGGGGCTGGAGTGGGTGGCAACTATATGGTATGATGGCAGTAATAAATACTAT  
                      
 
Germline3-33*01      GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTAT  
CloneA-I             GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTAT 
CloneJ               GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAGTTCCAAGAACACGCTGTAT  
CloneK               GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTAT  
CloneL               GCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTAT  
                      
                   CDR3 
Germline3-33*01      CTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGA  
CloneA-I             TTGCAAATGAACAGCCTGCGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGA  
CloneJ               TTGCAAATGAACAGCCTGCGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGA  
CloneK               TTGCAAATGAACAGCCTGCGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGA  
CloneL               TTGCAAATGAACAGCCTGCGAGCTGAGGACACGGCTGTGTATTACTGTGCGAAAGA  
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Figure 4.32 Clonal Proliferation in Sample MYO23 
 
A set of sequences was isolated from sample MYO23 which demonstrated somatic hypermutation and clonal 
proliferation.  Figure A - The letters in the circles refer to individual sequences isolated from each B cell clone.  
Numbers indicate the minimum number of mutations required between each sequence with bracketed figures 
representing  additional silent  mutations.    The  dashed  circle  represents  a  hypothetical  intermediate  whose 
sequence was not found amongst the isolated sequences.  Figure B - The DNA sequences of the clonally 
related sequences were aligned using ClustalW software to highlight the common and independent mutations.  
CDR regions are highlighted in yellow, replacement mutations in blue and silent mutations in purple. 
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4.2.10 Sample MYO24  
Infiltrating  B  cells  were  not  observed  within  sample  MYO24  but  their 
differentiated  counter-parts  plasma  cells  were  identified  within  the  infiltrating 
population.  These areas of plasma cells were microdissected and the resultant 
DNA was amplified for VH1-6 families (Figure 4.33).  Despite the presence of 
amplification bands for the VH5 family no functional rearrangement sequences 
could be identified from these or subsequent microdissections. 
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Figure 4.33 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample MYO24 
 
The  region  of  plasma  cell  infiltration  was  microdissected  from  sample  MYO24.    Figure 
4.33A demonstrates the microdissection of the region of cellular infiltration.  Images were 
taken at 200X.  DNA released from these microdissections was amplified using a Nested 
PCR system (Figure 4.33B), as described in Chapter 2.  – indicates negative control PCR 
reactions  where DNA  was substituted  with  water  while  + indicates positive control  PCR 
reactions  using  peripheral  blood  mononuclear  cells  isolated  from  peripheral  blood  of  a 
healthy individual. Results show amplification of VH 5 family genes. 
400 bp 
400 bp 
VH1  VH2  VH3 
VH4  VH5  VH6 
_  MYO 
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4.2.11 Sample MYOC 
Aggregates of infiltrating cells in sample MYOC were microdissected and the 
DNA amplified for all 6 VH families (Figure 4.34).  Despite the various areas of 
infiltration  within  sample  MYOC,  and  the  presence  of  both  CD20
+  cells  and 
plasma  cells,  only  1  gene  rearrangement  was  isolated  from  various 
microdissections, Table 4.28A.  This gene used the 3-33*01 VH gene segment 
along  with  JH2*01  in  its  functional  rearrangement,  no  DH  gene  could  be 
statistically  assigned.    The  rearrangement  contained  a  CDR3  length  of  13 
amino acids.  This gene rearrangement was isolated for every clone checked 
and from various sections and regions of the sample but was not evident in any 
other samples tested therefore could not be the result of contamination.  The 
sequence isolated from MYOC was highly mutated with a total of 47 mutations 
throughout the VH gene segment.  Examining the distribution of these mutations 
(Table 4.28A), the majority of mutations were located within the CDR2 region.  
Mutational percentages within framework regions of the sequence were similar 
to that of the CDRs.  Analysis of the R and S mutations within this sequence 
demonstrate a significant negative selection in the framework regions of this 
sequence (Table 4.28B).  A positive selection was observed in the CDR but this 
was not significant.  As no DH gene could be assigned to this Ig rearrangement 
the sequence composition, P and N Nucleotides, in the junctional regions of the 
sequence could not be identified. The lack of different gene rearrangements 
and clonally related sequences may indicate that memory cells are infiltrating 
the muscle and are proliferating without mutating.    
 
From the sequence isolated from the inflammatory infiltrate in sample MYOC no 
discrepancies  in  gene  assignment  was  observed  between the  JOINSOLVER 
and IMGT/V-QUEST software’s. 
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Figure 4.34 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample MYOC 
 
The region of B cell and plasma cell infiltration was microdissected from sample MYOC.  
Figure 4.34A demonstrates the microdissection of the region of cellular infiltration.  Images 
were taken at 200X.  DNA released from these microdissections  was amplified using a 
Nested PCR system (Figure 4.34B), as described in Chapter 2.  – indicates negative control 
PCR reactions  where DNA  was substituted  with  water while  + indicates positive control 
PCR reactions using peripheral blood mononuclear cells isolated from peripheral blood of a 
healthy individual. Results show amplification of all 6 VH families. 
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Mutational Distribution 
 (% of length) 
 
VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number 
of Point 
Mutations 
CDR3 
CDR3 
Length 
(aa)  Framework  CDR1  CDR2 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
3-33*01  No D gene 
Assignment  2*01  1  47  ARAIHITAWSFDL  13  12.2  13.3  33.3  29  7 
 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
15  5  0.46759  0.85564  16  11  0.67394  -0.0438 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
A 
Table 4.28 A&B Sequence Analysis from Sample MYOC 
 
Table 4.28A - Best matching germline sequences were identified from aligning sequences in the IMGT database using JOINSOLVER software from the 
MYOC myositis section.  Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  V-J lengths and consecutive D 
match lengths (bp) were also identified using the JOINSOLVER software and allowed assignment of the DH genes as described in section 2.3.12.3.    
 
The number of mutations within functional rearranged genes were analysed collectively from all region of dissected cellular infiltration.  Base differences within 
the first 24 bases of sequence were disregarded as this part of the sequence binds the 5’ VH primer.   
 
The locations of mutations observed within functional rearranged genes were categorised as being within FR or CDR regions.  The numbers of mutations 
within these regions were expressed as a percentage of the entire length of the region to correct for the longer lengths observed within the framework regions. 
 
Table 4.28B - The number of replacement and silent mutations and the presence of any positive and negative selection were conducted as per Hershberg et 
al (294) as previously described.   R-CDR/FW and S-CDR/FW represent the number of replacement and silent mutations in the CDR and FW respectively.  
pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while pFW 
represents the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative sign indicates negative selection.  p-values <0.05 were 
deemed significant. 
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4.2.12 Sample MYOE 
From the microdissections and DNA amplification of infiltrating plasma cells in 
sample MYOE (Figure 4.35), that were previously described in Chapter 3, only 
2  different  functional  rearrangements  were  isolated  from  various 
microdissections  within  sample  MYOE  (Table  4.29A).    One  of  the  isolated 
genes used the VH1-f*01 gene along with the DH2-2*01 and JH4*02 while the 
other gene isolated used the 3-09*01 VH gene with an unidentified DH gene 
while  JH6*02  completing  the  functional  rearrangement.    The  VH1  gene 
rearrangement  contained  6  mutations,  only  1  of  these  was  within  the  CDR 
region of the sequence.  Conversely the VH3 gene rearrangement contained a 
total of 36 mutations.  As described in Table 4.29A mutations were distributed 
within all regions of the functional gene, 12.2% of the framework regions of the 
sequence contained mutations while 31.1% of CDR regions of the sequence 
contained mutations.  Analysis of the R and S mutations of these sequences 
demonstrated that negative selection was occurring in both the CDR and FW 
regions of these sequences, but these selections were not deemed significant 
(Table 4.29B).  Both sequences contained similar CDR3 lengths with only 1 
amino acid difference between the two sequences which may be representative 
of a common antigenic epitope.  As no DH gene could be assigned to the VH3-
09*01 gene rearrangement, P and N nucleotides at the VD and DJ regions of 
the junctions as well as exonuclease activity at the VH5’ and JH3’ regions could 
not  be  assigned.    For  the  other  isolated  gene  from  sample  MYOE  no  P 
nucleotides were identified as either of the VD or DJ junctions while 6 and 11 N 
nucleotides were observed at the VD and DJ respectively.  There appeared to 
be no exonuclease activity at the 5’VH end of the rearrangement but 8, 4 and 5 
nucleotides were removed by exonuclease activity at the 5’DH, 3’DH and 3’JH 
regions of the rearrangement.    
 
No anomalies between the JOINSOLVER and IMGT/V-QUEST algorithms were 
observed. 
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Figure 4.35 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample MYOE 
 
The region of plasma cell infiltration was microdissected from sample MYOE.  Figure 4.35A 
demonstrates the microdissection of the region of cellular infiltration.  Images were taken at 
200X.    DNA  released  from  these  microdissections  was  amplified  using  a  Nested  PCR 
system  (Figure  4.35B),  as  described  in  Chapter  2.    –  indicates  negative  control  PCR 
reactions  where DNA  was substituted  with  water  while  + indicates positive control  PCR 
reactions  using  peripheral  blood  mononuclear  cells  isolated  from  peripheral  blood  of  a 
healthy individual. Results show amplification of VH 3, 4 and 5 families. 
400 bp 
400 bp 
VH1  VH2  VH3 
VH4  VH5  VH6 
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Mutational Distribution  
(% of length)  VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number 
of Point 
Mutations 
CDR3 
CDR3 
Length 
(aa)  Framework  CDR1  CDR2 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
1-f*01  2-2*01  4*02  1  6  ATGRVVVPAATASIFDF  17  2.3  6.7  0  44  19 
3-09*01  No D gene 
Assignment  6*02  1  36  VQDVSRLTDLWRSMDV  16  12.2  20  11.1  38  7 
 
 
VH Gene  DH Gene  JH Gene  R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
1-f*01  2-2*01  4*02  1  0  0.42032  -0.8133  3  2  0.68787  -0.6761 
3-09*01  No D gene 
Assignment  6*02  7  2  0.46315  -0.3223  16  11  0.67147  -0.1822 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.29 A&B Sequence Analysis from Sample MYOE 
 
Table 4.29A - Best matching germline sequences were identified from aligning sequences in the IMGT database using JOINSOLVER software from the MYOE 
myositis section.  Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  V-J lengths and consecutive D match 
lengths (bp) were also identified using the JOINSOLVER software and allowed assignment of the DH genes as described in section 2.3.12.3.    
 
The number of mutations within functional rearranged genes were analysed collectively from all region of dissected cellular infiltration.  Base differences within 
the first 24 bases of sequence were disregarded as this part of the sequence binds the 5’ VH primer.   
 
The locations of mutations observed within functional rearranged genes were categorised as being within FR or CDR regions.  The numbers of mutations 
within these regions were expressed as a percentage of the entire length of the region to correct for the longer lengths observed within the framework regions. 
 
Table 4.29B - The number of replacement and silent mutations and the presence of any positive and negative selection was conducted as per Hershberg et al 
(294) as previously described.   R-CDR/FW and S-CDR/FW represent the number of replacement and silent mutations in the CDR and FW respectively.  
pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while pFW 
represents the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative sign indicates negative selection.  p-values <0.05 were 
deemed significant. 
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4.2.13 Sample MYO25 (Myositis Control Sample from Healthy Volunteer) 
 
Immunohistochemical studies to identify any infiltrating cell populations within 
control muscle demonstrated that only a few CD68
+ cells were present within 
the  control  muscle  sample.  To  further  substantiate  this  finding  DNA  was 
released  from  an  entire  section  of  the  control  sample  and  the  DNA  was 
amplified for all 6 VH families by nested PCR (Figure 4.36).  Analysis of these 
PCR products on an agarose gels showed that no amplification products were 
observed from the control muscle sample.  Consequently no further work was 
carried out with this sample. 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.36 Amplification of VH-gene rearrangements from Sample MYO25 
 
As  no  distinct  aggregation  of  infiltrating  cells  was  observed  within  sample  MYO25  and 
infiltrating cells were observed through out the whole section, the whole section was used to 
obtain DNA.  DNA released from the section was amplified using a nested PCR system, as 
previously described in Chapter 2.  – indicates negative control PCR reactions where DNA 
was substituted with water while + indicates positive control PCR reactions using peripheral 
blood mononuclear cells isolated from peripheral blood of a healthy individual. Results show 
no amplification for all 6 VH families. 
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4.2.14 VH Repertoire in Myositis 
In addition to determining the repertoire of infiltrating B cells and plasma cells in 
individual  patients  the  gene  usage  distribution  and  mutational  patterns  were 
also examined collectively for all patients, as well as in the DM and PM myositis 
subsets,  to  establish  if  any  particular  gene  family  was  used  preferentially  in 
functional gene rearrangements.  As shown in Chapter 2 (Table 2.1) there was 
some discrepancy in the diagnosis of patient MYO17 between PM and IBM in 
the clinical notes, therefore the sequences generated from this sample were not 
included  in  the  PM  subset  but  were  for  the  full  collective  set  of  sequences.  
Collective examination of all sequences to establish a common gene selection 
between  the  different  myositis  subsets  illustrated  a  selection  for  VH3  gene 
segments compared to normal control values, which was also observed for the 
sequences  identified  from  DM  patients  (Figure  4.37A).    A  selection  for  VH2 
gene segments and a selection against VH1 and VH4 gene segments, against 
normal control values, were also observed in sequences from DM patients.  No 
significant  positive  or  negative  selections  were  observed  for  the  sequences 
isolated  from  PM  patients,  the  repertoire  mirrored  that  of  the  normal  control 
values  as  well  as  the  germline  values.    A  comparison  of  the  DM  and  PM 
repertoires revealed a significant difference for the use of VH5 gene segments 
between  the  2  myositis  subsets.    Examining  the  use  of  individual  gene 
segments indicated that in the myositis collective repertoire there was selection 
for the use of various gene segments, VH3-11, 3-15, 3-30, 3-33, 3-66 and 3-7, 
while selection against VH1-2, 3-23 and 4-34 was observed compared to the 
frequency observed for normal control values, although variations in the allele 
use of each gene were observed.  For the DM repertoires a selection for VH2-5, 
3-11, 3-15, 3-30, 3-66, 3-7 and 3-9 and against VH4-34 was observed while in 
the PM repertoire a selection for the use of gene segments VH1-f, 3-30, 3-33, 3-
72 and 5-51 and against the use of VH3-23 was observed compared to normal 
control values.  For DH family genes, genes could be statistically assigned in 
52.7,  59.1  and  41.8%  of  the  sequences  from  the  myositis,  DM  and  PM 
collective sets respectively.  A selection for DH6 gene segments against normal 
control values was observed for both the myositis collective repertoire and the 
DM repertoire, while a decline in the use of DH2 gene segments against normal 
controls  was  also  observed  within  infiltrating  cells  for  the  myositis  collective 248 
repertoire  (Figure  4.37B).    Similarly  with  the  individual  VH  gene  segments, 
selection  for  the  use  of  DH  gene  segments  was  observed.    In  the  myositis 
collective repertoire a selection for the use of DH3-22 and 6-6 was observed 
while  a  selection  against  DH2-2  and  6-19  was  also  observed.    In  the  DM 
repertoire the only selection found was a selection for the use of gene segment 
DH6-6 while in the PM repertoire positive selections were observed for the use 
of DH1-7, 3-22, 5-12, 5-24 and 6-19 gene segments.  As previously discussed 
variations in the allele use within these genes were observed.  Selection against 
the use of JH1 gene segments was observed for the myositis and DM collective 
repertoires  against  normal  control  values  (Figure  4.37C).    These  were  also 
significant against the germline values for both sets of sequences as well as the 
PM sequence collection.  A selection against the use of JH2 gene segments 
was also observed in the DM sequences which were only significant against 
germline values, conversely a selection for the use of the JH2 as well as JH5, 
gene  segments  was  observed  for  sequences  isolated  from  the  PM  patients 
which was significant against normal control values.  A comparison of the DM 
and PM sequence repertoire demonstrated a significant difference in the use of 
JH2, 5 and 6 gene segments.  A significant increase in the use of JH2 and JH5 
gene  segments  was  observed  in  the  PM  repertoire  compared  to  the  DM 
repertoire while a selection for JH6 gene segments was observed in the DM 
repertoire compared to the PM repertoire.    
 
The numbers of point mutations within the whole collective myositis repertoire 
were found to have a diverse number of mutations and similar distribution in 
each mutational group (Figure 4.38A).  Conversely the sequences in the DM 
repertoire were found to be largely a naïve population of cells with almost 50% 
of  sequences  containing  0  to  2  mutations  in  the  VH  region,  although  a 
considerable  proportion  of  the  sequences  from  infiltrating  cells  were  highly 
mutated.  Very few naïve cells were found in the PM repertoire, less than 10% 
of  the  sequences  were  essentially  unmutated  with  the  majority  of  cells 
containing  a  large  number  of  mutations.    As  expected  the  majority  of  these 
mutations were found within the CDRs, for each subset of sequences (Figure 
4.38B).  For the DM repertoire this was greater in CDR1 and was found to be 
almost similar in the PM repertoire between CDR1 and CDR2. 249 
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Figure 4.37 VH Gene Family Usage in Myositis Patients 
 
VH gene family usage.  Distribution of functional genes was compared with published normal 
control values from Volpe and Kepler (251) as well as the germline complexity assuming every 
germline gene is capable of producing a functional rearrangement.  Absolute values were used 
in Chi Square Analysis to determine gene selections.  § represent a significant difference from 
normal control values; * represent  a significant difference from the germline; ξ represents a 
significant difference between DM and PM myositis subsets (p<0.05). ￿ From all DM, PM and IBM 
patients. 
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A collective summary of the mutational selections (Table 4.30) conducted as 
per Hershberg et al (294) revealed that sequences, with significant selections, 
from all 3 subsets mostly demonstrated negative selection with the FW regions 
in  contrast  to  positive  selection  in  the  CDR  which  would  be  expected  in  an 
antigen-driven response.  A small percentage of sequences in the myositis and 
PM  collective  sets  demonstrated  positive  selection  in  the  CDRs  but  in  the 
myositis  collective  repertoire  negative  selection  was  also  found  within  the 
CDRs.    This  negative  selection  in  the  CDRs  was  also  observed  in  some 
sequences of the DM repertoire. 
 
    MYO
￿ (n=148)  DM (n=93)  PM (n=55) 
    CDR  FW  CDR  FW  CDR  FW 
    #  %  #  %  #  %  #  %  #  %  #  % 
Positive 
Selection  3  2.0  0  0  0  0  0  0  3  5.5  0  0 
Negative 
Selection  2  1.4  21  14.2  2  2.2  10  10.8  0  0  11  20 
 
Table 4.30 Summary Table of Myositis Sequences with Significant Selection 
 
The total number of sequences with significant selection, positive or negative, in CDR or FW 
regions was calculated (#) and the percentage (%) calculated for each myositis category to 
reveal  a  higher  percentage  of  sequences  contained  negative  selection  in  the  FW  regions 
compared to other selections within the Ig sequences. ￿ From all DM, PM and IBM patients. 
Figure  4.38  Numbers  of  Mutations  and 
Mutational  Distribution  of  Functional 
Sequences in Myositis Patients 
 
Figure  4.38A  -  The  number  of  mutations 
within  functional  rearranged  genes  were 
analysed collectively from all myositis patients 
as well as in the DM and PM subsets.  Base 
differences  within  the  first  24  bases  of 
sequence were disregarded as this part of the 
sequence  binds  the  5’  VH  primer.    Graph 
demonstrates  sequences  collectively  from 
myositis patients show a diverse distribution 
of mutational numbers while sequences from 
DM  patients  were  primarily  from  a  naïve 
populations and sequences from PM patients 
were highly mutated.   
 
Figure  4.38B  -  The  locations  of  mutations 
observed within functional rearranged genes 
were categorised as being within FR or CDR 
regions.    The  numbers  of  mutations  within 
these  regions  were  expressed  as  a 
percentage of the entire length of the region 
to  correct  for  the  longer  lengths  observed 
within  the  framework  regions.    Graph 
demonstrates  a  higher  percentage  of 
mutations  within  CDR  regions  compared  to 
framework regions for all 3 groups. 
 
￿ From all DM, PM and IBM patients. 
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In  each  set  of  sequences  no  significant  differences  in  CDR3  length  was 
observed and a similar CDR3 length was observed for all functional and non-
functional  sequences  in  each  group  (Table  4.31).    Analysis  of  these  CDR3 
lengths in correlation with the VH mutational numbers revealed no significant 
differences between the CDR3 length in unmutated and mutated sequences for 
the myositis and DM collective repertoires (Figure 4.39). A significantly shorter 
CDR3  length  was  observed  in  the  PM  collective  repertoire  for  the  group  of 
sequences  containing  21+  mutations  in  comparison  to  the  sequences  with 
between 11 and 20 mutations.  For the additional of P nucleotides there was a 
significant increase observed at the VD junction between functional and non-
functional populations in the myositis and DM sequence sets.  No significant 
differences in N nucleotide additions were observed for any group of sequences 
except the increased addition of N nucleotides in the DJ junction of functional 
sequences in the PM sequence set compared to the VD junction.  A similar 
pattern of exonuclease activity was observed for all 3 groups, an increase in 
exonuclease activity was observed and the 5’DH and 5’JH regions of the junction 
compared to the 3’VH region.  No significant differences were observed, for any 
group  of  sequences,  between  the  5’  and  3’DH  regions  or  the  3’DH  and  5’JH 
regions of the DJ junction. 
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Figure 4.39 Mean CDR3 Lengths in Relation to VH Mutational Numbers 
 
The mean CDR3 length was calculated for immunoglobulin sequences according the number 
of mutations within the VH segment of the gene rearrangement to establish any relationship 
between mutational number and CDR3 length.  Results are given as Mean amino acid CDR3 
length  ±  SEM.    Groups  within  each  myositis  category  were  compared  for  statistical 
significance  using  the  Tukey-Kramer  test  for  multiple  comparisons.    ***  represents  a 
significant difference from 11-20 mutations.  p-values <0.05 were deemed significant. ￿ From 
all DM, PM and IBM patients.  252 
Functional  15.7 ± 0.3  MYO  Non-Functional  15.8 ± 1.7 
Functional  15.8 ± 0.4  DM  Non-Functional  15.8 ± 1.7 
Functional  15.4 ± 0.5 
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PM  Non-Functional  N/A 
  VD Junction  DJ Junction 
Functional  0.5 ± 0.1  0.4 ± 0.1  MYO  Non-Functional  1.4 ± 0.7*  0.4 ± 0.4 
Functional  0.5 ± 0.1  0.5 ± 0.1  DM  Non-Functional  1.4 ± 0.7*  0.4 ± 0.4 
Functional  0.4 ± 0.2  0.3 ± 0.1 
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PM  Non-Functional  N/A  N/A 
Functional  7.4 ± 0.5  8.5 ± 0.5  MYO  Non-Functional  6.0 ± 0.5  10.2 ± 4.1 
Functional  7.9 ± 0.7  8.1 ± 0.7  DM  Non-Functional  6.0 ± 1.5  10.2 ± 4.1 
Functional  6.2 ± 1.0  9.4 ± 0.6** 
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PM  Non-Functional  N/A  N/A 
  3’ VH  5’ DH  3’ DH  5’JH 
Functional  1.2 ± 0.2  5.0 ± 0.5
 θ  3.9 ± 0.4  4.8 ± 0.4
 θ  MYO  Non-Functional  2.0 ± 0.7  2.2 ± 1.2
 θ  6.2 ± 2.9  4.6 ± 1.6
 θ 
Functional  1.1 ± 0.2  5.2 ± 0.6
 θ  4.1 ± 0.4  4.6 ± 0.5
 θ  DM  Non-Functional  2.0 ± 0.7  2.2 ± 1.2
 θ  6.2 ± 2.9  4.6 ± 1.6
 θ 
Functional  1.2 ± 0.2  4.7 ± 1.3
 θ  3.2 ± 0.8  5.3 ± 0.6
 θ 
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PM  Non-Functional  N/A  N/A  N/A  N/A 
 
Table 4.31 CDR3 and Junctional Analysis in Myositis 
 
The mean amino acid length of the CDR3, the mean nucleotide numbers corresponding to P 
and N nucleotides as well as the mean number of germline nucleotides lost due to exonuclease 
activity were calculated from the junctional regions of all myositis immunoglobulin sequences as 
well as in DM and PM subsets.  Results are given as the Mean ± SEM.  Instances where no 
non-functional sequences were identified and values could not be calculated were recorded as 
non applicable (N/A).  * indicates a significant difference between functional and non-functional 
sequences  while  **  indicates  a  significant  difference  between  the  VD  and  DJ  junctions 
established using an unpaired t-test.   Θ represents a significant difference from 3’VH. 
 
A total of 9 clonally related sets of sequences were found in approximately a 
third of all myositis patients.  Both DM patients, MYO1 and MYO16, contained 
clonally related sets of sequences, 1 from sample MYO1 and 2 from sample 
MYO16,  although  due  to  the  detection  of  a  deletion  in  the  clonally  related 
sequences of sample MYO1 this set of clonally related sequences may not be 
valid  depending  on  the  alignment  algorithm  used.    Sets  of  clonally  related 
sequences were found in 3 of 11 PM patients, MYO3, MYO5 and MYO23, with 
4 different clonal sets in sample MYO5 and 1 each from samples MYO3 and 
MYO23.    In  each  set  of  clonal  sequences  there  was  no  positive  selection 
observed within the CDRs, as would have been expected for clonally related 
and  antigen-driven  sequences.    For  4  of  the  9  clones  a  significant  negative 253 
selection was observed in the FW regions; remaining clones did not exhibit any 
significant positive or negative selection in either CDR or FW.     
 
Comparison of the different mutations within all sequences identified common 
replacement  mutations  within  a  number  of  sequences.    The  replacement 
mutation at amino acid 31 within the CDR1 region, serine to asparagine (S→N), 
was found within all 4 MYO5 clones.  In addition to this mutation within the VH5-
51, VH3-04, VH3-33 and VH3-53 sequences of MYO5, the mutation was also 
observed  within  the  VH1-69  gene  in  sample  MYO3  and  the  VH3-30  gene  in 
sample MYO23.  Other common mutations were also observed within CDR2.  
Silent  mutations  within  amino  acids  51  and  59,  isoleucine  and  tyrosine 
respectively,  were  found  in  sequences  from  both  MYO3  and  MYO5;  a 
replacement mutation at amino acid 65 was found in sequences from MYO3, 
MYO5 and MYO7.  At amino acid 65 the glycine amino acid was mutated to an 
aspartic  acid  amino  acid  (G→D).  Within  the  same  patient  these  common 
mutations may represent that a common antigenic determinant is driving the 
immune  response  and  hence  the  mutational  patterns  of  the  Ig  genes  while 
common mutations across different patients suggests mutational hot-spots are 
present within the Ig genes found in these autoimmune disorders.        
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4.3 Discussion 
The role of B cells in myositis is still currently unresolved and it was previously 
thought that myositis was essentially T cell mediated, especially PM and IBM.  
The core aim of this study was to establish if muscle infiltrating B cells were 
being locally stimulated resulting in an antigen-driven response leading to tissue 
pathology.  To address this hypothesis DNA was extracted from microdissected 
B  cells  from  frozen  muscle  sections  and  identification  of  the  gene 
rearrangement of Ig sequences from muscle infiltrating B cells was conducted.  
Analysis of these sequences determined if any gene or clonal selection process 
was occurring within the muscle tissue.   At the start of this work no previous 
studies had investigated the gene repertoire or clonal diversification of B cells 
within muscle tissue of myositis patients.   
 
Results  from  Chapter  3  verified  the  occurrence  of  B  cells,  and  their 
differentiated counter-parts plasma cells, within the muscle infiltrating population 
of cells.  The results also established a number of proliferating B cells within the 
inflamed muscle tissue.  This suggested that muscle infiltrating B cells may be 
proliferating,  undergoing  somatic  hypermutation  and  diversification  in  an 
antigen-driven  response.    Further  confirmation  of  gene  selections  and 
diversification of the Ig repertoire from normal control values, accumulation of 
mutations  and  identification  of  clonally  related  sequences  with  common 
mutations  would  substantiate  the  hypothesis  that  muscle  infiltrating  B  cells 
within  inflamed  muscle  were  undergoing  an  antigen-driven  response.    The 
results presented in this chapter support these characteristics of antigen-driven 
diversification  as  well  as  the  hypothesis  of  a  B  cell  antigen-driven  response 
within inflamed muscle of myositis patients. 
 
Gene  selections  were  observed  for  all  3  segments  of the  Ig  rearrangement, 
these  were  shown  to  be  both  disease  specific  as  well  as  patient  specific.  
Conclusive clonal diversification of these genes was also observed in 4 of 12 
patients, 1 DM patient and 3 PM patients.  Collectively these results indicate 
that  an  antigen-driven  response  occurs  within  the  target  tissues  of  these 
patients and that clonal B cells may play a significant role in the pathogenesis of 
these diseases, similar to studies in other disorders of autoimmune origin or 255 
where ectopic lymphoid tissues have been identified (52;283-285;289;317-325).  
In  some  instances  gene  selection  and  clonal  diversification  could  not  be 
assessed  in  some  patients  due  to  the  small  numbers  of  rearrangements 
identified  from  the  muscle  infiltrating  B  cell  population,  a  larger  number  of 
sequences may be required for these samples.  This could be a result of the 
variations  in  cell  phenotypes  found  to  be  infiltrating  the muscle  described  in 
Chapter 3.  For patients MYO1, 3, 5 and 16, where gene selections and clonal 
diversification were observed, a significant infiltrating population of B cells was 
observed within frozen muscle sections.  Conversely for other samples, MYO6, 
7, 17, 19, 23, 24, C, E, a larger population of plasma cells were observed within 
muscle sections which could account for the diminished Ig repertoire or lack of 
clonal proliferation within these samples although despite the large plasma cell 
infiltration  in  sample  MYO23  gene  selections  and  clonal  diversification  of  Ig 
genes were observed.  The mutational analysis of some of these sequences 
from  these  patients  would  suggest  that  an  antigen-driven  response  had 
occurred.  It could be postulated that the plasma cells in these samples had 
been recruited to the sites of inflammation in their activated B cell or memory 
state and prior to biopsy had differentiated into plasma cells whereas in the 
previous samples the B cells are expanding and diversifying within the muscle 
and had not yet matured into plasma cells.  The work conducted in this study 
was  unable  to  differentiate  between  the  B  cell  and  plasma  cell  repertoires; 
further  single  cell  or  cell  sorting  analysis  would  need  to  be  conducted  to 
distinguish the two populations of cells.  A re-stimulation of memory cells may 
also  account  for  the  diminished  Ig  repertoire;  chronic  stimulation  of  antigen-
specific  memory  B  cells  could  account  for  the  large  number  of  replicate 
sequences  identified  in  this  study,  for  all  samples,  with  the  same  Ig 
rearrangement.    Alternatively  memory  B  cells  could  have  entered  a 
differentiation  stage  of  proliferation  without  further  somatic  hypermutation 
accounting for the lack of clonal proliferation.  The process used in this study 
could  not  differentiate  between  this  chronic  stimulation  and  repeated 
amplification of a single amplicon within the PCR reactions unless consecutive 
sections  or  different  regions  of  the  section  were  analysed  in  separate  PCR 
reactions.    In  order  to  account  for  this  repeated  amplification  and  prevent 
misinterpretation of clonal expansion without mutation these sequences were 256 
only  counted  once  within  the  sample  repertoire.    If  a  chronic  stimulation  of 
antigen specific memory B cells was to occur within the inflamed muscle tissue 
what  remains  uncertain  is  whether  these  memory  cells  are  recruited  to  the 
inflamed muscle site in this mature state or whether peripherally activated B 
cells are initially recruited which later mature into memory cells.  It could be that 
the timings of the clinical investigations into the inflamed muscle have missed 
the initial expansion and mutation phase of the B cell antigen driven response.  
The use of a memory B cell marker, CD27, in the previous immunohistological 
studies described in Chapter 3 may have provided additional evidence of the B 
cell  role  in  inflamed muscle of myositis  patients. In  circumstances  where  no 
clonally related sets of sequences were identified it may indicate that infiltrating 
B cells are not mutating within the regions of cellular infiltration but are mutating 
and migrating into infected tissue from other locations, presumably the draining 
lymph  nodes,  in  contrast  to  the  proposed  hypothesis.    Recent  studies  have 
demonstrated  the  expression  of  AID,  the  enzyme  responsible  for  SHM  and 
CSR,  and  the  functional  relationship  between  AID,  CSR  and  autoantibody 
production within the FDC networks of ectopic GC-like structures in SS and RA 
patients (55;326).  AID expression was not found within target tissues where no 
FDCs or GCs were present except for in interfollicular (IF) large B cells outwith 
these GC compartments where AID has been shown to be functionally active 
(327-329).    Identification  and  classification  of  AID  expressing  cells  within 
inflamed muscle would corroborate the findings of this study, SHM and clonal 
diversification,  and  provide  greater  insight  into  antigen-driven  responses  in 
autoimmune  target  tissues  where  no  GC  structures  are  present.    The 
participation of ectopic lymphoid tissues in generating antigen specific B cell 
responses has also been recently described by Weinstein et al (330) to further 
substantiate that the target tissue in various autoimmune diseases are sites of 
active antigen-specific response rather than sites of lymphocyte accumulation.      
 
From the results described in Chapter 3 a number of samples contained Ki67
+ 
proliferating  B  cells,  MYO1,  17,  19,  24  and  E,  but  evidence  of  clonal 
diversification was only observed for sample MYO1.  The need for analysis of 
additional  muscle  sections  may  be  required  to  fully  evaluate  the  process  of 
clonal diversification in these samples. 257 
As previously described in Chapter 3 the impact of patient’s therapy on cellular 
infiltration  as  well  as  Ig  gene  repertoire  and  identification  of  clonally  related 
sequences in this chapter cannot be overlooked.  As previously described in 
Chapter 2 (Table 2.1) and Chapter 3, section 3.3, six patients, MYO5, 19, 23, 
24, C and E, were receiving steroid therapy at the time or just prior to biopsy.  
Additionally patient MYO5 was receiving IVIg therapy while patient MYO19 was 
receiving  methotrexate.    These  therapies  could  have  distorted  the  true 
heterogeneity of the B cell response in these patients.  Despite the therapeutic 
interventions gene selections and clonally related sets of sequences in MYO5 
and MYO23 indicate that B cell antigen-driven diversification was still occurring 
within the inflamed muscle tissue.  This is more significant for patient MYO5 
who had been receiving therapy for three years prior to the biopsy while patient 
MYO23 had only received a week of therapy which was stopped two weeks 
prior to the biopsy.  As previously mentioned in Chapter 2 the biopsy for patient 
MYO5 used in this study was conducted approximately 3 years following the 
initial biopsy for clinical investigations for diagnosis.  Examination of this initial 
biopsy  would  have  provided  interesting  insights  into  the  original  Ig  gene 
repertoire and clonal diversification sequence sets of B cells within the inflamed 
muscle at the onset of the disease while also revealing the impact of therapy on 
these two factors but unfortunately this biopsy was not available for analysis.    
 
A surprising finding from this study was the lack of significant positive selection 
within  CDRs.    The  accumulation  of  mutations  and  identification  of  clonally 
related sequences indicate the occurrence of B cell antigen-driven responses 
within  the  inflamed muscle  but are  not  substantiated  with  significant positive 
selection in Ig sequences.  Positive CDR selection was observed for a small 
percentage of sequences but the bulk of selection was found to be negative 
selection in the FW regions, although this negative selection was also observed 
in the CDRs (Table 4.30).   Antigen driven responses have traditionally been 
associated  with  an  increase  in  replacement  mutations  from  expected 
frequencies  in  CDRs  indicating  positive  selection  while  decreased  levels  of 
replacement  mutations  within  FW  regions  indicated  negative  selection.    The 
methods previously and currently used to detect selection based on the analysis 
of mutation patterns in Ig sequences are described in section 4.3.3.  Current 258 
analysis has indicated that previous methods have misinterpreted positive CDR 
selection with negative selection in the FW regions due to crosstalk which could 
not be differentiated in previous methods.  This may indicate that studies that 
have previously established positive selection above expected frequencies in 
antigen-driven  studies  may  be  based  on  flawed  methodology  and  generate 
false positive selection within the Ig sequences.  Taking into consideration the 
updated  parameters  of  analysis  by  Hershberg  et  al  (294)  which  incorporate 
fundamental  aspects  of  sequence  variation  and  diversity  into  assigning 
selection,  provides  a  more  accurate  assessment  of  selection  within  Ig 
sequences.  The lack of positive selection in CDRs observed in this study may 
relate  to  findings  previously  described  where  selection  against  amino  acid 
replacement  in  CDRs  may  occur  to  prevent  the  degradation  of  high  affinity 
autoantibodies (331).  Other possibilities may include a lower rate of SHM at 
ectopic sites in comparison to secondary lymph nodes (330) or a defect may 
occur in affinity maturation if there is less competition over lower affinity cells at 
ectopic sites (330) due to an abundance of self antigen or a lack of regulation 
outside  GCs  (301;332;333).    This  could  also  correspond  to  the  absence  of 
FDCs from a large cohort of samples in Chapter 3 and recent studies which 
demonstrated the expression and function of AID in FDC networks (55;326). 
 
Analysis of the CDR3 regions, the addition of P and N nucleotides as well as 
exonuclease  activity  at  the  junctional  regions  in  the  current  study  yielded 
different  results  compared  to  published  studies  (238;241;242;251;291).  
Generally  previous  studies  have  demonstrated  that  CDR3  lengths  are 
significantly  shorter  in  functional  rearrangements.    In  the  current  study  no 
significant differences were observed between the CDR3 lengths in functional 
and  non-functional  populations  for  individual  patients  as  well  as  collective 
analysis  for  the  different  disease  subsets.    In  this  study  very  few  cells 
expressing  non-functional  Ig  sequences  were  detected  within  the  infiltrating 
repertoire and in some cases no non-functional sequences were examined in 
individual patients, therefore comparison to the non-functional repertoire could 
not  be  conducted.    Analysis  of  a  larger  population  of  sequences  may  be 
required  in  order  to  fully  determine  if  selection  for  smaller  CDR3  lengths  is 
present  within  functional  sequences  in  the  disease  repertoires.    Differences 259 
between disease repertoires and the normal control repertoire may also account 
for  this  change  in  CDR3  lengths  in  the  functional  and  non-functional 
populations.  One  study  also  demonstrated  a  significant  decrease  in  CDR3 
length  in  mutated  sequences  compared  to  unmutated  sequences  (238), 
generally within this study this pattern was not observed with exception for the 
collective  PM  sequences  and  sample  MYO16  (Figure  4.25)  where  highly 
mutated  sequences  contained  a  significantly  shorter  CDR3  compared  to  the 
sequences with fewer mutations.  Again this may indicate a difference in the 
enzymatic mechanisms and gene selections within disease models compared 
to normal control models, although in addition to the CDR3 length the amino 
acid  composition  of  the  CDR3  would  also have  to  be  considered.   Previous 
studies have also examined the addition of P an N nucleotides as well as the 
exonuclease  activity  with  the  junctional  regions  (251;291;334).    Generally  a 
significant increase in P and N nucleotides were found within the VD junction 
compared to the DJ junction, a pattern that was not observed in the current 
study.  The increased addition of N nucleotides at the VD junction is thought to 
relate to the increased TdT expression during the development stage of V-DJ 
joining.  TdT was found to be initially upregulated during the D-J recombination 
in  pre-pro-B  development  stage  with  a  further  increase  at  the  V-DJ 
recombination  stage  observed  in  pro-B  cells,  it  was  then  observed  that  TdT 
expression  quickly  declines  (251).    The  results  of  the  current  study  do  not 
correspond to these findings but may relate to selection in the target tissues.  
Previous  studies  have  also  reported  a  significant  decrease  in  exonuclease 
activity  at  the  VH  region  compared  to  the  5’DH  and  JH  regions  (291;334),  a 
similar pattern to that observed in this study.  These variations in exonuclease 
activity at various regions within the CDR3 have been thought to relate to the 
primary  sequence  of  the  gene  rearrangements.    An  increased  exonuclease 
activity was observed in DH2, DH3 and JH6 genes compared to other DH and JH 
genes (334).   It had been proposed that the slightly more AT rich region at the 
5’JH region is preferentially targeted by exonuclease activity (291).      
 
One aspect of antigen-driven B cells not examined in this study was the process 
of isotype switching.  Evidence showing the isotype switching of antibodies in 
these responses would further substantiate the antigen driven response in the 260 
target tissues of myositis patients.  If these studies were to continue constant 
region  primers  could  be  used  in  PCR  reactions  to  establish  the  isotype  of 
antibody  produced  from  muscle  infiltrating  B  cells  alternatively 
immunohistochemical studies could be conducted with antibodies specific to the 
various  antibody  isotypes.    The  occurrence  of  isotype  switching  was 
demonstrated in a recent study by Bradshaw et al (90) which also examined the 
incidence of antigen-driven B cell responses in the target tissues of myositis 
patients  is discussed fully  in  section  4.3.1.   Briefly  Bradshaw  et al  identified 
clonal  variants  of  different  antibody  isotypes  (IgG  and  IgA)  in  DM  patient, 
providing  further  evidence  of  antigen-driven  diversification  of  B  cells  within 
inflamed muscle.  A recent review (335) has suggested that the constant region 
may also influence antibody specificity and affinity.  Another aspect of the B cell 
response not examined in this study was the Ig repertoire and mutations of the 
light  chains.    Examination  of  the  light  chain  sequences  from  the  muscle 
infiltrating B cell population would have given a rounded examination of the full 
B cell response in this study.  Amplification of lambda and kappa light chains 
were  conducted  for  a  number  of  samples  in  this  study  with  successful 
amplification but due to the extensive nature of the work required for the light 
chain analysis, time constraints and the sufficient use of heavy chain sequences 
to  determine  antigen-driven  clonal  diversification  this  aspect  of  the  response 
was  not  fully  pursued  but  should  be  considered  in  subsequent  studies.  
Examination of paired peripheral blood samples, taken at the time of biopsy, 
would  also  be  extremely  beneficial  in  subsequent  studies.    Due  to  the 
constraints of examining archival material and the difficulty in obtaining fresh 
muscle biopsies for this study paired blood analysis was not conducted.  Such 
analysis  would  allow  a  comparison  of  any  V,  D  or  J  gene  selections  in  the 
peripheral blood to that observed within the muscle as well as identification of 
clonal rearrangements or variants from the muscle infiltrating repertoire in the 
blood.  A study conducted by Voswinkel et al (336) examined and compared the 
B  cell  repertoires  between  the  synovial  tissue  and  peripheral  blood  B  cell 
repertoire in a patient with RA.  The study detected identically rearranged genes 
within  different  joints  and  within  the  PBL  indicating  the  recirculation  of  B 
lymphocytes between joint and peripheral blood.  Although affinity maturation 
was observed from the sequences, authors suggested that a primary selection 261 
occurred before distribution to the joints and following migration to the joints 
antigen-driven  diversification  was  continued  before  re-circulating  into  the 
peripheral blood B cell repertoire. Re-circulation of activated synovial B cells 
has  also  been  demonstrated  in  another  study  by  Souto-Carneiro  et  al  (337) 
which described the identification of clonally related B cells at different sites of 
synovial inflammation.  The absence of FDCs within these sites suggested to 
the authors that these stimulated B cells from early RA lesions migrate to other 
areas of inflammation and re-enter a cyclic hypermutation process.  This work 
supports  previous  work  (338;339)  which  demonstrates  the  cyclic  re-entry  of 
stimulated B cells.  This could be a plausible situation from the work described 
in  the  current  study  where  some  samples  lacked  the  presence  of  FDCs  as 
previously  described  in  chapter  3.    Conversely  Owens  et  al  (340),  while 
studying  the  B  cell  repertoires  in  Multiple  Sclerosis  plaques,  found  that  this 
repertoire was distinct from the repertoire of the PBL.  The results indicated that 
a compartmentalised humoral response was occurring and that there was no 
entry of the CNS sequences into the peripheral blood repertoire.  Comparison of 
the  sequences  isolated  from  the  muscle  and  the  peripheral  blood  were 
conducted in the current study from sample MYO5 which demonstrated that no 
sequences with the same rearrangements were found in the two different sites, 
although only a small sample of the total PBL was examined.  Gene selections 
from MYO5 PBL were observed when compared to normal control values as 
well as the MYO5 muscle repertoire.  The peripheral blood sample obtained for 
patient MYO5 was obtained 3 years after the biopsy was conducted and the 
biopsy examined in this study was taken two years after the diagnostic biopsy 
so  alterations  in  the  repertoire  as  a  result  of  treatments  and  other  immune 
responses cannot be overlooked. 
 
4.3.1 Somatic Hypermutation and Clonal Diversification in Myositis 
At  the  commencement  of  this  study  no  previous  studies  addressed  if  B  cell 
antigen driven responses were occurring within the inflamed muscle of myositis 
patients.    Recently  Bradshaw  et  al  (90)  demonstrated  that  antigen  specific 
responses were occurring in muscle of DM, PM and IBM patients.  This study 
examined the Ig isotype usage, somatic mutations and clonal expansion of B 
cell and plasma cell infiltrates within myositis samples.  Twelve different muscle 262 
samples (7 IBM, 3 DM and 2 PM) were examined for the presence of B cells 
and plasma cells, in contrast to the results described in Chapter 3 of this study 
very few CD19
+ or CD20
+ cells were found within the infiltrating population.  The 
majority  of  B  cell  derived  cells  present  within  these  samples  were  CD138
+ 
plasma cells.  The Ig sequences from these 12 patients were examined and 
reveal  that  the  majority  of  cells  infiltrating  these  muscle  biopsies  had  class 
switched  from  IgM  to  either  IgG  or  IgA,  indicating  a  stimulated response  as 
naïve cells do not perform class switching until they have encountered antigen.  
Conversely most of the sequences isolated from control blood samples, 2 from 
IBM patients and 2 from normal controls, contained sequences mostly derived 
from B cells producing IgM sequences.  In obtaining the results for this chapter 
the constant regions of Ig were not accounted for but analysis of these regions 
may have provided evidence of class switching occurring within the myositis 
samples  used  for  this  study,  similar  to  that  observed  by  Bradshaw  et  al,  to 
suggest  a  stimulated  response  within  the  muscle.    No  collective  repertoire 
analysis  or  gene  usage  percentages  were  conducted  for  each  patient  of 
myositis subset by Bradshaw et al therefore no comparisons of VH, DH and JH 
gene selections could be made.  Mutational numbers within the sequences from 
the  twelve  patients  isolated  by  Bradshaw  et  al  demonstrated  that  these 
sequences  contained  considerably  more  mutations  in  comparison  to  blood 
control samples.  Bradshaw et al demonstrated that mutational numbers within 
inflammatory myopathies were shown to range from between 16 mutations per 
sequence to 27 per sequence; this was in contrast to control sequences which 
contained between 2 and 17 mutations per sequence.  Interestingly it was noted 
by the authors that approximately 50% of the IgM sequences had between 11 
and  30  mutations  per  sequence  and  appeared  to  have  undergone  affinity 
maturation  without  class  switching.    In  the  current  study  a  wide  range  of 
mutational numbers were observed from essentially naïve cells, in contrast to 
Bradshaw et al, to highly mutated cells.  Clonally related sequences were found 
in 10 of the 12 myositis patients with up to four different clonal sets isolated 
from each muscle section and were not observed in any of the blood samples 
used from  either  the IBM  patients  or normal  control  patients.  These  clones 
were mostly found to consist of two clonal variants but up to six different clonal 
variants were observed for some clonally related sets of sequences.  Similarly 263 
up to four different clonal sets of sequences were found within muscle sections 
in the current study but this was only observed for sample MYO5 where the 
whole section was used instead of microdissected cellular aggregates from the 
muscle sections.  In contrast only a single clonal set of sequences was isolated 
from each microdissected cellular aggregation which contained between 2 and 
8 clonal variants.   Three of the clones from Bradshaw et al, one from each 
myositis subset, were shown to be derived from VH5-51, VH3-23 and VH3-30 
gene rearrangements.  Clonally related sets of sequences containing the VH 
gene segments VH5-51 and VH3-30 were also found within this study which may 
suggest  a  common  selection  for  these  particular  genes  between  different 
patients.  Further mutational analysis of these clones isolated by Bradshaw et al 
demonstrated that a number of identical replacement mutations were found in 
clones  of  the  same  patient,  indicating  that  these  clonally  related  sets  of 
sequences may be being driven by the same antigen, while other replacement 
mutations  were  found  in  many  clones  from  different  patients  suggests  the 
location of mutational hotspots within the Ig sequence as well as indicating that 
a  common  antigen  may  be  driving  the  B  cell  response.    Laser  capture 
microdissection (LCM) experiments were used to further assess the degree of 
clonal expansion within inflammatory myopathy tissue.  LCM was used to divide 
tissue sections from each of the 3 inflammatory myopathies into distinct regions 
from  which  Ig  sequences  were  obtained  and  analysed.    Using  this  method, 
further evidence of clonally related sets of sequences were obtained from DM 
and  IBM  samples  demonstrating  the  presence  of  clonally  related  sets  of 
sequences within the same and different regions of the same muscle samples 
indicating the expansion of B cells within inflamed muscle tissue.  This could be 
further examined, in both studies, to incorporate additional muscle sections to 
determine if the clonal expansion extends into additional sections.   Results of 
Bradshaw et al, together with the results presented in this chapter indicate that 
antigen driven B cell responses are occurring within muscle rather than in a 
local lymph node as is classically thought.  In contrast a number of patients 
within  the  current  study  did  not display  evidence  of  an antigen-driven  B  cell 
response which may also indicate that these infiltrating B cells and plasma cells 
are mutating in other locations and migrating into these areas of infiltration but 
may also be the result of previous immunosuppressive therapy in some patients 264 
as previously discussed, although four sets of clonal related sequences were 
isolated from sample MYO5 who had extensive therapy prior to the biopsy used 
in this study. None of the patients in the study by Bradshaw et al had received 
therapy prior to the study.  In comparison to the entire myositis response only a 
small fraction of the response was assessed in several muscle sections which 
may  underestimate  the  true  heterogeneity  of  the  B  cell  response.  Clonal 
diversification may be occurring within other areas of muscle which were not 
examined.        
 
4.3.2 Assignment of Ig Genes  
Ig  gene  assignments  in  this  study  were  conducted  using  the  JOINSOLVER 
(291)  as  well  as  the  IMGT/V-QUEST  software  (292;293).    Numerous 
programmes are available for identification and assignment of germline genes 
in  rearranged  Ig  gene  sequences  but  as  JOINSOLVER  concentrates  on 
characterisation of the CDR3, a region pivotal in identification of clonally related 
Ig genes which addresses the central aim of this study, this programme was 
deemed  appropriate  for  the  current  study.    To  account  for  any  anomalies 
between  software  algorithms  IMGT/V-QUEST  was  also  used  in  this  study.  
Recent updates to the IMGT/V-QUEST software (293), including detection of 
insertions and deletions which is not carried out by the JOINSOLVER software, 
provided a more accurate comparison between the two algorithms.  Following 
completion  of  the  sequence  analysis  described  in  this  chapter  the 
JOINSOLVER  algorithm  was  updated  (The  Characterization  of  Mutations  in 
Complementarity  Determining  Region  3  of  Human  Ig  Gene  Rearrangements 
using JoinSolver, Nancy S. Longo, Daniel E. Russ, Eric Schloeffler and Peter E. 
Lipsky  (manuscript  in  preparation))  to accommodate  mutations  within  the  DH 
and JH gene segments.  This algorithm change creates a greater accuracy of 
gene assignment as well as assignments of P and N nucleotides, in addition to 
those lost by exonuclease activity.  These changes correspond to the manual 
sequence  changes  conducted  within  this  study  but  repeat  analysis  of  the 
sequences  generated  may  result  in  subtle changes to the  results  described.  
The  use  of  the  original  JOINSOLVER  algorithm  and  the  updated  IMGT/V-
QUEST algorithm in this study generated alignments, which for the most part, 
corresponded to each alignment programme.  A difference in gene assignment 265 
was  observed  for  approximately  5%  of  the  sequences  isolated  from  muscle 
infiltrating cells while only 2% of sequences contained insertions and deletions. 
Most of these sequences contained deletions in multiples of 3 from the CDR2 
which allowed the reading frame to be maintained and productive translation of 
the Ig. Although rare, the process of insertions and deletions, especially in the 
CDRs, does create further diversification within the Ig repertoire.    
 
The JOINSOLVER software was compared to the DNAPLOT software (Centre 
for  Protein  Engineering,  www.mrc.cpe.cam.ac.uk)  (291)  using  144  randomly 
selected  unmutated  and  mutated  Ig  rearrangements.    For  50%  of  the 
rearrangements both programmes gave comparable D gene assignments but 
JOINSOLVER  performed  better  than  DNAPLOT  for  22%  of  rearrangements 
either by finding a higher consecutive match or because DNAPLOT failed to 
identify  any  D  gene  for  25%  of  the  rearrangements.    For  all  sequences 
JOINSOLVER was able to generate some D gene alignment although this was 
not always significant.  New algorithms have recently been described (341;342).  
SoDA  (Somatic  Diversification  Analysis,  http://dulci.org/soda/)  (342)  is  a 
dynamic programming alignment algorithm which takes into consideration the 
variation  around  the  recombination  sites  from  nucleotide  addition  and 
exonuclease  activity  and allows  for  insertions  and deletions  within  the  gene.  
This algorithm was compared to both JOINSOLVER and IMGT/V-QUEST using 
a  set  of  artificial  Ig  sequences  generated  using  a  simulation  programme;  all 
programmes use the same libraries from IMGT.  The authors report that SoDA 
identified more rearrangements accurately compared to both JOINSOLVER and 
IMGT/V-QUEST and observed that JOINSOLVER did not perform as well in 
assigning  VH  gene  segments.    It  was  also  observed  that  IMGT/V-QUEST 
identified  fewer  DH  genes.    All  3  programmes  were  similar  in  identifying  JH 
genes  but  at  a  15%  mutational  rate  in  the  artificial  sequences  both 
JOINSOLVER and IMGT/V-QUEST performed better.  The SoDA algorithm was 
also tested using 30 randomly selected sequences of which some were used in 
the  testing  of  JOINSOLVER  (291).    For  18  of  these  sequences  all  3 
programmes agreed in the gene identification and for the remaining 12 SoDA 
never made an identification, for the V and J genes, that was not supported by 
either  JOINSOLVER  or  IMGT/V-QUEST.  The  iHMMune  align 266 
(www.emi.unsw.edu.au/~ihmmune/)  algorithm  has  recently  been  described 
(341) and is an alignment application that uses a hidden Markov model (HMM) 
to model the processes involved in Ig gene rearrangement and maturation. This 
algorithm was compared to JOINSOLVER, IMGT/V-QUEST and SoDA using 
both clonally related and randomly selected Ig sequences.  Analysis of clonally 
related  sequences  demonstrated  that  all  four  programmes  agreed  with  the 
assignment of the longer VH and JH genes, although variations in the predicted 
alleles were observed.  Differences were noted within the DH gene assignments 
between the four programmes. Analysis of randomly selected sequences, from 
the same collection as previous studies was also conducted (251;291).  From 
662 sequences total agreement was only observed for 104 of the sequences, 
while agreement in the VH, DH and JH gene assignments was observed for 357, 
291 and 322 sequences respectively.  From this analysis it was observed that 
iHMMune provided a more accurate identification of the rearranged germline 
genes as fewer disagreements were observed with this algorithm compared to 
the other 3 programmes and DH gene alignments were generally longer and 
contained  fewer  mismatches.    Although  iHMMune  accounts  for  modelling  Ig 
processes that are not represented by other algorithms it does not account for 
insertions and deletions within germline genes. 
 
Analysis  of  the  sequences  from  this  study  with  the  SoDA  and  iHMMune 
algorithms  may  provide  a  more  accurate  assignment  of  gene  as  well  as 
mutational analysis but due to time constraints and timing of publications this 
was not possible for the current study presented.  The difficulties in assigning 
germline  genes,  especially  DH  genes,  to  rearranged  Ig  genes  because  of 
germline  gene  similarities,  somatic  mutations,  exonuclease  and  TdT  activity 
may  make  it  difficult  to  determine  which  algorithm  would  provide  the  most 
accurate gene assignments.   
 
4.3.3 Detecting Selection of Ig Sequences  
Analysis of selection in this study was conducted by the method proposed by 
Hershberg et al (294) to detect positive antigen-driven selection in the B cell Ig 
genes  from  the  infiltrating  B  cell  population  in  both  the  inflamed  muscle  of 
myositis patients and skin of vasculitis patients.  Many methods and studies 267 
have previously been conducted in order to detect selection (343-346), which 
are based on mutation patterns in Ig sequences.  Shlomchik et al (346) used a 
binomial  distribution model  to  study  selection  which  was  based on detecting 
positive selection by comparing the fraction of R mutations in the CDR to all 
other mutations while assuming a fixed level of negative selection.  In the study 
by these authors it was expected that half of R mutations within FW regions 
would  be  eliminated  through  negative  selection,  therefore  to  compensate for 
this fixed level of negative selection the observed number of R mutations in the 
FW was doubled.  The study also assumed that all V-region mutations occurred 
at random which was later accounted for by a revised and extended binomial 
test by Chang and Casali (344).  This test took into consideration that codons 
with a higher susceptibility for R mutations were generally found within CDRs as 
well as removing the fixed level of negative selection from the test by allowing 
for the total number of mutations within the FW.  Following this method Lossos 
et al (345) described a multinomial distribution test which allowed the frequency 
of mutations to be considered in four categories, R and S mutations in CDR 
and/or FW regions of the gene, which the previous binomial methods had failed 
to  account  for  and  were  based  only  on  two  distribution  possibilities.    This 
modified  method  provided  a  more  accurate  method  of  determining  antigen 
selection.  This method consisted of a sum of all the binomial probabilities which 
also took into account the inherent susceptibility of the codons of the CDR and 
FW to R mutations.  The results of this multinomial distribution were tested on 
86  VH  gene  sequences  and  were  compared  to  that  of  the  binomial  test 
described by Chang and Casali.  In the majority of sequences the p values 
obtained  using  both  methods  varied  in  magnitude  but  not  in  statistical 
significance,  inconsistencies  were  only  found  in  8  sequences  resulting  in 
opposite  statistical  conclusions,  but  the  authors  argue  that  the  proper 
multinomial  test  should  be  applied  when  determining  selection  even  though 
results from each test proved similar.  Despite the increased accuracy of this 
test  in  comparison  to  previous  methods,  the  method  failed  to  consider  the 
presence of mutational hot-spots within the gene and assumed that mutations in 
the VH genes occurred randomly which can produce the false appearance of 
selection.      Bose  and  Sinha  (343)  also  examined  antigen  selection  using  a 
modified Chang and Cascali / Lossos method which included the effects of hot-268 
spot regions in the Ig gene.  While the Chang and Cascali / Lossos method 
assumes that an Ig gene becomes somatically mutated across its length, the 
Bose and Sinha method depends on the length, the codon usage as well as the 
built-in mutability of different regions of the Ig gene.  The results of this study 
identified false positive results and failed to establish the role of antigen-driven 
selection in clonal maturation and concluded that selection can act both for and 
against R mutations in the CDR as well as in the FW regions depending on the 
relative  contribution  to  affinity  and  structural  integrity  of  the  Ig.    Recently 
Hershberg et al (294) have proposed a new focused binomial test for detecting 
selection  in  Ig  V  region  sequences.    This  study  demonstrated  that  the 
multinomial  test  by  Lossos  et  al,  referred  to  as  a  global  binomial  test  by 
Hershberg  et  al,  was  mathematically  equivalent  to  the  previously  proposed 
method  by  Chang  and  Cascali.  The  previous  method  produced  a  high 
frequency of Type 1 (specificity) false positives and was unable to distinguish 
whether a relatively high frequency of R mutations in CDR was due to positive 
selection  in  the  CDR  or  negative  selection  in  the  FW  -  crosstalk  between 
positive and negative selection.  The authors also concluded that the statistical 
method of Bose and Sinha was also flawed as it was based on these previous 
methods.  The study by Hershberg et al proposed the focused binomial test for 
selection  which  corrects  for  the  specificity  problem  exhibited  in  the  global 
binomial test and eliminates crosstalk.  The newly proposed test fully accounts 
for the effects of microsequence specificity, the likelihood of each nucleotide to 
mutate depending on its local sequence, and incorporated the transition over 
transversion  bias  of  somatic  hypermutation  for  the  first  time  in  this  type  of 
analysis.    This  method  of  detecting  selection  was  tested  by  re-analysis  of 
sequences from diffuse large B cell lymphomas (DLBCL) by Lossos et al (347), 
re-analysis  of  76  non-functional  rearrangements  from  previously  published 
studies and sequences generated in response to the nitrophenyl (NP) antigen in 
conventional Ig heavy chain transgenic mice which do not mutate or isotype 
switch  their heavy chain loci.  In this system positive selection was expected to 
dominate  due  to  a  fixed  heavy  chain  which  would  cause  all  mutation  and 
selection  to  be  focused  on  the  light  lambda  chain.    Re-examination  of 
sequences from DLBCL using the focused binomial test indicated that many 
false positive results were assigned; positive selection was not found in any of 269 
the 54 sequences using the focused binomial test compared to 16 out of 54 
sequences using the method proposed by Lossos et al.  It was thought by the 
authors that this false positive selection was a result of crosstalk as negative 
selection  was  detected  in  88%  of  the  16  sequences  with  positive  selection.  
Studies from the transgenic mice established that positive selection could be 
detected while the analysis of non-functional sequences detected no selection 
and demonstrated  that  previous  positive  selection found  in  these  sequences 
was the result of false positive errors.  The results of this study demonstrate that 
the focused binomial test can be used to detect positive and negative selection 
with high specificity and increased sensitivity  which can be applied to single 
sequences  in  addition  to  independent  mutations  in  clonally  related  Ig 
sequences.   
 
4.3.4 Summary 
In  summary,  the  work  presented  in  this  chapter  demonstrates  that  B  cell 
antigen-driven  responses  are  occurring  within  the  target  tissues  of  myositis 
patients, even in PM patients where B cells are traditionally not thought to play 
a  significant  part  in  the  pathological  process.    Ig  sequence  analysis  from 
infiltrating  B  cells  within  these  myositis  samples  established  positive  and 
negative gene selections within individual patients as well as between different 
myositis subsets.  An accumulation of mutations was also observed in these 
sequences with a number of common mutations observed between various sets 
of  sequences  which  share  the  same  Ig  gene  rearrangements  in  addition  to 
further independent VH mutations, indicating clonal diversification.  Collectively 
these results strongly indicate that B cells present within the inflamed muscle of 
myositis patients are acting in response to an antigen present at the sites of 
inflammation.  In these samples, especially where clonally related sequences 
were  not  isolated,  the  mutational  features  of  the  sequences  indicated  the 
occurrence of antigen-driven diversification, possibly at another site or the re-
circulation of antigen specific B cells from other sites of inflammation.  Although 
the  work  conducted  in  this  chapter  demonstrates  B  cell  antigen-driven 
responses in the target tissues of myositis patients and implicates B cells in the 
pathological process of myositis it does not identify the antigen(s) stimulating 
these responses. 270 
Chapter 5 - Phenotypic Cellular Characterisation, VH Gene Repertoire and 
Clonal Diversification of Skin Infiltrating B cells in Vasculitis Patients 
5.1 Introduction 
As  previously  discussed  in  Chapter  1,  vasculitis  is  another  inflammatory 
condition with unknown aetiology.  Vasculitis can act both systemically or locally 
and  in  both  instances  vasculitis  can  manifest  within  the  skin  due  to  the 
abundant vascular supply.  Very few studies have established a role for B cells 
within  the  vasculitis  disorders  but  the  suspected  contribution  of  immune 
complexes and autoantibodies in vascular pathology, in addition to the clinical 
improvements  observed  using  Rituximab  B  cell  depletive  therapy  in  these 
disorders,  strongly  indicates  a  pathogenic  role  for  B  cells  in  vasculitis 
conditions.    The  previous  work  in  this  study  supports  the  hypothesis  that 
infiltrating  lymphocytes  were  being  stimulated  locally  to  respond  to  an 
endogenous antigen resulting in tissue damage and has established an antigen-
driven role for B cells in muscle inflammation.  The work of this chapter tests the 
same hypothesis within skin inflammation of vasculitis patients by addressing 
the following key aims: 
 
·  Determine  the  occurrence,  organisation  and  proliferation  of  skin 
infiltrating  B  cells  and  plasma  cells  along  with  the  additional  cell 
phenotypes (T cells (CD3, CD4, and CD8), macrophages (CD68), 
Follicular  dendritic  cells  (FDC),  proliferating  cells  (Ki67)  and 
regulatory T cell (FoxP3)) within skin biopsies. 
·  Establish  the  Ig  gene  repertoire  and  VH  mutational  patterns  of 
infiltrating  B  cells  and  plasma  cells  to  assess  sequence 
characteristics from infiltrating B cells and plasma cells which may 
indicate  if  clonally  related  B  cells  are  present  within  the  skin 
inflammatory infiltrate undergoing an antigen-driven B cell response 
·  Compare  the  Ig  gene  repertoire  from  skin  infiltrating  cells  to  the 
paired peripheral blood repertoire to further assess gene selections 
within the vasculitis patients. 
 
The immunohistological data described in this chapter is summarised in Table 
5.1.271 
 
 
 
 
 
 
 
Table 5.1 Immunohistochemistry Summary Table from Vasculitis Samples 
 
Table 5.1 provides a summary overview of the immunohistochemistry profiles observed from each sample for each vasculitis patient.  The table summarises the 
infiltration of each cell phenotype observed throughout the entire biopsy (n=3-7 sections for each cell phenotype depending on tissue availability) and is not 
based solely on the representative images presented in Figures 5.1, 5.3 and 5.5.  Comparisons were made between cell phenotypes in the same patient and not 
between  different  patients.    For  germinal  centre  formation,  –  represents  the  absence  of  these  structures  within  the  skin  sections.    The  extent  of  cellular 
aggregation of infiltrating cells was established for each sample and was based on semi quantitative observations; - represents no cellular aggregation with a 
widespread scattering of lymphocytes throughout the skin section; +, ++, +++ represents an increasing degree of aggregation of lymphocytes respectively 
observed within the skin sections.  N/A was applied to samples where no or very little infiltration was present.  Immunohistochemistry summary profiles were 
based on semi-quantitative observations of cellular infiltration; - indicates where cell phenotypes were absent from the infiltrating population while +, ++, +++ 
represent increasing numbers of cell phenotypes respectively within the skin infiltrating population.  Areas highlighted in yellow indicate where proliferating cell 
phenotypes  were  observed  from fluorescent  double  immunohistochemistry  (IF)  experiments,  these  experiments  were  not  included  in  the  semi  quantitative 
analysis and were used solely to establish the population of proliferating cells.   
 
 
 
 
 
 
 
 
Sample 
Germinal 
Centre 
Formation 
Cellular 
Aggregation  CD20  Plasma 
Cell  FDC  CD3  CD4  CD8  CD68  FoxP3  Ki67  -IgG1  -IgG2a  -IgM 
VAS1  -  -  -  +++  -  ++  ++  +  ++  + 
-  
(+ IF only)  -  -  - 
VAS6  -  +  +  +++  -  ++  ++  +  +++  +  ++  -  -  - 
VAS7  -  +  -  +++  -  +  +  +  ++  +  -  -  -  - 272 
5.2  Phenotypic  Characterisation  of  Cellular  Infiltrates  in  Vasculitis 
Patients 
5.2.1 Sample VAS1 
For sample VAS1 no significant regions of aggregation were observed within 
the skin biopsy, infiltrating cells were distributed throughout the entire biopsy 
(Figure  5.1).    No  clear  association  between  infiltrating  cell  populations  and 
blood vessels was observed in the sections examined.   No CD20
+ (A) cells or 
FDCs (B) were present within the section; small numbers of CD20
+ cells were 
later  observed  in  double  immunofluorescent  experiments  (Figure  5.2).    The 
major types of infiltrating cells included plasma cells (C), CD3
+ (D), CD4
+ (E) 
and CD8
+ (F) cells.  As observed within myositis samples the numbers of CD8
+ 
cells appears to be reduced in comparison to the CD3 and CD4 cell markers.  
Unlike some of the myositis samples the number of CD4
+ cells did not appear to 
be greater than that of the CD3
+ cells.  No proliferating cells (G) were observed 
within  the  VAS1  sections  used  in  these  experiments  but  there  was  a  large 
infiltrate  of  CD68
+  (H)  cells.    FoxP3  (I)  staining  revealed  a  small  number  of 
FoxP3
+  cells  were  present  within  the  biopsy.    The  use  of  negative  control 
isotype antibodies produced no non-specific staining (J-L). 
 
Analysis  of  Ki67
+ proliferating  cells  at  a  greater  tissue  depth  to the  sections 
used for the above experiments identified proliferating CD4
+ (C) and CD68
+ (E) 
cells (Figure 5.2).  Although FoxP3
+ cells were identified from initial staining, 
Figure 5.1, no FoxP3 cells were observed during double staining experiments.  
Negative control staining produced no non-specific staining. 
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Figure 5.1 Immunohistochemistry of serial skin sections of Sample VAS1. 
 
A  representative  example  of  serial  skin  sections  from  sample  VAS1  stained  for 
CD20 (A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 
(H), FoxP3 (I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative 
control (L) and visualised by APAAP and New Fuschin substrate to establish cellular 
infiltrates within the skin section.  Images A – L: 400X 
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Figure 5.2 Double Immunohistochemical staining of serial vasculitis sections of sample 
VAS1  
 
A representative example of serial skin sections from sample VAS1 stained for CD20 (A), CD3 (B), 
CD4 (C), CD8 (D), CD68 (E) and visualised by Fluorescein Avidin D before all sections were stained 
with Ki67 and visualised by Texas Red Avidin D.  This allowed the type of proliferating cells within 
the vasculitis sample to be identified.  Images were taken at 630X; Scale Bar represents 15 µm.  
Arrows identify proliferating cells within the sections. 
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5.2.2 Sample VAS6 
 
A  heavy  cellular  infiltrate  was  observed  within  sample  VAS6  (Figure  5.3).  
These infiltrating cells formed very loose aggregates of cells in a few areas of 
the section but a large proportion of cells were distributed throughout the whole 
section.    No  clear association  between  infiltrating  cell  populations  and  blood 
vessels  was  observed  in  the  sections  examined.    The  dominant  cell  type 
present within sample VAS6 was identified as plasma cells (C). Very few CD20
+ 
(A) cells and no FDCs (B) were found within the sample.  CD20
+ cells present 
in the sample did appear to form part of the aggregates of cells and were not 
found dispersed throughout the entire section.  CD3
+ (D) and CD4
+ (E) cells 
were  present,  both  within  cellular  aggregates  as  well  as  the  other  areas  of 
infiltration.    CD8
+  (F)  cells  were  also  observed  but  this  was  reduced  in 
comparison to CD3
+ and CD4
+ cells.  A considerable infiltration of Ki67
+ (G) and 
CD68
+ (H) cells were also present within sections of sample VAS6 as well as a 
number of FoxP3
+ (I) cells.  As with previous staining no non-specific staining 
was observed within the sample (J-L). 
 
In  sample  VAS6  proliferating  cells  were  identified  as  CD4
+  (C),  CD8
+  (D), 
CD68
+ (E), FoxP3
+ (F) cells with a random CD20
+ (A) cell also present within 
the infiltrating population (Figure 5.4).  Negative control experiments with the 
antibody isotype controls showed no non-specific staining within sections.   
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Figure 5.3 Immunohistochemistry of serial skin sections of Sample VAS6. 
 
A representative example of serial skin sections from sample VAS6 stained for CD20 
(A), FDC (B), Plasma cells (C), CD3 (D), CD4 (E), CD8 (F), Ki67 (G), CD68 (H), FoxP3 
(I), IgG1 Negative control (J), IgG2a Negative control (K), IgM Negative control (L) and 
visualised by APAAP and New Fuschin substrate to establish cellular infiltrates within 
the skin section.  Images A – L: 400X 
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Figure 5.4 Double Immunohistochemical staining of serial vasculitis sections of 
sample VAS6  
 
A representative example of serial skin sections from sample VAS6 stained for CD20 (A), 
CD3 (B), CD4 (C), CD8 (D), CD68 (E) FoxP3 (F) and visualised by Fluorescein Avidin D 
before all sections  were stained  with  Ki67 and  visualised  by Texas Red Avidin  D.   This 
allowed the type of proliferating cells within the vasculitis sample to be identified.  Images 
were taken at 630X; Scale Bar represents 15 µm.  Arrows identify proliferating cells within 
the sections. 
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5.2.3 Sample VAS7 
 
For sample VAS7 the cellular distribution and phenotypes were similar to that of 
the previous vasculitis sample, VAS6 (Figure 5.5), although a small proportion 
of  infiltrating  cell  populations  were  shown  to  associate  with  blood  vessels.  
Predominately plasma cells (C) infiltrated sample VAS7 with very few CD20
+ 
(A) cells or FDCs (B).  CD3
+ (D), CD4
+ (E), CD8
+ (F) and CD68
+ (H) cells were 
also present within the sample as well as a number of FoxP3
+ (I) cells.  VAS6 
and  VAS7  cellular  populations  were  similar  to  each  other  except  for  the 
presence of Ki67
+ (G) cells.  No Ki67
+ cells were present within these sections 
of VAS7 tested for cellular markers.  As with previous samples no non-specific 
staining was observed within sample VAS7 (J-L). 
 
Despite  Ki67
+  cells  being  absent from  the cellular  infiltrate  for  the  initial  cell 
characterisation further sections were tested for the presence of Ki67
+ cells in 
double staining experiments (Figure 5.6).   No further evidence of proliferating 
cells could be found within sample VAS7.  Negative control staining produced 
no non-specific staining. 
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Figure 5.5 Immunohistochemistry of serial skin sections of Sample VAS7. 
 
A representative example of serial skin sections from sample VAS7 stained for CD20 
(A),  FDC  (B),  Plasma  cells  (C),  CD3  (D),  CD4  (E),  CD8  (F),  Ki67  (G),  CD68  (H), 
FoxP3, denoted by circle, (I), IgG1 Negative control (J), IgG2a Negative control (K), 
IgM  Negative  control  (L)  and  visualised  by  APAAP  and  New  Fuschin  substrate  to 
establish cellular infiltrates within the skin section.  Images A – L: 400X 
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Figure 5.6 Double Immunohistochemical staining of serial vasculitis sections of sample VAS7  
 
A representative example of serial skin sections from sample VAS7 stained for CD3(A), CD4 (B), CD8 
(C), CD68 (D), FoxP3 (E) and visualised by Fluorescein Avidin D before all sections were stained with 
Ki67  and  visualised  by  Texas  Red  Avidin  D.    This allowed  the  type  of  proliferating  cells  within  the 
vasculitis sample to be identified.  Images were taken at 630X; Scale Bar represents 15 µm.  Arrows 
identify proliferating cells within the sections. 
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5.3 VH Repertoire in Vasculitis Patients 
 
5.3.1 Sample VAS1 
As previously described in section 5.2.1 the cellular infiltrate of sample VAS1 
contained limited CD20
+ B cells but plasma cells were widely distributed within 
the sample.  Microdissection and DNA amplification was conducted to establish 
the Ig gene rearrangements present within these infiltrating cells (Figure 5.7). 
Three different functional gene rearrangements were isolated from infiltrating 
cells (Table 5.2A).  These sequences utilised the VH1-18*01, VH3-23*01 and 
VH3-33*01 gene segments which were highly mutated, with between 21 and 30 
mutations  per  sequence.    A  DH  gene  could  only  be  assigned  to  1 
rearrangement,  VH1-18*01,  in  all  other  cases  the  number  of  consecutive 
matches was too short to statistically assign a DH gene.  JH5, 4 and 6 gene 
segments were used in the VH1-18*01, VH3-23*01 and 3-33*01 gene segments 
respectively.  The isolated sequences were highly mutated and the percentage 
of mutations present within CDR1 was comparable to that of framework regions 
but an increase in mutational percentages was observed within CDR2 of all of 
the isolated sequences.  Analysis of the R and S mutations revealed that there 
was only significant selection for the VH1-18*01 Ig rearrangement, where there 
was a significant negative selection within the FW regions (Table 5.2B).  CDR3 
lengths were found to range from 13 to 23 amino acids in these sequences.  As 
a DH gene assignment could only be made for the VH1-18*01 rearrangement, 
this  was  the  only  Ig  rearrangement  where  analysis  of  the  junctional  regions 
could be conducted.  In this Ig rearrangement no P nucleotides were assigned 
at either the VD or DJ junction.  3 and 6 N nucleotides were assigned at the VD 
and DJ junctions respectively while exonuclease activity was found to remove 1, 
5, 7 and 10 nucleotides respectively from the 3’VH, 5’DH, 3’DH and 5’JH gene 
segments of the junction.    For gene rearrangements containing the VH gene 
segments VH3-23 and VH3-33, duplicate copies of the sequence were isolated 
that  contained  different  somatic  mutations.    These  could  not  be  deemed  as 
clonally related sets of genes as there was only one somatic mutation difference 
between each set which could have occurred as a result of PCR error. 
 
No differences in gene assignments between the JOINSOLVER and IMGT/V-
QUEST were observed for any of the Ig rearrangements. 282 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
Before Microdissection  After Microdissection 
A 
B 
Figure 5.7 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample VAS1 
 
The region of plasma cell infiltration was microdissected from sample VAS1.  Figure 5.7A 
demonstrates the microdissection of the region of cellular infiltration.  Images were taken at 
400X.  PCR reactions were conducted for DNA isolated form the muscle sections (Figure 
5.7B)  in  addition  to  DNA  isolated  from  PBL  (Figure  5.7C),  as  previously  described  in 
Chapter 2.  – indicates negative control PCR reactions where DNA was substituted with 
water while + indicates positive control PCR reactions using peripheral blood mononuclear 
cells isolated from peripheral blood of a healthy individual. Results show amplification of all 
VH families.     
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Mutational Distribution  
(% of length) 
 
VH Gene  DH Gene  JH 
Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3 
CDR3 
Length 
(aa)  Framework  CDR1  CDR2 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
1-18*01  2-2*01  5*02  1  30  ARDDCSGTSCHADL  14  7.7  13.3  20.4  33  16 (+3) 
3-23*01  No D gene 
Assignment  4*02  2  25, 26  VKTTVINLSYFED  13  7.7, 8.1  6.7, 6.7  13, 13  36  8 
3-33*01  No D gene 
Assignment  6*03  2  21, 22  ARAKIVAVSASPSMGSYYHYMDV  23  6.3, 6.8  6.7, 6.7  11.1, 11.1  50  9 
 
VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
1-18*01  2-2*01  5*02  1  30  10  3  0.47674  -0.9986  9  8  0.68809  -0.0303 
3-23*01  No D gene 
Assignment  4*02  2  25  7  1  0.45266  0.72724  11  6  0.65  -0.7226 
        26  7  1  0.43496  0.63113  12  6  0.65077  -0.8478 
3-33*01  No D gene 
Assignment  6*03  2  21  4  3  0.46759  -0.3722  9  5  0.67394  -0.2219 
        22  4  3  0.46759  -0.3722  10  5  0.67394  -0.299 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.2 A&B Sequence Analysis from Sample VAS1 
 
Table 5.2A - Best matching germline sequences were identified from aligning sequences in the IMGT database using JOINSOLVER software from the VAS1 
vasculitis section.  Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  V-J lengths and consecutive D match 
lengths (bp) were also identified using the JOINSOLVER software and allowed assignment of the DH genes as described in section 2.3.12.3.    
 
The number of mutations within functional rearranged genes were analysed collectively from all region of dissected cellular infiltration.  Base differences within 
the first 24 bases of sequence were disregarded as this part of the sequence binds the 5’ VH primer.   
 
The locations of mutations observed within functional rearranged genes were categorised as being within FR or CDR regions.  The numbers of mutations 
within these regions were expressed as a percentage of the entire length of the region to correct for the longer lengths observed within the framework regions. 
 
Table 5.2B - The number of replacement and silent mutations and the presence of any positive and negative selection was conducted as per Hershberg et al  
(294) as previously described.   R-CDR/FW and S-CDR/FW represent the number of replacement and silent mutations in the CDR and FW respectively.  
pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while pFW 
represents the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative sign indicates negative selection.  p-values <0.05 were 
deemed significant. 
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5.3.1.1 VH Repertoire from VAS1 PBL 
From the paired blood sample obtained at the time of biopsy, 29 functional and 
2  non-functional  sequences  were  identified  (Table  5.3).    Using  Chi  Square 
analysis, a significant selection for the use of VH2 gene segments was observed 
which was significant against normal control values (Figure 5.8A).  A selection 
against  VH4  gene  segments  was  also  observed,  significant  against  both  the 
normal  control  values  and  the  baseline  germline  composition.    No  other 
selections for the remaining VH families was observed, although selections for 
VH1-3, 1-69, 2-26, 2-5 and 3-21 individual gene segments was observed.  DH 
genes could be statistically assigned in 55.2% of the sequences isolated from 
the blood repertoire, as described using the method in section 2.3.12.3 and the 
V-J  lengths  and  consecutive  D  match  lengths  in  Table  5.3.    Comparing  the 
distribution  of  these  identified  DH  gene  segments  against  control  values 
demonstrated a significant selection for the use of DH3 gene segments in the Ig 
rearrangements,  in  particular  DH3-22  gene  segments  which  was  used 
significantly more than normal controls (Figure 5.8B).  DH3 family selection was 
significant against both control values.  No other gene selections were observed 
within the DH repertoire.  Analysis of the JH gene segments revealed a selection 
against JH1 and JH2 gene segments which was only significant to the baseline 
germline complexity (Figure 5.8C).  Negative selection was also observed for 
the use of JH4 and JH5 gene segments, both were significant against normal 
control  values  but  JH5  was  also  significant  against  the  germline  values.  
Conversely a selection for the use of JH3 and JH6 gene segments was observed 
within the VAS1 PBL repertoire, both were significant against the normal control 
values only.  No common gene rearrangements were observed between the 
infiltrating population in the skin and the peripheral blood.    
 
The  IMGT/V-QUEST  found  deletions  in  the  VH3-38*02  DH3-9*01  JH4*02  Ig 
rearrangement.  Using JOINSOLVER this rearrangement was non-functional, 
the  same  arrangement  was  observed  using  IMGT/V-QUEST  before  the 
detection of deletions.  6 nucleotides were found to have been deleted from the 
CDR2.    Once  restored  both  algorithms  identified  a  functional  rearrangement 
consisting  of  the  VH3-23*04  DH3-9*01  JH4*02  gene  segments  with  23  VH 
mutations.  No other anomalies were detected. 285 
VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number 
of Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
1-03*01  No D gene 
Assignment  4*02  1  30  ARDLPDTGYFDP  27  6 
1-03*01  3-10*01  4*02  1  0  ARVGVVRGDFYFDY  22  12 
1-18*01  No D gene 
Assignment  3*02  1  3  ARASGDDDAFDI  13  6 
1-46*01  3-22*01  3*02  1  0  ARRGPLAGNYYDSSGYYSGAFDI  51  28 (+3) 
1-69*04  No D gene 
Assignment  3*02  1  0  ARGRGDAFDI  11  7 
1-69*04  3-22*01  3*02  1  0  ARRGPLAGNYYDSSGYYSGAFDI  51  28 (+3) 
1-69*04  3-22*01  3*02  1  0  ARGSDYYDSSGSNYEAFDI  38  22 (+1) 
1-69*09  No D gene 
Assignment  6*03  1  1  ARVSESWEVTVAKSVHMDV  39  8 
1-69*09  3-22*01  4*02  1  0  ARETGYYDSSGYWN  32  23 
2-05*09  3-22*01  3*02  1  7  AHRRYSDSSGHGGAFDI  29  17 (+1) 
2-05*10  5-24*01  4*02  1  0  AHTERWLPLDY  23  14 (+1) 
2-05*10  No D gene 
Assignment  6*03  1  26  VHTPPHYYYIDV  29  6 
2-26*01  No D gene 
Assignment  6*03  1  35  ARVQKVQLWREAYYYYLDV  43  8 
3-07*01  3-10*02  4*02  1  14  ARILSGNSYDTCDF  38  14 (+2) 
3-21*01  2-2*01  6*03  2  0  ARDGVYCSSTSCYLRNYYYYMDV  38  25 
        1  ARDGVYCSSTSCYLRNYYYYMDV  38  25 
3-21*01  3-3*01  6*03  2  0  ARDRGLYDFWSHTPNYMDV  35  14 
        2  ARDRGLYDFWSHTPNYMDV  35  14 
3-21*01  6-6*01  6*03  1  0  ARDTSSGIAARDYYYMDV  28  13 
3-21*01  No D gene 
Assignment  6*03  1  0  ARVPTSRGDYYMDV  18  7 
3-21*01  No D gene 
Assignment  6*03  1  1  ARDPPPLGNQGYYYMDV  24  7 
3-23*01  2-15*01R  3*02  1  18  AKGGVAAGYSFDI  29  12 
3-30*03  3-3*01  4*02  1  12  AKDGAPRTPFGVVIIFGFDY  46  18 
3-38*02  3-9*01  4*02  (1)  37  AKIGNHDLSTAYYNLFDY  43  18 (+2) 
3-48*02  No D gene 
Assignment  3*01  1  0  ARDSARQDPIL  23  5 
3-66*01  No D gene 
Assignment  4*02  1  15  ATVSRGALDY  18  6 
4-39*01  No D gene 
Assignment  6*03  1  0  ARCRYEVPVFYYMDV  24  6 
5-51*01  2-15*01  6*03  1  0  ARLYCSGGSCKTRAPYYYYMDV  38  21 
5-51*01  3-22*01  2*01  (1)  2  ARLVDYYYDSSGYSPAVLRS  40  25 
5-51*01  No D gene 
Assignment  6*03  1  0  ARHYATVRYYYMDV  16  7 
6-01*01  No D gene 
Assignment  3*01  1  16  VRGFRSAFDF  27  5 
 
 
 
 
 
Table 5.3 Heavy chain genes identified from the PBL sample of vasculitis patient VAS1 
 
Best matching germline sequences were identified from aligning sequences in the IMGT database 
using JOINSOLVER software from the VAS1 PBL sample.  The total number of sequences isolated 
is given in the 4
th column of the table; non-functional rearrangements indicated in brackets.  Identical 
sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  CDR3 
amino  acid  sequences  were  also  identified  using  the  JOINSOLVER  software.    V-J  lengths  and 
consecutive D match lengths (bp) were also identified using the JOINSOLVER software and allowed 
assignment of the DH genes as described in section 2.3.12.3.    
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Figure 5.8 VH Gene Family Usage of VAS1 PBL 
 
VH gene family usage.  Distribution of functional genes was compared with published normal 
control values from Volpe and Kepler (251) as well as the germline complexity assuming every 
germline gene is capable of producing a functional rearrangement.  Absolute values were used 
in Chi Square Analysis to determine gene selections.  § represent a significant difference from 
normal PBL values; * represent a significant difference from the germline (p<0.05).  
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5.3.1.2 Mutational Analysis of PBL B Cell Ig Sequences of Sample VAS1 
Analysis  of  the  VH  mutations  of  these  sequences  demonstrated  that 
approximately  65%  of  the  sequences  contained  2  or  less  mutations,  an 
essentially naïve population (Figure 5.9A).  The remainder of the sequences 
were  highly  mutated;  approximately  10%  of  the  Ig  sequences  from  the  PBL 
repertoire  contained  over  21  VH  mutations.    In  Ig  rearrangements  where 
mutations were observed, a slightly higher percentage of these mutations were 
found within CDRs compared to the FW regions (Figure 5.9B).  Analysis of the 
R  and  S  mutations  to  assess  selection  within  these  Ig  rearrangements 
demonstrated  that  a  significant  selection  was  only  observed  for  one  Ig 
rearrangement (Table 5.4).  Positive selection within the CDRs was observed 
for  the  VH3-07*01  DH3-10*02  JH4*02  rearrangement,  no  other  significant 
selection were observed.       
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5.3.1.3 CDR3 Analysis 
Analysis of the VDJ junctional area of these sequences demonstrated that the 
functional Ig rearrangements had a mean CDR3 length of 16.1 ± 0.8 amino 
acids while non-functional rearrangements contained CDR3 lengths of 19 ± 1.0 
amino  acids,  which  were  not  significantly  different  (Table  5.5).
A 
B 
Figure 5.9 Numbers of Mutations and 
Mutational  Distribution  of  Functional 
Sequences in VAS1 PBL 
 
Figure 5.9A - The number of mutations 
within functional rearranged genes were 
analysed  in  the  PBL  sample  of  VAS1.  
Base differences within the first 24 bases 
of  sequence  were  disregarded  as  this 
part  of  the  sequence  binds  the  5’  VH 
primer.  Graph demonstrates that PBL Ig 
rearrangements  were  essentially  from  a 
naïve population with a small percentage 
of highly mutated rearrangements. 
 
 Figure 5.9B - The locations of mutations 
observed  within  functional  rearranged 
genes were categorised as being within 
FR  or  CDR  regions.    The  numbers  of 
mutations  within  these  regions  were 
expressed as a percentage of the entire 
length  of  the  region  to  correct  for  the 
longer  lengths  observed  within  the 
framework regions.  Graph demonstrates 
a higher percentage of mutations within 
CDR  regions  compared  to  framework 
regions. 288 
 
VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
1-03*01  No D gene 
Assignment  4*02  1  30  11  1  0.47328  0.16256  13  5  0.7011  -0.8525 
1-03*01  3-10*01  4*02  1  0  -  -  -  -  -  -  -  - 
1-18*01  No D gene 
Assignment  3*02  1  3  0  1  0.47868  -0.2718  1  1  0.68628  -0.2644 
1-46*01  3-22*01  3*02  1  0  -  -  -  -  -  -  -  - 
1-69*04  No D gene 
Assignment  3*02  1  0  -  -  -  -  -  -  -  - 
1-69*04  3-22*01  3*02  1  0  -  -  -  -  -  -  -  - 
1-69*04  3-22*01  3*02  1  0  -  -  -  -  -  -  -  - 
1-69*09  No D gene 
Assignment  6*03  1  1  0  0  0.46644  0  1  0  0.67237  0.67237 
2-05*09  3-22*01  3*02  1  7  5  0  0.43955  0.17116  0  2  0.67868  -0.1032 
2-05*10  5-24*01  4*02  1  0  -  -  -  -  -  -  -  - 
2-05*10  No D gene 
Assignment  6*03  1  26  5  4  0.44582  -0.3986  11  6  0.67963  -0.1421 
2-26*01  No D gene 
Assignment  6*03  1  35  10  4  0.46467  -0.6477  11  10  0.68234  -0.0138 
3-07*01  3-10*02  4*02  1  14  10  0  0.44584  0.02267  1  3  0.668  -0.1221 
3-21*01  2-2*01  6*03  2  0  -  -  -  -  -  -  -  - 
        1  0  0  0.49844  0  1  0  0.65896  0.65896 
3-21*01  3-3*01  6*03  2  0  -  -  -  -  -  -  -  - 
        2  0  0  0.49844  -0.5016  2  1  0.65896  1.01654 
3-21*01  6-6*01  6*03  1  0  -  -  -  -  -  -  -  - 
3-21*01  No D gene 
Assignment  6*03  1  0  -  -  -  -  -  -  -  - 
3-21*01  No D gene 
Assignment  6*03  1  1  0  0  0.49844  0  1  0  0.65896 
0.65896 
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VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
3-23*01  2-15*01R  3*02  1  18  8  0  0.45436  0.39523  4  6  0.64769  -0.1247 
3-30*03  3-3*01  4*02  1  12  5  0  0.46794  0.09263  6  1  0.6723  0.33596 
3-38*02  3-9*01  4*02  (1)  37  13  2  0.4377  0.31463  13  9  0.66934  -0.1977 
3-48*02  No D gene 
Assignment  3*01  1  0  -  -  -  -  -  -  -  - 
3-66*01  No D gene 
Assignment  4*02  1  15  8  1  0.46708  0.18261  3  3  0.66604  -0.2199 
4-39*01  No D gene 
Assignment  6*03  1  0  -  -  -  -  -  -  -  - 
5-51*01  2-15*01  6*03  1  0  -  -  -  -  -  -  -  - 
5-51*01  3-22*01  2*01  (1)  2  1  0  0.43336  0.43336  1  0  0.69901  0.69901 
5-51*01  No D gene 
Assignment  6*03  1  0  -  -  -  -  -  -  -  - 
6-01*01  No D gene 
Assignment  3*01  1  16  6  1  0.47428  0.65021  5  4  0.65306  -0.3332 
 
Table 5.4 Analysis of Replacement and Silent Mutations and Positive and Negative Selection in Sample VAS1 PBL 
 
Replacement and silent mutations within the immunoglobulin sequences and antigen-driven selection were determined according to Hershberg et al (294) and 
the corresponding computer programme (http://clip.med.yale.edu/selection).  This improved method of analysis uses a focused binomial test to establish positive 
or negative mutational selections within the sequence with high specificity and increased sensitivity accounting for known biases within the immunoglobulin gene 
sequence.  R-CDR and S-CDR represents the number of replacement and silent mutations within the CDR respectively.  pCDR represents the probability of 
having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while p-CDR is the p-value of the focused binominal 
test on the CDR.  Conversely R-FW and S-FW represents the number of replacement and silent mutations within the FW respectively. pFW represent the 
probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR while p-FW is the p-value of the focused 
binominal test on the FW.  If the number of R mutations is less than expected the software will test for negative selection and p-values will be preceded by a 
negative sign or if the number of mutations is more than expected the software will test for positive selection.  p-values <0.05 are highlighted in yellow and were 
deemed significant for selection. 
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Analysis of these CDR3 lengths in comparison to the VH mutational numbers did 
not  reveal  any  significant  changes  to  the  CDR3  lengths  in  the  different 
mutational  groups  (Figure  5.10).    Further  analysis  of  the  junctional  areas 
demonstrated that there were an increased number of P nucleotides at the VD 
junction  in  functional  sequences  compared  to  the  DJ  junction.    A  significant 
increase  in  exonuclease  activity  was  found  at  the  3’VH  gene  portion  of  the 
junction  in  non-functional  rearrangements  compared  to  the  functional 
population.  This reduced exonuclease activity at the 3’VH gene portion of the 
junction  was  also  significantly  reduced  compared  to  the  5’DH  and  5’JH  gene 
portions of the junction.      
Functional  16.1 ± 0.8  CDR3 Length 
Non-Functional  19 ± 1.0 
  VD Junction  DJ Junction 
Functional  0.8 ± 0.2**  0.2 ± 0.1  P Nucleotide 
Non-Functional  0.5 ± 0.5  0.5 ± 0.5 
Functional  8 ± 1.5  7 ± 0.9  N Nucleotide 
Non-Functional  13.5 ± 5.5  4.5 ± 1.5 
  3’ VH  5’ DH  3’ DH  5’JH 
Functional  0.9 ± 0.3*  4.3 ± 0.8 
Θ  6.6 ± 1.3  7.1 ± 1
 Θ  Exonuclease 
Activity  Non-Functional  4 ± 3*  6 ± 5  2.5 ± 2.5  5 ± 0 
 
Table 5.5 CDR3 and Junctional Analysis in VAS1 PBL 
 
The mean amino acid length of the CDR3, the mean nucleotide numbers corresponding to P and N 
nucleotides as well as the mean number of germline nucleotides lost due to exonuclease activity 
were calculated from the junctional regions of all myositis immunoglobulin sequences as well as in 
DM and PM subsets.  Results are given as the Mean ± SEM.  Instances where no non-functional 
sequences  were  identified  and  values  could  not  be  calculated  were  recorded  as  non  applicable 
(N/A).  * indicates a significant difference between functional and non-functional sequences while ** 
indicates a significant difference between the VD and DJ junctions established using an unpaired t 
test.   Θ represents a significant difference from 3’VH. 
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No clonally related sequences were observed in the PBL repertoire. 
 
Figure  5.10  Mean  CDR3  Lengths  in 
Relation to VH Mutational Numbers  
 
The mean CDR3 length was calculated for 
immunoglobulin  sequences  according  the 
number of mutations within the VH segment 
of the gene rearrangement to establish any 
relationship  between  mutational  number 
and  CDR3  length.    Results  are  given  as 
Mean  amino  acid  CDR3  length  ±  SEM.  
Groups  were  compared  for  statistical 
significance  using  the  Tukey-Kramer  test 
for  multiple  comparisons.    The  graph 
demonstrates that no significant changes in 
CDR3 length were observed at the various 
number  of  mutations.    p-values  <0.05 
would have been deemed significant. 291 
5.3.2 Sample VAS6 
As  shown  in  Figure  5.3  there  was  very  little  evidence  of  CD20
+  cells  within 
sample VAS6 but there was a large infiltration of plasma cells.  Nested PCR 
reactions  (Figure  5.11)  from  2  areas  of  plasma  cells  dissected  yielded  7 
functional Ig’s with 4 different gene rearrangements, as shown in Table 5.6A.  
These sequences were isolated multiple times from the same vasculitis sample.  
As shown in Table 5.6, the infiltrating cells used VH1, VH3 and VH4 family gene 
segments, DH genes, DH4-17*01 and DH5-12*01, could only be assigned in the 
VH3-30*03  and  VH4-59*01  rearrangements  respectively.    The  remaining 
segments of the gene rearrangements were composed of JH2, 4 and 6 family 
members. The VH1 gene rearrangement and both sets of the VH3 family genes 
were highly mutated with over 16 mutations whilst the VH4 set of genes were 
essentially  non-mutated  with  between  0  and  2  mutations.    Mutational 
distribution within the genes showed a similar pattern to that observed within 
muscle biopsies; a greater percentage of mutations were evident within CDRs 
in comparison to framework regions for each mutated sequence, with a higher 
percentage  of  mutations  within  CDR2  in  comparison  to  CDR1.    Despite  the 
large number of mutations in most of the Ig rearrangements from sample VAS6 
no significant positive or negative selection was observed in either of the FW or 
CDRs (Table 5.6B).  Similar CDR3 lengths were observed for these sequences 
with a range between 14 and 18 amino acids which may correspond to a similar 
epitope mediating the response within the skin of sample VAS6.  Junctional 
analysis could be conducted on the VH3-30*03 and VH4-59*01 rearrangements 
where DH genes could be assigned.  P nucleotides, 2, were assigned at the VD 
junction  of  the  VH3-30*03  rearrangements,  no  other  P  nucleotides  were 
identified  in  any  other  gene.    For  the  VH3-30*03  rearrangement  4  and  8  N 
nucleotides  were  observed  at  the  VD  and  DJ  junctions  while  3  and  6  were 
observed in the VH4-59*01 Ig genes.  Exonuclease activity was only observed 
at the 5’JH region of the VH3-30*03 genes where 3 nucleotides were removed.  
For the VH4-59*01 2, 8, 2 and 0 nucleotides were found to be removed at the 
3’VH, 5’DH, 3’DH and 5’JH regions respectively.  The different mutational patterns 
evident within this repertoire were not sufficient evidence for clonal diversity as 
the mutations present  were  within  the  PCR  error  rate.    No  differences  were 
observed between the two gene assignment algorithms used in this study. 292 
    
 
    
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
 
 
Before Microdissection  After Microdissection 
A 
B 
C 
Figure 5.11 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample VAS6 
 
Regions of plasma cell infiltration were microdissected from sample VAS6.  Figure 5.11A 
and B demonstrates the microdissection of 2 regions of cellular infiltration.  Images were 
taken at 400X.  PCR reactions were conducted for DNA isolated form the muscle sections 
(Figure  5.11C)  in  addition  to  DNA  isolated  from  PBL  (Figure  5.11D),  as  previously 
described  in  Chapter  2.    –  indicates  negative  control  PCR  reactions  where  DNA  was 
substituted  with  water  while  +  indicates  positive  control  PCR  reactions  using  peripheral 
blood mononuclear cells isolated from peripheral  blood  of a healthy  individual.   Results 
show amplification of VH1 to 5 families from muscle tissue but amplification of all 6 families 
from the blood sample. 
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Mutational Distribution (% of 
length)  VH 
Gene  DH Gene  JH 
Gene 
Number of 
Isolated 
Sequences 
Number of 
Mutations  CDR3 
CDR3 
Length 
(aa)  Framework  CDR1  CDR2 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
1-46*02  No D gene 
Assignment  4*02  1  17  ARDPLDCPNNKCYLYFDH  18  3.2  13.3  14.8  44  7 
3-23*01  No D gene 
Assignment  6*02  1  25  AKDPILRGSWRGVVAMDV  18  6.3  13.3  16.7  36  8 
3-30*03  4-17*01  2*01  2  16, 17  AKEGHDYGDYFYVWLDH  17  4.5, 5  6.7, 
6.7  9.3, 9.3  49  16 
4-59*01  5-12*01  4*02  3  0, 2, 2  ARQSGYDSPNYFDY  14  0, 0.9, 0.5  0, 0, 0  0, 0, 2  22  13 
 
 
 
 
VH Gene 
DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Mutations  R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
1-46*02  No D gene 
Assignment  4*02  1  17  7  3  0.47666  0.47764  5  2  0.67527  -0.2639 
3-23*01  No D gene 
Assignment  6*02  1  25  8  3  0.44592  0.50796  10  4  0.65167  -0.584 
3-30*03  4-17*01  2*01  2  16  6  0  0.46606  0.41859  6  4  0.67432  -0.6176 
        17  6  0  0.46606  0.41859  7  4  0.67432  -0.7755 
4-59*01  5-12*01  4*02  3  0  -  -  -  -  -  -  -  - 
        2  0  0  0.44001  -0.56  0  2  0.65645  -0.118 
        2  1  0  0.44001  0.44001  1  0  0.65645  0.65645 
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Table 5.6 A&B Sequence Analysis from Sample VAS6 
 
Table 5.6A - Best matching germline sequences were identified from aligning sequences in the IMGT database using JOINSOLVER software from the VAS6 
vasculitis section.  Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  V-J lengths and consecutive D match 
lengths were also identified using the JOINSOLVER software and allowed assignment of the DH genes as described in section 2.3.12.3.    
 
The number of mutations within functional rearranged genes were analysed collectively from all region of dissected cellular infiltration.  Base differences within 
the first 24 bases of sequence were disregarded as this part of the sequence binds the 5’ VH primer.   
 
The locations of mutations observed within functional rearranged genes were categorised as being within FR or CDR regions.  The numbers of mutations 
within these regions were expressed as a percentage of the entire length of the region to correct for the longer lengths observed within the framework regions. 
 
Table 5.6B - The number of replacement and silent mutations and the presence of any positive and negative selection was conducted as per Hershberg et al 
(294) as previously described.   R-CDR/FW and S-CDR/FW represent the number of replacement and silent mutations in the CDR and FW respectively.  
pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while pFW 
represents the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative sign indicates negative selection.  p-values <0.05 were 
deemed significant. 
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5.3.2.1 VH Repertoire from VAS6 PBL 
In addition to Ig analysis from the skin infiltrating repertoire of sample VAS6, the 
Ig repertoire of the patient’s peripheral blood was also assessed from a paired 
blood sample at the time of biopsy.  From this sample 36 functional and 9 non-
functional sequences were identified (Table 5.7).  Gene usage analysis of these 
functional rearrangements demonstrated a positive selection for the use of VH2 
gene segments which was significant against both normal control values and 
the baseline germline complexity (Figure 5.12A).  In addition to this positive 
selection, a selection for VH7 gene segments was also observed within the PBL 
repertoire  which  was  significant  against  normal  control  values.    A  selection 
against  VH3  and  VH4  gene  segments  was  also  observed,  these  were  both 
significant against normal control values while the declined use of VH4 gene 
segments was also significant against the baseline germline complexity.  The 
selection for VH2 and against VH4 gene segments was also observed from the 
PBL sample of patient VAS1 (Figure 5.8A).  Analysis for the use of individual 
gene segments demonstrated a significant selection for the use of the VH1-3, 1-
69 and 2-5 gene segments, these gene selections were also observed within 
the PBL sample of patient VAS1.  In this sample DH genes could be statistically 
assigned  in  66.7%  of  the  Ig  rearrangements.    From  these  assignments  a 
positive  selection  was  observed  for  DH3  gene  but  this  was  only  significant 
against the germline complexity and not against normal control values (Figure 
5.12B).  The use of all other DH gene family segments mirrored the use of the 
normal control values.  Comparing the use of the individual DH gene segments 
to the normal control values, a selection for the use of DH3-9, 5-12 and 6-13 
gene segments was observed.  The repertoire for the use of the JH segments 
also mirrored the normal control repertoire with the exception of the JH2 gene 
segments.  Analysis of this sample demonstrated that there was a significant 
selection for the use of these gene segments.  This selection was significant 
against  normal  control  values  but not  the  baseline  germline  complexity.    No 
common  gene  rearrangements  were  observed  between  the  infiltrating 
population in the skin and the peripheral blood.    
 
No  differences  in  gene  assignments  from  the  JOINSOLVER  and  IMGT/V-
QUEST algorithms were observed for this sample.     296 
 
VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number 
of Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
1-03*01  2-2*01  3*02  1  0  ARDRKVVPALDAFDI  21  12 
1-03*01  5-12*01  6*02  1  1  ARVDIVASNSYYYGMDV  23  14 
1-69*01  2-21*02  3*02  1  0  AREALAYCGGDCYSRDAFDI  37  28 
1-69*01  3-10*01  4*02  1  17  ATEIGDMDRGVTRPEF  43  16 (+1) 
1-69*01  6-13*01  6*02  1  2  ARATGYSSRYYYYGMDV  20  14 
1-69*01  6-19*01  3*02  (1)  0  ARGGSHAKYPRIAVAGTPSRGWMLLLI  58  19 
1-69*01  No D gene 
Assignment  2*01  1  24  ASVRFGESWYFDL  36  8 
1-69*01  No D gene 
Assignment  5*02  (1)  1  ARDLG*VYQLSHTPEDPTGST  41  9 
1-69*02  3-10*01  3*02  1  0  ARVLDLGYGSGSYYNVFDAFDI  44  24 
2-05*04  3-9*01  5*02  1  20  AHRRNPEYSLTGVNWFDP  41  10 
2-05*04  No D gene 
Assignment  4*02  1  20  AHRLSISYYFDF  34  7 
2-05*10  1-26*01  5*02  1  13  AHSPSGTYHKQYNWFDP  30  12 (+1) 
2-05*10  3-10*01  1*01  1  0  ARLTPTITMVRGVIITTGEYFQH  49  29 
2-05*10  3-16*02  2*01  1  0  AHWSYDYVWGSYRSPISDWYFDL  48  28 
2-05*10  3-22*01  4*02  1  8  VLLTYYDSSVYPYS  40  21 (+1) 
2-05*10  No D gene 
Assignment  4*01  1  7  AHRRGAPGYFDY  19  7 
2-05*10  No D gene 
Assignment  4*02  (1)  1  AHPTELTILARL  27  7 
2-05*10  No D gene 
Assignment  4*02  1  2  AVAANADYFDY  16  7 
3-11*03  3-22*01  3*02  1  1  ARGVYDSSGYTAFDI  26  18 
3-15*01  No D gene 
Assignment  4*02  1  10  TTEEYTFGYYIDY  25  7 
3-15*01  No D gene 
Assignment  4*02  1  9  STVDD  13  7 
3-21*01  5-12*01  4*02  1  0  ARDVEVVATEPDY  24  11 
3-21*01  6-13*01  6*02  1  0  AREGDSSSWGRGGGKYGMDV  37  14 
3-30*03  3-10*01  6*02  1  0  AKRRGSGSYYKLYYYYGMDV  32  20 
3-33*01  No D gene 
Assignment  2*01  1  12  ARDPPISISVAVSYWYFDL  30  9 
3-49*01  2-15*01  2*01  1  1  AREGPGLLTPYCSGGSCLYWYFDL  53  22 
3-66*01  3-10*01  5*02  (1)  31  SPITMVRGVIITSCLL*FLVRP  54  29 
3-66*01  4-23*01  4*02  1  27  ARVGNSCGIEY  28  10 
4-34*01  3-22*01  1*01  1  1  ARYRLTPNYYDSREGQEDQH  47  16 
4-34*01  3-22*01  6*02  (1)  1  ASRRITMIVVVPQVWT  33  23 
4-34*03  3-22*01  3*02  1  31  ARDAYGEEGYYDSSGYYYSLQDAFDI  63  27 
5-51*01  No D gene 
Assignment  2*01  1  13  ARGNTGWSEYWYFDL  21  8 
5-51*03  3-10*01  5*02  (1)  0  VNAGRITMVRGVIRPSTTGST  47  27 
5-51*03  4-17*01  2*01  1  0  ARVNDYGDSWYFDL  21  12 
6-01*01  No D gene 
Assignment  3*02  1  10  VRDSGIGLDAFDI  23  7 
6*01-01  No D gene 
Assignment  3*02  (1)  0  ARRGS*APMMLLI  23  8 
6-01*01  6-19*01  4*02  (1)  0  ARDLWQWLACTTLT  22 
11 
Cont… 297 
VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number 
of Point 
Mutations 
CDR3 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
6-01*01  6-13*01  6*02  1  1  ARGGAAAGTDYYYYGMDV  21  15 
7-04-1*01  2-2*03  6*02  (1)  0  APLGTWRA**YQLLWGMPTTTTVWT  50  20 
7-04-1*02  No D gene 
Assignment  1*01  1  14  AREGSIEVTAPGYFQH  27  9 
7-04-1*02  No D gene 
Assignment  5*02  1  1  ARDEKGFGFDP  14  7 
7-04-1*02  No D gene 
Assignment  6*02  1  1  AREGGHVYMDV  15  6 
7-04-1*02  3-9*01  4*02  2  1  AREHYDILTGYYEWRGPDYFDY  44  26 
        2  AREHYDILTGYYEWRGPDYFDY  44  26 
7-04-1*02  6-13*01R  3*02  1  0  ARDFRYQLPHDAFDI  21  11 
 
 
 
 
 
 
 
 
 
 
 
5.3.2.2 Mutational Analysis of PBL B Cell Ig Sequences of Sample VAS6  
 
As observed within the PBL sample of VAS1 the majority of cells within the 
blood sample VAS6 were essentially from a naïve population; approximately 
60%  of  the  sequences  contained  between  0  and  2  mutations  within  the  VH 
region (Figure 5.13A).  The remaining sequences contained from 3 mutations 
per sequence to over 21 mutations per sequence.  Most of these remaining 
sequences, approximately 20%, contained between 11 and 20 mutations.  A 
higher percentage of these mutations were located within the CDRs of the Ig 
rearrangements,  with  a  higher  percentage  observed  in  CDR1  compared  to 
CDR2 (Figure 5.13B).  Further analysis of these mutations in assessing the 
selection  within  these  genes  demonstrated  that  a  significant  selection  was 
observed in 4 different gene rearrangements within the PBL samples of VAS6 
(Table 5.8).  As shown in Table 5.8 this selection was observed in 3 functional 
genes and 1 non-functional gene.  All Ig rearrangements contained a negative 
selection within the FW regions.  Other positive and negative selections were 
observed in all the sequences in both the FW and CDRs but they were not 
statistically significant.  
 
 
Table 5.7 Heavy chain genes identified from the PBL sample of vasculitis patient VAS6 
 
Best matching germline sequences were identified from aligning sequences in the IMGT database 
using JOINSOLVER software from the VAS6 PBL sample.  The total number of sequences isolated 
is given in the 4
th column of the table; non-functional rearrangements indicated in brackets.  Identical 
sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  CDR3 
amino  acid  sequences  were  also  identified  using  the  JOINSOLVER  software;  *  indicates  the 
presence of a stop codon within the CDR3. V-J lengths and consecutive D match lengths (bp) were 
also  identified  using  the  JOINSOLVER  software  and  allowed  assignment  of  the  DH  genes  as 
described in section 2.3.12.3.    
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Figure 5.12 VH Gene Family Usage of VAS6 PBL 
 
VH gene family usage.  Distribution of functional genes was compared with published normal 
control values from Volpe and Kepler (251) as well as the germline complexity assuming every 
germline gene is capable of producing a functional rearrangement.  Absolute values were used 
in Chi Square Analysis to determine gene selections.  § represent a significant difference from 
normal PBL values; * represent a significant difference from the germline (p<0.05).  
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5.3.2.3 CDR3 Analysis 
No significant differences in the mean CDR3 amino acid length were observed 
in  these  sequences  between  the  functional  and  non-functional  populations 
(Table 5.9).  Despite these results a significant decrease in CDR3 length was 
observed for the sequences containing between 3 and 10 mutations (Figure 
5.14).    This  significance  was  only  against  sequences  containing  2  or  less 
mutations and not significant against sequences with more than 10 mutations 
per sequence.  Further analysis of the CDR3 region examined the addition of P 
and  N  nucleotides  at  the  VD  and  DJ  junctions  as  well  as  the  exonuclease 
activity at the gene segment ends, 3’VH, 5’DH, 3’DH and 5’JH, within the VDJ 
junction.    Within  these  sequences  no  significant  differences  were  observed 
between  the  VD  and  DJ  junction,  or  between  functional  and  non-functional 
sequences,  for  the  addition  of  P  and  N  nucleotides  at  these  regions.  
Conversely a significant difference in exonuclease activity was observed at the 
3’VH gene segment of the junction between the functional and non-functional Ig 
rearrangements,  with  a  significant  reduced  exonuclease  activity  in  functional 
rearrangements.  This reduced enzyme activity was also significant against the 
5’DH and 5’JH regions in functional rearrangements.      
Figure 5.13 Numbers of Mutations and 
Mutational  Distribution  of  Functional 
Sequences in VAS6 PBL 
 
Figure 5.13A - The number of mutations 
within functional rearranged genes were 
analysed  in  the  PBL  sample  of  VAS6 
PBL.  Base differences within the first 24 
bases of sequence were disregarded as 
this part of the sequence binds the 5’ VH 
primer.  Graph demonstrates that PBL Ig 
rearrangements  were  essentially  from  a 
naïve population with a small percentage 
of highly mutated rearrangements. 
 
 Figure  5.13B  -  The  locations  of 
mutations  observed  within  functional 
rearranged  genes  were  categorised  as 
being  within  FR  or  CDR  regions.    The 
numbers  of  mutations  within  these 
regions were expressed as a percentage 
of  the  entire  length  of  the  region  to 
correct  for  the  longer  lengths  observed 
within  the  framework  regions.    Graph 
demonstrates  a  higher  percentage  of 
mutations within CDR regions compared 
to framework regions. 300 
VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
1-03*01  2-2*01  3*02  1  0  -  -  -  -  -  -  -  - 
1-03*01  5-12*01  6*02  1  1  0  0  0.47328  0  1  0  0.7011  0.7011 
1-69*01  2-21*01  3*02  1  0  -  -  -  -  -  -  -  - 
1-69*01  3-10*01  4*02  1  17  5  1  0.45038  0.5459  8  3  0.66893  -0.9625 
1-69*01  6-13*01  6*02  1  2  1  0  0.45038  0.45038  1  0  0.66893  0.66893 
1-69*01  6-19*01  3*02  1  0  -  -  -  -  -  -  -  - 
1-69*01  No D gene 
Assignment  2*01  1  24  7  1  0.45038  0.53682  11  5  0.66893  -0.8331 
1-69*01  No D gene 
Assignment  5*02  (1)  1  0  0  0.45038  0  1  0  0.66893  0.69488 
1-69*02  3-10*01  3*02  1  0  -  -  -  -  -  -  -  - 
2-05*04  3-9*01  5*02  1  20  5  2  0.44921  -0.5082  6  7  0.67583  -0.0325 
2-05*04  No D gene 
Assignment  4*02  1  20  4  1  0.44921  -0.2326  6  9  0.67583  -0.0161 
2-05*10  1-26*01  5*02  1  13  6  0  0.44582  0.20661  4  3  0.67963  -0.5535 
2-05*10  3-10*01  1*01  1  0  -  -  -  -  -  -  -  - 
2-05*10  3-16*01  2*01  1  0  -  -  -  -  -  -  -  - 
2-05*10  3-22*01  4*02  1  8  2  0  0.44582  0.19875  6  0  0.67963  0.09855 
2-05*10  No D gene 
Assignment  4*01  1  7  1  0  0.44582  -0.4922  3  3  0.67963  -0.3821 
2-05*10  No D gene 
Assignment  4*02  (1)  1  0  0  0.44582  0  1  0  0.67963  0.67963 
2-05*10  No D gene 
Assignment  4*02  1  2  1  0  0.44582  0.67963  1  0  0.67963  0.67963 
3-11*03  3-22*01  3*02  1  1  0  0  0.45384  -0.5462  0  1  0.66416  -0.3358 
3-15*01  No D gene 
Assignment  4*02  1  10  3  2  0.44151  0.78267  4  1  0.65731  -0.6389 
3-15*01  No D gene 
Assignment  4*02  1  9  2  1  0.44151  -0.633  3  3  0.65731  -0.2389 
3-21*01  5-12*01  4*02  1  0  -  -  -  -  -  -  -  - 
Cont… 301 
VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
3-21*01  6-13*01  6*02  1  0  -  -  -  -  -  -  -  - 
3-30*03  3-10*01  6*02  1  0  -  -  -  -  -  -  -  - 
3-33*01  No D gene 
Assignment  2*01  1  12  6  3  0.46949  0.43089  2  1  0.67189  -0.1116 
3-49*01  2-15*01  2*01  1  1  0  0  0.44792  -0.5521  0  1  0.66152  -0.3385 
3-66*01  3-10*01  5*02  (1)  31  13  4  0.46708  0.35578  5  6  0.66604  -0.0105 
3-66*01  4-23*01  4*02  1  27  7  1  0.46166  0.41664  15  4  0.66979  0.46598 
4-34*01  3-22*01  1*01  1  1  0  0  0.42295  -0.5771  0  1  0.65147  -0.3485 
4-34*01  3-22*01  6*02  (1)  1  0  0  0.42295  0  1  0  0.65147  0.65147 
4-34*03  3-22*01  3*02  1  31  9  3  0.42279  0.6563  12  7  0.6487  -0.3217 
5-51*01  No D gene 
Assignment  2*01  1  13  6  0  0.43336  0.08806  5  2  0.69901  0.97214 
5-51*03  3-10*01  5*02  (1)  0  -  -  -  -  -  -  -  - 
5-51*03  4-17*01  2*01  1  0  -  -  -  -  -  -  -  - 
6-01*01  No D gene 
Assignment  3*02  1  10  2  2  0.47428  -0.5285  4  2  0.65306  -0.3897 
6*01-01  No D gene 
Assignment  3*02  (1)  0  -  -  -  -  -  -  -  - 
6-01*01  6-19*01  4*02  (1)  0  -  -  -  -  -  -  -  - 
6-01*01  6-13*01  6*02  1  1  0  0  0.47428  0  1  0  0.65306  0.65306 
7-04-1*01  2-2*03  6*02  (1)  0  -  -  -  -  -  -  -  - 
7-04-1*02  No D gene 
Assignment  1*01  1  14  4  0  0.42769  -0.533  2  8  0.66832  -0.0036 
7-04-1*02  No D gene 
Assignment  5*02  1  1  1  0  0.42587  0.42587  0  0  0.67038  - 
7-04-1*02  No D gene 
Assignment  6*02  1  1  0  0  0.42587 
-
0.57412  0  1  0.67038 
-
0.32961 
7-04-1*02  3-9*01  4*02  2  1  0  1  0.42587  -
0.54412 
0  0  0.67038  -
0.32961 
        2  1  0  0.42769  0.42769  1  0  0.66832  0.66832 
7-04-1*02  6-13*01R  3*02  1  0  -  -  -  -  -  -  -  - 302 
 
 
 
Table 5.8 Analysis of Replacement and Silent Mutations and Positive and Negative Selection in Sample VAS6 PBL 
 
Replacement and silent mutations within the immunoglobulin sequences and antigen-driven selection were determined according as per Hershberg et al (294) 
and the corresponding computer programme (http://clip.med.yale.edu/selection).  This improved method of analysis uses a focused binomial test to establish 
positive  or  negative  mutational  selections  within  the  sequence  with  high  specificity  and  increased  sensitivity  accounting  for  known  biases  within  the 
immunoglobulin gene sequence.  R-CDR and S-CDR represents the number of replacement and silent mutations within the CDR respectively.  pCDR represents 
the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while p-CDR is the p-value of the 
focused binominal test on the CDR.  Conversely R-FW and S-FW represents the number of replacement and silent mutations within the FW respectively. pFW 
represent the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR while p-FW is the p-value 
of the focused binominal test on the FW.  If the number of R mutations is less than expected the software will test for negative selection and p-values will be 
preceded by a negative sign or if the number of mutations is more than expected the software will test for positive selection.  p-values <0.05 are highlighted in 
yellow and were deemed significant for selection. 
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Functional  16.5 ± 0.8  CDR3 Length 
Non-Functional  19 ± 1.8 
  VD Junction  DJ Junction 
Functional  0.8 ± 0.2  0.4 ± 0.1  P Nucleotide 
Non-Functional  1.6 ± 0.7  1 ± 0.8 
Functional  8.8 ± 1.5  7 ± 1.1  N Nucleotide 
Non-Functional  8.6 ± 3.6  8 ± 3 
  3’ VH  5’ DH  3’ DH  5’JH 
Functional  1.1 ± 0.3*  4.4 ± 0.7 
Θ  4.1 ± 0.7  3.8 ± 0.8
 Θ  Exonuclease 
Activity  Non-Functional  4 ± 1.3*  3.6 ± 1.9  3.4 ± 1.3  5 ± 3.1 
 
Table 5.9 CDR3 and Junctional Analysis in VAS6 PBL 
 
The mean amino acid length of the CDR3, the mean nucleotide numbers corresponding to P 
and N nucleotides as well as the mean number of germline nucleotides lost due to exonuclease 
activity were calculated from the junctional regions of all myositis immunoglobulin sequences as 
well as in DM and PM subsets.  Results are given as the Mean ± SEM.  Instances where no 
non-functional sequences were identified and values could not be calculated were recorded as 
non applicable (N/A).  * indicates a significant difference between functional and non-functional 
sequences using an unpaired t test.   Θ represents a significant difference from 3’VH. 
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No clonally related sequences were observed in the repertoire isolated from the 
PBL,  but  as  only  a  small  sample  of  the  whole  repertoire  was  isolated  and 
identified clonally related sequences were not expected within the Ig repertoire. 
 
 
 
 
Figure  5.14  Mean  CDR3  Lengths  in 
Relation to VH Mutational Numbers  
 
The mean  CDR3  length  was  calculated 
for immunoglobulin sequences according 
the  number  of  mutations  within  the  VH 
segment  of  the  gene  rearrangement  to 
establish  any  relationship  between 
mutational  number  and  CDR3  length.  
Results  are  given  as  Mean  amino  acid 
CDR3  length  ±  SEM.    Groups  were 
compared  for  statistical  significance 
using the Tukey-Kramer test for multiple 
comparisons.    The  graph  demonstrates 
that  no  significant  changes  in  CDR3 
length  were  observed  at  the  various 
number  of  mutations.    p-values  <0.05 
would have been deemed significant. 304 
5.3.3 Sample VAS7 
As previously described in section 5.2.3 very few B cells were present within the 
cellular infiltrates of sample VAS7, but plasma cells were shown to be present 
within cellular aggregates. A similar observation to that observed in the other 
vasculitis samples.  Figure 5.15 demonstrates the microdissection and DNA 
amplification from these cells which was used to establish the gene repertoire 
these  infiltrating  cells.    Five  different  functional  gene  rearrangements  were 
amplified  from  DNA  released  from  the  VAS7  microdissection  (Table  5.10A).  
Two  of  the  amplified  genes  contained  VH1  gene  segments,  1-46*01  and  1-
69*09,  while  the  remaining  3  gene  rearrangements  contained  VH3  gene 
segments, 3-12*01, 3-30*03 and 3-73*01.  DH3-10*01 could only be assigned in 
the VH1-46*01 gene rearrangement.  JH1, 4 and 5 gene segments were also 
assigned.    Mutational  numbers  were  high  in  the  gene  rearrangements 
containing the VH1-46*01, 3-21*01 and 3-73*01 gene segments with over 15 
mutations per sequence.  The remaining two sequences isolated from VAS7 
sections contained less than 10 mutations per sequence.  Location analysis of 
these mutations demonstrated that the majority of mutations occurred within the 
CDR compared to framework regions.  Table 5.10A demonstrates that these 
were largely found within CDR1 compared to CDR2.  No significant selection 
could be assigned to any of the gene rearrangements regardless of the large 
number of mutations within the VH region of the sequence (Table 5.10B).  For 
these  sequences  isolated  from  the  skin  infiltrating  population,  CDR3  lengths 
were found to range from 9 to 17 amino acids.  Junctional analysis in the VH1-
46*01 gene rearrangement where a DH gene could be assigned demonstrated 
that no P nucleotides were present at either the VD or DJ junction.  On the 
contrary 17 and 3 N nucleotides were assigned respectively at the VD and DJ 
regions of the junction.  Analysis of the exonuclease activity demonstrated that 
0, 8, 8 and 6 nucleotides were removed from the respective 3’VH, 5’DH, 3’DH 
and 5’JH gene segments of the junction.  No clonally related sets of sequences 
were  found  within  the  infiltrating  cells  and  all  gene  assignments  from  the 
JOINSOLVER  algorithm  corresponded  to  the  gene  assignments  of  IMGT/V-
QUEST.  
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Before Microdissection  After Microdissection 
A 
B 
Figure 5.15 Microdissection of infiltrating B cells and amplification of VH-gene 
rearrangements from Sample VAS7 
 
A region of plasma cell infiltration was microdissected from sample VAS7.  Figure 5.15A 
demonstrates the microdissection of 2 regions of cellular infiltration.  Images were taken at 
400X.    DNA  released  from  these  microdissections  was  amplified  using  a  Nested  PCR 
system (Figure 5.15B), as previously described in Chapter 2.  – indicates negative control 
PCR reactions  where DNA  was substituted  with  water while  + indicates positive control 
PCR reactions using peripheral blood mononuclear cells isolated from peripheral blood of a 
healthy individual.  Results show amplification of all 6 VH families. 
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VH Gene  DH Gene  JH Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
1-46*01  3-10*01  4*02  1  16  5  0  0.47813  0.65911  7  4  0.67198  -0.788 
1-69*09  No D gene 
Assignment  1*01  1  2  0  1  0.46644  -0.2847  0  1  0.67237  -0.1073 
3-21*01  No D gene 
Assignment  4*02  1  24  6  4  0.51535  -0.3872  9  5  0.65709  -0.1773 
3-30*03  No D gene 
Assignment  4*02  1  8  5  1  0.46794  0.09263  2  0  0.6723  -0.9479 
3-73*01  No D gene 
Assignment  5*02  1  21  5  2  0.47451  -0.5352  8  6  0.66316  -0.1863 
 
 
 
Mutational Distribution 
 (% of length)  VH 
Gene  DH Gene  JH 
Gene 
Number of 
Isolated 
Sequences 
Number of 
Point 
Mutations 
CDR3 
CDR3 
Length 
(aa)  Framework  CDR1  CDR2 
V-J 
Length 
(bp) 
Consecutive D 
length (bp) 
(+Mismatches) 
1-46*01  3-10*01  4*02  1  16  ARESIIFADGSGSYGDY  17  5  33.3  0  37  17 
1-69*09  No D gene 
Assignment  1*01  1  2  VIHLIQLST  9  0.5  0  2  25  7 
3-21*01  No D gene 
Assignment  4*02  1  24  AREHWELLRGNDYYLDY  17  6.3  20  13.7  43  6 
3-30*03  No D gene 
Assignment  4*02  1  8  ARRGYLNSVDY  11  0.9  20  5.9  20  8 
3-73*01  No D gene 
Assignment  5*02  1  21  TRREDGSGSFSA  12  6.3  13.3  9.8  28  8 
A 
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Table 5.10 A&B Sequence Analysis from Sample VAS7 
 
Table 5.10A - Best matching germline sequences were identified from aligning sequences in the IMGT database using JOINSOLVER software from the VAS7 
vasculitis section.  Identical sequences with the same VH, DH, JH, CDR3 and base mutations were only counted once.  V-J lengths and consecutive D match 
lengths (bp) were also identified using the JOINSOLVER software and allowed assignment of the DH genes as described in section 2.3.12.3.    
 
The number of mutations within functional rearranged genes were analysed collectively from all region of dissected cellular infiltration.  Base differences within 
the first 24 bases of sequence were disregarded as this part of the sequence binds the 5’ VH primer.   
 
The locations of mutations observed within functional rearranged genes were categorised as being within FR or CDR regions.  The numbers of mutations 
within these regions were expressed as a percentage of the entire length of the region to correct for the longer lengths observed within the framework regions. 
 
Table 5.10B - The number of replacement and silent mutations and the presence of any positive and negative selection was conducted as per Hershberg et al 
(294) as previously described.   R-CDR/FW and S-CDR/FW represent the number of replacement and silent mutations in the CDR and FW respectively.  
pCDR represents the probability of having a R mutation in the CDR given all the mutations in the sequence except R mutations within the FW while pFW 
represents the probability of having a R mutation in the FW given all the mutations in the sequence except R mutations within the CDR and p-CDR/FW 
represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative sign indicates negative selection.  p-values <0.05 were 
deemed significant. 
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5.3.4 VH Repertoire in Vasculitis 
As a limited number of Ig sequences were obtained from skin infiltrating cells in 
each individual vasculitis patient, the results from all three patients were pooled 
to  establish  if  a  common  pattern  of  gene  usage  and  mutational  patterns 
occurred.  The results demonstrated that the collective repertoire of VH gene 
usage  mirrored  the  normal  control  values  as  well  as  the  baseline  germline 
complexity (Figure 5.16A).  These findings are in contrast to those observed 
within  the  PBL  repertoire  of  samples  VAS1  and  VAS6  where  a  common 
selection for the use of VH2 gene segments and selection against VH4 gene 
segments was observed in both samples.  Despite the lack of selection for the 
different VH gene families as a whole within the skin, selections were observed 
for the use of VH1-46, 3-33, 3-73 and 4-59 individual gene segments.  From the 
Ig repertoire from skin infiltrating cells DH genes could be assigned in 41.2% of 
gene rearrangements.  From this a selection for the use of DH4 and DH5 gene 
segments was observed which was significant against normal control values, in 
particular the DH4-17 and 5-12 gene segments which were significantly selected 
(Figure 5.16B).  Similar to the VH repertoire these selections were in contrast to 
that observed within the two paired blood samples.  The positive selection for 
the  use  of  DH3  gene  segments  within  the  PBL  was  not  observed  in  the  Ig 
rearrangements from the cellular infiltrates within the skin.  JH2 gene segments 
were  found  to  be  over-represented  in  the  3  vasculitis  patients,  which  was 
significant  against  the  normal  control  values  but  not  the  baseline  germline 
complexity  (Figure  5.16C).    This  selection  was  also  observed  within  the 
repertoire from one of the peripheral blood samples, VAS6, but is in contrast to 
the results from the second blood sample, VAS1.        
 
5.3.4.1 Mutational Analysis in Vasculitis 
Analysis  of  mutational  numbers  from  the  17  functional  Ig  rearrangements 
isolated demonstrated that approximately a quarter of the sequences isolated 
were essentially non-mutated and from a naïve population (Figure 5.17A).  The 
remaining  sequences  were  highly  mutated  with  over  50%  of  the  sequences 
containing  over  11  mutations  per  sequence.    These  mutations  were  largely 
observed  in  the  CDRs  compared  to  FW  regions,  with  a  slightly  higher 
percentage within CDR1 compared to CDR2 (Figure 5.17B). 
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Figure 5.16 VH Gene Family Usage of Vasculitis samples 
 
VH gene family usage.  Distribution of functional genes was compared with published normal 
control values from Volpe and Kepler (251) as well as the germline complexity assuming every 
germline gene is capable of producing a functional rearrangement.  Absolute values were used 
in Chi Square Analysis to determine gene selections.  § represent a significant difference from 
normal PBL values; * represent a significant difference from the germline (p<0.05).  
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From the collective repertoire of 17 functional sequences, selection was only 
significantly observed in 1 functional Ig rearrangement.  In this Ig rearrangement 
negative selection was observed in the FW region, no other significant selection 
was observed from any other rearrangement. 
 
5.3.4.2 CDR3 Analysis 
 
In  the  isolated  repertoire  from  the  vasculitis  samples  no  non-functional  Ig 
rearrangements  were  identified,  therefore  significant  differences  in  the 
junctional  characteristics  between  functional  and  non-functional  sequences 
could not be established.  For the functional repertoire the mean amino acid 
CDR3  length  was  15.5  ±  0.9  amino  acids  (Table  5.11)  and  no  significant 
difference in CDR3 length was observed within the various mutational groups of 
sequences (Figure 5.18). The addition of P and N nucleotides at the VD and DJ 
junctions  were  not  found  to  be  significantly  different  within  the  functional 
population  of  sequences.    Examination  of  the  exonuclease  activity  at  the 
various gene segments of the junctional area demonstrated a significant decline 
in the enzymatic activity at the 3’VH region compared to the 5’DH region in the 
VD region of the junction.  No other significant differences were observed.     
 
Figure 5.17 Numbers of Mutations and 
Mutational  Distribution  of  Functional 
Sequences in Vasculitis Patients 
 
Figure 5.17A - The number of mutations 
within functional rearranged genes were 
analysed  collectively  from  all  vasculitis 
patients.  Base differences within the first 
24 bases of sequence were disregarded 
as this part of the sequence binds the 5’ 
VH  primer.    Graph  demonstrates 
sequences within cellular infiltrates show 
a  diverse  distribution  of  mutational 
numbers. 
 
 Figure  5.17B  -  The  locations  of 
mutations  observed  within  functional 
rearranged  genes  were  categorised  as 
being  within  FR  or  CDR  regions.    The 
numbers  of  mutations  within  these 
regions were expressed as a percentage 
of  the  entire  length  of  the  region  to 
correct  for  the  longer  lengths  observed 
within  the  framework  regions.    Graph 
demonstrates  a  higher  percentage  of 
mutations within CDR regions compared 
to framework regions. 
A 
B 311 
Functional  15.5 ± 0.9  CDR3 Length 
Non-Functional  N/A 
  VD Junction  DJ Junction 
Functional  0.8 ± 0.4  0  P Nucleotide 
Non-Functional  N/A  N/A 
Functional  5.3 ± 2  6.1 ± 0.6  N Nucleotide 
Non-Functional  N/A  N/A 
  3’ VH  5’ DH  3’ DH  5’JH 
Functional  1 ± 0.4  5.3 ± 1.4
 Θ  2.7 ± 1.1  3.4 ± 1.5  Exonuclease 
Activity  Non-Functional  N/A  N/A  N/A  N/A 
 
Table 5.11 CDR3 and Junctional Analysis in Vasculitis 
 
The mean amino acid length of the CDR3, the mean nucleotide numbers corresponding to P 
and N nucleotides as well as the mean number of germline nucleotides lost due to exonuclease 
activity were calculated from the junctional regions of all vasculitis immunoglobulin sequences 
as well as in DM and PM subsets.  Results are given as the Mean ± SEM, statistical significance 
was established using an unpaired t-test.  Instances where no non-functional sequences were 
identified  and  values  could  not  be  calculated  were  recorded  as  non  applicable  (N/A).    Θ 
represents a significant difference from 3’VH. 
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One  common  replacement  mutation  was  observed  between  the  VH1-18*01 
gene isolated from sample VAS1 and the VH1-46*01 gene isolated from sample 
VAS6.    At  amino  acid  69,  situated  close  to  CDR2,  a  replacement  mutation 
occurred within both sequences converting the methionine to a valine amino 
acid (M→V).  The serine to asparagine replacement mutation (S→N), amino 
acid 31, which was observed within some of the myositis samples was also 
observed within the VH3-33*01 isolated from sample VAS1. 
 
 
Figure  5.18  Mean  CDR3  Lengths  in 
Relation to VH Mutational Numbers  
 
The mean  CDR3  length  was  calculated 
for immunoglobulin sequences according 
the  number  of  mutations  within  the  VH 
segment  of  the  gene  rearrangement  to 
establish  any  relationship  between 
mutational  number  and  CDR3  length.  
Results  are  given  as  Mean  amino  acid 
CDR3  length  ±  SEM.    Groups  were 
compared  for  statistical  significance 
using the Tukey-Kramer test for multiple 
comparisons.    The  graph  demonstrates 
that  no  significant  changes  in  CDR3 
length  were  observed  at  the  various 
number  of  mutations.    p-values  <0.05 
would have been deemed significant. 312 
5.4 Discussion  
In a similar situation to myositis, the role of B cells in the inflammatory process 
of vasculitis is unknown.  Pathological manifestations within vasculitic disorders 
have  been  attributed  to  the  activation  of  T  cells  but  the  presence  and 
contribution  of  immune  complexes  and  autoantibodies  within  these 
inflammatory disorders strongly implicates a pathological role for B cells.  This is 
substantiated by the clinical improvement observed in patients undergoing B 
cell  depletive  therapy  as  previously  described.    Previous  work  in  this  study 
aimed to define a possible role for B cells in muscle inflammation by testing the 
hypothesis that muscle infiltrating B cells were being locally stimulated resulting 
in an antigen-driven response contributing to tissue pathology.  This hypothesis 
was also tested for skin infiltrating lymphocytes in vasculitis patients using the 
same procedures described for muscle infiltrating cells to determine if antigen-
driven  Ig  sequence  characteristics  such  as  gene  selection,  mutational 
accumulation  and  clonal  diversification  were  present  within  the  Ig  gene 
rearrangements expressed on skin infiltrating B cells. 
 
Initially  the  identification  and  organisation  of  skin  infiltrating  cells  was 
determined.  In contrast to some of the muscle samples very few B cells were 
present within the infiltrating population and the vast majority of infiltrating cells 
were plasma cells.  Skin infiltrating cells were widely distributed throughout the 
entire  biopsy  with  very  little  aggregation  and  likewise  to  the  organisation 
observed within myositis samples no ectopic germinal centre type structures 
were observed.  Other cell markers were also identified, CD3, CD4, CD8, CD68 
and FoxP3, while FDCs were entirely absent from the infiltrating population for 
all samples.  Very few Ki67
+ proliferating cells were identified, collectively these 
results  may  indicate  that  an  active  antigen-driven  response  is  not  occurring 
within  the  skin  and  the  infiltrating  cell  population  is  present  as  a  result  of 
inflammatory mediator gradients. 
 
The lack of B cells, FDCs and ectopic germinal centre structures in the samples 
of the current study is in contrast to studies by Voswinkel et al (348;349) in 
Wegener’s granulomatosis (WG), a disease of unknown aetiology characterised 
by  necrotising  granulomatosus  inflammation  and  systemic  vasculitis 313 
predominately affecting small vessels.  Voswinkel et al (348) observed different 
lymphocytic  phenotypes  ranging  from  diffusely  infiltrating  cells  to  cellular 
aggregates of T and/or B cells without FDCs in addition to germinal centre type 
structures  containing  FDCs.  The  initial  study  (348)  identified  B  lymphocyte 
containing  infiltrates  in  endonasal  biopsies  of  all  6  WG  patients  studied.  
Approximately 30% of the cells within the follicle-like structures were identified 
as CD20
+ B cells; plasma cells were also evident but did not appear to be as 
substantial  to  the  infiltrating  plasma  cell  population  in  the  three  vasculitis 
patients used within the current study.  The findings of Voswinkel et al are also 
supported  by  additional  studies  (350).    The  variations  in  immunohistological 
findings between these studies and the current study may represent different 
disease and B cell mechanisms occurring at various target sites of vasculitis. 
 
To  address  the  hypothesis  that  skin  infiltrating  B  cells  are  being  stimulated 
locally  in  an  antigen-driven  response  the  sequence  characteristics  of  Ig 
rearrangements  expressed  on  infiltrating  cells  was  assessed.    Within  each 
individual patient a limited number of rearrangements were identified.  Due to 
the low numbers a comparison of gene usage could not be conducted on each 
individual patient, therefore a collective analysis was required to determine the 
sequence characteristics of the Ig rearrangements.  The different methods used 
to  assign  gene  segments  within  the  Ig  rearrangements  which  may  result  in 
alterations in gene assignments, previously discussed in section 4.3.2, are also 
relevant to this part of the study.  From the collective repertoire gene selections 
were  observed  for  DH  and  JH  gene  segments  and  mutations  were  found  in 
approximately 75% of sequences with over 40% of sequences containing 21 or 
more mutations.  These results would indicate that antigen-driven diversification 
of  B  cells  had  occurred  but  the  lack  of  VH  selection  and  clonal  related 
sequences  from  the  infiltrating  lymphocytes  contradicts  the  proposed 
hypothesis  of  this  study.    Analysis  of  a  larger  number  of  sequences  from  a 
larger cohort of patients may be required to fully assess B cell antigen driven 
diversification.  Modifications to the Ig repertoire from patient therapies, Table 
2.1,  must  also  be  considered.    The  sequence  results  could  relate  to  the 
previous immunohistological studies in these samples.  As previously described 
a large number of plasma cells were found within the infiltrating populations 314 
along  with  a  limited  proliferating  population  of  cells.    Taken  together  the  Ig 
rearrangements  identified  may  correspond  to  the  highest  affinity,  antigen-
specific  and  clonally  diversified  rearrangements  from  B  cells  which  have 
terminally differentiated into plasma cells and infiltrated into target areas of the 
skin  with  the  secreted  antibodies  from  these  cells  contributing  to  the  tissue 
pathology. In such a situation it would be expected that the sequences isolated 
would  exhibit  positive  selection  based  on  the  R  and  S  mutation  within  the 
sequence.  Selection in this study was based on the newly proposed method 
described by Hershberg et al (294), which was previously discussed in section 
4.3.3.  Using this method selection was only detected in 1 Ig rearrangement, 
which  was  found  within  the  FW  regions  and  was  significant  for  negative 
selection.  The lack of positive selection, in a similar situation to myositis Ig 
rearrangements discussed in section 4.3, may be the result of the improved 
parameters used to assign selection which now account for the fundamental 
aspects of sequence variation and diversity.      
 
It  could  also  be  postulated  that  the  accumulation  of  plasma  cells  observed 
within these samples is simply a consequence of the immune response which, 
as a result of inflammatory mediators, had provided a suitable niche for plasma 
cells within the inflamed skin and that the cells do not bear Ig rearrangements 
which are specific to a vasculitis specific or associated antigen.  Alternatively 
the work of this study may suggest a different B cell mechanism in contrast to 
the proposed hypothesis of this study.  Initiation of inflammation within the skin, 
in  response  to  a  vasculitis  specific  autoantigen,  may  generate  a  favourable 
environment  for  the  migration  and  transition  of  high  affinity  pre-plasma  cells 
which  have  the  capacity  to  generate  long-lived  plasma  cells  and  secrete 
pathogenic autoantibodies.  Identification of the antigen specificity of antibodies 
secreted from plasma cells within the 3 vasculitis samples of this study would 
help clarify the mechanism of these cells in inflamed skin.  This hypothesis may 
result in the limited Ig repertoire observed within this study and substantiates 
the significance of these B cell derived cells in the pathogenesis of vasculitis.  
The importance of modulating production, survival and mechanisms of plasma 
cells  in  vasculitis  disorders  is  substantiated  by  previous  studies  which 
demonstrate the importance of these cells and the antibodies they produce in 315 
the  pathogenesis  of  vasculitis  (6;171;178;188;202;351-355),  reviewed 
(149;157;179;185;356).     
 
As well as analysing the gene segment usage and mutational patterns of Ig 
rearrangements identified from vasculitis biopsies, the different mechanisms at 
the  junctional  regions  of  VDJ  recombination  were  examined.    Within  this 
repertoire  of  sequences  no  non-functional  sequences  were  isolated  so 
significant differences between CDR3 lengths in functional and non-functional 
populations  could  not  be  examined  to  support  previous  findings 
(238;241;242;251;291).    There  was  also  no  significant  difference  between 
CDR3  lengths  in  different  mutational  groups  in  contrast  to  previous  studies 
(238).  The addition of P and N nucleotides between the VD and DJ junctions 
was also found not to be significant between the two regions of the junction, as 
previously observed (251;291;334), while a significant decrease in exonuclease 
activity  at  the  3’VH  region  was  found  compared  to  the  5’DH  region.    These 
results mirror that found within the Ig gene isolated from inflamed muscle and 
may  correlate  differences  within  diseased  repertoires  compared  to  normal 
control repertoires. 
 
In contrast to the work of Chapter 4, paired blood samples were obtained for 
two  of  the  vasculitis  patients.    Both  Ig  gene  repertoires  demonstrated  both 
positive and negative gene selections when compared to normal control values, 
with common selections observed in both patients.  These selections were not 
observed in the repertoire from Ig expressed on skin infiltrating cells.  From 
these  samples  identically  rearranged  genes  were  not  found  in  both  the 
peripheral blood and inflamed skin which may represent a compartmentalisation 
of the immune response within the skin, although analysis from a larger number 
of patients and of a larger number of sequences from both sources may be 
required to fully examine the differences between peripheral blood repertoires 
and the repertoires observed within the target tissues of autoimmune diseases.  
These results are in contrast to previous studies where recirculation of activated 
B  cells  was  observed  in  the  synovial  membranes  and  peripheral  blood 
repertoires of RA patients (336).  Patient VAS6 had a past medical history of 
ankylosing spondylitis (AS).  A previous study has demonstrated that antigen-
driven B cell responses occurred within synovial membranes of an AS patient 316 
(320), it would be interesting to assess the repertoires from different sites in this 
patient to fully assess the mechanisms involved in gene selection as well as 
recirculation  and  maturation  of  activated  B  cells.    Collectively  these  results 
would indicate whether clones isolated from the skin have recirculated from the 
synovial membranes and the skin infiltration is non-specific and the vasculitis is 
secondary to the chronic inflammation of the ankylosing spondylitis.   
 
Studies by Voswinkel et al (348;349) have demonstrated the antigen-driven and 
clonal diversification of B cells in WG, a subset of vasculitis.  B lymphocyte 
infiltrates, in various organisations as described above, were observed in all 6 
endonasal biopsies tested from which 184 VH rearrangements were compared 
to healthy VH repertoires (348).  Five samples displayed a VH repertoire with 
prevalence for VH3 and VH4 gene rearrangements with a predominance of VH3-
30, VH3-23, VH4-34 and VH4-59 genes.  A high proportion of mutations within 
sequences were observed compared to healthy repertoires which were found to 
relate to an increased disease activity and clonally related sets of sequences 
were found in 4 of the 6 patients suggesting antigen-driven affinity maturation.  
These results were substantiated by the presence of autoantigen specific PR3
+ 
cells  within  the  cellular  infiltrate.    Another  recent  study  by  this  group  has 
analysed the Ig rearrangements from single B cells laser dissected from frozen 
sections from endonasal biopsies of WG patients (349).  The results confirm the 
previous study but also allowed characterisation of individual B cell receptors by 
analysing the L chain sequences and pairings from these cells.  Both studies 
conclude  the  selection  and  maturation  of  antigen-specific  B  cells  in  an 
autoimmune response of WG, a disease characterised by vasculitis, but a direct 
comparison cannot be made to the study of this chapter as different responses 
may occur at different sites of inflammation and the stimulating antigen may 
also be different at various locations and between different patients.     
 
In summary, these results suggest that antigen-driven B cell responses may 
play a role in the inflamed skin of these vasculitis patients but with very few B 
cells and no clonally related sequences identified, the primary responses may 
be  occurring  at  other  sites  of  inflammation,  or  secondary  lymphoid  organs, 
resulting in migration of high affinity antigen-specific cells into inflamed skin.      317 
Chapter  6  -  Identification  of  Antigens  Driving  the  Immune  Response  in 
Myositis Patients 
6.1 Introduction 
Previous  results  within  this  study,  Chapters  4  &  5,  have  demonstrated  the 
presence of antigen-driven diversified cells at the sites of inflammation within 
the target tissues of myositis and vasculitis.  Gene selections and mutational 
analysis of the Ig gene rearrangements, where no clonally related sequences 
were  identified,  indicate  that  cells  had  undergone  an  antigen-driven 
diversification  and  were  possibly  stimulated  by  antigen  at  other  locations, 
presumably  the  draining  lymph  node,  and  migrating  into  the  sites  of 
inflammation while identification of clonally related sequences suggested that 
infiltrating cells were being stimulated locally by antigens present at these sites 
of inflammation.  Although the results have demonstrated the occurrence of an 
antigen-driven  response  they  do  not  indicate  the  identity  of  the  antigen(s) 
stimulating the response.   
 
Autoantibodies were detected in the sera of five myositis patients, Table 2.1.  
To summarise patient MYO3 and MYO23 were Jo-1
+ while patient MYO3 also 
tested positive for Sm/RNP antibodies.  Two of the myositis patients, MYO16 & 
MYO19, tested positive for anti-nuclear antigens (ANA).  The nucleolar pattern 
of staining indicated that the antigen may be topoisomerase 1 (Scl70) which is 
normally  found  within  systemic  sclerosis  patients  (113;357).    Anti-DNA 
antibodies were also found in serum samples of patient MYOE, a characteristic 
of SLE patients.  Therefore to identify the stimulating antigens occurring within 
the  target  tissues  of  these  patients,  biotinylated  recombinant  antigens  were 
used to establish the following aims of the chapter: 
·  Identify antigen-specific muscle infiltrating lymphocytes. 
·  Establish the phenotype of these antigen specific cells as B cells and/or 
plasma cells using double immunohistochemical experiments. 
·  Use laser capture microdissection to isolate antigen specific cells and 
determine the Ig gene rearrangements of these cells.  
 
The  results  described  in  this  chapter  were  in  preliminary  stages  and  were 
intended as provisional for future work in autoantigen identification. 318 
6.2  Identification  of  Antigen-Specific  Cells  within  Cellular  Infiltrates  in 
Myositis Muscle Biopsies  
6.2.1 Sample MYO3 
Patient  MYO3  was  positive  for  both  serum  Sm/RNP  and  Jo-1  antibodies.  
Staining with these biotinylated antigens provided two very diverse patterns of 
staining (Figure 6.1).  Staining for Jo-1 (Figure 6.1A-B) demonstrated that Jo-
1
+  cells  were  located  sporadically  throughout  the  muscle  section.    In  some 
cases a small cluster of Jo-1
+ cells were found but it also appeared that single 
Jo-1
+  cells  were  also  located  within  the  sample.    The  use  of  biotinylated 
Sm/RNP  (Figure  6.1C-D)  showed  extensive  staining  throughout  the  whole 
biopsy located between the muscle fibres.  Negative control staining showed no 
non-specific staining as did the use of biotinylated Sm/RNP on tonsil sections 
(data not shown).  Single cells were not able to be identified within the extensive 
staining of Sm/RNP.  Extensive staining with the Sm/RNP antigen may have 
occurred as a result of large numbers of anti-Sm/RNP antibodies secreted by 
infiltrating plasma cells in the inflamed muscle.    
 
Double  immunofluorescence  experiments  with  the  recombinant  antigens 
revealed that the Jo-1 specific cells were mostly CD20
+ cells (Figure 6.2A-B) 
while the Sm/RNP
+ cells were found to be mostly plasma cells (Figure 6.2C-D).  
The extensive staining of Sm/RNP in areas of plasma cell infiltration made it 
difficult to identify isolated single antigen-specific cells, but a small cluster of 
plasma cells were found within that large area of Sm/RNP staining.       
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Figure 6.1 Immunohistochemical staining using biotinylated antigen in Sample MYO3  
 
Muscle sections from sample MYO3 were stained with biotinylated antigen, Jo-1 (A-B) and Sm/RNP 
(C-D), and visualised by APAAP and New Fuschin substrate to establish if antigen specific cells were 
present within the muscle section.  Biotinylated BSA was used as a negative control protein.  Images 
taken at 400X. 
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Figure 6.2 Double Immunohistochemical staining using biotinylated antigens in 
sample MYO3  
 
Muscle sections from sample MYO3 were stained for Plasma cells (A&C) and CD20 (B&D) 
and biotinylated antigen; Jo-1 (A-B) and Sm/RNP (C-D).  Cell phenotypes were visualised 
by Texas Red Avidin D and antigen-specific cells by Fluorescein Avidin D.  This allowed the 
phenotype of antigen-specific cells within the myositis sample to be identified.  Images were 
taken at 630X; Scale Bar represents 15 µm.  Arrows identify antigen specific cells within the 
sections. 321 
6.2.2 Sample MYO16 
Patient  MYO16  was  positive  for  anti-nuclear  antigens  (ANA),  the  nucleolar 
pattern of staining indicated that the antigen may be Scl70 (Topoisomerase 1).  
Recombinant  Scl70  used  for  staining  the  muscle  sections  demonstrated  the 
occurrence  of  small  clusters  of  Scl70
+  cells  within  the  sample  (Figure 
6.3.1A&B).  In comparison to the levels of infiltrating B cells and plasma cells 
within the sample, identified in Chapter 3, it appears that Scl70 may not be the 
only  antigen  stimulating  a  response  within  patient  MYO16.    Double  staining 
experiments  with  recombinant  Scl70  indicated  that  the  antigen-specific  cells 
were plasma cells (Figure 6.3.2A&B), there was no evidence of any antigen 
specific B cells within the sections used for staining.  For B cell staining very few 
infiltrating cells were observed, this is in contrast to the staining experiments 
used  in  Chapter  3  where  a  very  dense  cluster  of  B  cells  was  observed.  
Although these experiments were conducted on serial sections, these sections 
were  at  a  greater  depth  of tissue  than the  sections  described  in  Chapter  3, 
which may explain the absence of B cell infiltration in later sections.  Clonally 
related sets of sequences observed within this patient may be in response to 
Scl70.         
   
6.2.3 Sample MYO19 
For sample MYO19, who also tested positive for ANA with a nucleolar pattern, 
results were similar to that of patient MYO16.  Small clusters of Scl70
+ cells 
were observed throughout the sample (Figure 6.4.1 A&B).  In double staining 
experiments  both  antigen-specific  B  cells  and  plasma  cells  were  observed 
(Figure 6.4.2 A&B).  The lack of clonally related sets within patient MYO19 may 
suggest, like the other samples, that B cells are stimulated by the antigen at 
another location which then migrate into inflamed muscle.  As with MYO16 the 
frequency of antigen-specific cells in comparison to the frequency of B cells and 
plasma cells previously found within the sample sections indicates that other 
antigens may be participating in the response.   
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Figure 6.3 Immunohistochemical staining using biotinylated antigen in Sample MYO16 
 
Figure 6.3.1 - Muscle sections from sample MYO16 were stained with biotinylated antigen, Scl70, 
(A&B) and visualised by APAAP and New Fuschin substrate to establish if antigen specific cells were 
present within the muscle section.  Biotinylated BSA was used as a negative control protein.  Images 
taken at 400X. 
 
Figure 6.3.2 - Muscle sections from sample MYO16 were stained for Plasma cells (A) and CD20 (B) 
and biotinylated Scl70.  Cell phenotypes were visualised by Texas Red Avidin D and antigen specific 
cells by Fluorescein Avidin D.  This allowed the phenotype of antigen-specific cells within the myositis 
sample to be identified.  Images were taken at 630X; Scale Bar represents 15 µm.  Arrows identify 
antigen specific cells within the sections. 
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Figure 6.4 Immunohistochemical staining using biotinylated antigen in Sample MYO19 
 
Figure 6.4.1 - Muscle sections from sample MYO19 were stained with biotinylated antigen, Scl70, 
(A&B) and visualised by APAAP and New Fuschin substrate to establish if antigen specific cells were 
present within the muscle section.  Biotinylated BSA was used as a negative control protein.  Images 
taken at 400X. 
 
Figure 6.4.2 - Muscle sections from sample MYO19 were stained for Plasma cells (A) and CD20 (B) 
and biotinylated Scl70.  Cell phenotypes were visualised by Texas Red Avidin D and antigen specific 
cells by Fluorescein Avidin D. This allowed the phenotype of antigen-specific cells within the myositis 
sample to be identified.  Images were taken at 630X; Scale Bar represents 15 µm.  Arrows identify 
antigen specific cells within the sections. 
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6.2.4 Sample MYO23 
Patient MYO23 tested positive for serum Jo-1 autoantibodies.  Staining with 
recombinant  Jo-1  identified  antigen  positive  cells  within  the  sample  (Figure 
6.5.1A&B).  In contrast to sample MYO3 these mostly appeared to be isolated 
single  cells.    Double  staining  experiments  on  MYO23  (Figure  6.5.2A&B) 
sections  showed  the  presence  of  antigen-specific  plasma  cells  within  the 
sample.  Antigen-specific B cells were not observed in the samples tested for by 
double immunofluorescence staining using recombinant antigen, but this does 
not exclude their presence in other sections of the sample but as very few B 
cells were identified in the initial cell phenotype staining this suggests that the 
antigen-specific cells may solely be infiltrating plasma cells.  Clonally related 
sets of sequences were observed within this patient, which may be in response 
to Jo-1.       
 
6.2.5 Sample MYOE 
As shown in Table 2.1 patient MYOE tested positive for anti-DNA antibodies.  
Staining MYOE sections with biotinylated ds-DNA identified a small number of 
DNA
+ cells within the infiltrating population (Figure 6.6.1A&B).  The occurrence 
of anti-DNA
+ cells was reduced in comparison to other types of antigen specific 
cells identified in the other myositis patients, although no direct quantification 
was conducted.  Some of these DNA
+ cells appeared to form small aggregated 
clusters.  Double staining experiments established the phenotype of antigen-
specific cells as plasma cells (Figure 6.6.2A&B).  The low frequency of DNA
+ 
cells infiltrating the sample and the low numbers of infiltrating B and plasma 
cells  identified  in  Chapter  3  meant  very  few  antigen  positive  cells  could  be 
identified.  
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Figure 6.5 Immunohistochemical staining using biotinylated antigen in Sample MYO23 
 
Figure 6.5.1 - Muscle sections from sample MYO23  were stained  with biotinylated antigen, Jo-1, 
(A&B) and visualised by APAAP and New Fuschin substrate to establish if antigen specific cells were 
present within the muscle section.  Biotinylated BSA was used as a negative control protein.  Images 
taken at 400X. 
 
Figure 6.5.2 - Muscle sections from sample MYO23 were stained for Plasma cells (A) and CD20 (B) 
and biotinylated Jo-1.  Cell phenotypes were visualised by Fluorescein Avidin D and antigen specific 
cells by Texas Red Avidin D.  This allowed the phenotype of antigen-specific cells within the myositis 
sample to be identified.  Images were taken at 630X; Scale Bar represents 15 µm.  Arrows identify 
antigen specific cells within the sections. 
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Figure 6.6 Immunohistochemical staining using biotinylated antigen in Sample MYOE 
 
Figure  6.6.1  -  Muscle  sections  from  sample  MYOE  were  stained  with  biotinylated  antigen,  DNA, 
(A&B) and visualised by APAAP and New Fuschin substrate to establish if antigen specific cells were 
present within the muscle section.  Biotinylated BSA was used as a negative control protein.  Images 
taken at 400X. 
 
Figure 6.6.2 - Muscle sections from sample MYOE were stained for Plasma cells (A) and CD20 (B) 
and biotinylated DNA.  Cell phenotypes were visualised by Texas Red Avidin D and antigen specific 
cells by Fluorescein Avidin D.  This allowed the phenotype of antigen-specific cells within the myositis 
sample to be identified.  Images were taken at 630X; Scale Bar represents 15 µm.  Arrows identify 
antigen specific cells within the sections. 
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6.3 Sequence Identification of Antigen-Specific Cells 
After identification of antigen specific cells within these 5 myositis patients, and 
the confirmation of these cells as B cells or plasma cells by double staining 
immunofluorescence  experiments,  further  nested  PCR  reactions  were 
conducted to identify the immunoglobulin genes of these antigen-specific cells.  
Antigen-specific cells were isolated using laser capture microdissection (Figure 
6.7) and the Ig genes were amplified from the RNA released from these cells 
using the methods described in Chapter 2.  These experiments were only in the 
primary  stages  and  from  the  microdissections  from  Figure  6.7  a  rearranged 
immunoglobulin sequence was isolated from sample MYO16 for a Scl70
+ cell 
which displayed sequence characteristics of an antigen-driven response (Table 
6.1).  This VH5-51 gene rearrangement contained 14 different point mutations 
which  were  concentrated  within  the  CDR,  mostly  CDR1;  a  sequence 
characteristic  of  a  B  cell  from  antigen-driven  response  or  a  memory  B  cell.  
Despite  this  no  significant  selection  was  observed  in  either  the  CDR  or  FW 
regions of the sequence.  This gene rearrangement was not observed in any 
other  patients,  including  MYO16  which  could  be  the  result  of  using  tissue 
sections  from  different  depths  of  the  biopsy  and  also  cannot  be  a  result  of 
contamination.  Additional isolation and amplification of immunoglobulin genes 
for  antigen-specific  cells  would  provide  greater  insight  into  the  gene 
rearrangements of cells specific for autoantigens.    
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Figure 6.7 Laser Capture Microscopy for Antigen-Specific Cells in Myositis 
Patients 
 
Laser-capture microscopy for single antigen specific cells identified by APAAP staining 
using biotinylated recombinant antigens.   Arrows denote antigen-specific cells to be 
microdissected.  Images taken after antigen specific cells have been microdissected, 
both  in  the  muscle  section  (middle  column)  and  on  the  LCM  HS  Cap  (right-hand 
column).  All images taken at x400.  
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VH Gene  DH Gene  JH Gene  Number of 
Mutations 
V-J 
Length 
(bp) 
Consecutive D 
Match Length (bp) 
5-51*01  No D Gene 
Assignment  2*01  14  28  7 
CDR3  Mutational Distribution  
(% of length) 
Framework  CDR1  CDR2 
ARREDSGPLHWFFDL (15aa) 
3.6  20  6 
R-CDR  S-CDR  pCDR  p-CDR  R-FW  S-FW  pFW  p-FW 
6  0  0.4336  0.18182  5  3  0.69714  -0.6548 
 
Table 6.1 Sequence Analysis from Scl70 Positive Cell from Patient MYO16 
 
Best matching germline sequences were identified from aligning sequences in the IMGT database using 
JOINSOLVER software.  V-J lengths and consecutive D match lengths (bp) were also identified using the 
JOINSOLVER  software  to  allow  assignment  of  the  DH  genes  as  described  in  section  2.3.12.3.    The 
number of mutations within functional rearranged VH genes were analysed, base differences within the first 
24 bases of sequence were disregarded as this part of the sequence binds the 5’ VH primer.  The locations 
of VH mutations were categorised as being within FR or CDR regions.  The numbers of mutations were 
expressed as a percentage of the entire length of the region to correct for the longer lengths observed 
within the framework regions.  The number of replacement and silent mutations and the presence of any 
positive and negative selection was conducted as per Hershberg et al (294) as previously described.   R-
CDR/FW and S-CDR/FW represent the number of replacement and silent mutations in the CDR and FW 
respectively.  pCDR represents the probability of having a R mutation in the CDR given all the mutations in 
the  sequence  except  R  mutations  within  the  FW  while  pFW  represents  the  probability  of  having  a  R 
mutation in the FW given all the mutations in the sequence except R mutations within the CDR and p-
CDR/FW represent the p-value of the focused binominal test on the CDR and FW respectively.  A negative 
sign indicates negative selection.  p-values <0.05 were deemed significant. 
 
6.4 Discussion 
 
Previous results in this study have demonstrated antigen-driven diversification 
of infiltrating cells within the target tissues of myositis and vasculitis patients 
either  by  the  identification  of  clonally  related  sequences  or  antigen-driven 
sequence  characteristics  such  as  gene  selection  and  mutational  patterns.  
Collectively the results may indicate local antigen stimulation within the target 
tissues and/or stimulation at other sites, presumably the draining lymph nodes, 
resulting in migration of affinity matured lymphocytes into the target tissues of 
these  autoinflammatory  disorders.    Regardless  of  the  location  of  antigen 
stimulation,  the  results  presented  thus far do  not  provide  information  on  the 
identity  of  the  stimulating  antigen.    In  some  of  the  myositis  cases, 
autoantibodies were detected in serum samples from the patients therefore the 
presence  of  antigen  positive  cells  for  these  autoantibodies  within  myositis 
samples was tested.  Biotinylated recombinant antigens were used to determine 
if  antigen  specific  cells  were  part  of  the  infiltrating  repertoire  of  myositis 
samples. 
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The results presented in this chapter demonstrate that autoantigen-specific cells 
were  included  within  the  inflammatory  infiltrating  cell  population  in  myositis 
samples.    Antigen  positive  cells  were  identified  in  each  of  the  five  myositis 
cases for all four antigens tested and were identified as a combination of B cells 
and plasma cells.  Most of the antigen specific cells formed small clusters of 
cells or existed as single isolated cells.  Staining for Sm/RNP produced a very 
different  pattern  of  staining,  extensive  staining  was  observed  throughout  the 
entire section between the muscle fibres.  Individual antigen positive cells could 
not be observed amongst the widespread staining which may have occurred 
due to enhanced antibody secretion from infiltrating plasma cells.  Taking the 
frequency of the other antigen-positive cells in comparison to the number of B 
cell  or  plasma  cell  infiltration,  identified  in  Chapter  3,  results  from  these 
experiments  may  indicate  that  other  antigens  are  also  participating  in  the 
inflammatory response.  In most of the cases described in this chapter there 
was a small number of antigen positive cells in comparison to the number of 
infiltrating  B  cells  or  plasma  cells  observed  in  Chapter  3.    A  wide  range  of 
additional  antigens  or  modified  version  of  the  antigens  used  in  these 
experiments may be responsible for some of the remaining infiltrating cells.  The 
other autoantigens tested for in these five patients have also been observed in 
other disorders and may indicate myositis as a secondary disorder within these 
patients; DNA, in the form of dsDNA, and Sm are specific for SLE, which is also 
associated  with  RNP  autoantibodies  and  Scl70  antibodies  are  generally 
observed within systemic sclerosis (scleroderma) patients. 
 
The presence of antigen-specific plasma cells could indicate that B cells were 
stimulated  and  underwent  diversification  in  other  locations  and  that  antigen 
specific  plasma  cells  migrated  into  areas  of  muscle  inflammation.    It  is  also 
possible that B cells are being stimulated directly within the muscle and the B 
cells are also undergoing maturation and diversification into plasma cells at the 
sites  of  inflammation  within  the  muscle.    Following  the  confirmation  of  the 
phenotypes of the antigen specific cells, the cells were isolated by laser capture 
microdissection to establish the immunoglobulin gene rearrangements used by 
these antigen-specific cells.  These experiments were only in the primary stages 
and only a few samples were tested prior to completion of this study.  From the 331 
samples tested a single gene rearrangement was isolated from Scl70
+ cells in 
patient MYO16.  This gene rearrangement or gene family was not observed in 
the original gene repertoire described in Chapter 4 where selection against VH5 
gene  segments  was  also  observed.    Variations  in  the  gene  rearrangements 
isolated for MYO16 could be attributed to different serial sections being used for 
the  different  experiments;  each  section  could  possibly  contain  B  cells 
expressing alternative gene rearrangements not observed in previous sections.  
Due  to  the  difficulty  for  successful  Ig  amplification  from  a  small  number  of 
antigen specific cells, additional testing of isolated antigen-specific cells would 
establish if this gene rearrangement is specific for Scl70 antigen positive cells or 
if  additional  gene  rearrangements  are  specific  for  the  Scl70  antigen.    Also, 
additional  testing  of  the  other  antigen  positive  cells  would  allow  the  gene 
rearrangements specific for the other antigens to be assessed.  Similar studies 
could  also  be  conducted  on  two  of  the  vasculitis  patients  as  these  patients 
tested  positive  for  Ro,  La  and  c-ANCA  autoantibodies  (Table  2.3);  these 
patients were not included in the original study due to a lack of recombinant 
antigen.     
 
Similar studies to those discussed in this chapter have been conducted in other 
autoimmune disorders, SS, MG, WG, Hashimoto’s Thyroiditis (HT) and most 
recently in RA.  Tengnér et al (358) demonstrated the presence of Ro/SSA and 
La/SSB antibody producing cells in salivary gland biopsies from SS patients 
indicating that anti-Ro/SSA and anti-La/SSB autoantibodies were produced and 
present  at  the  sites  of  inflammation  implicating  their  involvement  within  the 
disorder.    Biotinylated  antigens  were  used  to  identify  antigen  positive  cells 
which were thought to exhibit plasma cell morphology.  These antigen-specific 
cells  appeared  scattered,  singularly  or  in  clusters  primarily  within  the 
inflammatory infiltrates, findings similar to that presented in this chapter.  The 
study also established that patients with higher levels of serum autoantibodies 
contained higher numbers of autoantibody producing cells within the salivary 
glands.    Salomonsson  et  al  (359),  in  a  later  study  into  the  ectopic  germinal 
centre formation in SS, also used biotinylated recombinant antigens (Ro and 
La) as probes and located antigen-specific cells within salivary gland biopsies of 
SS patients.  The frequency of these positive cells was significantly higher in 332 
patients  with  germinal  centre  formation  compared  to  those  without  germinal 
centres.  The study demonstrated that these antigen-specific cells were located 
at the periphery of the inflammatory infiltrates and also demonstrated a strong 
correlation between local salivary gland production and serum autoantibodies.  
Although present at the sites of inflammation it has also been shown that some 
autoantibody  producing  cells  for  Ro/SSA  and  La/SSB  are  present  in  the 
circulating peripheral blood (360). 
 
Antigen-specific  cells have  also  been  identified  in  the  thymus of  Myasthenia 
Gravis patients (52;361).  MG is mediated by autoantibodies directed against 
various  epitopes  of  the  adult  acetylcholine  receptor  (AchR)  at  the 
neuromusclular junction, resulting in muscle weakness.  These autoantibodies 
can also bind to the foetal AchR also present in the thymus.  Sims et al (52) 
used complexes containing an antagonist of AchR function, 
125I-αBungarotoxin 
(αBuTx),  to  identify  the  occurrence  of  AchR  antigen-specific  cells  within  the 
thymus.  Approximately 50% of the germinal centres present within the thymus 
contained  antigen  positive  cells,  in  a  similar  pattern  to  the  FDC  network.  
Results  demonstrated  that  the  germinal  centres  containing  these  antigen-
specific  cells  were  undergoing  antigen-driven  clonal  proliferation,  somatic 
hypermutation  and  selection.    In  a  subsequent  study  Matthews  et  al  (361) 
demonstrated  that  autoantibodies  directed  towards  the  foetal  AchR  were 
significantly more common in females sampled after pregnancy than those who 
present before pregnancy suggesting that they may be induced by the foetus.  
Cloning  the  Fabs  of  these  high  affinity  antibodies  demonstrated  that  these 
antibodies  used  the  VH3-07,  4-61,  3-23  and  3-21  gene  segments.    These 
antibodies  were  shown  to  undergo  clonal  diversification  and  antigen-driven 
selection.     
 
While analysing the VH gene repertoires of infiltrating B cells from endonasal 
lesions in WG patients Voswinkel et al (348) identified PR3-ANCA positive cells 
in the vicinity of B cell-rich follicle-like structures and plasma cells.  The authors 
suggest that potentially PR3-ANCA producing cells might be selected in PR3
+ 
granulomatous lesions starting in localised WG and continuing in generalised 
WG.  Armengol et al (54) demonstrated the presence of antigen-specific cells 333 
within active intrathyrodial germinal centres of Hashimoto thyroditis patients, an 
autoimmune  thyroid  disease.    Antigen  specific  cells  to  two  thyroid-specific 
antigens  were  found  to  be  present  within  GCs,  thyroglobulin  (Tg)  and 
thyroperoxidase (TPO).  The results showed that two types of cells bound the 
thyroid  antigens;  numerous  small  cells,  which  demonstrated  a  similar 
distribution to B cells, as well as strongly positive cells with a strong cytoplasmic 
staining scattered all over the lymphoid follicles within the thymus, plasma cells.  
Double  staining  experiments  revealed  that  most  of  the  antigen  specific  cells 
were  also  IgG
+.    Results  of  this  study  suggest  that  intrathyrodial  lymphoid 
follicles were committed to thyroid antigen immune responses.  Recently anti-
citrullinated  protein/peptide  antibody  (ACPA)  producing  plasma  cells  were 
identified  in  the  synovial  tissue  of  RA patients  using  biotinylated citrullinated 
fibrinogen in double immunofluorescence experiments (55).  These antibodies 
are highly specific markers for RA and are potentially pathogenic.                                
 
In  summary,  the  work  presented  in  this  chapter  demonstrated  that  antigen-
specific  B  cells  and  plasma  cells  are  present  within  sites  of  inflammation  in 
myositis patients and support previous studies where antigen specific cells were 
found at ectopic sites in autoimmune diseases.  These results in conjunction 
with those of Chapter 4, identifying clonally related sets of genes, indicate that B 
cells  may  be  stimulated  at  the  site  of  inflammation  demonstrating  that  an 
antigen-driven response occurs within the muscle but it may also be possible 
that  cells  are  also  stimulated  at  other  sites  and  migrate  into  the  sites  of 
inflammation  within  the  muscle.    Additional,  but  extremely  preliminary, 
experiments to identify the immunoglobulin genes of these antigen-specific cells 
isolated  the  gene  rearrangements  and  sequence  of  a  Scl70
+  cell.    The 
mutational  characteristics  of  the  isolated  gene  support  the  occurrence  of  an 
antigen-driven  response,  possibly  within  sites  of muscle  inflammation  but  as 
previously mentioned these reactions may also occur at other sites leading to 
migration  of  antigen  specific  cells  into  inflamed  muscle.    Further  analysis  of 
immunoglobulin genes from antigen-specific cells would be required to provide 
further insight into the gene rearrangements, sequence mutations and clonal 
diversification  mechanisms  occurring  within  inflamed  muscle  specific  to 
autoantigens.      334 
Chapter 7 – General Discussion 
Of  paramount  importance  in  the  understanding  of  autoimmune  inflammatory 
disorders  is  whether  highly  specific  B  cell  antigen-driven  adaptive  immune 
responses  are  present  within  the  target  tissues  of  these  disorders.    In  the 
current study this question was addressed in the target tissues, muscle and 
skin,  of  myositis  and  vasculitis  patients  respectively  by  examining  the  Ig 
repertoire and mutational characteristics of tissue infiltrating B  and plasma cells 
and  establishing  if  clonal  diversification  and  affinity  maturation  mechanisms 
were ongoing within the target tissues.  Collectively the data presented in this 
thesis demonstrated that antigen-driven B cell responses were occurring within 
inflamed  muscle  of  the  various  myopathy  subsets.    Ig  gene  selections  and 
oligoclonal expansion of B cells were observed in these samples signifying that 
muscle infiltrating B cells were being stimulated by antigen(s) within the muscle 
and  could  contribute  to  the  pathological  mechanisms  in  play  at  the  sites  of 
inflammation.    Conversely  in  inflamed  skin,  gene  selections  and  oligoclonal 
expansion were not observed from the sequences isolated from skin infiltrating 
cells indicating that there is no antigen driven B cell responses occurring within 
the inflamed skin but infiltrating plasma cells, outwith their normal bone marrow 
residence, may be contributing to the response and the pathology within the 
skin through the secretion of autoantibodies.  Ig sequences isolated from these 
cells contained antigen-driven sequence characteristics. At the commencement 
of  this  work  no  other  study  had  established  these  antigen-driven  responses 
within these target tissues and despite the different outcomes of both disorders 
of this study the results presented do suggest the active participation of antigen-
driven responses in the target tissues of autoimmune disorders as well as a role 
for B cells in the pathophysiology of these diseases.              
 
The main objective of this work was to test the hypothesis that B cells play an 
antigen-driven  role  within  these  disorders.    In  some  instances  disorders  are 
characterised as B cell mediated due to the presence of autoantibodies which 
are implicated in the associated pathology of the disease.  In others, despite the 
presence of autoantibodies, disorders are categorised, or previously have been 
categorised, as T cell mediated disorders and the true involvement of B cells 
within  these  disorders  was  not  fully  recognised  until  studies,  similar  to  the 335 
current study, have identified biased gene repertoires and oligoclonal expansion 
of B cells within target tissues.  Such studies support the involvement of B cells 
within the complex immune responses in the target tissues of these disorders 
which  could  be  associated  with  the  pathological  mechanisms  involved  and 
provide a greater understanding into the course of autoimmune disease.  Such 
studies have been conducted in a number of diseases including SLE, RA, MG, 
SS,  MS,  OS  and  AS  (52;283;284;289;317-325;362).    Despite  the  different 
methodologies and source tissues involved in all these studies, the results are 
in  parallel  with  those  described  in  this  study,  particularly  in  the  myositis 
disorders.  In each study a bias in the Ig gene repertoires was found along with 
the identification of gene segments which were clonally expanded in immune 
reactions within the target tissues, providing insights into the usage of preferred 
VH gene families and possible gene dysregulation in response to antigen within 
these autoimmune disorders.  Additional studies could indicate if certain gene 
combinations are prone to mutations which result in high affinity autoantibodies 
or  are  associated  with  pathogenicity.    Subsequent  to  this,  work  has  been 
conducted which has used the sequences generated in such studies to analyse 
the  lineage  trees  generated  from  the  clonally  expanded  B  cells  (363-366).  
Lineage  trees  were  constructed  from  published  Ig  sequences  from  ectopic 
germinal  centres  or  affected  tissue  B  cell  clones  in  patients  with  various 
autoimmune  disorders  using  the  IgTree
©  algorithm  (366).    These  were  then 
compared to lineage trees from normal PBL and germinal centre samples using 
MTree
©, a computer aided algorithm for the measurement of graphical shape 
properties of lineage trees.  This method allowed the interplay between somatic 
hypermutation  and  antigen-driven  selection  in  different  lymphoid  tissues  and 
disease  situations  to  be  assessed  while  alleviating  the  effects  of  different 
experimental  protocols  between  research  groups.    Comparing  lineage  trees 
from  diseased  states  with  normal  controls  demonstrated  that  lineage  trees 
generated  from  autoimmune  disorders  were  larger  than  in  normal  controls. 
Analysis of mutational characteristics suggested a more vigorous diversification 
process  and  accumulation  of  more  mutations  within  autoimmune  disorders 
compared  with  normal  controls;  lineage  trees  from  autoimmune  disorders 
demonstrated a longer diversification process.  The changes in B cell selection 
were also assessed from clonal trees based on the degree of tree branching 336 
and  were  found  to  be  similar  between  normal  controls  and  autoimmune 
disorders suggesting a normal selection strength acting on the B cells within 
autoimmune  disorders.    However  a  recent  study  (367)  by  this  group  in 
ulcerative  colitis  (UC)  using  these  methodologies  revealed  no  significant 
difference  in  tree  shape  properties  between  sequences  isolated  from  UC 
samples and control samples.  In this study normal Ig gene diversification and 
trafficking  of  clones  between  the  gut  and  associated  lymph  nodes  was 
observed.  
 
Antigen-driven reactions are typically thought to occur within the confinements 
of GC structures in secondary lymphoid organs but are commonly found in the 
target tissues of several autoimmune diseases.  As previously described, the 
functionality  and  potential  contribution  of  these  GC  reactions  in  disease 
pathogenesis has recently been described in SS and RA patients (55;326).  In 
addition to these GC reactions the enzyme required for SHM and CSR, AID, 
has been observed and found to be functional in a subset of B cells outside 
GCs.  Prior to this, studies have described antigen-driven reactions occurring 
outside GCs.  These reactions were found to occur outside GC structures in 
areas lacking a FDC network in autoimmune murine models (301;332;333).  It 
has been postulated that such reactions give rise to autoreactive B cells which 
are not governed by the protective mechanisms that occur within GCs.  The 
cells participating in these extrafollicular reactions were found to be activated B 
cells as well as plasmablasts, the dominant producer of autoantibodies in these 
models (333;368;369).  These findings have been extended to mice with normal 
backgrounds and collectively implicate that factors such as antigen density, T 
cell  help,  BCR  affinity  and  TLR  signals  may  regulate  the  occurrence  of 
extrafollicular responses and GC responses (332;370-372).  Another study has 
demonstrated  affinity  maturation  by  SHM  in  a  lymphotoxin-α  mouse  models 
which  fails  to  develop  germinal  centres  (255).    In  the  current  study  clonal 
diversification of B cells has been observed within the target tissues of myositis 
patients  although  no  GC  structures  were  observed.    Such  studies  do  not 
exclude the involvement of GC reactions but indicate an alternative pathway for 
the  disease  mechanisms  generating  autoantibodies  towards  self  antigens.  
Contrary  to  this  Cantaert  et al  concluded that  synovial  lymphoid  neogenesis 337 
was  a  process  associated  with  inflammation  and  was  independent  to  B 
lymphocyte autoimmunity (373).     
  
As  well  as  identification  of  clonally  expanded  B  cells  the  outcomes  of  such 
studies also provide insight into the mechanisms of diversification in play during 
autoimmune  reactions.    Mechanisms  such  as  receptor  revision  and  codon 
insertions  and  deletions  can  also  be  examined  to  establish  if  defects  or 
irregularities in these mechanisms contribute to the repertoire and pathogenicity 
of autoimmune reactions.  Class switching is another mechanism which can be 
analysed from gene repertoire studies, providing that constant region primers 
have  been  used.  As  previously  described  in  Chapter  4,  section  4.3.1,  class 
switching to other isotypes, including IgA, is evident within the infiltrating B and 
plasma cell populations in myositis samples (90) and authors hypothesised that 
the different Ig isotypes may have a broader role in autoimmunity, especially 
IgA  which  would  normally  reside  on  mucosal  surfaces.  Class  switching  has 
been  identified  by  various  methods  in  a  number  of  myositis  studies  by  this 
group (89;90) and the presence of isotype switched secreting plasma cells (IgA, 
IgG and IgM) has also been observed in MS (374).  IgA secreting plasma cells, 
as  previously  described,  are  also  thought  to  contribute  to  the  pathology 
associated with a subset of vasculitis, KD (171).  The work of Bradshaw et al 
(90) demonstrated that this class switching was occurring within the muscle with 
the identification of clonal variants with different isotypes.  The process of class 
switching  in  target  tissue  of  autoimmune  disorders  has  recently  been 
substantiated  by  the  identification  if  AID  in  the  target  tissues  of SS  and  RA 
patients  (326).    The  findings  of  such  studies  enhance  the  understanding  of 
immune  mechanisms  within  the  target  tissues  of  autoimmune  disorders  and 
indicate that these responses are occurring within the target tissues and not 
solely within the periphery resulting in infiltration into target tissues.  This would 
be  especially  significant  in  the  two  disorders  of  the  current  study  where  no 
classic germinal centre structures, the typical site of class switch recombination, 
were observed.  Identification of Ig gene repertoires and oligoclonal expansion 
of  autoreactive  B  cells  can  also  provide  the  foundation  for  examining  the 
mechanism of somatic hypermutation and the influence of particular mutations 
on antigen affinity within these sequences.  Studies have been conducted on 338 
anti-dsDNA  antibodies  isolated  from  SLE  patients  which  demonstrate  the 
influence  of  particular  mutations  on  antigen  affinity  (375-379).  Li  et  al  (375) 
established that the binding activity of a monoclonal anti-DNA antibody, with 11 
somatic  mutations,  to  its  target  antigen  was  mediated  through  Arg105  and 
Arg107.    Conversion  of  each  of  these  residues,  independently,  to  glycine 
resulted in comparable binding efficiency to ssDNA and to that of the original 
antibody  but  the  binding  efficiency  to  dsDNA  was  lost,  indicating  that  both 
arginine residues were required for dsDNA binding but either was sufficient for 
ssDNA binding.  More recently (376) a combinational library was constructed 
from splenic lymphocytes of a male patient with active SLE.  Selection against 
dsDNA isolated 15 IgG Fabs where a strong correlation was observed between 
the R:S ratios on the CDRs 1 and 2 and affinities for ssDNA and dsDNA; high 
R:S  ratios  correlated  with  increased  affinity.    Subsequent  studies  have  also 
linked  arginine  mutations  to  DNA  antigen  affinity  but  have  also  gone  onto 
demonstrate  the  relationship  between  somatic  mutations  that  influence  the 
affinity  to  multiple  antigens  rather  than  focussing  on  one  antigen  (377-379).  
Specific heavy chain and light chain mutations have been found that can either 
enhance  an  antibody  affinity  to  DNA  or  eliminate  the  affinity.    For  the  light 
chains involved in these experiments arginine residues at position 94 (CDR3) in 
one light chain abolished DNA binding while somatic mutations resulting in an 
arginine residue at position 92 in two other light chains had the opposite effect.  
The work of this group also observed that a mutation to an arginine residue at 
position 27 within CDR1 played a role in binding to histones, further enhancing 
the affinity for dsDNA and was confirmed by a reduction in binding when the 
residue was altered to serine.  In the heavy chain of these anti-DNA antibodies 
an  arginine  residue  at  position  53  (CDR2)  was  found  to  contribute  to  the 
enhanced DNA binding.  Conversion of this residue to 3 other variants by site 
directed mutagenesis and  the  germline  configuration  of  the  gene resulted  in 
reduced binding to DNA.  A mutation within the germline at position 53 was also 
found to be insufficient for binding indicating that other mutations or sequence 
characteristics are required.  The mutation at position 53 was also shown to 
enhance  the  antibody  binding  to  a  number  of  other  antigens,  α-actinin  and 
glycoproteins  which  are  significant  in  the  pathogenesis  of  antiphospholipid 
syndrome (APS).  Such studies examine the effects of somatic hypermutation 339 
on  the  relationship  between  sequence,  structure  and  antigen  binding  and 
highlight the influence of individual somatic mutations in autoantibodies.  
 
As previously described in Chapter 1 the B cell depletive therapy, Rituximab, 
has  emerged  as  an  influential  therapeutic  strategy  in  the  treatment  of  both 
myositis and vasculitis, in addition to a number of other autoimmune disorders 
where  clinical  improvements,  stabilisation  and  remission  are  observed  in 
patients (140-145;147;148;150-152;159;202;203;205;206;355;380-384).  This is 
further substantiated by the emergence of alternative B cell depletive therapies 
which are targeting B cells from alternate approaches (385) and fully illustrates 
the importance and contribution of B cells within these disorders.  Although this 
therapy has been found effective in various studies the emergence of B cell 
populations  associated  with  clinical  relapses,  variations  in  autoantibody  and 
autoantigen  levels,  which  may  suggest  that  some  of  the  underlying  disease 
mechanisms  are  still  ongoing,  and  the  wider  immunological  effects  such  as 
cellular modulations (386;387) illustrates the complexity of the B cell role within 
autoimmune disorders.  In the context of this study, many studies examining the 
Ig  gene  repertoire  and  diversification  of  B  cells  within  target  tissues  or 
peripheral  blood  of  autoimmune  patients  are  conducted  prior  to  specifically 
targeted therapeutic interventions and the impact of therapies like Rituximab on 
the repertoire and diversification of B cells within target tissues or peripheral 
blood have not been extensively studied.  Studies have been conducted in RA 
which  examined  the  peripheral  blood  repertoire  following  Rituximab  therapy 
(388) which illustrated that the use of Rituximab resulted in subtle modulation of 
the RA repertoire. Although the objective of this therapy is removal of CD20
+ 
populations of B cells, the influence and modulatory effect of Rituximab on the 
Ig repertoires of the remaining CD20
- population of B cells along with the re-
emerging CD20
+ populations would be of interest to study.  Such studies would 
aid the understanding of Ig gene profiles associated with clinical remission and 
relapse as well as highlighting those Ig sequences that are of importance within 
the disorders.   
 
The work presented in this thesis has focussed in on the antigen-driven role and 
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patients but multifunctional roles have been attributed to B cells within immune 
responses,  which  influence  and  are  influenced  by  an  extensive  number  of 
parameters  of the  immune  response.   B  cells  are  also  capable of  acting  as 
antigen presenting, regulatory and stimulatory cells.  Antigen-specific B cells are 
capable of taking up, internalising, processing and presenting antigen to T cells 
as well as other cells and may be the primary role of B cells in contributing to 
pathogenesis.  These functions have been implicated in the initiation of immune 
responses, particularly those that are autoimmune.  Antigen presentation by B 
cells could enhance the antibody production and expansion of antigen specific 
B and T cells, thus intensify the immune response to self antigens.    Studies 
have shown that antigen specific B cells can capture soluble antigen and initiate 
a T cell response earlier than DCs and recently the transfer of antigen from B 
cells to other antigen presenting cells, macrophages, has been observed which 
could  possibly  lead  to  amplification  or  editing  of  antigen  specific  immune 
responses  resulting  in  chronic  autoimmune  responses  (313;389).  The  B  cell 
receptor (BCR) is proposed to play a significant role in antigen presentation by 
B cells; antigens are internalised by receptor-mediated endocytosis in B cells, a 
mechanism carried out by the BCR.  Two features of antigen processing within 
B cells are not observed within other APCs.  Firstly BCR ligation with antigen 
induces  internalisation  and  directs  the  BCR–antigen  complex  through  the 
endocytic  pathway  towards  MHC  class  II  rich  compartments  promoting  the 
formation  of  MHC  class  II-peptide  complexes  (390).  The  signalling  resulting 
from  BCR  ligation  upregulates  MHC  class  II  expression  and  stimulates  their 
traffic  through  the  same  compartments  used  by  the  antigen-BCR  complexes 
(391).  These methods allow B cells to combine antigen recognition with the 
complexes  in  charge  of  its  processing,  favouring  presentation  of  these 
internalised  antigens  in  comparison  to  antigens  internalised  by  pinocytosis.  
Secondly,  antigen  processing  within  B  cells  has  been  shown  to  induce  the 
expression of HLA-DO, a non-classical MHC class II molecule which functions 
to inhibit the actions of HLA-DM, which favours presentation of peptides derived 
from  antigen  internalised  through  the  BCR  (392).    Receptor-mediated 
endocytosis  through  the  BCR  also  allows  the  concentration  of  very  small 
quantities of antigen for efficient presentation.  It has been reported that BCR 
affinity  is  directly  proportional  to  the  capacity  of  the  B  cell  to  participate  in 341 
antigen presentation to CD4
+ T cells (393).  The study also demonstrated that 
presentation via the pinocytosis method required a 5000 fold increase in antigen 
concentration.  In SLE, B cells have been shown to act as APCs of the target 
antigen  snRNP  (394).    Transfer  of  B  cells  obtained  from  mice  primed  with 
snRNP  from  a  different  species  lead  to  autoreactive  CD4
+  T  cell  activation.  
Transgenic mice expressing a BCR specific for snRNP was also used in studies 
to demonstrate that high numbers of autoantigen-specific B cells can activate 
CD4
+ T cells in an autoimmune background and tolerize them in a wild-type 
background, supporting the role of B cells as pathogenic APCs (395).  Anti-DNA 
B cells in lupus have also been shown to act as APCs (396).   
 
In addition to their possible role as antigen presenting cells, B cells have been 
shown  to  exert  effects  through  possible  regulation  of  immune  responses  in 
autoimmune  disorders.    A  subset  of  B  cells,  regulatory  B  cells,  exist  that 
suppress  the  exacerbation  of  and/or  enhance  the  recovery  from  acquired 
immune-mediated inflammations by mechanisms that include IL-10 and TGF-β1 
production, secondary antigen presentation and interaction with other immune 
cells either directly or through secreted antibodies (397).  B cells have the ability 
to produce detectable quantities of immunoregulatory cytokines such as IL-2, 
IFN-γ, IL-12 and IL-4 in addition to IL-6, TNF-α and IL-10 which have a long 
term association with B cells (398).  Two populations of effector B cells were 
identified, Be1 and Be2.  Both cell types produced IL-2, IL-6 and IL-10 upon 
restimulation but higher levels were observed within Be2 cell populations, Be2 
cell populations also produced IL-4 while Be1 cells produced IFN-γ; only trace 
amounts of IFN-γ were observed in Be2 cells while IL-4 was completely absent 
from Be1 populations.  The role of these cytokine profiles in regulating T cell 
differentiation  was  studied  by  addition  of  cytokine-blocking  antibodies  to 
cultures  of  effector  B  cells  and  naïve  T  cells.    Anti-IFN-γ  added  to  cultures 
containing  Be1  cells  and  T  cells  severely  reduced  the  IFN-γ  production 
produced by the effector T cells, suggesting that IFN-γ produced by Be1 cells 
was sufficient to differentiate T cells into IFN-γ producing effector-cells. Similar 
cultures  containing  Be2  cells  and  anti-IL-4  antibodies  demonstrated  the 
requirement of IL-4 to differentiate T cells to Th2-like cells.  The use of anti-IL-4 
antibodies  resulted  in  no  detectable  levels  of  IL-4,  IL-5,  IL-6  or  IL-10,  but 342 
conversely  produced  increased  levels  of  IFN-γ  indicating  that  Be2  cells may 
negatively  regulate  the  differentiation  of  T  cells  into  IFN-γ  producing  cells.  
Results  suggest  that  like  other  APCs,  effector  B  cells  have  the  capacity  to 
regulate the type of immune response generated in response to antigen. 
 
With a focus on the inflammatory myopathies, widespread studies have been 
conducted examining the various cell phenotypes within myositis, as well as 
other  autoimmune  disorders,  as  previously  described  in  Chapter  3.    Such 
studies demonstrate the complex nature of immune responses and are required 
to analyse the B cell response in context with the overall immune mechanisms.  
The  influence  of  cytokines  and  chemokines  on  the  responses  involved  in 
autoimmune disorders is also of interest.  In recent studies levels of BAFF/BLys 
(B  cell  activating  factor/B  lymphocyte  stimulator),  which  is  crucial  in  B  cell 
maturation  and  survival  and  is  also  thought  to  play  a  role  in  autoantibody 
production, have been examined in serum samples of myositis patients (42).  
Serum levels were found to be elevated in myositis patients compared to control 
individuals  and  it  was  also  noted  that  patients  with  DM  or  anti-Jo-1 
autoantibodies had higher serum levels compared to other myositis subsets or 
other  patients  without  any  specific  autoantibodies  respectively.    BAFF  levels 
were  also  shown  to  correlate  positively  with  CK  levels  and  negatively  with 
glucocorticoid treatment.  This study demonstrates the important role of B cells, 
and  BAFF,  in  myositis  patients  and  provides  further  insights  into  the 
mechanisms involved within the muscle but could also relate to mechanisms of 
other disorders such as vasculitis.  Following Rituximab therapy in SS patients, 
the repopulation of B cells has been shown to be modulated by BAFF (399) 
which again demonstrates the importance for further studies on B cells within 
autoimmune  disorders.    A  marked  increase  in  BAFF  levels  have  also  been 
observed in RA and SLE patients following Rituximab therapy which declined 
with  the  re-emergence  of  B  cells  (380;400).    It  has  been  suggested  that 
elevated BAFF levels in myositis samples are induced by the type I IFN system 
produced by PDCs (42); levels of type I IFN cytokines in DM and PM have been 
found to correlate with disease activity (305).  As described in Chapter 3 these 
cell phenotypes have been identified within myositis patients and in addition to 
influencing BAFF serum levels these cells and their products have been shown 343 
to act in the differentiation of plasma cells as well as antigen presenting cells, all 
of which could contribute to the functions and actions of B cells as well as the 
pathophysiology with inflamed muscle.  Recently IFN-α stimulation has been 
shown to up-regulate Ro52, at both the messenger and protein levels (401); 
autoantibodies  to  Ro52  are  found  in  correlation  with  anti-Jo-1  antibodies  in 
myositis patients as well as in other autoimmune disorders.  This stimulation 
was also shown to result in translocation of the Ro52 protein into the nuclear 
compartment  from  the  cytoplasm  which  could  contribute  to  the  pathological 
mechanisms  observed  in  myositis  and  other  autoimmune  disorders.    A 
correlation,  and  possible  link  to  disease  mechanisms,  between  IFN-α  and 
immune complexes containing anti-Ro52 autoantibodies has also been shown 
be Elorenta et al (123).   Another cytokine, and cell phenotype, that is reported 
to contribute to the development of germinal centre derived autoantibodies and 
play a role in autoimmune disease is IL-17, produced by Th-17 cells which are a 
distinct  population  of  CD4
+  T  helper  effector  cell  population  that  differs  in 
phenotype and function from classical T helper cells (402-405).  Initially IL-17 
was  characterised  as  a  potent  proinflammatory  cytokine  coordinating  local 
tissue  inflammation  but  it  has  also  been  linked  with  the  induction  of 
autoimmunity.    Reduced  or  eliminated  levels  of  this  cytokine  have  been 
associated  with  a  reduced  autoantibody  response,  the  cytokine  has  been 
associated with the development of RA, MS and inflammatory bowel disease 
and IL-17 had been found to accelerate and stabilise germinal centre reactions 
and autoantibody formation of enhanced somatic hypermutation although the 
exact mechanisms are unresolved.  Continued characterisation of autoimmune 
reactions  provides  greater  insight  into  the  mechanisms  involved  in  these 
diseases and how these may influence the roles and actions of B cells within 
these disorders.                         
 
In addition to the number of factors of the immune system which might regulate 
the immune response within the muscle of the myositis patients described in 
this  study  the  muscle  cells  themselves  are  also  thought  to  contribute  to  the 
responses.    It  has  been  proposed  that  muscle  cells  themselves  may  act  as 
antigen  presenting  cells  during  inflammatory  reactions  (406),  as  well  as 
modulating the function of other APCs (407) present within the muscle during 344 
immune  responses.    Antigen  presentation  capabilities  were  demonstrated  in 
human myoblasts, cultured from muscle which constitutively express MHC class 
I  molecules  but  no  detectable  amounts  of  MHC  class  II.    IFN-γ  and  TNF-α 
stimulation  induced  MHC  class  II  expression  which  was  necessary  but  not 
sufficient for functional antigen presentation to CD4
+ T cells.  These functions of 
muscle cells have been shown to be mediated through expression of MHC and 
co-stimulatory  molecules  such  as  CD40,  ICOSL  and  B7  ligands  (408-415), 
mostly recently B7-H3 which was shown to be expressed on muscle cells from 
different myositis subsets and was found to be a potent inhibitor of immune 
CD8
+ mediated lysis of muscle cells (411).  The active participation of muscle 
cells in immune responses is also supported by the variety of cytokines and 
chemokine  secreted  from  muscle  cells  and  the  expression  of  cell  adhesion 
molecules,  ICAM-1,  which  results  in  the  interaction  between  muscle  and 
immune cells (406).  As well as antigen presenting functions human skeletal 
muscle derived myoblasts were found to increase the phagocytic capacity of 
macrophages and modulate DC maturation (407).  
 
Nagaraju et al (79) demonstrated that the sustained up-regulation of MHC Class 
I molecules in mice leads to self-sustaining myositis, with similar features to 
human  myositis,  and  the  production  of  MSAs.    Results  suggest  that 
autoimmune  myositis  may  occur  as  a  consequence  of  an  apparently  non-
specific event, like the sustained up-regulation of MHC Class I molecules.  
 
Besides  the  study  of  antigen-specific  immune  responses,  non-immune 
mechanisms  are  also  thought  to  contribute  to  the  pathology  associated  with 
myopathies.  These mechanisms could also be related to the pathology in other 
target tissues such as the skin (86;416).  One such nonimmune mechanism 
may  be  the  endoplasmic  reticulum  (ER)  stress  response.    The  ER  plays  a 
critical  role  in  the  synthesis,  folding,  processing  and  exporting  of  newly 
synthesised proteins.  The ER stress response occurs when there is an excess 
accumulation of proteins within the ER, which is greater than the muscle cells 
ability  to  process.    Ischaemia,  hyperhomocysteinemia,  viral  infections  and 
mutations  that  impair  protein  processing  may  also  result  in  the  ER  stress 
response. Cells have a variety of self-protection responses to ER stress and 345 
include  the  up-regulation  of  the  NF-κB  pathway,  up-regulation  of  protein 
assembly associated proteins to prevent further accumulation of proteins within 
the ER, reduction in protein translation to prevent further accumulation and cell 
death.  This ER stress response has recently been proposed to participate in 
the  pathological  mechanisms  associated  with  myositis.    Nagaraju  et  al  (86) 
demonstrated,  using  human myositis  samples  and  tissue from  class  I  MHC-
transgenic mice, that ER stress responses are highly activated in both samples 
of myositis.  Data also demonstrated that the NF-κB pathway is highly activated 
in myositis samples in response to ER stress.  Activated NF-κB induces target 
genes including class 1 MHC which in turn further exacerbates the ER stress 
response,  thus  initiating  a  self-sustained  loop.    This  pathway  and  its  role  in 
pathogenesis of myositis have also recently been demonstrated by Grundtman 
and Lundberg (416). 
 
The work of this study has established an antigen-driven role for B cells in the 
target tissues of myositis and has demonstrated the potential influence of B cell 
antigen driven mechanisms from other sites on the target tissues of vasculitis 
patients  where  no  direct  and  active  mechanisms  were  observed.    These 
findings are substantiated and correlate with other studies examining the role of 
B cells in such mechanisms.  Despite this a number of questions still need to be 
explored  to  fully  understand  the  mechanisms  occurring  within  these 
autoimmune  diseases.    From  the  work  of  this  study  identification  of  the 
stimulating antigen(s), epitopes and sequence characteristics of the responding 
high-affinity  antibodies  would  provide  a  greater  insight  into  pathological 
mechanisms.    Sequence  characteristics  of  antigen  specific  cells  were  very 
transiently  explored  and  examined  in  this  study,  Chapter  6,  but  further 
identification  of  Ig  rearrangements  and  mutational  characteristics  of  antigen-
specific cells would greatly enhance the understanding of the antibody response 
to autoantigens.  Alternative approaches could include the use of phage-display 
technologies  (417-420)  or  production  of  recombinant  antibody  molecules  to 
isolate  high-affinity  antibodies.    Such  methods  have  been  used  in  the 
characterisation of antibodies in Wegener’s granulomatosis to PR3 (421), SLE 
to  DNA  (422)  and  in  subacute  sclerosing  panencephalitis  (423).  Antigen 
specificity,  antibody  affinity  characteristics  and  the  effects  of  individual 346 
mutations  on  specificity  or  affinity  between  different  members  of  the  same 
clonally related set of Ig V-gene sequences could then be assessed in these 
antibodies.    Computer  modelling  techniques  could  also  be  used  on  isolated 
antibodies  to  establish  important  characteristics  of  these  antibodies  such  as 
selected  mutations  which  contribute  to  autoantibody  specificity  and  affinity.  
Patients with autoimmune disorders could mount immune responses to various 
and some as yet unidentified antigens and produce a wide range of pathogenic 
and  non-pathogenic  antibodies  as  a  result.    Characterisation  of  pathogenic 
antibodies and their stimulating antigens could assist the understanding of why 
some protein targets are selected in autoimmune disorders resulting in a loss of 
B cell tolerance and how the pathogenic antibodies mediate their actions which 
result in pathology.  Such studies would also provide a greater insight into the 
initiation of such reactions and determine the compartmentalisation within target 
tissues or widespread actions of these reactions in the periphery.  Wider studies 
could address the promotion and regulation of autoreactive B cells and how 
other cell phenotypes, cytokines and co-stimulatory molecules contribute to the 
development and maintenance of these autoreactive B cells.  Ultimately further 
work is required to fully ascertain the role of B cells and their antibodies within 
the target tissues of autoimmune disorders as greater understanding of these 
roles will facilitate the diagnosis, treatment and management of disorders.                
 
To  conclude,  the  work  of  this  study  has  examined  the  antigen-driven  B  cell 
responses  in  the  target  tissues  of  myositis  and  vasculitis  patients  and 
demonstrated  that  these  responses  are  present  and  active  within  inflamed 
muscle of myositis patients but absent from inflamed skin of vasculitis patients.  
Despite  this,  pathological  mechanisms  in  the  skin,  secretion  of  potentially 
pathogenic autoantibodies from infiltrating plasma cells for example, could still 
be influenced by antigen-driven B cell responses occurring at alternative sites, 
presumably in peripheral lymphoid organs or at other ectopic locations.  The 
results of this study highlight the involvement of B cells within the target tissues 
of autoimmune disorders and provide a foundation for future characterisation of 
autoantibodies, autoantigens and the autoimmune reactions of these disorders.    
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Appendix 1 – Ig DNA Sequence Alignments using the JOINSOLVER Software 
 
The JOINSOLVER algorithm (http://joinsolver.niams.nih.gov) (241) was used to 
match the isolated Ig DNA sequences from myositis and vasculitis samples to 
the  corresponding  germline  genes.  The  software  was  used  with  the  default 
parameters.    For  illustration  purposes  only  the  alignments  for  the  assigned 
genes have been shown, in most instances this was the best matching and 
highest scoring alignment but where alternative, lower scoring, matches have 
been assigned the higher scoring alignments have also been given with the 
assigned gene highlighted in yellow.  Assignment of DH genes and junctional 
analysis was conducted as described in section 2.3.12.3.  Primer regions, the 
first 24 bases at the 5’ VH region, were disregarded; for illustration purposes in 
the sequence alignments below and on the attached CD these regions were 
converted  back  to  germline  configurations  once  the  best  matching  germline 
gene had been assigned to allow mutational numbers to correspond to those 
used  in  the  analysis  of  these  sequences  in  Chapters  4  and  5.    Junctional 
nucleotides highlighted in yellow illustrate the P and N nucleotides used in the 
analysis of these regions after manual analysis of the D gene assignment and 
junctional regions.   
 
In  addition  to  JOINSOLVER  the  IMGT/V-QUEST  algorithm  was  also  used 
match the isolated Ig DNA sequences to the corresponding germline genes.  
Any  anomalies  between  the  two  alignment  algorithms  are  given  within  the 
results section of Chapters 4 and 5.  The IMGT/V-QUEST algorithm has the 
capability of searching the isolated sequence for the presence of insertions and 
deletions  of  nucleotides,  which  is  not  available  using  the  JOINSOLVER 
algorithm.   Where  insertions  and  deletions  were  detected  the  corresponding 
alignments from the IMGT/V-QUEST algorithm are provided in addition to the 
subsequent  alignments,  using  both  programmes,  following  restoration  of  the 
insertions or deletions.  
 
Sequence alignments to gene assignments for all sequences used in this study 
can  be  found  on  the  attached  CD;  alignments  from  one  patient  from  each 
principal disorder of this study are shown below. 
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Sample MYO17 
Sequence – VH3-30*03, DH3-9*01, JH4*02 
 
Raw Sequence 
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCTCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTACCTATGCCATGCACTGGGTCCGCCAGG
CTCCAGGCAAGGGGCTGGAGTGGCTGGCAATTATTTCATATGATGGAGGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATTTCCAGAGACAATTCCAAGAATACGCT
GTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTATATTGGTGTGCGACAGGCGCGTATTATGATATTTTGAGTGGTGCTCGGCCGTTTGACTACTGGGGCCAGGGAACC
CTGGTCACCGTCTCCTA 
 
Joinsolver Alignment 
Summary 
Amino acid translation of the sequence: 
QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYAMHWVRQAPGKGLEWLAIISYDGGNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAED 
TAVYWCATGAYYDILSGARPFDYWGQGTLVTVS 
 
JoinSolver 
Rearrangement is productive: 
 
Highest scoring matches:  
V: IGHV3-30*03  D:IGHD3-9*01  J: IGHJ4*02 
The VH segment has 12 mutations 
CDR3 Length:  51 
 A   T   G   A   Y   Y   D   I   L   S   G   A   R   P   F   D   Y   
GCG ACA GGC GCG TAT TAT GAT ATT TTG AGT GGT GCT CGG CCG TTT GAC TAC  
V Match Results 
   ----------------------------------------------------------FR1----------- 
    1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16  17  18  
    Q   V   Q   L   V   E   S   G   G   G   V   V   Q   P   G   R   S   L   
  score CAG GTG CAG CTG GTG GAG TCT GGG GGA GGC GTG GTC CAG CCT GGG AGG TCT CTG  
IGHV3-30*03  1317  ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ..C ...  
    
   ----------------------------------------------- ___________CDR1_________ 
    19  20  21  22  23  24  25  26  27  28  29  30  31 31a 31b  32  33  34  
    R   L   S   C   A   A   S   G   F   T   F   S   T           Y   A   M   
  AGA CTC TCC TGT GCA GCC TCT GGA TTC ACC TTC AGT ACC --- --- TAT GCC ATG  
IGHV3-30*03  ... ... ... ... ... ... ... ... ... ... ... ... .G. --- --- ... .G. ...  
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   ___ --------------------------------FR2-------------------- ____________ 
    35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  
    H   W   V   R   Q   A   P   G   K   G   L   E   W   L   A   I   I   S   
  CAC TGG GTC CGC CAG GCT CCA GGC AAG GGG CTG GAG TGG CTG GCA ATT ATT TCA  
IGHV3-30*03  ... ... ... ... ... ... ... ... ... ... ... ... ... G.. ... G.. ..A ...  
    
   ________________________CDR2___________________________________ -------- 
   52a 52b 52c  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  
    Y           D   G   G   N   K   Y   Y   A   D   S   V   K   G   R   F   
  TAT --- --- GAT GGA GGT AAT AAA TAC TAT GCA GAC TCC GTG AAG GGC CGA TTC  
IGHV3-30*03  ... --- --- ... ... A.. ... ... ... ... ... ... ... ... ... ... ... ...  
    
   ------------------FR3--------------------------------------------------- 
    68  69  70  71  72  73  74  75  76  77  78  79  80  81  82 82a 82b 82c  
    T   I   S   R   D   N   S   K   N   T   L   Y   L   Q   M   N   S   L   
  ACC ATT TCC AGA GAC AAT TCC AAG AAT ACG CTG TAT CTG CAA ATG AAC AGC CTG  
IGHV3-30*03  ... ..C ... ... ... ... ... ... ..C ... ... ... ... ... ... ... ... ...  
    
   -------------------------------------- ___CDR3_____  
    83  84  85  86  87  88  89  90  91  92  93  94  95  
    R   A   E   D   T   A   V   Y   W   C   A   T   G   
  AGA GCT GAG GAC ACG GCT GTA TAT TGG TGT GCG ACA GGC  
IGHV3-30*03  ... ... ... ... ... ... ..G ... .AC ... ... .G. .A   
    
D Match Results 
    A   T   G   A   Y   Y   D   I   L   S   G   A   R   P   F   D   Y   W   G   Q   G   T   L   V   T   V   S           
  len|rf  GCG ACA GGC GCG TAT TAT GAT ATT TTG AGT GGT GCT CGG CCG TTT GAC TAC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCC TA       
IGHD3-
9*01  10|2               . ... ..C ... ... ... .C. ... TA. TAT AAC  
  
     
J Match Results 
    A   T   G   A   Y   Y   D   I   L   S   G   A   R   P   F   D   Y   W   G   Q   G   T   L   V   T   V   S           
  score  GCG ACA GGC GCG TAT TAT GAT ATT TTG AGT GGT GCT CGG CCG TTT GAC TAC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCC TA       
IGHJ4*02  176                                                   AC TAC ... ... ... ... ... ... ... ... ... ... ... ... ... .CA G    
  
     
Junction Analysis 
V Match: IGHV3-30*03  D Match: IGHD3-9*01  J Match: IGHJ4*02 
  V-J Distance: 38 
VD Junction: # of P,N Nucleotides: (0,14)  CAGGCGCGTATTAT 
DJ Junction: # of P,N Nucleotides: (0,14)  GTGGTGCTCGGCCG 381 
Sequence – VH6-01*01, No D Gene Assignment, JH5*02 
 
Raw Sequence 
CAGGTACAGCTGCAGCAGTCAGGTCCAGGACTGGTGAAGCCCTCGCAGACCCTCTCACTCACCTGTGCCATCTCCGGGGACAGTGTCTCTAGCAACAGTGCTGCTTGGAACTGGATCA
GGCAGTCCCCATCGAGAGGCCTTGAGTGGCTGGCAAGGACATACTACAGGTCCAAGTGGTATAATGATTATGCAGTATCTGTGAAAAGCCGAATAACCATCAACCCAGACACATCCAA
GAACCAGTTCTCCCTGCAGCTGAACTCTGTGATTCCCGAAGACACGGCTGTCTATTACTGTGTAAGATCCCCCCTTAAGCAGTGGCTGGAACCCTGGGGCAAGGGAACCCTGGTCACC
GTCTCCTCAA 
 
Joinsolver Alignment 
Summary 
Amino acid translation of the sequence: 
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLARTYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVI 
PEDTAVYYCVRSPLKQWLEPWGKGTLVTVSS 
 
JoinSolver 
Rearrangement is productive: 
Highest scoring matches:  
V: IGHV6-01*01   D:IGHD3-16*02R  J: IGHJ5*02 
The VH segment has 5 mutations 
CDR3 Length:  33 
 V   R   S   P   L   K   Q   W   L   E   P   
GTA AGA TCC CCC CTT AAG CAG TGG CTG GAA CCC  
V Match Results 
   ----------------------------------------------------------FR1----------- 
    1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16  17  18  
    Q   V   Q   L   Q   Q   S   G   P   G   L   V   K   P   S   Q   T   L   
  score CAG GTA CAG CTG CAG CAG TCA GGT CCA GGA CTG GTG AAG CCC TCG CAG ACC CTC  
IGHV6-01*01   1425  ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...  
    
   ----------------------------------------------- ___________CDR1_________ 
    19  20  21  22  23  24  25  26  27  28  29  30  31 31a 31b  32  33  34  
    S   L   T   C   A   I   S   G   D   S   V   S   S   N   S   A   A   W   
  TCA CTC ACC TGT GCC ATC TCC GGG GAC AGT GTC TCT AGC AAC AGT GCT GCT TGG  
IGHV6-01*01   ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...  
    
   ___ --------------------------------FR2-------------------- ____________ 
    35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  
    N   W   I   R   Q   S   P   S   R   G   L   E   W   L   A   R   T   Y   
  AAC TGG ATC AGG CAG TCC CCA TCG AGA GGC CTT GAG TGG CTG GCA AGG ACA TAC  
IGHV6-01*01   ... ... ... ... ... ... ... ... ... ... ... ... ... ... .G. ... ... ...  382 
 
   ________________________CDR2___________________________________ -------- 
   52a 52b 52c  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  
    Y   R       S   K   W   Y   N   D   Y   A   V   S   V   K   S   R   I   
  TAC AGG --- TCC AAG TGG TAT AAT GAT TAT GCA GTA TCT GTG AAA AGC CGA ATA  
IGHV6-01*01   ... ... --- ... ... ... ... ... ... ... ... ... ... ... ... ..T ... ...  
    
   ------------------FR3--------------------------------------------------- 
    68  69  70  71  72  73  74  75  76  77  78  79  80  81  82 82a 82b 82c  
    T   I   N   P   D   T   S   K   N   Q   F   S   L   Q   L   N   S   V   
  ACC ATC AAC CCA GAC ACA TCC AAG AAC CAG TTC TCC CTG CAG CTG AAC TCT GTG  
IGHV6-01*01   ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...  
    
   -------------------------------------- ___CDR3_____  
    83  84  85  86  87  88  89  90  91  92  93  94  95  
    I   P   E   D   T   A   V   Y   Y   C   V   R   S   
  ATT CCC GAA GAC ACG GCT GTC TAT TAC TGT GTA AGA TCC  
IGHV6-01*01   .C. ... ..G ... ... ... ..G ... ... ... .C. ... GA   
    
D Match Results 
    V   R   S   P   L   K   Q   W   L   E   P   W   G   K   G   T   L   V   T   V   S   S       
  len|rf  GTA AGA TCC CCC CTT AAG CAG TGG CTG GAA CCC TGG GGC AAG GGA ACC CTG GTC ACC GTC TCC TCA A    
IGHD3-16*02R  6|3  .AT .AC ... ... AAA CGT A.T CAT AAT AC   
  
J Match Results 
    V   R   S   P   L   K   Q   W   L   E   P   W   G   K   G   T   L   V   T   V   S   S       
  score GTA AGA TCC CCC CTT AAG CAG TGG CTG GAA CCC TGG GGC AAG GGA ACC CTG GTC ACC GTC TCC TCA A    
IGHJ5*02  183                       .C A.C ... T.C ..C ... ... ... C.. ... ... ... ... ... ... ... ... G    
  
Junction Analysis 
V Match: IGHV6-01*01   D Match: IGHD3-16*02R  J Match: IGHJ5*02 
  V-J Distance: 29 
VD Junction: # of P,N Nucleotides: (2,3)  TAAga(tc) 
DJ Junction: # of P,N Nucleotides: (0,18)  CTTAAGCAGTGGCTGGAA 
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Sample VAS1 
Sequence – VH1-18*01, DH2-2*01, JH5*02 
 
Raw Sequence 
CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGACGGTCTCCTGCACGGCCTCTGGTTACACCTTTACCAGCTATGCTGTCAGCTGGGTGCGACAGG
CCCCTGGACAAGGTCTTGAGTGGATGGCGTGGATCAGCACTTACTATGATGATGCAAAATATGCGCCGAAATTCCAGGGCAGACTTTCCGTGACCACGGACACATCCACGAGCACAGC
CTACATGGAACTGAGGAGCCTGAGATCTGACGACACGGCCAGATACTTCTGTGCGAGAGACGATTGTTCTGGTACCAGCTGTCATGCCGACCTCTGGGGCCAGGGAACCCTGGTCACC
AAGCCG 
 
Joinsolver Alignment 
Summary 
Amino acid translation of the sequence: 
QVQLVQSGAEVKKPGASVTVSCTASGYTFTSYAVSWVRQAPGQGLEWMAWISTYYDDAKYAPKFQGRLSVTTDTSTSTAYMELRSLRSDD 
TARYFCARDDCSGTSCHADLWGQGTLVTK 
 
JoinSolver 
Rearrangement is productive: 
 
Highest scoring matches:  
V: IGHV1-18*01  D:IGHD2-2*01  J: IGHJ5*02 
The VH segment has 30 mutations 
CDR3 Length:  42 
 A   R   D   D   C   S   G   T   S   C   H   A   D   L   
GCG AGA GAC GAT TGT TCT GGT ACC AGC TGT CAT GCC GAC CTC  
V Match Results 
   ----------------------------------------------------------FR1----------- 
    1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16  17  18  
    Q   V   Q   L   V   Q   S   G   A   E   V   K   K   P   G   A   S   V   
  score CAG GTT CAG CTG GTG CAG TCT GGA GCT GAG GTG AAG AAG CCT GGG GCC TCA GTG  
IGHV1-18*01  1155  ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...  
    
     
   ----------------------------------------------- ___________CDR1_________ 
    19  20  21  22  23  24  25  26  27  28  29  30  31 31a 31b  32  33  34  
    T   V   S   C   T   A   S   G   Y   T   F   T   S           Y   A   V   
  ACG GTC TCC TGC ACG GCC TCT GGT TAC ACC TTT ACC AGC --- --- TAT GCT GTC  
IGHV1-18*01  .A. ... ... ... .A. ..T ... ... ... ... ... ... ... --- --- ... .G. A..  
    
 
     384 
     
     
   ___ --------------------------------FR2-------------------- ____________ 
    35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  
    S   W   V   R   Q   A   P   G   Q   G   L   E   W   M   A   W   I   S   
  AGC TGG GTG CGA CAG GCC CCT GGA CAA GGT CTT GAG TGG ATG GCG TGG ATC AGC  
IGHV1-18*01  ... ... ... ... ... ... ... ... ... ..G ... ... ... ... .GA ... ... ...  
    
   ________________________CDR2___________________________________ -------- 
   52a 52b 52c  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  
    T           Y   Y   D   D   A   K   Y   A   P   K   F   Q   G   R   L   
  ACT --- --- TAC TAT GAT GAT GCA AAA TAT GCG CCG AAA TTC CAG GGC AGA CTT  
IGHV1-18*01  G.. --- --- ... A.. .G. A.C A.. ..C ... ..A .A. ..G C.. ... ... ... G.C  
    
   ------------------FR3--------------------------------------------------- 
    68  69  70  71  72  73  74  75  76  77  78  79  80  81  82 82a 82b 82c  
    S   V   T   T   D   T   S   T   S   T   A   Y   M   E   L   R   S   L   
  TCC GTG ACC ACG GAC ACA TCC ACG AGC ACA GCC TAC ATG GAA CTG AGG AGC CTG  
IGHV1-18*01  A.. A.. ... ..A ... ... ... ... ... ... ... ... ... ..G ... ... ... ...  
    
   -------------------------------------- ___CDR3_____  
    83  84  85  86  87  88  89  90  91  92  93  94  95  
    R   S   D   D   T   A   R   Y   F   C   A   R   D   
  AGA TCT GAC GAC ACG GCC AGA TAC TTC TGT GCG AGA GAC  
IGHV1-18*01  ... ... ... ... ... ... GTG ..T .A. ... ... ... ..   
    
D Match Results 
    A   R   D   D   C   S   G   T   S   C   H   A   D   L   W   G   Q   G   T   L   V   T   K   P           
  len|rf  GCG AGA GAC GAT TGT TCT GGT ACC AGC TGT CAT GCC GAC CTC TGG GGC CAG GGA ACC CTG GTC ACC AAG CCG          
IGHD2-2*01 10|2        . .GA T.. ... AG. A.. ... ... ..C T.. ...  
  
J Match Results 
    A   R   D   D   C   S   G   T   S   C   H   A   D   L   W   G   Q   G   T   L   V   T   K   P           
  score  GCG AGA GAC GAT TGT TCT GGT ACC AGC TGT CAT GCC GAC CTC TGG GGC CAG GGA ACC CTG GTC ACC AAG CCG          
IGHJ5*02  100                                   A. AAC TGG TT. ... .C. ... ... ... ... ... ... ... ... GTC T.C TCA G    
  
Junction Analysis 
V Match: IGHV1-18*01  D Match: IGHD2-2*01  J Match: IGHJ5*02 
  V-J Distance: 33 
VD Junction: # of P,N Nucleotides: (0,11)  CGATTGTTCTG 
DJ Junction: # of P,N Nucleotides: (0,12)  TCATGCCGACCT 
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Sequence – VH3-23*01, No D Gene Assignment, JH4*02 (25 Mutations) 
 
Raw Sequence 
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTAGAGGTTGGGGGGTCCCTGAGACTCTCCTGTGCGGCCTCTGGACTCCCCTTTAGAAGCTCTGCCATGAGCTGGGTCCGCCAGG
CTCCAGGGAAGGGGCTGGAGTGGGTCTCAAGTATTAGTAGTAGTGGCAGTACCACATACTACGCAGACTCCGCGAAGGGCCGGTTCACCGTCTCCAGAGACAATTCCAGGAACACTTT
ATTTCTGCAATTGAACAGCCTGAGAGCCGAGGACACGGCCATATACTACTGCGTGAAGACCACGGTTATAAACCTGTCGTACTTTGAAGACTGGGGCCGGGGGACCACGGTCACCGTC
TCCTCAGGAACCCTGGTCACCGTCTCCTCAA 
 
Joinsolver Alignment 
Summary 
Amino acid translation of the sequence: 
EVQLLESGGGLVEVGGSLRLSCAASGLPFRSSAMSWVRQAPGKGLEWVSSISSSGSTTYYADSAKGRFTVSRDNSRNTLFLQLNSLRAED 
TAIYYCVKTTVINLSYFEDWGRGTTVTVSSGTLVTVSS 
 
JoinSolver 
Rearrangement is productive: 
Highest scoring matches:  
V: IGHV3-23*01  D:IGHD1-14*01R  J: IGHJ4*02 
The VH segment has 25 mutations 
CDR3 Length:  39 
 V   K   T   T   V   I   N   L   S   Y   F   E   D   
GTG AAG ACC ACG GTT ATA AAC CTG TCG TAC TTT GAA GAC  
V Match Results 
   ----------------------------------------------------------FR1----------- 
    1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16  17  18  
    E   V   Q   L   L   E   S   G   G   G   L   V   E   V   G   G   S   L   
  score GAG GTG CAG CTG TTG GAG TCT GGG GGA GGC TTG GTA GAG GTT GGG GGG TCC CTG  
IGHV3-23*01  1209  ... ... ... ... ... ... ... ... ... ... ... ... C.. CC. ... ... ... ...  
    
   ----------------------------------------------- ___________CDR1_________ 
    19  20  21  22  23  24  25  26  27  28  29  30  31 31a 31b  32  33  34  
    R   L   S   C   A   A   S   G   L   P   F   R   S           S   A   M   
  AGA CTC TCC TGT GCG GCC TCT GGA CTC CCC TTT AGA AGC --- --- TCT GCC ATG  
IGHV3-23*01  ... ... ... ... ..A ... ... ... T.. A.. ... ..C ... --- --- .A. ... ...  
    
   ___ --------------------------------FR2-------------------- ____________ 
    35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  
    S   W   V   R   Q   A   P   G   K   G   L   E   W   V   S   S   I   S   
  AGC TGG GTC CGC CAG GCT CCA GGG AAG GGG CTG GAG TGG GTC TCA AGT ATT AGT  
IGHV3-23*01  ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... GC. ... ...  
 386 
   ________________________CDR2___________________________________ -------- 
   52a 52b 52c  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  
    S           S   G   S   T   T   Y   Y   A   D   S   A   K   G   R   F   
  AGT --- --- AGT GGC AGT ACC ACA TAC TAC GCA GAC TCC GCG AAG GGC CGG TTC  
IGHV3-23*01  G.. --- --- ... ..T G.. .G. ... ... ... ... ... ... .T. ... ... ... ...  
    
   ------------------FR3--------------------------------------------------- 
    68  69  70  71  72  73  74  75  76  77  78  79  80  81  82 82a 82b 82c  
    T   V   S   R   D   N   S   R   N   T   L   F   L   Q   L   N   S   L   
  ACC GTC TCC AGA GAC AAT TCC AGG AAC ACT TTA TTT CTG CAA TTG AAC AGC CTG  
IGHV3-23*01  ... A.. ... ... ... ... ... .A. ... ..G C.G .A. ... ... A.. ... ... ...  
    
   -------------------------------------- ___CDR3_____  
    83  84  85  86  87  88  89  90  91  92  93  94  95  
    R   A   E   D   T   A   I   Y   Y   C   V   K   T   
  AGA GCC GAG GAC ACG GCC ATA TAC TAC TGC GTG AAG ACC  
IGHV3-23*01  ... ... ... ... ... ... G.. ..T ... ..T .C. ..A GA   
    
D Match Results 
    V   K   T   T   V   I   N   L   S   Y   F   E   D   W   G   R   G   T   T   V   T   V   S   S   G   T   L   V   T   V   S   S      
  len|rf  GTG AAG ACC ACG GTT ATA AAC CTG TCG TAC TTT GAA GAC TGG GGC CGG GGG ACC ACG GTC ACC GTC TCC TCA GGA ACC CTG GTC ACC GTC TCC TCA A   
IGHD1-14*01R  8|1      GT. GTT C.. ... ... CC   
  
J Match Results 
    V   K   T   T   V   I   N   L   S   Y   F   E   D   W   G   R   G   T   T   V   T   V   S   S   G   T   L   V   T   V   S   S      
  scoreGTG AAG ACC ACG GTT ATA AAC CTG TCG TAC TTT GAA GAC TGG GGC CGG GGG ACC ACG GTC ACC GTC TCC TCA GGA ACC CTG GTC ACC GTC TCC TCA A   
IGHJ4*02  168                                   AC ... ... ..C T.. ... ... .A. ..A ... CT. ... ... ... ... ... .    
  
Junction Analysis 
V Match: IGHV3-23*01  D Match: IGHD1-14*01R  J Match: IGHJ4*02 
  V-J Distance: 36 
VD Junction: # of P,N Nucleotides: (0,9)  TGAAGACCA 
DJ Junction: # of P,N Nucleotides: (0,19)  AACCTGTCGTACTTTGAAG 
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Sequence – VH3-23*01, No D Gene Assignment, JH4*02 (26 Mutations) 
 
Raw Sequence 
GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTAGAGGTTGGGGGGTCCCTGAGACTCTCCTGTGCGGCCTCTGGACTCCCCTTTAGAAGCTCTGCCATGAGCTGGGTCCGCCAGG
CTCCAGGGAAGGGGCTGGAGTGGGTCTCAAGTATTAGTAGTAGTGGCAGTACCACATACTACGCAGACTCCGCGAAGGGCCGGTTCACCGTCTCCAGAGACAATTCCAGGAACACTTC
ATTTCTGCAATTGAACAGCCTGAGAGCCGAGGACACGGCCATATACTACTGCGTGAAGACCACGGTTATAAACCTGTCGTACTTTGAAGACTGGGGCCGGGGGACCACGGTCACCGTC
TCCTCAA 
 
Joinsolver Alignment 
Summary 
Amino acid translation of the sequence: 
EVQLLESGGGLVEVGGSLRLSCAASGLPFRSSAMSWVRQAPGKGLEWVSSISSSGSTTYYADSAKGRFTVSRDNSRNTSFLQLNSLRAED 
TAIYYCVKTTVINLSYFEDWGRGTTVTVSS 
 
JoinSolver 
Rearrangement is productive: 
Highest scoring matches:  
V: IGHV3-23*01  D:IGHD1-14*01R  J: IGHJ4*02 
The VH segment has 26 mutations 
CDR3 Length:  39 
 V   K   T   T   V   I   N   L   S   Y   F   E   D   
GTG AAG ACC ACG GTT ATA AAC CTG TCG TAC TTT GAA GAC  
V Match Results 
   ----------------------------------------------------------FR1----------- 
    1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16  17  18  
    E   V   Q   L   L   E   S   G   G   G   L   V   E   V   G   G   S   L   
  score GAG GTG CAG CTG TTG GAG TCT GGG GGA GGC TTG GTA GAG GTT GGG GGG TCC CTG  
IGHV3-23*01  1200  ... ... ... ... ... ... ... ... ... ... ... ... C.. CC. ... ... ... ...  
    
   ----------------------------------------------- ___________CDR1_________ 
    19  20  21  22  23  24  25  26  27  28  29  30  31 31a 31b  32  33  34  
    R   L   S   C   A   A   S   G   L   P   F   R   S           S   A   M   
  AGA CTC TCC TGT GCG GCC TCT GGA CTC CCC TTT AGA AGC --- --- TCT GCC ATG  
IGHV3-23*01  ... ... ... ... ..A ... ... ... T.. A.. ... ..C ... --- --- .A. ... ...  
    
   ___ --------------------------------FR2-------------------- ____________ 
    35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  
    S   W   V   R   Q   A   P   G   K   G   L   E   W   V   S   S   I   S   
  AGC TGG GTC CGC CAG GCT CCA GGG AAG GGG CTG GAG TGG GTC TCA AGT ATT AGT  
IGHV3-23*01  ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... GC. ... ...  
 388 
   ________________________CDR2___________________________________ -------- 
   52a 52b 52c  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  
    S           S   G   S   T   T   Y   Y   A   D   S   A   K   G   R   F   
  AGT --- --- AGT GGC AGT ACC ACA TAC TAC GCA GAC TCC GCG AAG GGC CGG TTC  
IGHV3-23*01  G.. --- --- ... ..T G.. .G. ... ... ... ... ... ... .T. ... ... ... ...  
    
   ------------------FR3--------------------------------------------------- 
    68  69  70  71  72  73  74  75  76  77  78  79  80  81  82 82a 82b 82c  
    T   V   S   R   D   N   S   R   N   T   S   F   L   Q   L   N   S   L   
  ACC GTC TCC AGA GAC AAT TCC AGG AAC ACT TCA TTT CTG CAA TTG AAC AGC CTG  
IGHV3-23*01  ... A.. ... ... ... ... ... .A. ... ..G CTG .A. ... ... A.. ... ... ...  
    
   -------------------------------------- ___CDR3_____  
    83  84  85  86  87  88  89  90  91  92  93  94  95  
    R   A   E   D   T   A   I   Y   Y   C   V   K   T   
  AGA GCC GAG GAC ACG GCC ATA TAC TAC TGC GTG AAG ACC  
IGHV3-23*01  ... ... ... ... ... ... G.. ..T ... ..T .C. ..A GA   
    
D Match Results 
    V   K   T   T   V   I   N   L   S   Y   F   E   D   W   G   R   G   T   T   V   T   V   S   S       
  len|rf  GTG AAG ACC ACG GTT ATA AAC CTG TCG TAC TTT GAA GAC TGG GGC CGG GGG ACC ACG GTC ACC GTC TCC TCA A    
IGHD1-14*01R 8|1      GT. GTT C.. ... ... CC   
  
J Match Results 
    V   K   T   T   V   I   N   L   S   Y   F   E   D   W   G   R   G   T   T   V   T   V   S   S       
  score  GTG AAG ACC ACG GTT ATA AAC CTG TCG TAC TTT GAA GAC TGG GGC CGG GGG ACC ACG GTC ACC GTC TCC TCA A    
IGHJ4*02  159                                   AC ... ... ..C T.. ... ... .A. ..A ... CT. ... ... ... ... ... G    
  
Junction Analysis 
V Match: IGHV3-23*01  D Match: IGHD1-14*01R  J Match: IGHJ4*02 
  V-J Distance: 36 
VD Junction: # of P,N Nucleotides: (0,9)  TGAAGACCA 
DJ Junction: # of P,N Nucleotides: (0,19)  AACCTGTCGTACTTTGAAG 
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Sequence – VH3-33*01, No D Gene Assignment, JH6*03 (21 Mutations) 
 
Raw Sequence 
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGACGTCCCTGAGACTCTCCTGTAAAGGCTCTGGATTCAGTTTCAGCAACTATGGCATGCACTGGGTCCGCCAGG
CTCCAGGCAAGGGGCTGGAATGGGTGGCAGTTATCTGGTACGATGGAAGTCAGAAAAATTATGCAGACTCCGTGAAGGGCCGAGTCACCATCTCCAGAGAGAATTCCAAGAACACGCT
GTATCTGGAAATGAACAGCCTGAGAGGCGAGGACACGGCTGTATATTACTGTGCGAGGGCGAAAATTGTAGCAGTTTCAGCAAGCCCGTCGATGGGCTCCTACTATCACTACATGGAC
GTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCAA 
 
Joinsolver Alignment 
Summary 
Amino acid translation of the sequence: 
QVQLVESGGGVVQPGTSLRLSCKGSGFSFSNYGMHWVRQAPGKGLEWVAVIWYDGSQKNYADSVKGRVTISRENSKNTLYLEMNSLRGED 
TAVYYCARAKIVAVSASPSMGSYYHYMDVWGKGTTVTVSSK 
 
JoinSolver 
Rearrangement is productive: 
Highest scoring matches:  
V: IGHV3-33*01  D:IGHD5-24*01R  J: IGHJ6*03 
The VH segment has 21 mutations 
CDR3 Length:  69 
 A   R   A   K   I   V   A   V   S   A   S   P   S   M   G   S   Y   Y   H   Y   M   D   V   
GCG AGG GCG AAA ATT GTA GCA GTT TCA GCA AGC CCG TCG ATG GGC TCC TAC TAT CAC TAC ATG GAC GTC  
V Match Results 
   ----------------------------------------------------------FR1----------- 
    1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16  17  18  
    Q   V   Q   L   V   E   S   G   G   G   V   V   Q   P   G   T   S   L   
  score CAG GTG CAG CTG GTG GAG TCT GGG GGA GGC GTG GTC CAG CCT GGG ACG TCC CTG  
IGHV3-33*01  1236  ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... .G. ... ...  
    
   ----------------------------------------------- ___________CDR1_________ 
    19  20  21  22  23  24  25  26  27  28  29  30  31 31a 31b  32  33  34  
    R   L   S   C   K   G   S   G   F   S   F   S   N           Y   G   M   
  AGA CTC TCC TGT AAA GGC TCT GGA TTC AGT TTC AGC AAC --- --- TAT GGC ATG  
IGHV3-33*01  ... ... ... ... GC. .CG ... ... ... .CC ... ..T .G. --- --- ... ... ...  
    
   ___ --------------------------------FR2-------------------- ____________ 
    35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  
    H   W   V   R   Q   A   P   G   K   G   L   E   W   V   A   V   I   W   
  CAC TGG GTC CGC CAG GCT CCA GGC AAG GGG CTG GAA TGG GTG GCA GTT ATC TGG  
IGHV3-33*01  ... ... ... ... ... ... ... ... ... ... ... ..G ... ... ... ... ..A ...  
 390 
   ________________________CDR2___________________________________ -------- 
   52a 52b 52c  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  
    Y           D   G   S   Q   K   N   Y   A   D   S   V   K   G   R   V   
  TAC --- --- GAT GGA AGT CAG AAA AAT TAT GCA GAC TCC GTG AAG GGC CGA GTC  
IGHV3-33*01  ..T --- --- ... ... ... A.T ... T.C ... ... ... ... ... ... ... ... T..  
    
   ------------------FR3--------------------------------------------------- 
    68  69  70  71  72  73  74  75  76  77  78  79  80  81  82 82a 82b 82c  
    T   I   S   R   E   N   S   K   N   T   L   Y   L   E   M   N   S   L   
  ACC ATC TCC AGA GAG AAT TCC AAG AAC ACG CTG TAT CTG GAA ATG AAC AGC CTG  
IGHV3-33*01  ... ... ... ... ..C ... ... ... ... ... ... ... ... C.. ... ... ... ...  
    
   -------------------------------------- ___CDR3_____  
    83  84  85  86  87  88  89  90  91  92  93  94  95  
    R   G   E   D   T   A   V   Y   Y   C   A   R   A   
  AGA GGC GAG GAC ACG GCT GTA TAT TAC TGT GCG AGG GCG  
IGHV3-33*01  ... .C. ... ... ... ... ..G ... ... ... ... ..A .A   
    
D Match Results 
    A   R   A   K   I   V   A   V   S   A   S   P   S   M   G   S   Y   Y   H   Y   M   D   V   W   G   K   G   T   T   V   T   V   S   S   K    
  len|rf  GCG AGG GCG AAA ATT GTA GCA GTT TCA GCA AGC CCG TCG ATG GGC TCC TAC TAT CAC TAC ATG GAC GTC TGG GGC AAA GGG ACC ACG GTC ACC GTC TCC TCA A  
IGHD5-
24*01R  9|1              GT. ... ... ..C A.C ..T A.   
  
    
J Match Results 
    A   R   A   K   I   V   A   V   S   A   S   P   S   M   G   S   Y   Y   H   Y   M   D   V   W   G   K   G   T   T   V   T   V   S   S   K    
  score GCG AGG GCG AAA ATT GTA GCA GTT TCA GCA AGC CCG TCG ATG GGC TCC TAC TAT CAC TAC ATG GAC GTC TGG GGC AAA GGG ACC ACG GTC ACC GTC TCC TCA A  
IGHJ6*03  243                                                       AT TA. .A. ... ..C T.. ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... G    
  
    
Junction Analysis 
V Match: IGHV3-33*01  D Match: IGHD5-24*01R  J Match: IGHJ6*03 
  V-J Distance: 50 
VD Junction: # of P,N Nucleotides: (0,6)  GGCGAA 
DJ Junction: # of P,N Nucleotides: (0,35)  AGTTTCAGCAAGCCCGTCGATGGGCTCCTACTATC 
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Sequence – VH3-33*01, No D Gene Assignment, JH6*03 (22 Mutations) 
 
Raw Sequence 
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGACGTCCCTGAGACTCTCCTGTAAAGGCCCTGGATTCAGTTTCAGCAACTATGGCATGCACTGGGTCCGCCAGG
CTCCAGGCAAGGGGCTGGAATGGGTGGCAGTTATCTGGTACGATGGAAGTCAGAAAAATTATGCAGACTCCGTGAAGGGCCGAGTCACCATCTCCAGAGAGAATTCCAAGAACACGCT
GTATCTGGAAATGAACAGCCTGAGAGGCGAGGACACGGCTGTATATTACTGTGCGAGGGCGAAAATTGTAGCAGTTTCAGCAAGCCCGTCGATGGGCTCCTACTATCACTACATGGAC
GTCTGGGGCAAAGGGACCACGGTCACCGTCTCCTCAA 
 
Joinsolver Alignment 
Summary 
Amino acid translation of the sequence: 
QVQLVESGGGVVQPGTSLRLSCKGPGFSFSNYGMHWVRQAPGKGLEWVAVIWYDGSQKNYADSVKGRVTISRENSKNTLYLEMNSLRGED 
TAVYYCARAKIVAVSASPSMGSYYHYMDVWGKGTTVTVSS 
 
JoinSolver 
Rearrangement is productive: 
Highest scoring matches:  
V: IGHV3-33*01  D:IGHD5-24*01R  J: IGHJ6*03 
The VH segment has 22 mutations 
CDR3 Length:  69 
 A   R   A   K   I   V   A   V   S   A   S   P   S   M   G   S   Y   Y   H   Y   M   D   V   
GCG AGG GCG AAA ATT GTA GCA GTT TCA GCA AGC CCG TCG ATG GGC TCC TAC TAT CAC TAC ATG GAC GTC  
V Match Results 
   ----------------------------------------------------------FR1----------- 
    1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16  17  18  
    Q   V   Q   L   V   E   S   G   G   G   V   V   Q   P   G   T   S   L   
  score CAG GTG CAG CTG GTG GAG TCT GGG GGA GGC GTG GTC CAG CCT GGG ACG TCC CTG  
IGHV3-33*01  1227  ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... .G. ... ...  
    
   ----------------------------------------------- ___________CDR1_________ 
    19  20  21  22  23  24  25  26  27  28  29  30  31 31a 31b  32  33  34  
    R   L   S   C   K   G   P   G   F   S   F   S   N           Y   G   M   
  AGA CTC TCC TGT AAA GGC CCT GGA TTC AGT TTC AGC AAC --- --- TAT GGC ATG  
IGHV3-33*01  ... ... ... ... GC. .CG T.. ... ... .CC ... ..T .G. --- --- ... ... ...  
    
   ___ --------------------------------FR2-------------------- ____________ 
    35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  
    H   W   V   R   Q   A   P   G   K   G   L   E   W   V   A   V   I   W   
  CAC TGG GTC CGC CAG GCT CCA GGC AAG GGG CTG GAA TGG GTG GCA GTT ATC TGG  
IGHV3-33*01  ... ... ... ... ... ... ... ... ... ... ... ..G ... ... ... ... ..A ...  
 392 
   ________________________CDR2___________________________________ -------- 
   52a 52b 52c  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  
    Y           D   G   S   Q   K   N   Y   A   D   S   V   K   G   R   V   
  TAC --- --- GAT GGA AGT CAG AAA AAT TAT GCA GAC TCC GTG AAG GGC CGA GTC  
IGHV3-33*01  ..T --- --- ... ... ... A.T ... T.C ... ... ... ... ... ... ... ... T..  
    
   ------------------FR3--------------------------------------------------- 
    68  69  70  71  72  73  74  75  76  77  78  79  80  81  82 82a 82b 82c  
    T   I   S   R   E   N   S   K   N   T   L   Y   L   E   M   N   S   L   
  ACC ATC TCC AGA GAG AAT TCC AAG AAC ACG CTG TAT CTG GAA ATG AAC AGC CTG  
IGHV3-33*01  ... ... ... ... ..C ... ... ... ... ... ... ... ... C.. ... ... ... ...  
    
   -------------------------------------- ___CDR3_____  
    83  84  85  86  87  88  89  90  91  92  93  94  95  
    R   G   E   D   T   A   V   Y   Y   C   A   R   A   
  AGA GGC GAG GAC ACG GCT GTA TAT TAC TGT GCG AGG GCG  
IGHV3-33*01  ... .C. ... ... ... ... ..G ... ... ... ... ..A .A   
    
D Match Results 
    A   R   A   K   I   V   A   V   S   A   S   P   S   M   G   S   Y   Y   H   Y   M   D   V   W   G   K   G   T   T   V   T   V   S   S      
  len|rf  GCG AGG GCG AAA ATT GTA GCA GTT TCA GCA AGC CCG TCG ATG GGC TCC TAC TAT CAC TAC ATG GAC GTC TGG GGC AAA GGG ACC ACG GTC ACC GTC TCC TCA A   
IGHD5-
24*01R  9|1              GT. ... ... ..C A.C ..T A.   
  
J Match Results 
    A   R   A   K   I   V   A   V   S   A   S   P   S   M   G   S   Y   Y   H   Y   M   D   V   W   G   K   G   T   T   V   T   V   S   S      
  score  GCG AGG GCG AAA ATT GTA GCA GTT TCA GCA AGC CCG TCG ATG GGC TCC TAC TAT CAC TAC ATG GAC GTC TGG GGC AAA GGG ACC ACG GTC ACC GTC TCC TCA A   
IGHJ6*03  243                                                       AT TA. .A. ... ..C T.. ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... G   
  
Junction Analysis 
V Match: IGHV3-33*01  D Match: IGHD5-24*01R  J Match: IGHJ6*03 
  V-J Distance: 50 
VD Junction: # of P,N Nucleotides: (0,6)  GGCGAA 
DJ Junction: # of P,N Nucleotides: (0,35)  AGTTTCAGCAAGCCCGTCGATGGGCTCCTACTATC 
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Appendix 2- Statistical Analysis Results  
 
Statistical  analysis,  as  described  in  section  2.3.13  was  conducted  using 
GraphPad  Prism  4  (GraphPad  Software  Inc.,  San  Diego  CA,  USA).    The 
following  tables  present  the  p-values  obtained  from  each  statistical  test 
conducted in the analysis of results presented in this study.  Areas highlighted 
in yellow indicate where a statistically significant difference was observed and 
the p-values obtained were less than 0.05.  ‘N/A’ or ‘–’ illustrate where statistical 
analysis could not be conducted either because a non-productive repertoire was 
not identified within the samples or where numbers were not sufficient to allow 
the respective statistical analysis to be conducted.  
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Table  1a  -  Results  (p-values)  from  Chi  Square  Test  in  the  Statistical  Analysis  of  Functional  Ig  Gene  Distributions  from  Muscle 
Infiltrating B Cells in Individual Myositis Patients Compared with PBL or Germline V-gene Frequencies. 
 
 
  MYO1  MYO3  MYO5  MYO5 PBL  MYO16  MYO23 
  PBL  Germline  PBL  Germline  PBL  Germline  MYO5 
PBL  PBL  Germline  PBL  Germline  PBL  Germline 
VH1  0.3048  0.2966  <0.0001  0.0021  0.0311  0.0254  0.0016  0.0028  0.0949  0.0603  0.0612  0.1678  0.1456 
VH2  0.0003  0.567  0.5556  0.3064  0.3965  0.8179  0.3506  <0.0001  0.32  0.391  0.1386  0.668  0.4554 
VH3  0.0381  0.1305  0.0645  0.1155  0.7001  0.7  0.9848  0.0801  0.2151  <0.0001  0.0009  0.0097  0.0154 
VH4  0.1418  0.4402  0.5317  0.7291  0.514  0.7424  0.4177  0.0029  0.0179  0.1513  0.3625  0.3611  0.4696 
VH5  0.4842  0.9097  0.3128  0.4072  <0.0001  0.0034  0.0574  0.303  0.2877  0.1419  0.2339  0.4627  0.5457 
VH6  0.2377  0.2882  0.519  0.5608  0.5084  0.5084  0.21  0.0566  0.23  0.348  0.3981  0.6389  0.6718 
VH7  0.4696  0.2882  0.6929  0.5608  0.6532  0.5084  -  0.53  0.3559  0.5655  0.3981  0.7738  0.6718 
                           
DH1  0.6003  0.7725  0.9148  0.7935  0.4064  0.8079  0.0377  0.1022  0.0528  0.1122  0.0595 
DH2  0.1395  0.8488  0.5723  0.9719  0.0982  0.2207  0.1939  0.5053  0.8667  0.2605  0.7741 
DH3  0.6692  0.1095  0.1867  0.039  0.9886  0.3545  0.4113  0.1403  0.0254  0.3817  0.6883 
DH4  0.4237  0.604  0.4623  0.2783  0.4046  0.2207  0.2987  0.5171  0.7203  0.8377  0.3633 
DH5  0.559  0.1899  0.5237  0.9719  0.1079  0.6056  0.4436  0.6027  0.0723  0.2301  0.096 
DH6  0.3954  0.7024  0.2925  0.2783  0.4554  0.6056  0.4436  0.7525  0.0723  <0.0001  0.0023 
DH7  0.4383  0.2319  0.7394  0.6053  0.706  0.5582  -  0.5937  0.409  0.6042  0.4222 
N/A 
Expected frequency for 
observed values was 
below 5 therefore Chi 
Square Analysis could 
not be conducted. 
                           
JH1  0.1165  0.0019  0.3913  0.0852  0.3294  0.0512  -  0.1728  0.0068  0.2122  0.0132  0.5328  0.2049 
JH2  0.5385  0.0475  0.5285  0.4202  0.3946  0.0512  0.096  0.0019  0.7243  0.2762  0.0132  <0.0001  0.132 
JH3  0.3074  0.5309  0.1051  0.0852  0.5102  0.9315  0.9668  0.3174  0.9086  0.0117  0.5666  0.2382  0.2049 
JH4  0.6287  0.1729  0.7  0.1897  0.2513  0.0991  0.1817  0.4895  0.332  0.4439  0.3496  0.01  0.2049 
JH5  0.5898  0.8609  0.0238  0.541  0.7013  0.5949  0.1637  0.0195  0.7171  0.0955  0.1391  0.0023  0.2636 
JH6  0.0849  0.3421  0.4781  0.9566  0.4539  0.9315  0.3025  0.017  0.5767  0.2572  0.4136  0.0824  0.2049 
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Table 1b - Results (p-values) from Chi Square Test in the Statistical Analysis of Functional Ig Gene Distributions from Different 
Myositis Subsets Compared with PBL, Germline V-gene Frequencies or Between Myositis Subsets. 
 
  MYO  DM  PM   
  PBL  Germline  PBL  Germline  PBL  Germline  DM vs PM 
VH1  0.5548  0.2773  0.0491  0.0922  0.621  0.9596  0.0759 
VH2  0.0878  0.5744  0.0227  0.8991  0.9223  0.2726  0.2889 
VH3  <0.0001  0.0348  <0.0001  0.0081  0.3118  0.4324  0.0688 
VH4  0.0071  0.2504  0.0416  0.3236  0.0972  0.3462  0.9331 
VH5  0.8661  0.6687  0.1446  0.5362  0.0942  0.1736  0.0228 
VH6  0.1687  0.4212  0.1315  0.1754  0.2461  0.2968  N/A 
VH7  0.2408  0.0856  0.3557  0.1754  0.4775  0.2968  N/A 
               
DH1  0.6589  0.3451  0.6566  0.342  0.9868  0.5987  0.7879 
DH2  0.0126  0.6398  0.0641  0.7944  0.0977  0.5069  0.6113 
DH3  0.7246  0.1011  0.8965  0.1783  0.5722  0.1057  0.5878 
DH4  0.7094  0.1535  0.5817  0.4358  0.1828  0.0543  0.135 
DH5  0.5649  0.1535  0.2495  0.0677  0.3512  0.8572  0.1219 
DH6  <0.0001  0.141  0.0002  0.1166  0.0839  0.3206  0.6702 
DH7  0.2638  0.0857  0.3511  0.151  0.5465  0.3512  N/A 
               
JH1  0.0109  <0.0001  0.045  <0.0001  0.1231  0.0023  N/A 
JH2  0.1425  0.243  0.2471  0.0085  <0.0001  0.7861  0.0025 
JH3  0.984  0.8145  0.4417  0.9723  0.3507  0.5541  0.2262 
JH4  0.7873  0.2272  0.923  0.2215  0.716  0.2628  0.8172 
JH5  0.2695  0.8922  0.5417  0.5819  0.0209  0.7698  0.0408 
JH6  0.9515  0.6307  0.1809  0.4533  0.1358  0.9848  0.0461 
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Table 2 - Results (p-values) from Chi Square Test in the Statistical Analysis of Functional Ig Gene Distributions Collectively from Skin 
Infiltrating B cells and Two Paired Peripheral Blood Samples or Germline DNA. 
 
 
  VAS  VAS1 PBL  VAS6 PBL 
  PBL  Germline  PBL  Germline  PBL  Germline 
VH1  0.5103  0.7291  0.0551  0.2483  0.7542  0.9849 
VH2  0.5556  0.3064  <0.0001  0.1418  <0.0001  0.0239 
VH3  0.2856  0.3268  0.6258  0.7472  0.0121  0.0555 
VH4  0.5317  0.7291  0.0093  0.0291  0.0092  0.0391 
VH5  0.3128  0.4072  0.7728  0.5573  0.9795  0.72 
VH6  0.519  0.5608  0.7094  0.6821  0.2162  0.3654 
VH7  0.6926  0.5608  0.606  0.4524  <0.0001  0.013 
             
DH1  0.308  0.2177  0.1233  0.0616  0.2012  0.1123 
DH2  0.5723  0.9719  0.6663  0.7763  0.2018  0.8105 
DH3  0.2804  0.7935  0.0029  0.001  0.0888  0.0173 
DH4  0.0284  0.3949  0.2665  0.0991  0.8247  0.4733 
DH5  0.0006  0.102  0.8161  0.3747  0.9243  0.4733 
DH6  0.2925  0.2783  0.3881  0.3747  0.6695  0.856 
DH7  0.7394  0.6053  0.615  0.4272  0.5379  0.341 
             
JH1  0.7198  0.4202  0.2628  0.0257  0.2098  0.5197 
JH2  0.0452  0.7592  0.3284  0.0257  <0.0001  1 
JH3  0.1051  0.0852  0.0055  0.4782  0.2879  0.8725 
JH4  0.0787  0.1233  0.0466  0.6919  0.1503  0.4857 
JH5  0.4543  0.4202  0.0497  0.0257  0.5278  0.5197 
JH6  0.8803  0.7261  0.0147  0.2  0.2434  1 
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Table 3 - Results (p-values) from Chi Square Test in the Statistical Analysis of 
Individual  VH  Gene  Distributions  from  both  disorders  and  paired  peripheral 
blood samples compared to normal control values of Volpe and Kepler (251). 
 
 
VH Gene  MYO  DM  PM  MYO5 
PBL  VAS  VAS1 
PBL 
VAS6 
PBL 
1~18*01  0.2268  0.9154  0.1895  0.7867  0.4949  0.8972  0.2885 
1~2*01  0.016  0.0578  0.1445  0.1969  0.4171  0.2893  0.2377 
1~24*01  0.3813  0.4906  0.596  0.6392  0.7682  0.7003  0.668 
1~3*01  0.6717  0.3359  0.0501  0.0166  0.6807  0.0015  0.0063 
1~45*02  0.7338  0.7889  0.8368  0.8555  0.9089  0.8811  0.8677 
1~46*01  0.2187  0.3674  0.3598  0.3582  0.0034  0.5524  0.4005 
1~58*01  0.6304  0.7048  0.7708  0.7967  0.8713  0.8325  0.8137 
1~69*01  0.7845  0.3407  0.0797  0.197  0.9428  0.0057  0.0278 
1~8*01  0.4461  0.2502  0.3765  0.4342  0.6229  0.5208  0.4743 
1~f*01  0.127  0.7048  0.0027  0.7967  0.8713  0.8325  0.8137 
2~26*01  0.4436  0.5487  0.6447  <0.0001  0.7976  0.009  0.7091 
2~5*01  0.1336  0.0076  0.328  0.3454  0.5865  0.0004  <0.0001 
2~70*01  0.4252  0.2424  0.8194  0.4257  0.6164  0.513  0.4661 
3~11*01  0.004  <0.0001  0.7979  0.3099  0.5232  0.4043  0.8632 
3~13*01  0.4652  0.5652  0.6583  0.6958  0.8058  0.7481  0.7205 
3~15*01  0.0468  0.0007  0.264  0.3233  0.5346  0.4173  0.177 
3~19*01  -  -  -  -  -  -  - 
3~20*01  0.3886  0.4973  0.6016  0.6444  0.7716  0.7046  0.6728 
3~21*01  0.1189  0.1044  0.6713  0.9997  0.4328  <0.0001  0.3081 
3~23*01  0.0052  0.0971  0.0175  0.293  0.2389  0.2771  0.0545 
3~30*01  0.0018  0.0374  0.0382  0.6037  0.335  0.4311  0.302 
3~30-3*01  0.06761  0.1493  0.2673  0.3267  0.5375  0.4206  0.3695 
3~33*01  0.0131  0.5004  0.0009  0.2423  0.0393  0.337  0.9162 
3~35*01  0.8326  0.8655  0.8964  0.9083  0.9432  0.9247  0.9161 
3~38*02  0.8792  0.9047  0.9266  0.9351  0.9592  0.9467  0.9406 
3~43*01  0.5069  0.6013  0.6878  0.7198  0.8232  0.7704  0.7451 
3~48*01  0.8864  0.2184  0.1827  0.098  0.4555  0.9212  0.281 
3~49*01  0.826  0.9533  0.6281  0.4813  0.6579  0.563  0.3579 
3~53*01  0.7962  0.3071  0.0776  0.4874  0.6623  0.5684  0.5251 
3~64*01  0.3685  0.4714  0.5797  0.6243  0.7581  0.6575  0.6541 
3~66*01  0.0052  0.0044  0.3201  0.9877  0.7305  0.077  0.136 
3~7*01  <0.0001  <0.0001  0.2511  0.5476  0.3903  0.848  0.2113 
3~72*01  0.0617  0.5569  0.0001  0.6895  0.8017  0.7428  0.7147 
3~73*01  0.7165  0.5111  0.1447  0.0764  0.0012  0.7136  0.6826 
3~74*01  0.2483  0.1697  0.9285  0.3504  0.5571  0.4432  0.3929 
3~9*01  0.0774  0.0195  0.941  0.3543  0.5602  0.4468  0.3967 
4~28*01  0.7923  0.8357  0.8733  0.8879  0.9293  0.9078  0.8973 
4~30-2*01  0.142  0.2476  0.3729  0.4317  0.621  0.5184  0.4719 
4~30-4*01  -  -  -  -  -  -  - 
4~31*01  0.1532  0.1229  0.2354  0.2941  0.5095  0.3889  0.3371 
4~34*01  0.039  0.0402  0.8627  0.4301  0.2271  0.1147  0.6022 
4~39*01  0.1075  0.162  0.429  0.1876  0.4073  0.9038  0.2279 
4~4*01  0.7927  0.9109  0.8031  0.3315  0.5246  0.4059  0.3545 
4~55*01  -  -  -  -  -  -  - 
4~59*01  0.1753  0.0676  0.9386  0.1903  0.0032  0.2821  0.2308 
Cont… 398 
VH Gene  MYO  DM  PM  MYO5 
PBL  VAS  VAS1 
PBL 
VAS6 
PBL 
4~61*01  0.3315  0.6449  0.3302  0.3892  0.5882  0.4785  0.4308 
4~b*01  0.8836  0.4865  0.585  0.6292  0.7614  0.6917  0.6586 
5~51*01  0.8413  0.1238  0.0176  0.1116  0.3804  0.4985  0.7188 
5~a*01  0.4832  0.8241  0.3901  0.4473  0.6328  0.5326  0.4869 
6~1*01  0.1687  0.1315  0.2461  0.0509  0.519  0.7094  0.2162 
7~4-1*01  0.2249  0.3598  0.4813  0.5355  0.6954  0.6091  <0.0001 
7~81*01  0.8792  0.9047  0.9266  0.9351  0.9592  0.9467  0.9406 
 
Table 4 - Results (p-values) from Chi Square Test in the Statistical Analysis of 
Individual  DH  Gene  Distributions  from  both  disorders  and  paired  peripheral 
blood samples compared to normal control values of Volpe and Kepler (251). 
 
 
  MYO  DM  PM  MYO5 
PBL  VAS  VAS1 
PBL 
VAS6 
PBL 
0~IR*01  0.3465  0.4364  0.6115  0.6532  0.7793  0.6718  0.6038 
1~1*01  0.2781  0.0721  0.4879  0.5394  0.702  0.5629  0.4786 
1~14*01  0.407  0.493  0.6546  0.6922  0.805  0.709  0.6476 
1~20*01  0.727  0.1728  0.8506  0.8676  0.9172  0.8751  0.8474 
1~26*01  0.8431  0.0721  0.793  0.3011  0.519  0.3296  0.7592 
1~7*01  0.47  0.3604  0.0055  0.5975  0.7419  0.6186  0.5421 
1~IR1*01  0.2813  0.373  0.561  0.607  0.7484  0.6277  0.5526 
1~OR15*1  0.7142  0.7621  0.8434  0.8612  0.9132  0.8691  0.84 
2~15*01  0.2017  0.1273  0.9581  0.3786  0.5829  0.0936  0.9972 
2~2*01  0.0075  0.0511  0.2377  0.3735  0.8862  0.9996  0.2176 
2~21*01  0.0648  0.0721  0.4127  0.488  0.6513  0.4945  0.6951 
2~8*01  0.647  0.9432  0.4946  0.28  0.7063  0.5689  0.4854 
2~IR2*01  0.5252  0.5994  0.7317  0.7617  0.85  0.7749  0.7262 
2~OF15*2  0.2974  0.389  0.5739  0.6189  0.7564  0.6391  0.5657 
3~10*01  0.8907  0.4803  0.4816  0.6612  0.5773  0.5584  0.1477 
3~16*01  0.3435  0.702  0.2804  0.3396  0.5515  0.3679  0.8809 
3~22*01  0.0229  0.7604  <0.0001  0.6429  0.4316  0.0007  0.1267 
3~3*01  0.6988  0.9417  0.5495  0.0008  0.4456  0.0969  0.1579 
3~9*01  0.5596  0.4566  0.3412  0.3997  0.5995  0.4272  0.0263 
3~OR15*3  0.4478  0.5303  0.6821  0.7171  0.8212  0.7326  0.6756 
4~17*01  0.909  0.0721  0.3244  0.6975  0.001  0.4111  0.9774 
4~23*01  0.8925  0.805  0.561  0.607  0.7484  0.6277  0.2675 
4~4*01  0.9586  0.6631  0.5968  0.6398  0.7704  0.6591  0.589 
4~OR15*4  0.5447  0.6165  0.7438  0.7725  0.8569  0.7852  0.7385 
5~12*01  0.0904  0.4619  0.0362  0.3381  <0.0001  0.5468  0.0434 
5~24*01  0.5239  0.2536  0.0465  0.3727  0.681  0.3063  0.4465 
5~5*01  0.1208  0.1995  0.4024  0.4588  0.6441  0.4849  0.3924 
5~OR15*5  0.6393  0.6984  0.8003  0.823  0.889  0.8329  0.7961 
6~13*01  0.4175  0.0091  0.2954  0.3546  0.5637  0.3828  0.0046 
6~19*01  0.0022  0.1783  0.0002  0.435  0.4837  0.2897  0.6376 
6~25*01  0.573  0.6412  0.761  0.7879  0.8667  0.7997  0.756 
6~6*01  0.0012  <0.0001  0.4748  0.5272  0.6934  0.2649  0.4654 
7~27*01  0.2638  0.3556  0.5465  0.5937  0.7394  0.615  0.5379 399 
Table 5 – Results (p-values) from Two Tailed Unpaired t-tests in Individual Patients, Paired Peripheral Blood Samples, Collective 
Patients and Disease Subsets of both Myositis and Vasculitic Disorders in Comparison of CDR3 Lengths in the Functional and Non-
Functional Repertoires.   
 
 
 
 
Table 6 – Results (p-values) from Two Tailed Unpaired t-tests in Individual Patients, Paired Peripheral Blood Samples, Collective 
Patients and Disease Subsets of the Myositis Disorders in Comparison of P and N Nucleotide Lengths at Different Regions of the Ig 
Gene Recombination Junction and in the Functional and Non-Functional Repertoires.   
 
 
    MYO1  MYO3  MYO5  MYO5 PBL  MYO16  MYO23  MYO  MYO DM  MYO PM 
    VD vs DJ  VD vs DJ  VD vs DJ  VD vs DJ  VD vs DJ  VD vs DJ  VD vs DJ  VD vs DJ  VD vs DJ 
Productive  0.3758  0.3615  0.6239  0.5886  0.5262  N/A  0.6342  0.7839  0.6309 
Non-
Productive  0.2725  N/A  N/A  N/A  N/A  N/A  0.2725  0.2725  N/A 
  VD  DJ  VD  DJ  VD  DJ  VD  DJ  VD  DJ  VD  DJ  VD  DJ  VD  DJ  VD  DJ 
P
 
N
u
c
l
e
o
t
i
d
e
 
P vs NP  0.039  0.9447  N/A  N/A  N/A  N/A  0.2679  N/A  N/A  N/A  N/A  N/A  0.0124  0.9314  0.0239  0.7963  N/A  N/A 
Productive  0.4064  0.2261  0.3495  0.9787  0.0596  N/A  0.1654  0.8557  0.0073 
Non-
Productive  0.364  N/A  N/A  0.2589  N/A  N/A  0.364  0.364  N/A 
  VD  DJ  VD  DJ  VD  DJ  VD  DJ  VD  DJ  VD  DJ  VD  DJ  VD  DJ  VD  DJ 
 
N
 
N
u
c
l
e
o
t
i
d
e
 
 
P vs NP  0.2658  0.3928  N/A  N/A  N/A  N/A  0.4129  0.3212  N/A  N/A  N/A  N/A  0.5242  0.4644  0.4043  0.432  N/A  N/A 
 
 
  MYO1  MYO5 PBL  MYO  MYO DM  MYO PM  VAS  VAS1 PBL  VAS6 PBL 
CDR3 
Length 
P vs NP 
0.661  0.5017  0.9529  0.9461  N/A  0.0716  0.3613  0.1632 400 
Table  7  –  Results  (p-values)  from  Two  Tailed  Unpaired  t-tests  in  Collective 
Vasculitis Patients and Paired Peripheral Blood Samples in Comparison of P 
and N Nucleotide Lengths at Different Regions of the Ig Gene Recombination 
Junction and in the Functional and Non-Functional Repertoires.   
 
 
    VAS  VAS1 PBL  VAS6 PBL 
    VD vs DJ  VD vs DJ  VD vs DJ 
Productive  N/A  0.0343  0.202 
Non-
Productive  N/A  1  0.5761 
  VD  DJ  VD  DJ  VD  DJ 
P
 
N
u
c
l
e
o
t
i
d
e
 
P vs NP  N/A  N/A  0.721  0.3453  0.13  0.229 
Productive  0.6487  0.5394  0.3282 
Non-
Productive  N/A  0.2552  0.9017 
  VD  DJ  VD  DJ  VD  DJ 
N
 
N
u
c
l
e
o
t
i
d
e
 
P vs NP  N/A  N/A  0.238  0.3662  0.975  0.715 401 
Results (p-values) from Two Tailed Unpaired t-tests in Comparison of Exonuclease Activity at Different Regions of the Ig Gene 
Recombination Junction and in the Functional and Non-Functional Repertoires.   
Table 8a 
    MYO1  MYO3  MYO5  MYO5 PBL 
    3' VH  5' DH  3'DH   5' JH  3' VH  5' DH  3'DH   5' JH  3' VH  5' DH  3'DH   5' JH  3' VH  5' DH  3'DH   5' JH 
P vs NP  0.2468  0.1282  0.3957  0.8798  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  0.016  0.9219  0.8556  0.2724 
VH vs JH  <0.0001  0.0002  0.0008  0.0002 
5'DH vs3'DH  0.3414  0.8507  0.0787  0.6078 
VH vs 5'DH  <0.0001  0.0925  0.0472  0.0004 
E
x
o
n
u
c
l
e
a
s
e
 
A
c
t
i
v
i
t
y
 
3'DH vs JH  0.8918  0.7814  0.0035  0.4661 
 
Table 8b 
    MYO16  MYO23  MYO  MYO DM  MYO PM 
    3' VH  5' DH  3'DH  5' JH  3' VH  5' DH  3'DH  5' JH  3' VH  5' DH  3'DH  5' JH  3' VH  5' DH  3'DH  5' JH  3' VH  5' DH  3'DH  5' JH 
P vs NP  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  0.238  0.2155  0.181  0.9035  0.249  0.1359  0.2073  0.9947  N/A  N/A  N/A  N/A 
VH vs JH  0.0006  N/A  <0.0001  <0.0001  <0.0001 
5'DH vs3'DH  0.1346  N/A  0.1058  0.1286  0.3309 
VH vs 5'DH  0.0006  N/A  <0.0001  <0.0001  0.0103 
E
x
o
n
u
c
l
e
a
s
e
 
A
c
t
i
v
i
t
y
 
3'DH vs JH  0.1917  N/A  0.0923  0.4023  0.0593 
 
Table 9 
    VAS  VAS1 PBL  VAS6 PBL 
    3' 
VH  5' DH  3'DH  5' JH  3' VH  5' DH  3'DH  5' JH  3' VH  5' DH  3'DH  5' JH 
P vs NP  N/A  N/A  N/A  N/A  0.027  0.528  0.29  N/A*  0.003  0.6796  0.639  0.5869 
VH vs JH  0.1518  <0.0001  0.0021 
5'DH vs3'DH  0.1758  0.1333  0.7844 
VH vs 5'DH  0.0132  0.0007  0.0001 
E
x
o
n
u
c
l
e
a
s
e
 
A
c
t
i
v
i
t
y
 
3'DH vs JH  0.075  0.7324  0.7912 402 
Table 10 – Results (p-values) from One-Way Analysis of Variance Test Used In 
Conjunction with the Tukey-Kramer Multiple Comparison Post Test in Individual 
Patients,  Paired  Peripheral  Blood  Samples,  Collective  Patients  and  Disease 
Subsets  of  both  Myositis  and  Vasculitic  Disorders  to  Determine  Statistical 
Difference Between Mean CDR3 Lengths in Mutated Sequences. 
 
  0-2 vs 3-10  0-2 vs 11-20  0-2 vs 20+  3-10 vs 11-20  3-10 vs20+  11-20 vs 20+ 
MYO1  >0.05  >0.05  >0.05  >0.05  >0.05  >0.05 
MYO3  >0.05  >0.05  >0.05  >0.05  >0.05  >0.05 
MYO5  N/A  N/A  N/A  >0.05  >0.05  >0.05 
MYO5 PBL  >0.05  >0.05  >0.05  >0.05  >0.05  >0.05 
MYO16  >0.05  >0.05  <0.0001  >0.05  <0.05  <0.05 
MYO  >0.05  >0.05  <0.05  >0.05  >0.05  >0.05 
MYO DM  >0.05  >0.05  >0.05  >0.05  >0.05  >0.05 
MYO PM  >0.05  >0.05  >0.05  >0.05  >0.05  <0.05 
VAS  >0.05  >0.05  >0.05  >0.05  >0.05  >0.05 
VAS1 PBL  >0.05  >0.05  >0.05  >0.05  >0.05  >0.05 
VAS6 PBL  <0.05  >0.05  >0.05  >0.05  >0.05  >0.05 